id	sid	tid	token	lemma	pos
cord-302316-raf5rlkq	1	1	key	key	JJ
cord-302316-raf5rlkq	2	1	:	:	:
cord-302316-raf5rlkq	2	2	cord-302316-raf5rlkq	cord-302316-raf5rlkq	NNP
cord-302316-raf5rlkq	2	3	authors	author	NNS
cord-302316-raf5rlkq	2	4	:	:	:
cord-302316-raf5rlkq	2	5	Brüssow	Brüssow	NNP
cord-302316-raf5rlkq	2	6	,	,	,
cord-302316-raf5rlkq	2	7	Harald	Harald	NNP
cord-302316-raf5rlkq	2	8	title	title	NN
cord-302316-raf5rlkq	2	9	:	:	:
cord-302316-raf5rlkq	3	1	COVID‐19	COVID‐19	NNP
cord-302316-raf5rlkq	3	2	:	:	:
cord-302316-raf5rlkq	4	1	From	from	IN
cord-302316-raf5rlkq	4	2	pathogenesis	pathogenesis	NN
cord-302316-raf5rlkq	4	3	models	model	NNS
cord-302316-raf5rlkq	4	4	to	to	IN
cord-302316-raf5rlkq	4	5	the	the	DT
cord-302316-raf5rlkq	4	6	first	first	JJ
cord-302316-raf5rlkq	4	7	drug	drug	NN
cord-302316-raf5rlkq	4	8	trials	trial	NNS
cord-302316-raf5rlkq	4	9	date	date	NN
cord-302316-raf5rlkq	4	10	:	:	:
cord-302316-raf5rlkq	4	11	2020	2020	CD
cord-302316-raf5rlkq	4	12	-	-	HYPH
cord-302316-raf5rlkq	4	13	06	06	CD
cord-302316-raf5rlkq	4	14	-	-	SYM
cord-302316-raf5rlkq	4	15	23	23	CD
cord-302316-raf5rlkq	4	16	journal	journal	NN
cord-302316-raf5rlkq	4	17	:	:	:
cord-302316-raf5rlkq	5	1	Microb	Microb	NNP
cord-302316-raf5rlkq	5	2	Biotechnol	Biotechnol	NNP
cord-302316-raf5rlkq	5	3	DOI	DOI	NNP
cord-302316-raf5rlkq	5	4	:	:	:
cord-302316-raf5rlkq	6	1	10.1111/1751	10.1111/1751	CD
cord-302316-raf5rlkq	6	2	-	-	HYPH
cord-302316-raf5rlkq	6	3	7915.13611	7915.13611	CD
cord-302316-raf5rlkq	6	4	sha	sha	NNP
cord-302316-raf5rlkq	6	5	:	:	:
cord-302316-raf5rlkq	6	6	4ff99230184943cf2a9ccb2917e2dac74b330e25	4ff99230184943cf2a9ccb2917e2dac74b330e25	CD
cord-302316-raf5rlkq	6	7	doc_id	doc_id	CD
cord-302316-raf5rlkq	6	8	:	:	:
cord-302316-raf5rlkq	6	9	302316	302316	CD
cord-302316-raf5rlkq	6	10	cord_uid	cord_uid	NN
cord-302316-raf5rlkq	6	11	:	:	:
cord-302316-raf5rlkq	7	1	raf5rlkq	raf5rlkq	NNP
cord-302316-raf5rlkq	8	1	The	the	DT
cord-302316-raf5rlkq	8	2	number	number	NN
cord-302316-raf5rlkq	8	3	of	of	IN
cord-302316-raf5rlkq	8	4	people	people	NNS
cord-302316-raf5rlkq	8	5	infected	infect	VBN
cord-302316-raf5rlkq	8	6	with	with	IN
cord-302316-raf5rlkq	8	7	SARS‐CoV‐2	SARS‐CoV‐2	NNP
cord-302316-raf5rlkq	8	8	,	,	,
cord-302316-raf5rlkq	8	9	and	and	CC
cord-302316-raf5rlkq	8	10	sadly	sadly	RB
cord-302316-raf5rlkq	8	11	dying	die	VBG
cord-302316-raf5rlkq	8	12	from	from	IN
cord-302316-raf5rlkq	8	13	COVID‐19	COVID‐19	NNP
cord-302316-raf5rlkq	8	14	,	,	,
cord-302316-raf5rlkq	8	15	has	have	VBZ
cord-302316-raf5rlkq	8	16	exploded	explode	VBN
cord-302316-raf5rlkq	8	17	,	,	,
cord-302316-raf5rlkq	8	18	and	and	CC
cord-302316-raf5rlkq	8	19	so	so	RB
cord-302316-raf5rlkq	8	20	the	the	DT
cord-302316-raf5rlkq	8	21	amount	amount	NN
cord-302316-raf5rlkq	8	22	of	of	IN
cord-302316-raf5rlkq	8	23	literature	literature	NN
cord-302316-raf5rlkq	8	24	on	on	IN
cord-302316-raf5rlkq	8	25	the	the	DT
cord-302316-raf5rlkq	8	26	novel	novel	JJ
cord-302316-raf5rlkq	8	27	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	8	28	and	and	CC
cord-302316-raf5rlkq	8	29	the	the	DT
cord-302316-raf5rlkq	8	30	disease	disease	NN
cord-302316-raf5rlkq	8	31	it	-PRON-	PRP
cord-302316-raf5rlkq	8	32	causes	cause	VBZ
cord-302316-raf5rlkq	8	33	has	have	VBZ
cord-302316-raf5rlkq	8	34	increased	increase	VBN
cord-302316-raf5rlkq	8	35	proportionately	proportionately	RB
cord-302316-raf5rlkq	8	36	.	.	.
cord-302316-raf5rlkq	9	1	The	the	DT
cord-302316-raf5rlkq	9	2	case	case	NN
cord-302316-raf5rlkq	9	3	numbers	number	NNS
cord-302316-raf5rlkq	9	4	in	in	IN
cord-302316-raf5rlkq	9	5	some	some	DT
cord-302316-raf5rlkq	9	6	countries	country	NNS
cord-302316-raf5rlkq	9	7	are	be	VBP
cord-302316-raf5rlkq	9	8	beyond	beyond	IN
cord-302316-raf5rlkq	9	9	the	the	DT
cord-302316-raf5rlkq	9	10	epidemic	epidemic	NN
cord-302316-raf5rlkq	9	11	peak	peak	NN
cord-302316-raf5rlkq	9	12	,	,	,
cord-302316-raf5rlkq	9	13	but	but	CC
cord-302316-raf5rlkq	9	14	the	the	DT
cord-302316-raf5rlkq	9	15	uncertainty	uncertainty	NN
cord-302316-raf5rlkq	9	16	about	about	IN
cord-302316-raf5rlkq	9	17	a	a	DT
cord-302316-raf5rlkq	9	18	second	second	JJ
cord-302316-raf5rlkq	9	19	wave	wave	NN
cord-302316-raf5rlkq	9	20	keeps	keep	VBZ
cord-302316-raf5rlkq	9	21	politicians	politician	NNS
cord-302316-raf5rlkq	9	22	and	and	CC
cord-302316-raf5rlkq	9	23	societies	society	NNS
cord-302316-raf5rlkq	9	24	under	under	IN
cord-302316-raf5rlkq	9	25	pressure	pressure	NN
cord-302316-raf5rlkq	9	26	.	.	.
cord-302316-raf5rlkq	10	1	Appropriate	appropriate	JJ
cord-302316-raf5rlkq	10	2	decision‐making	decision‐making	NN
cord-302316-raf5rlkq	10	3	and	and	CC
cord-302316-raf5rlkq	10	4	winning	win	VBG
cord-302316-raf5rlkq	10	5	support	support	NN
cord-302316-raf5rlkq	10	6	from	from	IN
cord-302316-raf5rlkq	10	7	the	the	DT
cord-302316-raf5rlkq	10	8	population	population	NN
cord-302316-raf5rlkq	10	9	depends	depend	VBZ
cord-302316-raf5rlkq	10	10	on	on	IN
cord-302316-raf5rlkq	10	11	precise	precise	JJ
cord-302316-raf5rlkq	10	12	scientific	scientific	JJ
cord-302316-raf5rlkq	10	13	information	information	NN
cord-302316-raf5rlkq	10	14	rather	rather	RB
cord-302316-raf5rlkq	10	15	than	than	IN
cord-302316-raf5rlkq	10	16	leaving	leave	VBG
cord-302316-raf5rlkq	10	17	the	the	DT
cord-302316-raf5rlkq	10	18	field	field	NN
cord-302316-raf5rlkq	10	19	to	to	IN
cord-302316-raf5rlkq	10	20	scaremongers	scaremonger	NNS
cord-302316-raf5rlkq	10	21	of	of	IN
cord-302316-raf5rlkq	10	22	all	all	DT
cord-302316-raf5rlkq	10	23	proveniences	provenience	NNS
cord-302316-raf5rlkq	10	24	.	.	.
cord-302316-raf5rlkq	11	1	This	this	DT
cord-302316-raf5rlkq	11	2	mini‐review	mini‐review	NNP
cord-302316-raf5rlkq	11	3	is	be	VBZ
cord-302316-raf5rlkq	11	4	an	an	DT
cord-302316-raf5rlkq	11	5	update	update	NN
cord-302316-raf5rlkq	11	6	of	of	IN
cord-302316-raf5rlkq	11	7	earlier	early	JJR
cord-302316-raf5rlkq	11	8	reports	report	NNS
cord-302316-raf5rlkq	12	1	(	(	-LRB-
cord-302316-raf5rlkq	12	2	Brüssow	Brüssow	NNP
cord-302316-raf5rlkq	12	3	,	,	,
cord-302316-raf5rlkq	12	4	Microb	Microb	NNP
cord-302316-raf5rlkq	12	5	Biotechnol	Biotechnol	NNP
cord-302316-raf5rlkq	12	6	2020a;13:607	2020a;13:607	CD
cord-302316-raf5rlkq	12	7	;	;	:
cord-302316-raf5rlkq	12	8	Brüssow	Brüssow	NNP
cord-302316-raf5rlkq	12	9	,	,	,
cord-302316-raf5rlkq	12	10	Microb	Microb	NNP
cord-302316-raf5rlkq	12	11	Biotechnol	Biotechnol	NNP
cord-302316-raf5rlkq	12	12	2020b	2020b	NNS
cord-302316-raf5rlkq	12	13	;	;	:
cord-302316-raf5rlkq	12	14	https://doi.org/10.1111/1751-7915.13592	https://doi.org/10.1111/1751-7915.13592	ADD
cord-302316-raf5rlkq	12	15	)	)	-RRB-
cord-302316-raf5rlkq	12	16	.	.	.
cord-302316-raf5rlkq	13	1	The	the	DT
cord-302316-raf5rlkq	13	2	number	number	NN
cord-302316-raf5rlkq	13	3	of	of	IN
cord-302316-raf5rlkq	13	4	people	people	NNS
cord-302316-raf5rlkq	13	5	infected	infect	VBN
cord-302316-raf5rlkq	13	6	with	with	IN
cord-302316-raf5rlkq	13	7	SARS	SARS	NNP
cord-302316-raf5rlkq	13	8	-	-	HYPH
cord-302316-raf5rlkq	13	9	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	13	10	,	,	,
cord-302316-raf5rlkq	13	11	and	and	CC
cord-302316-raf5rlkq	13	12	sadly	sadly	RB
cord-302316-raf5rlkq	13	13	dying	die	VBG
cord-302316-raf5rlkq	13	14	from	from	IN
cord-302316-raf5rlkq	13	15	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	13	16	,	,	,
cord-302316-raf5rlkq	13	17	has	have	VBZ
cord-302316-raf5rlkq	13	18	exploded	explode	VBN
cord-302316-raf5rlkq	13	19	,	,	,
cord-302316-raf5rlkq	13	20	and	and	CC
cord-302316-raf5rlkq	13	21	so	so	RB
cord-302316-raf5rlkq	13	22	the	the	DT
cord-302316-raf5rlkq	13	23	amount	amount	NN
cord-302316-raf5rlkq	13	24	of	of	IN
cord-302316-raf5rlkq	13	25	literature	literature	NN
cord-302316-raf5rlkq	13	26	on	on	IN
cord-302316-raf5rlkq	13	27	the	the	DT
cord-302316-raf5rlkq	13	28	novel	novel	JJ
cord-302316-raf5rlkq	13	29	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	13	30	and	and	CC
cord-302316-raf5rlkq	13	31	the	the	DT
cord-302316-raf5rlkq	13	32	disease	disease	NN
cord-302316-raf5rlkq	13	33	it	-PRON-	PRP
cord-302316-raf5rlkq	13	34	causes	cause	VBZ
cord-302316-raf5rlkq	13	35	has	have	VBZ
cord-302316-raf5rlkq	13	36	increased	increase	VBN
cord-302316-raf5rlkq	13	37	proportionately	proportionately	RB
cord-302316-raf5rlkq	13	38	.	.	.
cord-302316-raf5rlkq	14	1	The	the	DT
cord-302316-raf5rlkq	14	2	case	case	NN
cord-302316-raf5rlkq	14	3	numbers	number	NNS
cord-302316-raf5rlkq	14	4	in	in	IN
cord-302316-raf5rlkq	14	5	some	some	DT
cord-302316-raf5rlkq	14	6	countries	country	NNS
cord-302316-raf5rlkq	14	7	are	be	VBP
cord-302316-raf5rlkq	14	8	beyond	beyond	IN
cord-302316-raf5rlkq	14	9	the	the	DT
cord-302316-raf5rlkq	14	10	epidemic	epidemic	NN
cord-302316-raf5rlkq	14	11	peak	peak	NN
cord-302316-raf5rlkq	14	12	,	,	,
cord-302316-raf5rlkq	14	13	but	but	CC
cord-302316-raf5rlkq	14	14	the	the	DT
cord-302316-raf5rlkq	14	15	uncertainty	uncertainty	NN
cord-302316-raf5rlkq	14	16	about	about	IN
cord-302316-raf5rlkq	14	17	a	a	DT
cord-302316-raf5rlkq	14	18	second	second	JJ
cord-302316-raf5rlkq	14	19	wave	wave	NN
cord-302316-raf5rlkq	14	20	keeps	keep	VBZ
cord-302316-raf5rlkq	14	21	politicians	politician	NNS
cord-302316-raf5rlkq	14	22	and	and	CC
cord-302316-raf5rlkq	14	23	societies	society	NNS
cord-302316-raf5rlkq	14	24	under	under	IN
cord-302316-raf5rlkq	14	25	pressure	pressure	NN
cord-302316-raf5rlkq	14	26	.	.	.
cord-302316-raf5rlkq	15	1	Appropriate	appropriate	JJ
cord-302316-raf5rlkq	15	2	decision	decision	NN
cord-302316-raf5rlkq	15	3	-	-	HYPH
cord-302316-raf5rlkq	15	4	making	making	NN
cord-302316-raf5rlkq	15	5	and	and	CC
cord-302316-raf5rlkq	15	6	winning	win	VBG
cord-302316-raf5rlkq	15	7	support	support	NN
cord-302316-raf5rlkq	15	8	from	from	IN
cord-302316-raf5rlkq	15	9	the	the	DT
cord-302316-raf5rlkq	15	10	population	population	NN
cord-302316-raf5rlkq	15	11	depends	depend	VBZ
cord-302316-raf5rlkq	15	12	on	on	IN
cord-302316-raf5rlkq	15	13	precise	precise	JJ
cord-302316-raf5rlkq	15	14	scientific	scientific	JJ
cord-302316-raf5rlkq	15	15	information	information	NN
cord-302316-raf5rlkq	15	16	rather	rather	RB
cord-302316-raf5rlkq	15	17	than	than	IN
cord-302316-raf5rlkq	15	18	leaving	leave	VBG
cord-302316-raf5rlkq	15	19	the	the	DT
cord-302316-raf5rlkq	15	20	field	field	NN
cord-302316-raf5rlkq	15	21	to	to	IN
cord-302316-raf5rlkq	15	22	scaremongers	scaremonger	NNS
cord-302316-raf5rlkq	15	23	of	of	IN
cord-302316-raf5rlkq	15	24	all	all	DT
cord-302316-raf5rlkq	15	25	proveniences	provenience	NNS
cord-302316-raf5rlkq	15	26	.	.	.
cord-302316-raf5rlkq	16	1	This	this	DT
cord-302316-raf5rlkq	16	2	mini	mini	JJ
cord-302316-raf5rlkq	16	3	-	-	NN
cord-302316-raf5rlkq	16	4	review	review	NN
cord-302316-raf5rlkq	16	5	is	be	VBZ
cord-302316-raf5rlkq	16	6	an	an	DT
cord-302316-raf5rlkq	16	7	update	update	NN
cord-302316-raf5rlkq	16	8	of	of	IN
cord-302316-raf5rlkq	16	9	earlier	early	JJR
cord-302316-raf5rlkq	16	10	reports	report	NNS
cord-302316-raf5rlkq	16	11	(	(	-LRB-
cord-302316-raf5rlkq	16	12	Br€	Br€	NNP
cord-302316-raf5rlkq	16	13	ussow	ussow	NNP
cord-302316-raf5rlkq	16	14	,	,	,
cord-302316-raf5rlkq	16	15	Microb	Microb	NNP
cord-302316-raf5rlkq	16	16	Biotechnol	Biotechnol	NNP
cord-302316-raf5rlkq	16	17	2020a	2020a	NNS
cord-302316-raf5rlkq	16	18	;	;	:
cord-302316-raf5rlkq	16	19	13:607	13:607	CD
cord-302316-raf5rlkq	16	20	;	;	:
cord-302316-raf5rlkq	16	21	Br€	Br€	NNP
cord-302316-raf5rlkq	16	22	ussow	ussow	NN
cord-302316-raf5rlkq	16	23	,	,	,
cord-302316-raf5rlkq	16	24	Microb	Microb	NNP
cord-302316-raf5rlkq	16	25	Biotechnol	Biotechnol	NNP
cord-302316-raf5rlkq	16	26	2020b	2020b	NNS
cord-302316-raf5rlkq	16	27	;	;	:
cord-302316-raf5rlkq	16	28	https://doi.org/10.1111	https://doi.org/10.1111	NN
cord-302316-raf5rlkq	16	29	/1751	/1751	NNP
cord-302316-raf5rlkq	16	30	)	)	-RRB-
cord-302316-raf5rlkq	16	31	.	.	.
cord-302316-raf5rlkq	17	1	Autopsies	autopsy	NNS
cord-302316-raf5rlkq	17	2	can	can	MD
cord-302316-raf5rlkq	17	3	provide	provide	VB
cord-302316-raf5rlkq	17	4	valuable	valuable	JJ
cord-302316-raf5rlkq	17	5	insight	insight	NN
cord-302316-raf5rlkq	17	6	into	into	IN
cord-302316-raf5rlkq	17	7	new	new	JJ
cord-302316-raf5rlkq	17	8	diseases	disease	NNS
cord-302316-raf5rlkq	17	9	which	which	WDT
cord-302316-raf5rlkq	17	10	complement	complement	VBP
cord-302316-raf5rlkq	17	11	or	or	CC
cord-302316-raf5rlkq	17	12	correct	correct	JJ
cord-302316-raf5rlkq	17	13	observations	observation	NNS
cord-302316-raf5rlkq	17	14	made	make	VBN
cord-302316-raf5rlkq	17	15	by	by	IN
cord-302316-raf5rlkq	17	16	clinicians	clinician	NNS
cord-302316-raf5rlkq	17	17	.	.	.
cord-302316-raf5rlkq	18	1	Surprisingly	surprisingly	RB
cord-302316-raf5rlkq	18	2	,	,	,
cord-302316-raf5rlkq	18	3	it	-PRON-	PRP
cord-302316-raf5rlkq	18	4	took	take	VBD
cord-302316-raf5rlkq	18	5	a	a	DT
cord-302316-raf5rlkq	18	6	while	while	NN
cord-302316-raf5rlkq	18	7	until	until	IN
cord-302316-raf5rlkq	18	8	the	the	DT
cord-302316-raf5rlkq	18	9	first	first	JJ
cord-302316-raf5rlkq	18	10	pathology	pathology	NN
cord-302316-raf5rlkq	18	11	reports	report	NNS
cord-302316-raf5rlkq	18	12	were	be	VBD
cord-302316-raf5rlkq	18	13	published	publish	VBN
cord-302316-raf5rlkq	18	14	for	for	IN
cord-302316-raf5rlkq	18	15	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	18	16	patients	patient	NNS
cord-302316-raf5rlkq	18	17	.	.	.
cord-302316-raf5rlkq	19	1	This	this	DT
cord-302316-raf5rlkq	19	2	delay	delay	NN
cord-302316-raf5rlkq	19	3	is	be	VBZ
cord-302316-raf5rlkq	19	4	explained	explain	VBN
cord-302316-raf5rlkq	19	5	by	by	IN
cord-302316-raf5rlkq	19	6	the	the	DT
cord-302316-raf5rlkq	19	7	emergency	emergency	NN
cord-302316-raf5rlkq	19	8	situation	situation	NN
cord-302316-raf5rlkq	19	9	of	of	IN
cord-302316-raf5rlkq	19	10	a	a	DT
cord-302316-raf5rlkq	19	11	pandemic	pandemic	NN
cord-302316-raf5rlkq	19	12	,	,	,
cord-302316-raf5rlkq	19	13	the	the	DT
cord-302316-raf5rlkq	19	14	limited	limited	JJ
cord-302316-raf5rlkq	19	15	number	number	NN
cord-302316-raf5rlkq	19	16	of	of	IN
cord-302316-raf5rlkq	19	17	complete	complete	JJ
cord-302316-raf5rlkq	19	18	sections	section	NNS
cord-302316-raf5rlkq	19	19	that	that	WDT
cord-302316-raf5rlkq	19	20	can	can	MD
cord-302316-raf5rlkq	19	21	be	be	VB
cord-302316-raf5rlkq	19	22	conducted	conduct	VBN
cord-302316-raf5rlkq	19	23	by	by	IN
cord-302316-raf5rlkq	19	24	a	a	DT
cord-302316-raf5rlkq	19	25	pathology	pathology	NN
cord-302316-raf5rlkq	19	26	institute	institute	NN
cord-302316-raf5rlkq	19	27	,	,	,
cord-302316-raf5rlkq	19	28	biosafety	biosafety	NN
cord-302316-raf5rlkq	19	29	issues	issue	NNS
cord-302316-raf5rlkq	19	30	and	and	CC
cord-302316-raf5rlkq	19	31	a	a	DT
cord-302316-raf5rlkq	19	32	decreasing	decrease	VBG
cord-302316-raf5rlkq	19	33	role	role	NN
cord-302316-raf5rlkq	19	34	of	of	IN
cord-302316-raf5rlkq	19	35	pathology	pathology	NN
cord-302316-raf5rlkq	19	36	in	in	IN
cord-302316-raf5rlkq	19	37	medical	medical	JJ
cord-302316-raf5rlkq	19	38	research	research	NN
cord-302316-raf5rlkq	19	39	.	.	.
cord-302316-raf5rlkq	20	1	In	in	IN
cord-302316-raf5rlkq	20	2	a	a	DT
cord-302316-raf5rlkq	20	3	US	US	NNP
cord-302316-raf5rlkq	20	4	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	20	5	patient	patient	NN
cord-302316-raf5rlkq	20	6	,	,	,
cord-302316-raf5rlkq	20	7	the	the	DT
cord-302316-raf5rlkq	20	8	lungs	lung	NNS
cord-302316-raf5rlkq	20	9	were	be	VBD
cord-302316-raf5rlkq	20	10	of	of	IN
cord-302316-raf5rlkq	20	11	firm	firm	JJ
cord-302316-raf5rlkq	20	12	consistency	consistency	NN
cord-302316-raf5rlkq	20	13	and	and	CC
cord-302316-raf5rlkq	20	14	heavy	heavy	JJ
cord-302316-raf5rlkq	20	15	with	with	IN
cord-302316-raf5rlkq	20	16	oedema	oedema	NN
cord-302316-raf5rlkq	20	17	.	.	.
cord-302316-raf5rlkq	21	1	Upon	upon	IN
cord-302316-raf5rlkq	21	2	histological	histological	JJ
cord-302316-raf5rlkq	21	3	analysis	analysis	NN
cord-302316-raf5rlkq	21	4	,	,	,
cord-302316-raf5rlkq	21	5	diffuse	diffuse	VB
cord-302316-raf5rlkq	21	6	alveolar	alveolar	NN
cord-302316-raf5rlkq	21	7	damage	damage	NN
cord-302316-raf5rlkq	21	8	(	(	-LRB-
cord-302316-raf5rlkq	21	9	DAD	DAD	NNP
cord-302316-raf5rlkq	21	10	)	)	-RRB-
cord-302316-raf5rlkq	21	11	was	be	VBD
cord-302316-raf5rlkq	21	12	diagnosed	diagnose	VBN
cord-302316-raf5rlkq	21	13	.	.	.
cord-302316-raf5rlkq	22	1	Thrombi	Thrombi	NNP
cord-302316-raf5rlkq	22	2	were	be	VBD
cord-302316-raf5rlkq	22	3	seen	see	VBN
cord-302316-raf5rlkq	22	4	in	in	IN
cord-302316-raf5rlkq	22	5	small	small	JJ
cord-302316-raf5rlkq	22	6	lung	lung	NN
cord-302316-raf5rlkq	22	7	arteries	artery	NNS
cord-302316-raf5rlkq	22	8	,	,	,
cord-302316-raf5rlkq	22	9	and	and	CC
cord-302316-raf5rlkq	22	10	there	there	EX
cord-302316-raf5rlkq	22	11	was	be	VBD
cord-302316-raf5rlkq	22	12	congestion	congestion	NN
cord-302316-raf5rlkq	22	13	in	in	IN
cord-302316-raf5rlkq	22	14	capillaries	capillary	NNS
cord-302316-raf5rlkq	22	15	.	.	.
cord-302316-raf5rlkq	23	1	Alveoli	Alveoli	NNP
cord-302316-raf5rlkq	23	2	showed	show	VBD
cord-302316-raf5rlkq	23	3	hyaline	hyaline	JJ
cord-302316-raf5rlkq	23	4	membrane	membrane	NN
cord-302316-raf5rlkq	23	5	formation	formation	NN
cord-302316-raf5rlkq	23	6	.	.	.
cord-302316-raf5rlkq	24	1	The	the	DT
cord-302316-raf5rlkq	24	2	lung	lung	NN
cord-302316-raf5rlkq	24	3	tissue	tissue	NN
cord-302316-raf5rlkq	24	4	displayed	display	VBD
cord-302316-raf5rlkq	24	5	chronic	chronic	JJ
cord-302316-raf5rlkq	24	6	inflammation	inflammation	NN
cord-302316-raf5rlkq	24	7	with	with	IN
cord-302316-raf5rlkq	24	8	invasion	invasion	NN
cord-302316-raf5rlkq	24	9	of	of	IN
cord-302316-raf5rlkq	24	10	T	t	NN
cord-302316-raf5rlkq	24	11	lymphocytes	lymphocyte	NNS
cord-302316-raf5rlkq	24	12	.	.	.
cord-302316-raf5rlkq	25	1	The	the	DT
cord-302316-raf5rlkq	25	2	patient	patient	NN
cord-302316-raf5rlkq	25	3	died	die	VBD
cord-302316-raf5rlkq	25	4	of	of	IN
cord-302316-raf5rlkq	25	5	cardiac	cardiac	JJ
cord-302316-raf5rlkq	25	6	arrest	arrest	NN
cord-302316-raf5rlkq	25	7	(	(	-LRB-
cord-302316-raf5rlkq	25	8	Barton	Barton	NNP
cord-302316-raf5rlkq	25	9	et	et	NNP
cord-302316-raf5rlkq	25	10	al	al	NNP
cord-302316-raf5rlkq	25	11	.	.	NNP
cord-302316-raf5rlkq	25	12	,	,	,
cord-302316-raf5rlkq	25	13	2020	2020	CD
cord-302316-raf5rlkq	25	14	)	)	-RRB-
cord-302316-raf5rlkq	25	15	.	.	.
cord-302316-raf5rlkq	26	1	A	a	DT
cord-302316-raf5rlkq	26	2	Chinese	chinese	JJ
cord-302316-raf5rlkq	26	3	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	26	4	patient	patient	NN
cord-302316-raf5rlkq	26	5	showed	show	VBD
cord-302316-raf5rlkq	26	6	,	,	,
cord-302316-raf5rlkq	26	7	likewise	likewise	RB
cord-302316-raf5rlkq	26	8	:	:	:
cord-302316-raf5rlkq	26	9	DAD	DAD	NNP
cord-302316-raf5rlkq	26	10	,	,	,
cord-302316-raf5rlkq	26	11	hyaline	hyaline	JJ
cord-302316-raf5rlkq	26	12	membranes	membrane	NNS
cord-302316-raf5rlkq	26	13	and	and	CC
cord-302316-raf5rlkq	26	14	pulmonary	pulmonary	JJ
cord-302316-raf5rlkq	26	15	oedema	oedema	NN
cord-302316-raf5rlkq	26	16	together	together	RB
cord-302316-raf5rlkq	26	17	with	with	IN
cord-302316-raf5rlkq	26	18	inflammatory	inflammatory	JJ
cord-302316-raf5rlkq	26	19	infiltrates	infiltrate	NNS
cord-302316-raf5rlkq	26	20	and	and	CC
cord-302316-raf5rlkq	26	21	multinuclear	multinuclear	NN
cord-302316-raf5rlkq	26	22	syncytia	syncytia	NN
cord-302316-raf5rlkq	26	23	,	,	,
cord-302316-raf5rlkq	26	24	typical	typical	JJ
cord-302316-raf5rlkq	26	25	cytopathic	cytopathic	JJ
cord-302316-raf5rlkq	26	26	effects	effect	NNS
cord-302316-raf5rlkq	26	27	of	of	IN
cord-302316-raf5rlkq	26	28	coronaviruses	coronaviruse	NNS
cord-302316-raf5rlkq	26	29	.	.	.
cord-302316-raf5rlkq	27	1	The	the	DT
cord-302316-raf5rlkq	27	2	patient	patient	NN
cord-302316-raf5rlkq	27	3	showed	show	VBD
cord-302316-raf5rlkq	27	4	overactive	overactive	JJ
cord-302316-raf5rlkq	27	5	T	t	NN
cord-302316-raf5rlkq	27	6	cells	cell	NNS
cord-302316-raf5rlkq	27	7	with	with	IN
cord-302316-raf5rlkq	27	8	a	a	DT
cord-302316-raf5rlkq	27	9	marked	marked	JJ
cord-302316-raf5rlkq	27	10	increase	increase	NN
cord-302316-raf5rlkq	27	11	in	in	IN
cord-302316-raf5rlkq	27	12	Th17	Th17	NNP
cord-302316-raf5rlkq	27	13	cells	cell	NNS
cord-302316-raf5rlkq	27	14	and	and	CC
cord-302316-raf5rlkq	27	15	high	high	JJ
cord-302316-raf5rlkq	27	16	cytotoxicity	cytotoxicity	NN
cord-302316-raf5rlkq	27	17	of	of	IN
cord-302316-raf5rlkq	27	18	CD8	CD8	NNP
cord-302316-raf5rlkq	27	19	T	T	NNP
cord-302316-raf5rlkq	27	20	cells	cell	NNS
cord-302316-raf5rlkq	27	21	,	,	,
cord-302316-raf5rlkq	27	22	potentially	potentially	RB
cord-302316-raf5rlkq	27	23	explaining	explain	VBG
cord-302316-raf5rlkq	27	24	the	the	DT
cord-302316-raf5rlkq	27	25	severe	severe	JJ
cord-302316-raf5rlkq	27	26	immune	immune	JJ
cord-302316-raf5rlkq	27	27	injury	injury	NN
cord-302316-raf5rlkq	27	28	seen	see	VBN
cord-302316-raf5rlkq	27	29	in	in	IN
cord-302316-raf5rlkq	27	30	the	the	DT
cord-302316-raf5rlkq	27	31	lung	lung	NN
cord-302316-raf5rlkq	27	32	of	of	IN
cord-302316-raf5rlkq	27	33	this	this	DT
cord-302316-raf5rlkq	27	34	patient	patient	NN
cord-302316-raf5rlkq	27	35	.	.	.
cord-302316-raf5rlkq	28	1	The	the	DT
cord-302316-raf5rlkq	28	2	first	first	JJ
cord-302316-raf5rlkq	28	3	larger	large	JJR
cord-302316-raf5rlkq	28	4	series	series	NN
cord-302316-raf5rlkq	28	5	of	of	IN
cord-302316-raf5rlkq	28	6	autopsies	autopsy	NNS
cord-302316-raf5rlkq	28	7	was	be	VBD
cord-302316-raf5rlkq	28	8	published	publish	VBN
cord-302316-raf5rlkq	28	9	for	for	IN
cord-302316-raf5rlkq	28	10	12	12	CD
cord-302316-raf5rlkq	28	11	German	german	JJ
cord-302316-raf5rlkq	28	12	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	28	13	patients	patient	NNS
cord-302316-raf5rlkq	28	14	.	.	.
cord-302316-raf5rlkq	29	1	Their	-PRON-	PRP$
cord-302316-raf5rlkq	29	2	average	average	JJ
cord-302316-raf5rlkq	29	3	age	age	NN
cord-302316-raf5rlkq	29	4	was	be	VBD
cord-302316-raf5rlkq	29	5	73	73	CD
cord-302316-raf5rlkq	29	6	years	year	NNS
cord-302316-raf5rlkq	29	7	,	,	,
cord-302316-raf5rlkq	29	8	and	and	CC
cord-302316-raf5rlkq	29	9	most	most	JJS
cord-302316-raf5rlkq	29	10	were	be	VBD
cord-302316-raf5rlkq	29	11	obese	obese	JJ
cord-302316-raf5rlkq	29	12	.	.	.
cord-302316-raf5rlkq	30	1	Deep	deep	JJ
cord-302316-raf5rlkq	30	2	venous	venous	JJ
cord-302316-raf5rlkq	30	3	thrombosis	thrombosis	NN
cord-302316-raf5rlkq	30	4	was	be	VBD
cord-302316-raf5rlkq	30	5	found	find	VBN
cord-302316-raf5rlkq	30	6	in	in	IN
cord-302316-raf5rlkq	30	7	7	7	CD
cord-302316-raf5rlkq	30	8	patients	patient	NNS
cord-302316-raf5rlkq	30	9	that	that	WDT
cord-302316-raf5rlkq	30	10	had	have	VBD
cord-302316-raf5rlkq	30	11	not	not	RB
cord-302316-raf5rlkq	30	12	been	be	VBN
cord-302316-raf5rlkq	30	13	suspected	suspect	VBN
cord-302316-raf5rlkq	30	14	before	before	IN
cord-302316-raf5rlkq	30	15	death	death	NN
cord-302316-raf5rlkq	30	16	.	.	.
cord-302316-raf5rlkq	31	1	Pulmonary	pulmonary	JJ
cord-302316-raf5rlkq	31	2	embolism	embolism	NN
cord-302316-raf5rlkq	31	3	was	be	VBD
cord-302316-raf5rlkq	31	4	the	the	DT
cord-302316-raf5rlkq	31	5	cause	cause	NN
cord-302316-raf5rlkq	31	6	of	of	IN
cord-302316-raf5rlkq	31	7	death	death	NN
cord-302316-raf5rlkq	31	8	in	in	IN
cord-302316-raf5rlkq	31	9	4	4	CD
cord-302316-raf5rlkq	31	10	patients	patient	NNS
cord-302316-raf5rlkq	31	11	.	.	.
cord-302316-raf5rlkq	32	1	The	the	DT
cord-302316-raf5rlkq	32	2	thrombi	thrombi	NN
cord-302316-raf5rlkq	32	3	were	be	VBD
cord-302316-raf5rlkq	32	4	derived	derive	VBN
cord-302316-raf5rlkq	32	5	from	from	IN
cord-302316-raf5rlkq	32	6	deep	deep	JJ
cord-302316-raf5rlkq	32	7	veins	vein	NNS
cord-302316-raf5rlkq	32	8	in	in	IN
cord-302316-raf5rlkq	32	9	the	the	DT
cord-302316-raf5rlkq	32	10	lower	low	JJR
cord-302316-raf5rlkq	32	11	extremities	extremity	NNS
cord-302316-raf5rlkq	32	12	.	.	.
cord-302316-raf5rlkq	33	1	In	in	IN
cord-302316-raf5rlkq	33	2	all	all	DT
cord-302316-raf5rlkq	33	3	cases	case	NNS
cord-302316-raf5rlkq	33	4	,	,	,
cord-302316-raf5rlkq	33	5	the	the	DT
cord-302316-raf5rlkq	33	6	cause	cause	NN
cord-302316-raf5rlkq	33	7	of	of	IN
cord-302316-raf5rlkq	33	8	death	death	NN
cord-302316-raf5rlkq	33	9	was	be	VBD
cord-302316-raf5rlkq	33	10	found	find	VBN
cord-302316-raf5rlkq	33	11	in	in	IN
cord-302316-raf5rlkq	33	12	the	the	DT
cord-302316-raf5rlkq	33	13	lungs	lung	NNS
cord-302316-raf5rlkq	33	14	which	which	WDT
cord-302316-raf5rlkq	33	15	were	be	VBD
cord-302316-raf5rlkq	33	16	congested	congested	JJ
cord-302316-raf5rlkq	33	17	and	and	CC
cord-302316-raf5rlkq	33	18	heavy	heavy	JJ
cord-302316-raf5rlkq	33	19	,	,	,
cord-302316-raf5rlkq	33	20	weighing	weigh	VBG
cord-302316-raf5rlkq	33	21	2	2	CD
cord-302316-raf5rlkq	33	22	kg	kg	NNS
cord-302316-raf5rlkq	33	23	instead	instead	RB
cord-302316-raf5rlkq	33	24	of	of	IN
cord-302316-raf5rlkq	33	25	800	800	CD
cord-302316-raf5rlkq	33	26	g.	g.	NNP
cord-302316-raf5rlkq	34	1	At	at	IN
cord-302316-raf5rlkq	34	2	a	a	DT
cord-302316-raf5rlkq	34	3	histological	histological	JJ
cord-302316-raf5rlkq	34	4	level	level	NN
cord-302316-raf5rlkq	34	5	,	,	,
cord-302316-raf5rlkq	34	6	diffuse	diffuse	VB
cord-302316-raf5rlkq	34	7	alveolar	alveolar	JJ
cord-302316-raf5rlkq	34	8	damage	damage	NN
cord-302316-raf5rlkq	34	9	was	be	VBD
cord-302316-raf5rlkq	34	10	seen	see	VBN
cord-302316-raf5rlkq	34	11	in	in	IN
cord-302316-raf5rlkq	34	12	8	8	CD
cord-302316-raf5rlkq	34	13	patients	patient	NNS
cord-302316-raf5rlkq	34	14	.	.	.
cord-302316-raf5rlkq	35	1	Viral	Viral	NNP
cord-302316-raf5rlkq	35	2	RNA	RNA	NNP
cord-302316-raf5rlkq	35	3	was	be	VBD
cord-302316-raf5rlkq	35	4	detected	detect	VBN
cord-302316-raf5rlkq	35	5	with	with	IN
cord-302316-raf5rlkq	35	6	high	high	JJ
cord-302316-raf5rlkq	35	7	titres	titre	NNS
cord-302316-raf5rlkq	35	8	in	in	IN
cord-302316-raf5rlkq	35	9	liver	liver	NN
cord-302316-raf5rlkq	35	10	,	,	,
cord-302316-raf5rlkq	35	11	heart	heart	NN
cord-302316-raf5rlkq	35	12	and	and	CC
cord-302316-raf5rlkq	35	13	kidney	kidney	NN
cord-302316-raf5rlkq	35	14	.	.	.
cord-302316-raf5rlkq	36	1	Clinical	clinical	JJ
cord-302316-raf5rlkq	36	2	chemistry	chemistry	NN
cord-302316-raf5rlkq	36	3	showed	show	VBD
cord-302316-raf5rlkq	36	4	increased	increase	VBN
cord-302316-raf5rlkq	36	5	levels	level	NNS
cord-302316-raf5rlkq	36	6	of	of	IN
cord-302316-raf5rlkq	36	7	lactate	lactate	NN
cord-302316-raf5rlkq	36	8	dehydrogenase	dehydrogenase	NN
cord-302316-raf5rlkq	36	9	,	,	,
cord-302316-raf5rlkq	36	10	D	d	NN
cord-302316-raf5rlkq	36	11	-	-	HYPH
cord-302316-raf5rlkq	36	12	dimer	dimer	NN
cord-302316-raf5rlkq	36	13	and	and	CC
cord-302316-raf5rlkq	36	14	C	c	NN
cord-302316-raf5rlkq	36	15	-	-	HYPH
cord-302316-raf5rlkq	36	16	reactive	reactive	JJ
cord-302316-raf5rlkq	36	17	protein	protein	NN
cord-302316-raf5rlkq	36	18	,	,	,
cord-302316-raf5rlkq	36	19	suggesting	suggest	VBG
cord-302316-raf5rlkq	36	20	coagulopathy	coagulopathy	NN
cord-302316-raf5rlkq	36	21	as	as	IN
cord-302316-raf5rlkq	36	22	a	a	DT
cord-302316-raf5rlkq	36	23	complication	complication	NN
cord-302316-raf5rlkq	36	24	in	in	IN
cord-302316-raf5rlkq	36	25	these	these	DT
cord-302316-raf5rlkq	36	26	severe	severe	JJ
cord-302316-raf5rlkq	36	27	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	36	28	cases	case	NNS
cord-302316-raf5rlkq	36	29	(	(	-LRB-
cord-302316-raf5rlkq	36	30	Wichmann	Wichmann	NNP
cord-302316-raf5rlkq	36	31	et	et	NNP
cord-302316-raf5rlkq	36	32	al	al	NNP
cord-302316-raf5rlkq	36	33	.	.	NNP
cord-302316-raf5rlkq	36	34	,	,	,
cord-302316-raf5rlkq	36	35	2020	2020	CD
cord-302316-raf5rlkq	36	36	)	)	-RRB-
cord-302316-raf5rlkq	36	37	.	.	.
cord-302316-raf5rlkq	37	1	Interestingly	interestingly	RB
cord-302316-raf5rlkq	37	2	,	,	,
cord-302316-raf5rlkq	37	3	obesity	obesity	NN
cord-302316-raf5rlkq	37	4	is	be	VBZ
cord-302316-raf5rlkq	37	5	increasingly	increasingly	RB
cord-302316-raf5rlkq	37	6	seen	see	VBN
cord-302316-raf5rlkq	37	7	as	as	IN
cord-302316-raf5rlkq	37	8	a	a	DT
cord-302316-raf5rlkq	37	9	risk	risk	NN
cord-302316-raf5rlkq	37	10	factor	factor	NN
cord-302316-raf5rlkq	37	11	for	for	IN
cord-302316-raf5rlkq	37	12	severe	severe	JJ
cord-302316-raf5rlkq	37	13	disease	disease	NN
cord-302316-raf5rlkq	37	14	.	.	.
cord-302316-raf5rlkq	38	1	In	in	IN
cord-302316-raf5rlkq	38	2	a	a	DT
cord-302316-raf5rlkq	38	3	retrospective	retrospective	JJ
cord-302316-raf5rlkq	38	4	study	study	NN
cord-302316-raf5rlkq	38	5	with	with	IN
cord-302316-raf5rlkq	38	6	3615	3615	CD
cord-302316-raf5rlkq	38	7	Covid-19	covid-19	NN
cord-302316-raf5rlkq	38	8	patients	patient	NNS
cord-302316-raf5rlkq	38	9	from	from	IN
cord-302316-raf5rlkq	38	10	New	New	NNP
cord-302316-raf5rlkq	38	11	York	York	NNP
cord-302316-raf5rlkq	38	12	City	City	NNP
cord-302316-raf5rlkq	38	13	,	,	,
cord-302316-raf5rlkq	38	14	clinicians	clinician	NNS
cord-302316-raf5rlkq	38	15	had	have	VBD
cord-302316-raf5rlkq	38	16	described	describe	VBN
cord-302316-raf5rlkq	38	17	obesity	obesity	NN
cord-302316-raf5rlkq	38	18	as	as	IN
cord-302316-raf5rlkq	38	19	a	a	DT
cord-302316-raf5rlkq	38	20	risk	risk	NN
cord-302316-raf5rlkq	38	21	factor	factor	NN
cord-302316-raf5rlkq	38	22	for	for	IN
cord-302316-raf5rlkq	38	23	intensive	intensive	JJ
cord-302316-raf5rlkq	38	24	care	care	NN
cord-302316-raf5rlkq	38	25	need	need	NN
cord-302316-raf5rlkq	38	26	(	(	-LRB-
cord-302316-raf5rlkq	38	27	OR	or	CC
cord-302316-raf5rlkq	38	28	1.8	1.8	CD
cord-302316-raf5rlkq	38	29	to	to	IN
cord-302316-raf5rlkq	38	30	3.6	3.6	CD
cord-302316-raf5rlkq	38	31	)	)	-RRB-
cord-302316-raf5rlkq	38	32	in	in	IN
cord-302316-raf5rlkq	38	33	patients	patient	NNS
cord-302316-raf5rlkq	38	34	<	<	NNP
cord-302316-raf5rlkq	38	35	60	60	CD
cord-302316-raf5rlkq	38	36	years	year	NNS
cord-302316-raf5rlkq	39	1	(	(	-LRB-
cord-302316-raf5rlkq	39	2	Lighter	light	JJR
cord-302316-raf5rlkq	39	3	et	et	NNP
cord-302316-raf5rlkq	39	4	al	al	NNP
cord-302316-raf5rlkq	39	5	.	.	NNP
cord-302316-raf5rlkq	39	6	,	,	,
cord-302316-raf5rlkq	39	7	2020	2020	CD
cord-302316-raf5rlkq	39	8	)	)	-RRB-
cord-302316-raf5rlkq	39	9	.	.	.
cord-302316-raf5rlkq	40	1	Clinicians	clinician	NNS
cord-302316-raf5rlkq	40	2	had	have	VBD
cord-302316-raf5rlkq	40	3	already	already	RB
cord-302316-raf5rlkq	40	4	elaborated	elaborate	VBN
cord-302316-raf5rlkq	40	5	concepts	concept	NNS
cord-302316-raf5rlkq	40	6	for	for	IN
cord-302316-raf5rlkq	40	7	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	40	8	pathogenesis	pathogenesis	NN
cord-302316-raf5rlkq	40	9	that	that	WDT
cord-302316-raf5rlkq	40	10	concur	concur	VBP
cord-302316-raf5rlkq	40	11	with	with	IN
cord-302316-raf5rlkq	40	12	these	these	DT
cord-302316-raf5rlkq	40	13	observations	observation	NNS
cord-302316-raf5rlkq	40	14	from	from	IN
cord-302316-raf5rlkq	40	15	the	the	DT
cord-302316-raf5rlkq	40	16	autopsies	autopsy	NNS
cord-302316-raf5rlkq	40	17	.	.	.
cord-302316-raf5rlkq	41	1	In	in	IN
cord-302316-raf5rlkq	41	2	one	one	CD
cord-302316-raf5rlkq	41	3	model	model	NN
cord-302316-raf5rlkq	41	4	,	,	,
cord-302316-raf5rlkq	41	5	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	41	6	patients	patient	NNS
cord-302316-raf5rlkq	41	7	show	show	VBP
cord-302316-raf5rlkq	41	8	a	a	DT
cord-302316-raf5rlkq	41	9	diffuse	diffuse	JJ
cord-302316-raf5rlkq	41	10	pulmonary	pulmonary	JJ
cord-302316-raf5rlkq	41	11	intravascular	intravascular	JJ
cord-302316-raf5rlkq	41	12	coagulopathy	coagulopathy	NN
cord-302316-raf5rlkq	41	13	which	which	WDT
cord-302316-raf5rlkq	41	14	isin	isin	NNP
cord-302316-raf5rlkq	41	15	contrast	contrast	NN
cord-302316-raf5rlkq	41	16	to	to	IN
cord-302316-raf5rlkq	41	17	disseminated	disseminate	VBN
cord-302316-raf5rlkq	41	18	intravascular	intravascular	JJ
cord-302316-raf5rlkq	41	19	coagulation	coagulation	NN
cord-302316-raf5rlkq	41	20	(	(	-LRB-
cord-302316-raf5rlkq	41	21	DIC)restricted	dic)restricte	VBN
cord-302316-raf5rlkq	41	22	to	to	IN
cord-302316-raf5rlkq	41	23	the	the	DT
cord-302316-raf5rlkq	41	24	lung	lung	NN
cord-302316-raf5rlkq	41	25	vascular	vascular	JJ
cord-302316-raf5rlkq	41	26	bed	bed	NN
cord-302316-raf5rlkq	41	27	.	.	.
cord-302316-raf5rlkq	42	1	The	the	DT
cord-302316-raf5rlkq	42	2	increased	increase	VBN
cord-302316-raf5rlkq	42	3	D	d	NN
cord-302316-raf5rlkq	42	4	-	-	HYPH
cord-302316-raf5rlkq	42	5	dimer	dimer	NN
cord-302316-raf5rlkq	42	6	concentrations	concentration	NNS
cord-302316-raf5rlkq	42	7	reflect	reflect	VBP
cord-302316-raf5rlkq	42	8	the	the	DT
cord-302316-raf5rlkq	42	9	pulmonary	pulmonary	JJ
cord-302316-raf5rlkq	42	10	thrombosis	thrombosis	NN
cord-302316-raf5rlkq	42	11	followed	follow	VBN
cord-302316-raf5rlkq	42	12	by	by	IN
cord-302316-raf5rlkq	42	13	fibrinolysis	fibrinolysis	NNP
cord-302316-raf5rlkq	42	14	,	,	,
cord-302316-raf5rlkq	42	15	and	and	CC
cord-302316-raf5rlkq	42	16	the	the	DT
cord-302316-raf5rlkq	42	17	elevated	elevated	JJ
cord-302316-raf5rlkq	42	18	cardiac	cardiac	JJ
cord-302316-raf5rlkq	42	19	enzymes	enzyme	NNS
cord-302316-raf5rlkq	42	20	reflect	reflect	VBP
cord-302316-raf5rlkq	42	21	the	the	DT
cord-302316-raf5rlkq	42	22	stress	stress	NN
cord-302316-raf5rlkq	42	23	imposed	impose	VBN
cord-302316-raf5rlkq	42	24	on	on	IN
cord-302316-raf5rlkq	42	25	the	the	DT
cord-302316-raf5rlkq	42	26	heart	heart	NN
cord-302316-raf5rlkq	42	27	ventricle	ventricle	NN
cord-302316-raf5rlkq	42	28	by	by	IN
cord-302316-raf5rlkq	42	29	pulmonary	pulmonary	JJ
cord-302316-raf5rlkq	42	30	hypertension	hypertension	NN
cord-302316-raf5rlkq	42	31	.	.	.
cord-302316-raf5rlkq	43	1	According	accord	VBG
cord-302316-raf5rlkq	43	2	to	to	IN
cord-302316-raf5rlkq	43	3	this	this	DT
cord-302316-raf5rlkq	43	4	model	model	NN
cord-302316-raf5rlkq	43	5	,	,	,
cord-302316-raf5rlkq	43	6	it	-PRON-	PRP
cord-302316-raf5rlkq	43	7	is	be	VBZ
cord-302316-raf5rlkq	43	8	not	not	RB
cord-302316-raf5rlkq	43	9	the	the	DT
cord-302316-raf5rlkq	43	10	viral	viral	JJ
cord-302316-raf5rlkq	43	11	infection	infection	NN
cord-302316-raf5rlkq	43	12	but	but	CC
cord-302316-raf5rlkq	43	13	the	the	DT
cord-302316-raf5rlkq	43	14	vascular	vascular	JJ
cord-302316-raf5rlkq	43	15	thrombosis	thrombosis	NN
cord-302316-raf5rlkq	43	16	induced	induce	VBN
cord-302316-raf5rlkq	43	17	by	by	IN
cord-302316-raf5rlkq	43	18	the	the	DT
cord-302316-raf5rlkq	43	19	infection	infection	NN
cord-302316-raf5rlkq	43	20	which	which	WDT
cord-302316-raf5rlkq	43	21	underlies	underlie	VBZ
cord-302316-raf5rlkq	43	22	the	the	DT
cord-302316-raf5rlkq	43	23	severe	severe	JJ
cord-302316-raf5rlkq	43	24	pathology	pathology	NN
cord-302316-raf5rlkq	43	25	.	.	.
cord-302316-raf5rlkq	44	1	The	the	DT
cord-302316-raf5rlkq	44	2	coagulopathy	coagulopathy	NN
cord-302316-raf5rlkq	44	3	might	may	MD
cord-302316-raf5rlkq	44	4	be	be	VB
cord-302316-raf5rlkq	44	5	caused	cause	VBN
cord-302316-raf5rlkq	44	6	by	by	IN
cord-302316-raf5rlkq	44	7	an	an	DT
cord-302316-raf5rlkq	44	8	activation	activation	NN
cord-302316-raf5rlkq	44	9	of	of	IN
cord-302316-raf5rlkq	44	10	an	an	DT
cord-302316-raf5rlkq	44	11	immune	immune	JJ
cord-302316-raf5rlkq	44	12	mechanism	mechanism	NN
cord-302316-raf5rlkq	44	13	involving	involve	VBG
cord-302316-raf5rlkq	44	14	macrophages	macrophage	NNS
cord-302316-raf5rlkq	44	15	as	as	IN
cord-302316-raf5rlkq	44	16	observed	observe	VBN
cord-302316-raf5rlkq	44	17	in	in	IN
cord-302316-raf5rlkq	44	18	'	'	``
cord-302316-raf5rlkq	44	19	macrophage	macrophage	NN
cord-302316-raf5rlkq	44	20	activation	activation	NN
cord-302316-raf5rlkq	44	21	syndrome	syndrome	NN
cord-302316-raf5rlkq	44	22	'	'	''
cord-302316-raf5rlkq	44	23	(	(	-LRB-
cord-302316-raf5rlkq	44	24	MAS	MAS	NNP
cord-302316-raf5rlkq	44	25	)	)	-RRB-
cord-302316-raf5rlkq	44	26	,	,	,
cord-302316-raf5rlkq	44	27	suggesting	suggest	VBG
cord-302316-raf5rlkq	44	28	targets	target	NNS
cord-302316-raf5rlkq	44	29	for	for	IN
cord-302316-raf5rlkq	44	30	drug	drug	NN
cord-302316-raf5rlkq	44	31	intervention	intervention	NN
cord-302316-raf5rlkq	44	32	(	(	-LRB-
cord-302316-raf5rlkq	44	33	McGonagle	McGonagle	NNP
cord-302316-raf5rlkq	44	34	et	et	NNP
cord-302316-raf5rlkq	44	35	al	al	NNP
cord-302316-raf5rlkq	44	36	.	.	NNP
cord-302316-raf5rlkq	44	37	,	,	,
cord-302316-raf5rlkq	44	38	2020	2020	CD
cord-302316-raf5rlkq	44	39	)	)	-RRB-
cord-302316-raf5rlkq	44	40	.	.	.
cord-302316-raf5rlkq	45	1	Another	another	DT
cord-302316-raf5rlkq	45	2	popular	popular	JJ
cord-302316-raf5rlkq	45	3	hypothesis	hypothesis	NN
cord-302316-raf5rlkq	45	4	for	for	IN
cord-302316-raf5rlkq	45	5	severe	severe	JJ
cord-302316-raf5rlkq	45	6	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	45	7	pathology	pathology	NN
cord-302316-raf5rlkq	45	8	is	be	VBZ
cord-302316-raf5rlkq	45	9	based	base	VBN
cord-302316-raf5rlkq	45	10	on	on	IN
cord-302316-raf5rlkq	45	11	observations	observation	NNS
cord-302316-raf5rlkq	45	12	of	of	IN
cord-302316-raf5rlkq	45	13	acute	acute	JJ
cord-302316-raf5rlkq	45	14	respiratory	respiratory	JJ
cord-302316-raf5rlkq	45	15	distress	distress	NN
cord-302316-raf5rlkq	45	16	syndrome	syndrome	NN
cord-302316-raf5rlkq	45	17	(	(	-LRB-
cord-302316-raf5rlkq	45	18	ARDS	ARDS	NNP
cord-302316-raf5rlkq	45	19	)	)	-RRB-
cord-302316-raf5rlkq	45	20	where	where	WRB
cord-302316-raf5rlkq	45	21	pneumonia	pneumonia	NN
cord-302316-raf5rlkq	45	22	,	,	,
cord-302316-raf5rlkq	45	23	sepsis	sepsis	NN
cord-302316-raf5rlkq	45	24	or	or	CC
cord-302316-raf5rlkq	45	25	aspiration	aspiration	NN
cord-302316-raf5rlkq	45	26	pneumonia	pneumonia	NN
cord-302316-raf5rlkq	45	27	lead	lead	VBP
cord-302316-raf5rlkq	45	28	via	via	IN
cord-302316-raf5rlkq	45	29	a	a	DT
cord-302316-raf5rlkq	45	30	release	release	NN
cord-302316-raf5rlkq	45	31	of	of	IN
cord-302316-raf5rlkq	45	32	pro	pro	JJ
cord-302316-raf5rlkq	45	33	-	-	JJ
cord-302316-raf5rlkq	45	34	inflammatory	inflammatory	JJ
cord-302316-raf5rlkq	45	35	cytokines	cytokine	NNS
cord-302316-raf5rlkq	45	36	from	from	IN
cord-302316-raf5rlkq	45	37	immune	immune	JJ
cord-302316-raf5rlkq	45	38	cells	cell	NNS
cord-302316-raf5rlkq	45	39	(	(	-LRB-
cord-302316-raf5rlkq	45	40	'	'	``
cord-302316-raf5rlkq	45	41	cytokine	cytokine	NN
cord-302316-raf5rlkq	45	42	storm	storm	NN
cord-302316-raf5rlkq	45	43	'	'	''
cord-302316-raf5rlkq	45	44	)	)	-RRB-
cord-302316-raf5rlkq	45	45	to	to	IN
cord-302316-raf5rlkq	45	46	severe	severe	JJ
cord-302316-raf5rlkq	45	47	lung	lung	NN
cord-302316-raf5rlkq	45	48	damage	damage	NN
cord-302316-raf5rlkq	45	49	.	.	.
cord-302316-raf5rlkq	46	1	In	in	IN
cord-302316-raf5rlkq	46	2	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	46	3	,	,	,
cord-302316-raf5rlkq	46	4	the	the	DT
cord-302316-raf5rlkq	46	5	recruitment	recruitment	NN
cord-302316-raf5rlkq	46	6	of	of	IN
cord-302316-raf5rlkq	46	7	the	the	DT
cord-302316-raf5rlkq	46	8	cellular	cellular	JJ
cord-302316-raf5rlkq	46	9	virus	virus	NN
cord-302316-raf5rlkq	46	10	receptor	receptor	NN
cord-302316-raf5rlkq	46	11	by	by	IN
cord-302316-raf5rlkq	46	12	the	the	DT
cord-302316-raf5rlkq	46	13	infecting	infect	VBG
cord-302316-raf5rlkq	46	14	virus	virus	NN
cord-302316-raf5rlkq	46	15	causes	cause	VBZ
cord-302316-raf5rlkq	46	16	disappearance	disappearance	NN
cord-302316-raf5rlkq	46	17	of	of	IN
cord-302316-raf5rlkq	46	18	the	the	DT
cord-302316-raf5rlkq	46	19	angiotensin	angiotensin	NN
cord-302316-raf5rlkq	46	20	-	-	HYPH
cord-302316-raf5rlkq	46	21	converting	convert	VBG
cord-302316-raf5rlkq	46	22	enzyme-2	enzyme-2	NNP
cord-302316-raf5rlkq	46	23	(	(	-LRB-
cord-302316-raf5rlkq	46	24	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	46	25	)	)	-RRB-
cord-302316-raf5rlkq	46	26	from	from	IN
cord-302316-raf5rlkq	46	27	the	the	DT
cord-302316-raf5rlkq	46	28	cell	cell	NN
cord-302316-raf5rlkq	46	29	surface	surface	NN
cord-302316-raf5rlkq	46	30	and	and	CC
cord-302316-raf5rlkq	46	31	by	by	IN
cord-302316-raf5rlkq	46	32	its	-PRON-	PRP$
cord-302316-raf5rlkq	46	33	absence	absence	NN
cord-302316-raf5rlkq	46	34	results	result	NNS
cord-302316-raf5rlkq	46	35	in	in	IN
cord-302316-raf5rlkq	46	36	an	an	DT
cord-302316-raf5rlkq	46	37	increase	increase	NN
cord-302316-raf5rlkq	46	38	in	in	IN
cord-302316-raf5rlkq	46	39	unprocessed	unprocessed	JJ
cord-302316-raf5rlkq	46	40	angiotensin	angiotensin	NN
cord-302316-raf5rlkq	46	41	2	2	CD
cord-302316-raf5rlkq	46	42	(	(	-LRB-
cord-302316-raf5rlkq	46	43	Ang	Ang	NNP
cord-302316-raf5rlkq	46	44	II	II	NNP
cord-302316-raf5rlkq	46	45	)	)	-RRB-
cord-302316-raf5rlkq	46	46	.	.	.
cord-302316-raf5rlkq	47	1	Via	via	IN
cord-302316-raf5rlkq	47	2	a	a	DT
cord-302316-raf5rlkq	47	3	cascade	cascade	NN
cord-302316-raf5rlkq	47	4	of	of	IN
cord-302316-raf5rlkq	47	5	reactions	reaction	NNS
cord-302316-raf5rlkq	47	6	involving	involve	VBG
cord-302316-raf5rlkq	47	7	the	the	DT
cord-302316-raf5rlkq	47	8	metalloproteinase	metalloproteinase	NN
cord-302316-raf5rlkq	47	9	ADAM17	adam17	NN
cord-302316-raf5rlkq	47	10	,	,	,
cord-302316-raf5rlkq	47	11	increased	increase	VBD
cord-302316-raf5rlkq	47	12	Ang	Ang	NNP
cord-302316-raf5rlkq	47	13	II	II	NNP
cord-302316-raf5rlkq	47	14	concentrations	concentration	NNS
cord-302316-raf5rlkq	47	15	induce	induce	VBP
cord-302316-raf5rlkq	47	16	the	the	DT
cord-302316-raf5rlkq	47	17	cytokines	cytokine	NNS
cord-302316-raf5rlkq	47	18	tumour	tumour	NN
cord-302316-raf5rlkq	47	19	necrosis	necrosis	NN
cord-302316-raf5rlkq	47	20	factor	factor	NN
cord-302316-raf5rlkq	47	21	alpha	alpha	NN
cord-302316-raf5rlkq	47	22	(	(	-LRB-
cord-302316-raf5rlkq	47	23	TNF	TNF	NNP
cord-302316-raf5rlkq	47	24	-	-	HYPH
cord-302316-raf5rlkq	47	25	a	a	LS
cord-302316-raf5rlkq	47	26	)	)	-RRB-
cord-302316-raf5rlkq	47	27	and	and	CC
cord-302316-raf5rlkq	47	28	interleukin	interleukin	NN
cord-302316-raf5rlkq	47	29	6	6	CD
cord-302316-raf5rlkq	47	30	(	(	-LRB-
cord-302316-raf5rlkq	47	31	IL-6	IL-6	NNP
cord-302316-raf5rlkq	47	32	)	)	-RRB-
cord-302316-raf5rlkq	47	33	which	which	WDT
cord-302316-raf5rlkq	47	34	activate	activate	VBP
cord-302316-raf5rlkq	47	35	the	the	DT
cord-302316-raf5rlkq	47	36	IL-6	IL-6	NNP
cord-302316-raf5rlkq	47	37	amplifier	amplifier	NN
cord-302316-raf5rlkq	47	38	(	(	-LRB-
cord-302316-raf5rlkq	47	39	IL-6	IL-6	NNP
cord-302316-raf5rlkq	47	40	AMP	AMP	NNP
cord-302316-raf5rlkq	47	41	)	)	-RRB-
cord-302316-raf5rlkq	47	42	,	,	,
cord-302316-raf5rlkq	47	43	leading	lead	VBG
cord-302316-raf5rlkq	47	44	to	to	IN
cord-302316-raf5rlkq	47	45	the	the	DT
cord-302316-raf5rlkq	47	46	release	release	NN
cord-302316-raf5rlkq	47	47	of	of	IN
cord-302316-raf5rlkq	47	48	inflammatory	inflammatory	JJ
cord-302316-raf5rlkq	47	49	cytokines	cytokine	NNS
cord-302316-raf5rlkq	47	50	.	.	.
cord-302316-raf5rlkq	48	1	In	in	IN
cord-302316-raf5rlkq	48	2	parallel	parallel	NN
cord-302316-raf5rlkq	48	3	,	,	,
cord-302316-raf5rlkq	48	4	the	the	DT
cord-302316-raf5rlkq	48	5	virus	virus	NN
cord-302316-raf5rlkq	48	6	induces	induce	VBZ
cord-302316-raf5rlkq	48	7	inflammatory	inflammatory	JJ
cord-302316-raf5rlkq	48	8	cytokines	cytokine	NNS
cord-302316-raf5rlkq	48	9	by	by	IN
cord-302316-raf5rlkq	48	10	activating	activate	VBG
cord-302316-raf5rlkq	48	11	the	the	DT
cord-302316-raf5rlkq	48	12	NF	nf	NN
cord-302316-raf5rlkq	48	13	-	-	HYPH
cord-302316-raf5rlkq	48	14	jB	jb	NN
cord-302316-raf5rlkq	48	15	pathway	pathway	NN
cord-302316-raf5rlkq	48	16	via	via	IN
cord-302316-raf5rlkq	48	17	pattern	pattern	NN
cord-302316-raf5rlkq	48	18	recognition	recognition	NN
cord-302316-raf5rlkq	48	19	receptors	receptor	NNS
cord-302316-raf5rlkq	48	20	(	(	-LRB-
cord-302316-raf5rlkq	48	21	PRRs	PRRs	NNP
cord-302316-raf5rlkq	48	22	)	)	-RRB-
cord-302316-raf5rlkq	48	23	.	.	.
cord-302316-raf5rlkq	49	1	This	this	DT
cord-302316-raf5rlkq	49	2	hypothesis	hypothesis	NN
cord-302316-raf5rlkq	49	3	explains	explain	VBZ
cord-302316-raf5rlkq	49	4	much	much	JJ
cord-302316-raf5rlkq	49	5	of	of	IN
cord-302316-raf5rlkq	49	6	the	the	DT
cord-302316-raf5rlkq	49	7	observed	observed	JJ
cord-302316-raf5rlkq	49	8	pathology	pathology	NN
cord-302316-raf5rlkq	49	9	in	in	IN
cord-302316-raf5rlkq	49	10	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	49	11	and	and	CC
cord-302316-raf5rlkq	49	12	suggests	suggest	VBZ
cord-302316-raf5rlkq	49	13	a	a	DT
cord-302316-raf5rlkq	49	14	number	number	NN
cord-302316-raf5rlkq	49	15	of	of	IN
cord-302316-raf5rlkq	49	16	targets	target	NNS
cord-302316-raf5rlkq	49	17	for	for	IN
cord-302316-raf5rlkq	49	18	pharmacological	pharmacological	JJ
cord-302316-raf5rlkq	49	19	intervention	intervention	NN
cord-302316-raf5rlkq	49	20	(	(	-LRB-
cord-302316-raf5rlkq	49	21	Hirano	Hirano	NNP
cord-302316-raf5rlkq	49	22	and	and	CC
cord-302316-raf5rlkq	49	23	Murakami	Murakami	NNP
cord-302316-raf5rlkq	49	24	,	,	,
cord-302316-raf5rlkq	49	25	2020	2020	CD
cord-302316-raf5rlkq	49	26	)	)	-RRB-
cord-302316-raf5rlkq	49	27	.	.	.
cord-302316-raf5rlkq	50	1	The	the	DT
cord-302316-raf5rlkq	50	2	expression	expression	NN
cord-302316-raf5rlkq	50	3	of	of	IN
cord-302316-raf5rlkq	50	4	immune	immune	JJ
cord-302316-raf5rlkq	50	5	genes	gene	NNS
cord-302316-raf5rlkq	50	6	was	be	VBD
cord-302316-raf5rlkq	50	7	studied	study	VBN
cord-302316-raf5rlkq	50	8	in	in	IN
cord-302316-raf5rlkq	50	9	3	3	CD
cord-302316-raf5rlkq	51	1	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	51	2	patients	patient	NNS
cord-302316-raf5rlkq	51	3	with	with	IN
cord-302316-raf5rlkq	51	4	severe	severe	JJ
cord-302316-raf5rlkq	51	5	,	,	,
cord-302316-raf5rlkq	51	6	moderate	moderate	JJ
cord-302316-raf5rlkq	51	7	and	and	CC
cord-302316-raf5rlkq	51	8	mild	mild	JJ
cord-302316-raf5rlkq	51	9	disease	disease	NN
cord-302316-raf5rlkq	51	10	.	.	.
cord-302316-raf5rlkq	52	1	Elevated	elevated	JJ
cord-302316-raf5rlkq	52	2	plasma	plasma	NN
cord-302316-raf5rlkq	52	3	levels	level	NNS
cord-302316-raf5rlkq	52	4	of	of	IN
cord-302316-raf5rlkq	52	5	pro	pro	JJ
cord-302316-raf5rlkq	52	6	-	-	JJ
cord-302316-raf5rlkq	52	7	inflammatory	inflammatory	JJ
cord-302316-raf5rlkq	52	8	cytokines	cytokine	NNS
cord-302316-raf5rlkq	52	9	(	(	-LRB-
cord-302316-raf5rlkq	52	10	IL-1b	IL-1b	NNS
cord-302316-raf5rlkq	52	11	,	,	,
cord-302316-raf5rlkq	52	12	IL-8	IL-8	NNP
cord-302316-raf5rlkq	52	13	and	and	CC
cord-302316-raf5rlkq	52	14	TNF	TNF	NNP
cord-302316-raf5rlkq	52	15	-	-	HYPH
cord-302316-raf5rlkq	52	16	a	a	LS
cord-302316-raf5rlkq	52	17	)	)	-RRB-
cord-302316-raf5rlkq	52	18	were	be	VBD
cord-302316-raf5rlkq	52	19	observed	observe	VBN
cord-302316-raf5rlkq	52	20	,	,	,
cord-302316-raf5rlkq	52	21	although	although	IN
cord-302316-raf5rlkq	52	22	they	-PRON-	PRP
cord-302316-raf5rlkq	52	23	occurred	occur	VBD
cord-302316-raf5rlkq	52	24	after	after	IN
cord-302316-raf5rlkq	52	25	the	the	DT
cord-302316-raf5rlkq	52	26	peak	peak	NN
cord-302316-raf5rlkq	52	27	of	of	IN
cord-302316-raf5rlkq	52	28	respiratory	respiratory	JJ
cord-302316-raf5rlkq	52	29	failure	failure	NN
cord-302316-raf5rlkq	53	1	(	(	-LRB-
cord-302316-raf5rlkq	53	2	Mehta	Mehta	NNP
cord-302316-raf5rlkq	53	3	et	et	NNP
cord-302316-raf5rlkq	53	4	al	al	NNP
cord-302316-raf5rlkq	53	5	.	.	.
cord-302316-raf5rlkq	54	1	,	,	,
cord-302316-raf5rlkq	54	2	2020	2020	CD
cord-302316-raf5rlkq	54	3	;	;	:
cord-302316-raf5rlkq	54	4	Ong	Ong	NNP
cord-302316-raf5rlkq	54	5	et	et	NNP
cord-302316-raf5rlkq	54	6	al	al	NNP
cord-302316-raf5rlkq	54	7	.	.	NNP
cord-302316-raf5rlkq	54	8	,	,	,
cord-302316-raf5rlkq	54	9	2020	2020	CD
cord-302316-raf5rlkq	54	10	)	)	-RRB-
cord-302316-raf5rlkq	54	11	.	.	.
cord-302316-raf5rlkq	55	1	Only	only	RB
cord-302316-raf5rlkq	55	2	5	5	CD
cord-302316-raf5rlkq	55	3	%	%	NN
cord-302316-raf5rlkq	55	4	of	of	IN
cord-302316-raf5rlkq	56	1	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	56	2	cases	case	NNS
cord-302316-raf5rlkq	56	3	show	show	VBP
cord-302316-raf5rlkq	56	4	severe	severe	JJ
cord-302316-raf5rlkq	56	5	infections	infection	NNS
cord-302316-raf5rlkq	56	6	that	that	WDT
cord-302316-raf5rlkq	56	7	lead	lead	VBP
cord-302316-raf5rlkq	56	8	to	to	IN
cord-302316-raf5rlkq	56	9	death	death	NN
cord-302316-raf5rlkq	56	10	in	in	IN
cord-302316-raf5rlkq	56	11	about	about	RB
cord-302316-raf5rlkq	56	12	1.4	1.4	CD
cord-302316-raf5rlkq	56	13	%	%	NN
cord-302316-raf5rlkq	56	14	of	of	IN
cord-302316-raf5rlkq	56	15	cases	case	NNS
cord-302316-raf5rlkq	56	16	from	from	IN
cord-302316-raf5rlkq	56	17	severe	severe	JJ
cord-302316-raf5rlkq	56	18	lung	lung	NN
cord-302316-raf5rlkq	56	19	injury	injury	NN
cord-302316-raf5rlkq	56	20	and	and	CC
cord-302316-raf5rlkq	56	21	multiorgan	multiorgan	NNP
cord-302316-raf5rlkq	56	22	dysfunction	dysfunction	NN
cord-302316-raf5rlkq	56	23	.	.	.
cord-302316-raf5rlkq	57	1	Chinese	chinese	JJ
cord-302316-raf5rlkq	57	2	clinicians	clinician	NNS
cord-302316-raf5rlkq	57	3	observed	observe	VBD
cord-302316-raf5rlkq	57	4	that	that	IN
cord-302316-raf5rlkq	57	5	critically	critically	RB
cord-302316-raf5rlkq	57	6	ill	ill	JJ
cord-302316-raf5rlkq	57	7	patients	patient	NNS
cord-302316-raf5rlkq	57	8	showed	show	VBD
cord-302316-raf5rlkq	57	9	signs	sign	NNS
cord-302316-raf5rlkq	57	10	of	of	IN
cord-302316-raf5rlkq	57	11	shock	shock	NN
cord-302316-raf5rlkq	57	12	with	with	IN
cord-302316-raf5rlkq	57	13	cold	cold	JJ
cord-302316-raf5rlkq	57	14	extremities	extremity	NNS
cord-302316-raf5rlkq	57	15	,	,	,
cord-302316-raf5rlkq	57	16	weak	weak	JJ
cord-302316-raf5rlkq	57	17	peripheral	peripheral	JJ
cord-302316-raf5rlkq	57	18	pulse	pulse	NN
cord-302316-raf5rlkq	57	19	,	,	,
cord-302316-raf5rlkq	57	20	metabolic	metabolic	JJ
cord-302316-raf5rlkq	57	21	acidosis	acidosis	NN
cord-302316-raf5rlkq	57	22	and	and	CC
cord-302316-raf5rlkq	57	23	microcirculation	microcirculation	NN
cord-302316-raf5rlkq	57	24	dysfunction	dysfunction	NN
cord-302316-raf5rlkq	57	25	.	.	.
cord-302316-raf5rlkq	58	1	This	this	DT
cord-302316-raf5rlkq	58	2	combination	combination	NN
cord-302316-raf5rlkq	58	3	of	of	IN
cord-302316-raf5rlkq	58	4	symptoms	symptom	NNS
cord-302316-raf5rlkq	58	5	suggests	suggest	VBZ
cord-302316-raf5rlkq	58	6	septic	septic	JJ
cord-302316-raf5rlkq	58	7	shock	shock	NN
cord-302316-raf5rlkq	58	8	,	,	,
cord-302316-raf5rlkq	58	9	but	but	CC
cord-302316-raf5rlkq	58	10	in	in	IN
cord-302316-raf5rlkq	58	11	76	76	CD
cord-302316-raf5rlkq	58	12	%	%	NN
cord-302316-raf5rlkq	58	13	of	of	IN
cord-302316-raf5rlkq	58	14	these	these	DT
cord-302316-raf5rlkq	58	15	patients	patient	NNS
cord-302316-raf5rlkq	58	16	,	,	,
cord-302316-raf5rlkq	58	17	SARS	SARS	NNP
cord-302316-raf5rlkq	58	18	-	-	HYPH
cord-302316-raf5rlkq	58	19	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	58	20	was	be	VBD
cord-302316-raf5rlkq	58	21	the	the	DT
cord-302316-raf5rlkq	58	22	only	only	JJ
cord-302316-raf5rlkq	58	23	pathogen	pathogen	NN
cord-302316-raf5rlkq	58	24	.	.	.
cord-302316-raf5rlkq	59	1	These	these	DT
cord-302316-raf5rlkq	59	2	researchers	researcher	NNS
cord-302316-raf5rlkq	59	3	propose	propose	VBP
cord-302316-raf5rlkq	59	4	'	'	``
cord-302316-raf5rlkq	59	5	viral	viral	JJ
cord-302316-raf5rlkq	59	6	sepsis	sepsis	NN
cord-302316-raf5rlkq	59	7	'	'	''
cord-302316-raf5rlkq	59	8	as	as	IN
cord-302316-raf5rlkq	59	9	the	the	DT
cord-302316-raf5rlkq	59	10	cause	cause	NN
cord-302316-raf5rlkq	59	11	for	for	IN
cord-302316-raf5rlkq	59	12	severe	severe	JJ
cord-302316-raf5rlkq	59	13	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	59	14	,	,	,
cord-302316-raf5rlkq	59	15	where	where	WRB
cord-302316-raf5rlkq	59	16	the	the	DT
cord-302316-raf5rlkq	59	17	virus	virus	NN
cord-302316-raf5rlkq	59	18	infects	infect	VBZ
cord-302316-raf5rlkq	59	19	the	the	DT
cord-302316-raf5rlkq	59	20	lymphocytes	lymphocyte	NNS
cord-302316-raf5rlkq	59	21	,	,	,
cord-302316-raf5rlkq	59	22	induces	induce	VBZ
cord-302316-raf5rlkq	59	23	detrimental	detrimental	JJ
cord-302316-raf5rlkq	59	24	immune	immune	JJ
cord-302316-raf5rlkq	59	25	reactions	reaction	NNS
cord-302316-raf5rlkq	59	26	and	and	CC
cord-302316-raf5rlkq	59	27	infects	infect	VBZ
cord-302316-raf5rlkq	59	28	vascular	vascular	JJ
cord-302316-raf5rlkq	59	29	epithelia	epithelium	NNS
cord-302316-raf5rlkq	59	30	leading	lead	VBG
cord-302316-raf5rlkq	59	31	to	to	IN
cord-302316-raf5rlkq	59	32	disseminated	disseminate	VBN
cord-302316-raf5rlkq	59	33	intravascular	intravascular	JJ
cord-302316-raf5rlkq	59	34	coagulation	coagulation	NN
cord-302316-raf5rlkq	59	35	.	.	.
cord-302316-raf5rlkq	60	1	These	these	DT
cord-302316-raf5rlkq	60	2	models	model	NNS
cord-302316-raf5rlkq	60	3	of	of	IN
cord-302316-raf5rlkq	60	4	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	60	5	pathogenesis	pathogenesis	NN
cord-302316-raf5rlkq	60	6	are	be	VBP
cord-302316-raf5rlkq	60	7	not	not	RB
cord-302316-raf5rlkq	60	8	mutually	mutually	RB
cord-302316-raf5rlkq	60	9	exclusive	exclusive	JJ
cord-302316-raf5rlkq	60	10	.	.	.
cord-302316-raf5rlkq	61	1	SARS	SARS	NNP
cord-302316-raf5rlkq	61	2	-	-	HYPH
cord-302316-raf5rlkq	61	3	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	61	4	infections	infection	NNS
cord-302316-raf5rlkq	61	5	have	have	VBP
cord-302316-raf5rlkq	61	6	a	a	DT
cord-302316-raf5rlkq	61	7	variable	variable	JJ
cord-302316-raf5rlkq	61	8	presentation	presentation	NN
cord-302316-raf5rlkq	61	9	ranging	range	VBG
cord-302316-raf5rlkq	61	10	from	from	IN
cord-302316-raf5rlkq	61	11	causing	cause	VBG
cord-302316-raf5rlkq	61	12	:	:	:
cord-302316-raf5rlkq	61	13	no	no	DT
cord-302316-raf5rlkq	61	14	symptoms	symptom	NNS
cord-302316-raf5rlkq	61	15	;	;	:
cord-302316-raf5rlkq	61	16	only	only	RB
cord-302316-raf5rlkq	61	17	mild	mild	JJ
cord-302316-raf5rlkq	61	18	symptoms	symptom	NNS
cord-302316-raf5rlkq	61	19	;	;	:
cord-302316-raf5rlkq	61	20	or	or	CC
cord-302316-raf5rlkq	61	21	severe	severe	JJ
cord-302316-raf5rlkq	61	22	disease	disease	NN
cord-302316-raf5rlkq	61	23	necessitating	necessitate	VBG
cord-302316-raf5rlkq	61	24	hospitalization	hospitalization	NN
cord-302316-raf5rlkq	61	25	,	,	,
cord-302316-raf5rlkq	61	26	if	if	IN
cord-302316-raf5rlkq	61	27	not	not	RB
cord-302316-raf5rlkq	61	28	intensive	intensive	JJ
cord-302316-raf5rlkq	61	29	care	care	NN
cord-302316-raf5rlkq	61	30	.	.	.
cord-302316-raf5rlkq	62	1	In	in	IN
cord-302316-raf5rlkq	62	2	addition	addition	NN
cord-302316-raf5rlkq	62	3	,	,	,
cord-302316-raf5rlkq	62	4	the	the	DT
cord-302316-raf5rlkq	62	5	clinical	clinical	JJ
cord-302316-raf5rlkq	62	6	presentation	presentation	NN
cord-302316-raf5rlkq	62	7	differs	differ	VBZ
cord-302316-raf5rlkq	62	8	with	with	IN
cord-302316-raf5rlkq	62	9	severe	severe	JJ
cord-302316-raf5rlkq	62	10	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	62	11	depending	depend	VBG
cord-302316-raf5rlkq	62	12	whether	whether	IN
cord-302316-raf5rlkq	62	13	diffuse	diffuse	JJ
cord-302316-raf5rlkq	62	14	alveolar	alveolar	JJ
cord-302316-raf5rlkq	62	15	damage	damage	NN
cord-302316-raf5rlkq	62	16	,	,	,
cord-302316-raf5rlkq	62	17	coagulopathy	coagulopathy	NN
cord-302316-raf5rlkq	62	18	,	,	,
cord-302316-raf5rlkq	62	19	cytokine	cytokine	NN
cord-302316-raf5rlkq	62	20	overproduction	overproduction	NN
cord-302316-raf5rlkq	62	21	or	or	CC
cord-302316-raf5rlkq	62	22	viral	viral	JJ
cord-302316-raf5rlkq	62	23	sepsis	sepsis	NN
cord-302316-raf5rlkq	62	24	dominates	dominate	VBZ
cord-302316-raf5rlkq	62	25	the	the	DT
cord-302316-raf5rlkq	62	26	disease	disease	NN
cord-302316-raf5rlkq	62	27	.	.	.
cord-302316-raf5rlkq	63	1	Viral	viral	JJ
cord-302316-raf5rlkq	63	2	sepsis	sepsis	NN
cord-302316-raf5rlkq	63	3	and	and	CC
cord-302316-raf5rlkq	63	4	cytokine	cytokine	NN
cord-302316-raf5rlkq	63	5	storm	storm	NN
cord-302316-raf5rlkq	63	6	might	may	MD
cord-302316-raf5rlkq	63	7	,	,	,
cord-302316-raf5rlkq	63	8	in	in	IN
cord-302316-raf5rlkq	63	9	fact	fact	NN
cord-302316-raf5rlkq	63	10	,	,	,
cord-302316-raf5rlkq	63	11	be	be	VB
cord-302316-raf5rlkq	63	12	connected	connect	VBN
cord-302316-raf5rlkq	63	13	.	.	.
cord-302316-raf5rlkq	64	1	Greek	greek	JJ
cord-302316-raf5rlkq	64	2	researchers	researcher	NNS
cord-302316-raf5rlkq	64	3	compared	compare	VBD
cord-302316-raf5rlkq	64	4	immune	immune	JJ
cord-302316-raf5rlkq	64	5	activation	activation	NN
cord-302316-raf5rlkq	64	6	and	and	CC
cord-302316-raf5rlkq	64	7	dysregulation	dysregulation	NN
cord-302316-raf5rlkq	64	8	in	in	IN
cord-302316-raf5rlkq	64	9	patients	patient	NNS
cord-302316-raf5rlkq	64	10	with	with	IN
cord-302316-raf5rlkq	64	11	pneumonia	pneumonia	NN
cord-302316-raf5rlkq	64	12	caused	cause	VBN
cord-302316-raf5rlkq	64	13	by	by	IN
cord-302316-raf5rlkq	64	14	bacteria	bacteria	NNS
cord-302316-raf5rlkq	64	15	,	,	,
cord-302316-raf5rlkq	64	16	influenza	influenza	NN
cord-302316-raf5rlkq	64	17	virus	virus	NN
cord-302316-raf5rlkq	64	18	or	or	CC
cord-302316-raf5rlkq	64	19	SARS	SARS	NNP
cord-302316-raf5rlkq	64	20	-	-	HYPH
cord-302316-raf5rlkq	64	21	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	64	22	.	.	.
cord-302316-raf5rlkq	65	1	At	at	IN
cord-302316-raf5rlkq	65	2	the	the	DT
cord-302316-raf5rlkq	65	3	moment	moment	NN
cord-302316-raf5rlkq	65	4	of	of	IN
cord-302316-raf5rlkq	65	5	hospitalization	hospitalization	NN
cord-302316-raf5rlkq	65	6	,	,	,
cord-302316-raf5rlkq	65	7	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	65	8	patients	patient	NNS
cord-302316-raf5rlkq	65	9	were	be	VBD
cord-302316-raf5rlkq	65	10	clinically	clinically	RB
cord-302316-raf5rlkq	65	11	less	less	RBR
cord-302316-raf5rlkq	65	12	affected	affected	JJ
cord-302316-raf5rlkq	65	13	than	than	IN
cord-302316-raf5rlkq	65	14	patients	patient	NNS
cord-302316-raf5rlkq	65	15	with	with	IN
cord-302316-raf5rlkq	65	16	bacterial	bacterial	JJ
cord-302316-raf5rlkq	65	17	pneumonia	pneumonia	NN
cord-302316-raf5rlkq	65	18	.	.	.
cord-302316-raf5rlkq	66	1	However	however	RB
cord-302316-raf5rlkq	66	2	,	,	,
cord-302316-raf5rlkq	66	3	a	a	DT
cord-302316-raf5rlkq	66	4	common	common	JJ
cord-302316-raf5rlkq	66	5	observation	observation	NN
cord-302316-raf5rlkq	66	6	in	in	IN
cord-302316-raf5rlkq	66	7	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	66	8	patients	patient	NNS
cord-302316-raf5rlkq	66	9	is	be	VBZ
cord-302316-raf5rlkq	66	10	that	that	IN
cord-302316-raf5rlkq	66	11	one	one	CD
cord-302316-raf5rlkq	66	12	week	week	NN
cord-302316-raf5rlkq	66	13	after	after	IN
cord-302316-raf5rlkq	66	14	hospitalization	hospitalization	NN
cord-302316-raf5rlkq	66	15	they	-PRON-	PRP
cord-302316-raf5rlkq	66	16	progressed	progress	VBD
cord-302316-raf5rlkq	66	17	from	from	IN
cord-302316-raf5rlkq	66	18	a	a	DT
cord-302316-raf5rlkq	66	19	relatively	relatively	RB
cord-302316-raf5rlkq	66	20	good	good	JJ
cord-302316-raf5rlkq	66	21	clinical	clinical	JJ
cord-302316-raf5rlkq	66	22	state	state	NN
cord-302316-raf5rlkq	66	23	into	into	IN
cord-302316-raf5rlkq	66	24	sudden	sudden	JJ
cord-302316-raf5rlkq	66	25	deterioration	deterioration	NN
cord-302316-raf5rlkq	66	26	.	.	.
cord-302316-raf5rlkq	67	1	These	these	DT
cord-302316-raf5rlkq	67	2	researchers	researcher	NNS
cord-302316-raf5rlkq	67	3	observed	observe	VBD
cord-302316-raf5rlkq	67	4	low	low	JJ
cord-302316-raf5rlkq	67	5	expression	expression	NN
cord-302316-raf5rlkq	67	6	of	of	IN
cord-302316-raf5rlkq	67	7	the	the	DT
cord-302316-raf5rlkq	67	8	human	human	JJ
cord-302316-raf5rlkq	67	9	leucocyte	leucocyte	NNP
cord-302316-raf5rlkq	67	10	antigen	antigen	NNP
cord-302316-raf5rlkq	67	11	(	(	-LRB-
cord-302316-raf5rlkq	67	12	HLA)-DR	HLA)-DR	NNP
cord-302316-raf5rlkq	67	13	on	on	IN
cord-302316-raf5rlkq	67	14	CD14	CD14	NNP
cord-302316-raf5rlkq	67	15	monocytes	monocyte	NNS
cord-302316-raf5rlkq	67	16	in	in	IN
cord-302316-raf5rlkq	67	17	COVID-19	covid-19	CD
cord-302316-raf5rlkq	67	18	patients	patient	NNS
cord-302316-raf5rlkq	67	19	in	in	IN
cord-302316-raf5rlkq	67	20	need	need	NN
cord-302316-raf5rlkq	67	21	of	of	IN
cord-302316-raf5rlkq	67	22	mechanical	mechanical	JJ
cord-302316-raf5rlkq	67	23	ventilation	ventilation	NN
cord-302316-raf5rlkq	67	24	.	.	.
cord-302316-raf5rlkq	68	1	The	the	DT
cord-302316-raf5rlkq	68	2	patients	patient	NNS
cord-302316-raf5rlkq	68	3	showed	show	VBD
cord-302316-raf5rlkq	68	4	a	a	DT
cord-302316-raf5rlkq	68	5	unique	unique	JJ
cord-302316-raf5rlkq	68	6	combination	combination	NN
cord-302316-raf5rlkq	68	7	of	of	IN
cord-302316-raf5rlkq	68	8	defective	defective	JJ
cord-302316-raf5rlkq	68	9	antigen	antigen	NN
cord-302316-raf5rlkq	68	10	presentation	presentation	NN
cord-302316-raf5rlkq	68	11	and	and	CC
cord-302316-raf5rlkq	68	12	lymphopenia	lymphopenia	NNP
cord-302316-raf5rlkq	68	13	.	.	.
cord-302316-raf5rlkq	69	1	Interleukin-6	Interleukin-6	NNP
cord-302316-raf5rlkq	70	1	(	(	-LRB-
cord-302316-raf5rlkq	70	2	IL-6	IL-6	NNP
cord-302316-raf5rlkq	70	3	)	)	-RRB-
cord-302316-raf5rlkq	70	4	and	and	CC
cord-302316-raf5rlkq	70	5	C	C	NNP
cord-302316-raf5rlkq	70	6	-	-	HYPH
cord-302316-raf5rlkq	70	7	reactive	reactive	JJ
cord-302316-raf5rlkq	70	8	protein	protein	NN
cord-302316-raf5rlkq	70	9	(	(	-LRB-
cord-302316-raf5rlkq	70	10	CRP	CRP	NNP
cord-302316-raf5rlkq	70	11	)	)	-RRB-
cord-302316-raf5rlkq	70	12	were	be	VBD
cord-302316-raf5rlkq	70	13	significantly	significantly	RB
cord-302316-raf5rlkq	70	14	increased	increase	VBN
cord-302316-raf5rlkq	70	15	in	in	IN
cord-302316-raf5rlkq	70	16	severe	severe	JJ
cord-302316-raf5rlkq	70	17	cases	case	NNS
cord-302316-raf5rlkq	70	18	.	.	.
cord-302316-raf5rlkq	71	1	IL-6	IL-6	NNP
cord-302316-raf5rlkq	71	2	is	be	VBZ
cord-302316-raf5rlkq	71	3	known	know	VBN
cord-302316-raf5rlkq	71	4	to	to	TO
cord-302316-raf5rlkq	71	5	inhibit	inhibit	VB
cord-302316-raf5rlkq	71	6	HLA	HLA	NNP
cord-302316-raf5rlkq	71	7	-	-	HYPH
cord-302316-raf5rlkq	71	8	DR	DR	NNP
cord-302316-raf5rlkq	71	9	expression	expression	NN
cord-302316-raf5rlkq	71	10	.	.	.
cord-302316-raf5rlkq	72	1	An	an	DT
cord-302316-raf5rlkq	72	2	inverse	inverse	JJ
cord-302316-raf5rlkq	72	3	correlation	correlation	NN
cord-302316-raf5rlkq	72	4	between	between	IN
cord-302316-raf5rlkq	72	5	these	these	DT
cord-302316-raf5rlkq	72	6	markers	marker	NNS
cord-302316-raf5rlkq	72	7	was	be	VBD
cord-302316-raf5rlkq	72	8	,	,	,
cord-302316-raf5rlkq	72	9	in	in	IN
cord-302316-raf5rlkq	72	10	fact	fact	NN
cord-302316-raf5rlkq	72	11	,	,	,
cord-302316-raf5rlkq	72	12	observed	observe	VBN
cord-302316-raf5rlkq	72	13	in	in	IN
cord-302316-raf5rlkq	72	14	severe	severe	JJ
cord-302316-raf5rlkq	72	15	cases	case	NNS
cord-302316-raf5rlkq	72	16	.	.	.
cord-302316-raf5rlkq	73	1	The	the	DT
cord-302316-raf5rlkq	73	2	authors	author	NNS
cord-302316-raf5rlkq	73	3	of	of	IN
cord-302316-raf5rlkq	73	4	this	this	DT
cord-302316-raf5rlkq	73	5	study	study	NN
cord-302316-raf5rlkq	73	6	suggest	suggest	VBP
cord-302316-raf5rlkq	73	7	a	a	DT
cord-302316-raf5rlkq	73	8	clinical	clinical	JJ
cord-302316-raf5rlkq	73	9	trial	trial	NN
cord-302316-raf5rlkq	73	10	exploring	explore	VBG
cord-302316-raf5rlkq	73	11	a	a	DT
cord-302316-raf5rlkq	73	12	specific	specific	JJ
cord-302316-raf5rlkq	73	13	blocker	blocker	NN
cord-302316-raf5rlkq	73	14	of	of	IN
cord-302316-raf5rlkq	73	15	the	the	DT
cord-302316-raf5rlkq	73	16	IL-6	IL-6	NNP
cord-302316-raf5rlkq	73	17	pathway	pathway	NN
cord-302316-raf5rlkq	73	18	such	such	JJ
cord-302316-raf5rlkq	73	19	as	as	IN
cord-302316-raf5rlkq	73	20	tocilizumab	tocilizumab	NNP
cord-302316-raf5rlkq	73	21	to	to	TO
cord-302316-raf5rlkq	73	22	restore	restore	VB
cord-302316-raf5rlkq	73	23	the	the	DT
cord-302316-raf5rlkq	73	24	expression	expression	NN
cord-302316-raf5rlkq	73	25	of	of	IN
cord-302316-raf5rlkq	73	26	HLA	HLA	NNP
cord-302316-raf5rlkq	73	27	-	-	HYPH
cord-302316-raf5rlkq	73	28	DR	DR	NNP
cord-302316-raf5rlkq	73	29	,	,	,
cord-302316-raf5rlkq	73	30	and	and	CC
cord-302316-raf5rlkq	73	31	to	to	TO
cord-302316-raf5rlkq	73	32	alleviate	alleviate	VB
cord-302316-raf5rlkq	73	33	the	the	DT
cord-302316-raf5rlkq	73	34	immune	immune	NN
cord-302316-raf5rlkq	73	35	-	-	HYPH
cord-302316-raf5rlkq	73	36	paralysis	paralysis	NN
cord-302316-raf5rlkq	73	37	seen	see	VBN
cord-302316-raf5rlkq	73	38	in	in	IN
cord-302316-raf5rlkq	73	39	severe	severe	JJ
cord-302316-raf5rlkq	73	40	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	73	41	cases	case	NNS
cord-302316-raf5rlkq	73	42	.	.	.
cord-302316-raf5rlkq	74	1	(	(	-LRB-
cord-302316-raf5rlkq	74	2	Giamarellos	Giamarellos	NNP
cord-302316-raf5rlkq	74	3	-	-	HYPH
cord-302316-raf5rlkq	74	4	Bourboulis	Bourboulis	NNP
cord-302316-raf5rlkq	74	5	et	et	NNP
cord-302316-raf5rlkq	74	6	al	al	NNP
cord-302316-raf5rlkq	74	7	.	.	NNP
cord-302316-raf5rlkq	74	8	,	,	,
cord-302316-raf5rlkq	74	9	2020	2020	CD
cord-302316-raf5rlkq	74	10	)	)	-RRB-
cord-302316-raf5rlkq	75	1	Data	datum	NNS
cord-302316-raf5rlkq	75	2	from	from	IN
cord-302316-raf5rlkq	75	3	Wuhan	Wuhan	NNP
cord-302316-raf5rlkq	75	4	concur	concur	VBP
cord-302316-raf5rlkq	75	5	with	with	IN
cord-302316-raf5rlkq	75	6	these	these	DT
cord-302316-raf5rlkq	75	7	observations	observation	NNS
cord-302316-raf5rlkq	75	8	.	.	.
cord-302316-raf5rlkq	76	1	When	when	WRB
cord-302316-raf5rlkq	76	2	investigating	investigate	VBG
cord-302316-raf5rlkq	76	3	48	48	CD
cord-302316-raf5rlkq	76	4	COVID-19	covid-19	CD
cord-302316-raf5rlkq	76	5	patients	patient	NNS
cord-302316-raf5rlkq	76	6	with	with	IN
cord-302316-raf5rlkq	76	7	distinct	distinct	JJ
cord-302316-raf5rlkq	76	8	disease	disease	NN
cord-302316-raf5rlkq	76	9	severity	severity	NN
cord-302316-raf5rlkq	76	10	,	,	,
cord-302316-raf5rlkq	76	11	the	the	DT
cord-302316-raf5rlkq	76	12	clinicians	clinician	NNS
cord-302316-raf5rlkq	76	13	observed	observe	VBD
cord-302316-raf5rlkq	76	14	viral	viral	JJ
cord-302316-raf5rlkq	76	15	RNA	RNA	NNP
cord-302316-raf5rlkq	76	16	in	in	IN
cord-302316-raf5rlkq	76	17	the	the	DT
cord-302316-raf5rlkq	76	18	blood	blood	NN
cord-302316-raf5rlkq	76	19	(	(	-LRB-
cord-302316-raf5rlkq	76	20	'	'	``
cord-302316-raf5rlkq	76	21	RNAaemia	rnaaemia	NN
cord-302316-raf5rlkq	76	22	'	'	''
cord-302316-raf5rlkq	76	23	)	)	-RRB-
cord-302316-raf5rlkq	76	24	of	of	IN
cord-302316-raf5rlkq	76	25	five	five	CD
cord-302316-raf5rlkq	76	26	critically	critically	RB
cord-302316-raf5rlkq	76	27	ill	ill	JJ
cord-302316-raf5rlkq	76	28	patients	patient	NNS
cord-302316-raf5rlkq	76	29	,	,	,
cord-302316-raf5rlkq	76	30	two	two	CD
cord-302316-raf5rlkq	76	31	of	of	IN
cord-302316-raf5rlkq	76	32	whom	whom	WP
cord-302316-raf5rlkq	76	33	died	die	VBD
cord-302316-raf5rlkq	76	34	of	of	IN
cord-302316-raf5rlkq	76	35	respiratory	respiratory	JJ
cord-302316-raf5rlkq	76	36	failure	failure	NN
cord-302316-raf5rlkq	76	37	.	.	.
cord-302316-raf5rlkq	77	1	Interestingly	interestingly	RB
cord-302316-raf5rlkq	77	2	,	,	,
cord-302316-raf5rlkq	77	3	all	all	DT
cord-302316-raf5rlkq	77	4	5	5	CD
cord-302316-raf5rlkq	77	5	patients	patient	NNS
cord-302316-raf5rlkq	77	6	also	also	RB
cord-302316-raf5rlkq	77	7	showed	show	VBD
cord-302316-raf5rlkq	77	8	sharply	sharply	RB
cord-302316-raf5rlkq	77	9	increased	increase	VBN
cord-302316-raf5rlkq	77	10	IL-6	IL-6	NNP
cord-302316-raf5rlkq	77	11	levels	level	NNS
cord-302316-raf5rlkq	77	12	.	.	.
cord-302316-raf5rlkq	78	1	Viral	Viral	NNP
cord-302316-raf5rlkq	78	2	RNA	RNA	NNP
cord-302316-raf5rlkq	78	3	in	in	IN
cord-302316-raf5rlkq	78	4	the	the	DT
cord-302316-raf5rlkq	78	5	blood	blood	NN
cord-302316-raf5rlkq	78	6	and	and	CC
cord-302316-raf5rlkq	78	7	high	high	JJ
cord-302316-raf5rlkq	78	8	IL-6	IL-6	NNP
cord-302316-raf5rlkq	78	9	were	be	VBD
cord-302316-raf5rlkq	78	10	biomarkers	biomarker	NNS
cord-302316-raf5rlkq	78	11	of	of	IN
cord-302316-raf5rlkq	78	12	severe	severe	JJ
cord-302316-raf5rlkq	78	13	disease	disease	NN
cord-302316-raf5rlkq	78	14	.	.	.
cord-302316-raf5rlkq	79	1	Defence	defence	NN
cord-302316-raf5rlkq	79	2	against	against	IN
cord-302316-raf5rlkq	79	3	viral	viral	JJ
cord-302316-raf5rlkq	79	4	infection	infection	NN
cord-302316-raf5rlkq	79	5	begins	begin	VBZ
cord-302316-raf5rlkq	79	6	at	at	IN
cord-302316-raf5rlkq	79	7	the	the	DT
cord-302316-raf5rlkq	79	8	cellular	cellular	JJ
cord-302316-raf5rlkq	79	9	level	level	NN
cord-302316-raf5rlkq	79	10	.	.	.
cord-302316-raf5rlkq	80	1	Cells	cell	NNS
cord-302316-raf5rlkq	80	2	detect	detect	VBP
cord-302316-raf5rlkq	80	3	a	a	DT
cord-302316-raf5rlkq	80	4	replicating	replicate	VBG
cord-302316-raf5rlkq	80	5	virus	virus	NN
cord-302316-raf5rlkq	80	6	by	by	IN
cord-302316-raf5rlkq	80	7	pattern	pattern	NN
cord-302316-raf5rlkq	80	8	recognition	recognition	NN
cord-302316-raf5rlkq	80	9	receptors	receptor	NNS
cord-302316-raf5rlkq	80	10	that	that	WDT
cord-302316-raf5rlkq	80	11	signal	signal	VBP
cord-302316-raf5rlkq	80	12	the	the	DT
cord-302316-raf5rlkq	80	13	presence	presence	NN
cord-302316-raf5rlkq	80	14	of	of	IN
cord-302316-raf5rlkq	80	15	unusual	unusual	JJ
cord-302316-raf5rlkq	80	16	RNA	RNA	NNP
cord-302316-raf5rlkq	80	17	structures	structure	NNS
cord-302316-raf5rlkq	80	18	.	.	.
cord-302316-raf5rlkq	81	1	These	these	DT
cord-302316-raf5rlkq	81	2	receptors	receptor	NNS
cord-302316-raf5rlkq	81	3	,	,	,
cord-302316-raf5rlkq	81	4	when	when	WRB
cord-302316-raf5rlkq	81	5	bound	bind	VBN
cord-302316-raf5rlkq	81	6	to	to	IN
cord-302316-raf5rlkq	81	7	these	these	DT
cord-302316-raf5rlkq	81	8	aberrant	aberrant	JJ
cord-302316-raf5rlkq	81	9	RNA	RNA	NNP
cord-302316-raf5rlkq	81	10	molecules	molecule	NNS
cord-302316-raf5rlkq	81	11	,	,	,
cord-302316-raf5rlkq	81	12	activate	activate	VBP
cord-302316-raf5rlkq	81	13	the	the	DT
cord-302316-raf5rlkq	81	14	transcription	transcription	NN
cord-302316-raf5rlkq	81	15	factors	factor	NNS
cord-302316-raf5rlkq	81	16	IRF	IRF	NNP
cord-302316-raf5rlkq	81	17	and	and	CC
cord-302316-raf5rlkq	81	18	NF	NF	NNP
cord-302316-raf5rlkq	81	19	-	-	HYPH
cord-302316-raf5rlkq	81	20	jB	jB	NNP
cord-302316-raf5rlkq	81	21	,	,	,
cord-302316-raf5rlkq	81	22	which	which	WDT
cord-302316-raf5rlkq	81	23	launch	launch	VBP
cord-302316-raf5rlkq	81	24	two	two	CD
cord-302316-raf5rlkq	81	25	antiviral	antiviral	JJ
cord-302316-raf5rlkq	81	26	programmes	programme	NNS
cord-302316-raf5rlkq	81	27	:	:	:
cord-302316-raf5rlkq	81	28	(	(	-LRB-
cord-302316-raf5rlkq	81	29	i	i	NN
cord-302316-raf5rlkq	81	30	)	)	-RRB-
cord-302316-raf5rlkq	81	31	induction	induction	NN
cord-302316-raf5rlkq	81	32	of	of	IN
cord-302316-raf5rlkq	81	33	type	type	NN
cord-302316-raf5rlkq	81	34	I	-PRON-	PRP
cord-302316-raf5rlkq	81	35	and	and	CC
cord-302316-raf5rlkq	81	36	III	III	NNP
cord-302316-raf5rlkq	82	1	interferon	interferon	NNP
cord-302316-raf5rlkq	83	1	(	(	-LRB-
cord-302316-raf5rlkq	83	2	INF	INF	NNP
cord-302316-raf5rlkq	83	3	-	-	HYPH
cord-302316-raf5rlkq	83	4	I	I	NNP
cord-302316-raf5rlkq	83	5	,	,	,
cord-302316-raf5rlkq	83	6	INF	INF	NNP
cord-302316-raf5rlkq	83	7	-	-	HYPH
cord-302316-raf5rlkq	83	8	III	III	NNP
cord-302316-raf5rlkq	83	9	)	)	-RRB-
cord-302316-raf5rlkq	83	10	,	,	,
cord-302316-raf5rlkq	83	11	which	which	WDT
cord-302316-raf5rlkq	83	12	upregulate	upregulate	VBP
cord-302316-raf5rlkq	83	13	interferon	interferon	NN
cord-302316-raf5rlkq	83	14	-	-	HYPH
cord-302316-raf5rlkq	83	15	stimulated	stimulate	VBN
cord-302316-raf5rlkq	83	16	genes	gene	NNS
cord-302316-raf5rlkq	83	17	(	(	-LRB-
cord-302316-raf5rlkq	83	18	ISG	ISG	NNP
cord-302316-raf5rlkq	83	19	)	)	-RRB-
cord-302316-raf5rlkq	83	20	;	;	:
cord-302316-raf5rlkq	83	21	(	(	-LRB-
cord-302316-raf5rlkq	83	22	ii	ii	NN
cord-302316-raf5rlkq	83	23	)	)	-RRB-
cord-302316-raf5rlkq	83	24	recruitment	recruitment	NN
cord-302316-raf5rlkq	83	25	of	of	IN
cord-302316-raf5rlkq	83	26	specific	specific	JJ
cord-302316-raf5rlkq	83	27	leucocytes	leucocyte	NNS
cord-302316-raf5rlkq	83	28	by	by	IN
cord-302316-raf5rlkq	83	29	chemokine	chemokine	NN
cord-302316-raf5rlkq	83	30	secretion	secretion	NN
cord-302316-raf5rlkq	83	31	.	.	.
cord-302316-raf5rlkq	84	1	US	US	NNP
cord-302316-raf5rlkq	84	2	researchers	researcher	NNS
cord-302316-raf5rlkq	84	3	studied	study	VBD
cord-302316-raf5rlkq	84	4	the	the	DT
cord-302316-raf5rlkq	84	5	viral	viral	JJ
cord-302316-raf5rlkq	84	6	and	and	CC
cord-302316-raf5rlkq	84	7	cellular	cellular	JJ
cord-302316-raf5rlkq	84	8	transcriptional	transcriptional	JJ
cord-302316-raf5rlkq	84	9	response	response	NN
cord-302316-raf5rlkq	84	10	upon	upon	IN
cord-302316-raf5rlkq	84	11	infection	infection	NN
cord-302316-raf5rlkq	84	12	of	of	IN
cord-302316-raf5rlkq	84	13	cell	cell	NN
cord-302316-raf5rlkq	84	14	cultures	culture	NNS
cord-302316-raf5rlkq	84	15	and	and	CC
cord-302316-raf5rlkq	84	16	in	in	IN
cord-302316-raf5rlkq	84	17	animal	animal	NN
cord-302316-raf5rlkq	84	18	models	model	NNS
cord-302316-raf5rlkq	84	19	with	with	IN
cord-302316-raf5rlkq	84	20	different	different	JJ
cord-302316-raf5rlkq	84	21	respiratory	respiratory	JJ
cord-302316-raf5rlkq	84	22	viruses	virus	NNS
cord-302316-raf5rlkq	84	23	including	include	VBG
cord-302316-raf5rlkq	84	24	influenza	influenza	NN
cord-302316-raf5rlkq	84	25	A	a	DT
cord-302316-raf5rlkq	84	26	virus	virus	NN
cord-302316-raf5rlkq	84	27	and	and	CC
cord-302316-raf5rlkq	84	28	SARS	SARS	NNP
cord-302316-raf5rlkq	84	29	-	-	HYPH
cord-302316-raf5rlkq	84	30	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	84	31	.	.	.
cord-302316-raf5rlkq	85	1	In	in	IN
cord-302316-raf5rlkq	85	2	cell	cell	NN
cord-302316-raf5rlkq	85	3	culture	culture	NN
cord-302316-raf5rlkq	85	4	,	,	,
cord-302316-raf5rlkq	85	5	viral	viral	JJ
cord-302316-raf5rlkq	85	6	RNA	RNA	NNP
cord-302316-raf5rlkq	85	7	represented	represent	VBD
cord-302316-raf5rlkq	85	8	50	50	CD
cord-302316-raf5rlkq	85	9	%	%	NN
cord-302316-raf5rlkq	85	10	or	or	CC
cord-302316-raf5rlkq	85	11	more	more	JJR
cord-302316-raf5rlkq	85	12	of	of	IN
cord-302316-raf5rlkq	85	13	all	all	DT
cord-302316-raf5rlkq	85	14	cellular	cellular	JJ
cord-302316-raf5rlkq	85	15	messenger	messenger	NN
cord-302316-raf5rlkq	85	16	RNA	RNA	NNP
cord-302316-raf5rlkq	85	17	(	(	-LRB-
cord-302316-raf5rlkq	85	18	mRNA	mrna	NN
cord-302316-raf5rlkq	85	19	)	)	-RRB-
cord-302316-raf5rlkq	85	20	.	.	.
cord-302316-raf5rlkq	86	1	The	the	DT
cord-302316-raf5rlkq	86	2	external	external	JJ
cord-302316-raf5rlkq	86	3	addition	addition	NN
cord-302316-raf5rlkq	86	4	of	of	IN
cord-302316-raf5rlkq	86	5	INF	INF	NNP
cord-302316-raf5rlkq	86	6	-	-	:
cord-302316-raf5rlkq	86	7	I	I	NNP
cord-302316-raf5rlkq	86	8	reduced	reduce	VBD
cord-302316-raf5rlkq	86	9	SARS	SARS	NNP
cord-302316-raf5rlkq	86	10	-	-	HYPH
cord-302316-raf5rlkq	86	11	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	86	12	replication	replication	NN
cord-302316-raf5rlkq	86	13	dramatically	dramatically	RB
cord-302316-raf5rlkq	86	14	.	.	.
cord-302316-raf5rlkq	87	1	However	however	RB
cord-302316-raf5rlkq	87	2	,	,	,
cord-302316-raf5rlkq	87	3	infection	infection	NN
cord-302316-raf5rlkq	87	4	of	of	IN
cord-302316-raf5rlkq	87	5	cells	cell	NNS
cord-302316-raf5rlkq	87	6	with	with	IN
cord-302316-raf5rlkq	87	7	SARS	SARS	NNP
cord-302316-raf5rlkq	87	8	-	-	HYPH
cord-302316-raf5rlkq	87	9	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	87	10	did	do	VBD
cord-302316-raf5rlkq	87	11	not	not	RB
cord-302316-raf5rlkq	87	12	induce	induce	VB
cord-302316-raf5rlkq	87	13	an	an	DT
cord-302316-raf5rlkq	87	14	interferon	interferon	NN
cord-302316-raf5rlkq	87	15	response	response	NN
cord-302316-raf5rlkq	87	16	,	,	,
cord-302316-raf5rlkq	87	17	but	but	CC
cord-302316-raf5rlkq	87	18	a	a	DT
cord-302316-raf5rlkq	87	19	strong	strong	JJ
cord-302316-raf5rlkq	87	20	chemotactic	chemotactic	JJ
cord-302316-raf5rlkq	87	21	and	and	CC
cord-302316-raf5rlkq	87	22	inflammatory	inflammatory	JJ
cord-302316-raf5rlkq	87	23	response	response	NN
cord-302316-raf5rlkq	87	24	instead	instead	RB
cord-302316-raf5rlkq	87	25	.	.	.
cord-302316-raf5rlkq	88	1	In	in	IN
cord-302316-raf5rlkq	88	2	nasal	nasal	JJ
cord-302316-raf5rlkq	88	3	washes	wash	NNS
cord-302316-raf5rlkq	88	4	from	from	IN
cord-302316-raf5rlkq	88	5	infected	infected	JJ
cord-302316-raf5rlkq	88	6	ferrets	ferret	NNS
cord-302316-raf5rlkq	88	7	,	,	,
cord-302316-raf5rlkq	88	8	viral	viral	JJ
cord-302316-raf5rlkq	88	9	RNA	RNA	NNP
cord-302316-raf5rlkq	88	10	represented	represent	VBD
cord-302316-raf5rlkq	88	11	<	<	XX
cord-302316-raf5rlkq	88	12	2	2	CD
cord-302316-raf5rlkq	88	13	%	%	NN
cord-302316-raf5rlkq	88	14	of	of	IN
cord-302316-raf5rlkq	88	15	all	all	DT
cord-302316-raf5rlkq	88	16	mRNA	mrna	NN
cord-302316-raf5rlkq	88	17	.	.	.
cord-302316-raf5rlkq	89	1	SARS	SARS	NNP
cord-302316-raf5rlkq	89	2	-	-	HYPH
cord-302316-raf5rlkq	89	3	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	89	4	induced	induce	VBD
cord-302316-raf5rlkq	89	5	a	a	DT
cord-302316-raf5rlkq	89	6	different	different	JJ
cord-302316-raf5rlkq	89	7	cellular	cellular	JJ
cord-302316-raf5rlkq	89	8	transcription	transcription	NN
cord-302316-raf5rlkq	89	9	response	response	NN
cord-302316-raf5rlkq	89	10	compared	compare	VBN
cord-302316-raf5rlkq	89	11	to	to	IN
cord-302316-raf5rlkq	89	12	the	the	DT
cord-302316-raf5rlkq	89	13	influenza	influenza	NN
cord-302316-raf5rlkq	89	14	virus	virus	NN
cord-302316-raf5rlkq	89	15	:	:	:
cord-302316-raf5rlkq	89	16	a	a	DT
cord-302316-raf5rlkq	89	17	cytokine	cytokine	NN
cord-302316-raf5rlkq	89	18	response	response	NN
cord-302316-raf5rlkq	89	19	was	be	VBD
cord-302316-raf5rlkq	89	20	followed	follow	VBN
cord-302316-raf5rlkq	89	21	by	by	IN
cord-302316-raf5rlkq	89	22	gene	gene	NN
cord-302316-raf5rlkq	89	23	transcripts	transcript	NNS
cord-302316-raf5rlkq	89	24	of	of	IN
cord-302316-raf5rlkq	89	25	cell	cell	NN
cord-302316-raf5rlkq	89	26	death	death	NN
cord-302316-raf5rlkq	89	27	and	and	CC
cord-302316-raf5rlkq	89	28	leucocyte	leucocyte	NNP
cord-302316-raf5rlkq	89	29	activation	activation	NN
cord-302316-raf5rlkq	89	30	.	.	.
cord-302316-raf5rlkq	90	1	Postmortem	postmortem	JJ
cord-302316-raf5rlkq	90	2	lung	lung	NN
cord-302316-raf5rlkq	90	3	samples	sample	NNS
cord-302316-raf5rlkq	90	4	from	from	IN
cord-302316-raf5rlkq	90	5	COVID-19	covid-19	CD
cord-302316-raf5rlkq	90	6	patients	patient	NNS
cord-302316-raf5rlkq	90	7	showed	show	VBD
cord-302316-raf5rlkq	90	8	no	no	DT
cord-302316-raf5rlkq	90	9	INF	inf	NN
cord-302316-raf5rlkq	90	10	-	-	HYPH
cord-302316-raf5rlkq	90	11	I	I	NNP
cord-302316-raf5rlkq	90	12	and	and	CC
cord-302316-raf5rlkq	90	13	INF	INF	NNP
cord-302316-raf5rlkq	90	14	-	-	HYPH
cord-302316-raf5rlkq	90	15	III	III	NNP
cord-302316-raf5rlkq	90	16	,	,	,
cord-302316-raf5rlkq	90	17	but	but	CC
cord-302316-raf5rlkq	90	18	a	a	DT
cord-302316-raf5rlkq	90	19	robust	robust	JJ
cord-302316-raf5rlkq	90	20	chemokine	chemokine	NN
cord-302316-raf5rlkq	90	21	transcription	transcription	NN
cord-302316-raf5rlkq	90	22	instead	instead	RB
cord-302316-raf5rlkq	90	23	.	.	.
cord-302316-raf5rlkq	91	1	The	the	DT
cord-302316-raf5rlkq	91	2	observations	observation	NNS
cord-302316-raf5rlkq	91	3	were	be	VBD
cord-302316-raf5rlkq	91	4	confirmed	confirm	VBN
cord-302316-raf5rlkq	91	5	in	in	IN
cord-302316-raf5rlkq	91	6	serum	serum	NN
cord-302316-raf5rlkq	91	7	samples	sample	NNS
cord-302316-raf5rlkq	91	8	of	of	IN
cord-302316-raf5rlkq	91	9	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	91	10	patients	patient	NNS
cord-302316-raf5rlkq	91	11	compared	compare	VBN
cord-302316-raf5rlkq	91	12	with	with	IN
cord-302316-raf5rlkq	91	13	samples	sample	NNS
cord-302316-raf5rlkq	91	14	from	from	IN
cord-302316-raf5rlkq	91	15	control	control	NN
cord-302316-raf5rlkq	91	16	subjects	subject	NNS
cord-302316-raf5rlkq	91	17	,	,	,
cord-302316-raf5rlkq	91	18	showing	show	VBG
cord-302316-raf5rlkq	91	19	no	no	DT
cord-302316-raf5rlkq	91	20	interferon	interferon	NN
cord-302316-raf5rlkq	91	21	,	,	,
cord-302316-raf5rlkq	91	22	but	but	CC
cord-302316-raf5rlkq	91	23	a	a	DT
cord-302316-raf5rlkq	91	24	cytokine	cytokine	NN
cord-302316-raf5rlkq	91	25	response	response	NN
cord-302316-raf5rlkq	91	26	.	.	.
cord-302316-raf5rlkq	92	1	The	the	DT
cord-302316-raf5rlkq	92	2	data	datum	NNS
cord-302316-raf5rlkq	92	3	suggest	suggest	VBP
cord-302316-raf5rlkq	92	4	that	that	IN
cord-302316-raf5rlkq	92	5	SARS	SARS	NNP
cord-302316-raf5rlkq	92	6	-	-	HYPH
cord-302316-raf5rlkq	92	7	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	92	8	has	have	VBZ
cord-302316-raf5rlkq	92	9	learned	learn	VBN
cord-302316-raf5rlkq	92	10	to	to	TO
cord-302316-raf5rlkq	92	11	suppress	suppress	VB
cord-302316-raf5rlkq	92	12	interferon	interferon	NN
cord-302316-raf5rlkq	92	13	induction	induction	NN
cord-302316-raf5rlkq	92	14	and	and	CC
cord-302316-raf5rlkq	92	15	to	to	TO
cord-302316-raf5rlkq	92	16	disarray	disarray	VB
cord-302316-raf5rlkq	92	17	the	the	DT
cord-302316-raf5rlkq	92	18	antiviral	antiviral	JJ
cord-302316-raf5rlkq	92	19	response	response	NN
cord-302316-raf5rlkq	92	20	(	(	-LRB-
cord-302316-raf5rlkq	92	21	Blanco	Blanco	NNP
cord-302316-raf5rlkq	92	22	-	-	HYPH
cord-302316-raf5rlkq	92	23	Melo	Melo	NNP
cord-302316-raf5rlkq	92	24	et	et	NNP
cord-302316-raf5rlkq	92	25	al	al	NNP
cord-302316-raf5rlkq	92	26	.	.	NNP
cord-302316-raf5rlkq	92	27	,	,	,
cord-302316-raf5rlkq	92	28	2020	2020	CD
cord-302316-raf5rlkq	92	29	)	)	-RRB-
cord-302316-raf5rlkq	92	30	.	.	.
cord-302316-raf5rlkq	93	1	Another	another	DT
cord-302316-raf5rlkq	93	2	impressive	impressive	JJ
cord-302316-raf5rlkq	93	3	US	US	NNP
cord-302316-raf5rlkq	93	4	study	study	NN
cord-302316-raf5rlkq	93	5	,	,	,
cord-302316-raf5rlkq	93	6	so	so	RB
cord-302316-raf5rlkq	93	7	far	far	RB
cord-302316-raf5rlkq	93	8	only	only	RB
cord-302316-raf5rlkq	93	9	available	available	JJ
cord-302316-raf5rlkq	93	10	as	as	IN
cord-302316-raf5rlkq	93	11	a	a	DT
cord-302316-raf5rlkq	93	12	preprint	preprint	NN
cord-302316-raf5rlkq	93	13	,	,	,
cord-302316-raf5rlkq	93	14	investigated	investigate	VBD
cord-302316-raf5rlkq	93	15	the	the	DT
cord-302316-raf5rlkq	93	16	expression	expression	NN
cord-302316-raf5rlkq	93	17	of	of	IN
cord-302316-raf5rlkq	93	18	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	93	19	,	,	,
cord-302316-raf5rlkq	93	20	the	the	DT
cord-302316-raf5rlkq	93	21	viral	viral	JJ
cord-302316-raf5rlkq	93	22	receptor	receptor	NN
cord-302316-raf5rlkq	93	23	of	of	IN
cord-302316-raf5rlkq	93	24	SARS	SARS	NNP
cord-302316-raf5rlkq	93	25	-	-	HYPH
cord-302316-raf5rlkq	93	26	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	93	27	,	,	,
cord-302316-raf5rlkq	93	28	and	and	CC
cord-302316-raf5rlkq	93	29	TMPRSS2	TMPRSS2	NNP
cord-302316-raf5rlkq	93	30	,	,	,
cord-302316-raf5rlkq	93	31	the	the	DT
cord-302316-raf5rlkq	93	32	protease	protease	NN
cord-302316-raf5rlkq	93	33	activating	activate	VBG
cord-302316-raf5rlkq	93	34	viral	viral	JJ
cord-302316-raf5rlkq	93	35	fusion	fusion	NN
cord-302316-raf5rlkq	93	36	with	with	IN
cord-302316-raf5rlkq	93	37	cell	cell	NN
cord-302316-raf5rlkq	93	38	membranes	membrane	NNS
cord-302316-raf5rlkq	93	39	leading	lead	VBG
cord-302316-raf5rlkq	93	40	to	to	IN
cord-302316-raf5rlkq	93	41	cell	cell	NN
cord-302316-raf5rlkq	93	42	entry	entry	NN
cord-302316-raf5rlkq	93	43	,	,	,
cord-302316-raf5rlkq	93	44	in	in	IN
cord-302316-raf5rlkq	93	45	a	a	DT
cord-302316-raf5rlkq	93	46	large	large	JJ
cord-302316-raf5rlkq	93	47	set	set	NN
cord-302316-raf5rlkq	93	48	of	of	IN
cord-302316-raf5rlkq	93	49	695	695	CD
cord-302316-raf5rlkq	93	50	healthy	healthy	JJ
cord-302316-raf5rlkq	93	51	and	and	CC
cord-302316-raf5rlkq	93	52	asthmatic	asthmatic	JJ
cord-302316-raf5rlkq	93	53	children	child	NNS
cord-302316-raf5rlkq	93	54	from	from	IN
cord-302316-raf5rlkq	93	55	Puerto	Puerto	NNP
cord-302316-raf5rlkq	93	56	Rico	Rico	NNP
cord-302316-raf5rlkq	93	57	(	(	-LRB-
cord-302316-raf5rlkq	93	58	Gala	Gala	NNP
cord-302316-raf5rlkq	93	59	II	II	NNP
cord-302316-raf5rlkq	93	60	study	study	NN
cord-302316-raf5rlkq	93	61	)	)	-RRB-
cord-302316-raf5rlkq	93	62	.	.	.
cord-302316-raf5rlkq	94	1	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	94	2	expression	expression	NN
cord-302316-raf5rlkq	94	3	was	be	VBD
cord-302316-raf5rlkq	94	4	highly	highly	RB
cord-302316-raf5rlkq	94	5	correlated	correlate	VBN
cord-302316-raf5rlkq	94	6	with	with	IN
cord-302316-raf5rlkq	94	7	the	the	DT
cord-302316-raf5rlkq	94	8	expression	expression	NN
cord-302316-raf5rlkq	94	9	of	of	IN
cord-302316-raf5rlkq	94	10	a	a	DT
cord-302316-raf5rlkq	94	11	gene	gene	NN
cord-302316-raf5rlkq	94	12	network	network	NN
cord-302316-raf5rlkq	94	13	associated	associate	VBN
cord-302316-raf5rlkq	94	14	with	with	IN
cord-302316-raf5rlkq	94	15	cytotoxic	cytotoxic	JJ
cord-302316-raf5rlkq	94	16	T	t	NN
cord-302316-raf5rlkq	94	17	cells	cell	NNS
cord-302316-raf5rlkq	94	18	,	,	,
cord-302316-raf5rlkq	94	19	induced	induce	VBN
cord-302316-raf5rlkq	94	20	in	in	IN
cord-302316-raf5rlkq	94	21	virally	virally	RB
cord-302316-raf5rlkq	94	22	infected	infect	VBN
cord-302316-raf5rlkq	94	23	epithelia	epithelium	NNS
cord-302316-raf5rlkq	94	24	and	and	CC
cord-302316-raf5rlkq	94	25	correlated	correlate	VBN
cord-302316-raf5rlkq	94	26	with	with	IN
cord-302316-raf5rlkq	94	27	a	a	DT
cord-302316-raf5rlkq	94	28	network	network	NN
cord-302316-raf5rlkq	94	29	of	of	IN
cord-302316-raf5rlkq	94	30	interferon	interferon	NN
cord-302316-raf5rlkq	94	31	and	and	CC
cord-302316-raf5rlkq	94	32	epithelial	epithelial	JJ
cord-302316-raf5rlkq	94	33	viral	viral	JJ
cord-302316-raf5rlkq	94	34	response	response	NN
cord-302316-raf5rlkq	94	35	genes	gene	NNS
cord-302316-raf5rlkq	94	36	.	.	.
cord-302316-raf5rlkq	95	1	Notably	notably	RB
cord-302316-raf5rlkq	95	2	,	,	,
cord-302316-raf5rlkq	95	3	78	78	CD
cord-302316-raf5rlkq	95	4	%	%	NN
cord-302316-raf5rlkq	95	5	of	of	IN
cord-302316-raf5rlkq	95	6	subjects	subject	NNS
cord-302316-raf5rlkq	95	7	showing	show	VBG
cord-302316-raf5rlkq	95	8	high	high	JJ
cord-302316-raf5rlkq	95	9	interferon	interferon	NN
cord-302316-raf5rlkq	95	10	levels	level	NNS
cord-302316-raf5rlkq	95	11	were	be	VBD
cord-302316-raf5rlkq	95	12	asymptomatic	asymptomatic	JJ
cord-302316-raf5rlkq	95	13	respiratory	respiratory	JJ
cord-302316-raf5rlkq	95	14	virus	virus	NN
cord-302316-raf5rlkq	95	15	carriers	carrier	NNS
cord-302316-raf5rlkq	95	16	(	(	-LRB-
cord-302316-raf5rlkq	95	17	not	not	RB
cord-302316-raf5rlkq	95	18	with	with	IN
cord-302316-raf5rlkq	95	19	SARS	SARS	NNP
cord-302316-raf5rlkq	95	20	-	-	HYPH
cord-302316-raf5rlkq	95	21	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	95	22	,	,	,
cord-302316-raf5rlkq	95	23	the	the	DT
cord-302316-raf5rlkq	95	24	study	study	NN
cord-302316-raf5rlkq	95	25	preceded	precede	VBD
cord-302316-raf5rlkq	95	26	the	the	DT
cord-302316-raf5rlkq	95	27	epidemic	epidemic	NN
cord-302316-raf5rlkq	95	28	)	)	-RRB-
cord-302316-raf5rlkq	95	29	compared	compare	VBN
cord-302316-raf5rlkq	95	30	with	with	IN
cord-302316-raf5rlkq	95	31	10	10	CD
cord-302316-raf5rlkq	95	32	%	%	NN
cord-302316-raf5rlkq	95	33	asymptomatic	asymptomatic	JJ
cord-302316-raf5rlkq	95	34	infections	infection	NNS
cord-302316-raf5rlkq	95	35	in	in	IN
cord-302316-raf5rlkq	95	36	subjects	subject	NNS
cord-302316-raf5rlkq	95	37	displaying	display	VBG
cord-302316-raf5rlkq	95	38	only	only	RB
cord-302316-raf5rlkq	95	39	low	low	JJ
cord-302316-raf5rlkq	95	40	interferon	interferon	NN
cord-302316-raf5rlkq	95	41	levels	level	NNS
cord-302316-raf5rlkq	95	42	.	.	.
cord-302316-raf5rlkq	96	1	Eighteen	eighteen	CD
cord-302316-raf5rlkq	96	2	children	child	NNS
cord-302316-raf5rlkq	96	3	were	be	VBD
cord-302316-raf5rlkq	96	4	infected	infect	VBN
cord-302316-raf5rlkq	96	5	with	with	IN
cord-302316-raf5rlkq	96	6	seasonal	seasonal	JJ
cord-302316-raf5rlkq	96	7	coronaviruses	coronaviruse	NNS
cord-302316-raf5rlkq	96	8	,	,	,
cord-302316-raf5rlkq	96	9	and	and	CC
cord-302316-raf5rlkq	96	10	they	-PRON-	PRP
cord-302316-raf5rlkq	96	11	demonstrated	demonstrate	VBD
cord-302316-raf5rlkq	96	12	an	an	DT
cord-302316-raf5rlkq	96	13	increased	increase	VBN
cord-302316-raf5rlkq	96	14	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	96	15	expression	expression	NN
cord-302316-raf5rlkq	96	16	.	.	.
cord-302316-raf5rlkq	97	1	The	the	DT
cord-302316-raf5rlkq	97	2	researchers	researcher	NNS
cord-302316-raf5rlkq	97	3	correlated	correlate	VBD
cord-302316-raf5rlkq	97	4	nasal	nasal	NN
cord-302316-raf5rlkq	97	5	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	97	6	and	and	CC
cord-302316-raf5rlkq	97	7	TMPRSS2	TMPRSS2	NNP
cord-302316-raf5rlkq	97	8	gene	gene	NN
cord-302316-raf5rlkq	97	9	expression	expression	NN
cord-302316-raf5rlkq	97	10	with	with	IN
cord-302316-raf5rlkq	97	11	genome	genome	NN
cord-302316-raf5rlkq	97	12	wide	wide	JJ
cord-302316-raf5rlkq	97	13	genetic	genetic	JJ
cord-302316-raf5rlkq	97	14	variation	variation	NN
cord-302316-raf5rlkq	97	15	data	datum	NNS
cord-302316-raf5rlkq	97	16	for	for	IN
cord-302316-raf5rlkq	97	17	these	these	DT
cord-302316-raf5rlkq	97	18	children	child	NNS
cord-302316-raf5rlkq	97	19	.	.	.
cord-302316-raf5rlkq	98	1	They	-PRON-	PRP
cord-302316-raf5rlkq	98	2	identified	identify	VBD
cord-302316-raf5rlkq	98	3	a	a	DT
cord-302316-raf5rlkq	98	4	variant	variant	JJ
cord-302316-raf5rlkq	98	5	locus	locus	NN
cord-302316-raf5rlkq	98	6	downstream	downstream	RB
cord-302316-raf5rlkq	98	7	of	of	IN
cord-302316-raf5rlkq	98	8	the	the	DT
cord-302316-raf5rlkq	98	9	transcription	transcription	NN
cord-302316-raf5rlkq	98	10	start	start	NN
cord-302316-raf5rlkq	98	11	site	site	NN
cord-302316-raf5rlkq	98	12	of	of	IN
cord-302316-raf5rlkq	98	13	the	the	DT
cord-302316-raf5rlkq	98	14	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	98	15	gene	gene	NN
cord-302316-raf5rlkq	98	16	which	which	WDT
cord-302316-raf5rlkq	98	17	was	be	VBD
cord-302316-raf5rlkq	98	18	associated	associate	VBN
cord-302316-raf5rlkq	98	19	with	with	IN
cord-302316-raf5rlkq	98	20	a	a	DT
cord-302316-raf5rlkq	98	21	large	large	JJ
cord-302316-raf5rlkq	98	22	decrease	decrease	NN
cord-302316-raf5rlkq	98	23	in	in	IN
cord-302316-raf5rlkq	98	24	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	98	25	expression	expression	NN
cord-302316-raf5rlkq	98	26	.	.	.
cord-302316-raf5rlkq	99	1	They	-PRON-	PRP
cord-302316-raf5rlkq	99	2	also	also	RB
cord-302316-raf5rlkq	99	3	found	find	VBD
cord-302316-raf5rlkq	99	4	variants	variant	NNS
cord-302316-raf5rlkq	99	5	that	that	WDT
cord-302316-raf5rlkq	99	6	were	be	VBD
cord-302316-raf5rlkq	99	7	associated	associate	VBN
cord-302316-raf5rlkq	99	8	with	with	IN
cord-302316-raf5rlkq	99	9	increased	increase	VBN
cord-302316-raf5rlkq	99	10	or	or	CC
cord-302316-raf5rlkq	99	11	decreased	decrease	VBD
cord-302316-raf5rlkq	99	12	TMPRSS2	TMPRSS2	NNP
cord-302316-raf5rlkq	99	13	expression	expression	NN
cord-302316-raf5rlkq	99	14	.	.	.
cord-302316-raf5rlkq	100	1	The	the	DT
cord-302316-raf5rlkq	100	2	distribution	distribution	NN
cord-302316-raf5rlkq	100	3	of	of	IN
cord-302316-raf5rlkq	100	4	these	these	DT
cord-302316-raf5rlkq	100	5	variants	variant	NNS
cord-302316-raf5rlkq	100	6	showed	show	VBD
cord-302316-raf5rlkq	100	7	clear	clear	JJ
cord-302316-raf5rlkq	100	8	differences	difference	NNS
cord-302316-raf5rlkq	100	9	in	in	IN
cord-302316-raf5rlkq	100	10	diverse	diverse	JJ
cord-302316-raf5rlkq	100	11	populations	population	NNS
cord-302316-raf5rlkq	100	12	worldwide	worldwide	RB
cord-302316-raf5rlkq	100	13	.	.	.
cord-302316-raf5rlkq	101	1	It	-PRON-	PRP
cord-302316-raf5rlkq	101	2	will	will	MD
cord-302316-raf5rlkq	101	3	be	be	VB
cord-302316-raf5rlkq	101	4	interesting	interesting	JJ
cord-302316-raf5rlkq	101	5	to	to	TO
cord-302316-raf5rlkq	101	6	study	study	VB
cord-302316-raf5rlkq	101	7	whether	whether	IN
cord-302316-raf5rlkq	101	8	distinct	distinct	JJ
cord-302316-raf5rlkq	101	9	expression	expression	NN
cord-302316-raf5rlkq	101	10	pattern	pattern	NN
cord-302316-raf5rlkq	101	11	and	and	CC
cord-302316-raf5rlkq	101	12	the	the	DT
cord-302316-raf5rlkq	101	13	observed	observed	JJ
cord-302316-raf5rlkq	101	14	genetic	genetic	JJ
cord-302316-raf5rlkq	101	15	variants	variant	NNS
cord-302316-raf5rlkq	101	16	explain	explain	VBP
cord-302316-raf5rlkq	101	17	the	the	DT
cord-302316-raf5rlkq	101	18	strikingly	strikingly	RB
cord-302316-raf5rlkq	101	19	different	different	JJ
cord-302316-raf5rlkq	101	20	clinical	clinical	JJ
cord-302316-raf5rlkq	101	21	symptomatology	symptomatology	NN
cord-302316-raf5rlkq	101	22	between	between	IN
cord-302316-raf5rlkq	101	23	individuals	individual	NNS
cord-302316-raf5rlkq	101	24	and	and	CC
cord-302316-raf5rlkq	101	25	whether	whether	IN
cord-302316-raf5rlkq	101	26	these	these	DT
cord-302316-raf5rlkq	101	27	genetic	genetic	JJ
cord-302316-raf5rlkq	101	28	markers	marker	NNS
cord-302316-raf5rlkq	101	29	can	can	MD
cord-302316-raf5rlkq	101	30	explain	explain	VB
cord-302316-raf5rlkq	101	31	geographical	geographical	JJ
cord-302316-raf5rlkq	101	32	differences	difference	NNS
cord-302316-raf5rlkq	101	33	in	in	IN
cord-302316-raf5rlkq	101	34	the	the	DT
cord-302316-raf5rlkq	101	35	worldwide	worldwide	JJ
cord-302316-raf5rlkq	101	36	prevalence	prevalence	NN
cord-302316-raf5rlkq	101	37	of	of	IN
cord-302316-raf5rlkq	101	38	the	the	DT
cord-302316-raf5rlkq	101	39	pandemic	pandemic	NN
cord-302316-raf5rlkq	102	1	(	(	-LRB-
cord-302316-raf5rlkq	102	2	Sajuthi	Sajuthi	NNP
cord-302316-raf5rlkq	102	3	et	et	NNP
cord-302316-raf5rlkq	102	4	al	al	NNP
cord-302316-raf5rlkq	102	5	.	.	NNP
cord-302316-raf5rlkq	102	6	,	,	,
cord-302316-raf5rlkq	102	7	2020	2020	CD
cord-302316-raf5rlkq	102	8	)	)	-RRB-
cord-302316-raf5rlkq	102	9	.	.	.
cord-302316-raf5rlkq	103	1	Data	datum	NNS
cord-302316-raf5rlkq	103	2	on	on	IN
cord-302316-raf5rlkq	103	3	the	the	DT
cord-302316-raf5rlkq	103	4	tissue	tissue	NN
cord-302316-raf5rlkq	103	5	tropism	tropism	NN
cord-302316-raf5rlkq	103	6	of	of	IN
cord-302316-raf5rlkq	103	7	SARS	SARS	NNP
cord-302316-raf5rlkq	103	8	-	-	HYPH
cord-302316-raf5rlkq	103	9	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	103	10	are	be	VBP
cord-302316-raf5rlkq	103	11	important	important	JJ
cord-302316-raf5rlkq	103	12	in	in	IN
cord-302316-raf5rlkq	103	13	order	order	NN
cord-302316-raf5rlkq	103	14	to	to	TO
cord-302316-raf5rlkq	103	15	understand	understand	VB
cord-302316-raf5rlkq	103	16	the	the	DT
cord-302316-raf5rlkq	103	17	clinical	clinical	JJ
cord-302316-raf5rlkq	103	18	aspects	aspect	NNS
cord-302316-raf5rlkq	103	19	of	of	IN
cord-302316-raf5rlkq	103	20	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	103	21	.	.	.
cord-302316-raf5rlkq	104	1	While	while	IN
cord-302316-raf5rlkq	104	2	both	both	DT
cord-302316-raf5rlkq	104	3	SARS	SARS	NNP
cord-302316-raf5rlkq	104	4	-	-	HYPH
cord-302316-raf5rlkq	104	5	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	104	6	and	and	CC
cord-302316-raf5rlkq	104	7	SARS	SARS	NNP
cord-302316-raf5rlkq	104	8	-	-	HYPH
cord-302316-raf5rlkq	104	9	CoV	CoV	NNP
cord-302316-raf5rlkq	104	10	(	(	-LRB-
cord-302316-raf5rlkq	104	11	the	the	DT
cord-302316-raf5rlkq	104	12	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	104	13	associated	associate	VBN
cord-302316-raf5rlkq	104	14	with	with	IN
cord-302316-raf5rlkq	104	15	the	the	DT
cord-302316-raf5rlkq	104	16	2002	2002	CD
cord-302316-raf5rlkq	104	17	SARS	SARS	NNP
cord-302316-raf5rlkq	104	18	epidemic	epidemic	NN
cord-302316-raf5rlkq	104	19	)	)	-RRB-
cord-302316-raf5rlkq	104	20	use	use	VBP
cord-302316-raf5rlkq	104	21	the	the	DT
cord-302316-raf5rlkq	104	22	same	same	JJ
cord-302316-raf5rlkq	104	23	cellular	cellular	JJ
cord-302316-raf5rlkq	104	24	receptor	receptor	NN
cord-302316-raf5rlkq	104	25	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	104	26	,	,	,
cord-302316-raf5rlkq	104	27	SARS	SARS	NNP
cord-302316-raf5rlkq	104	28	-	-	HYPH
cord-302316-raf5rlkq	104	29	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	104	30	causes	cause	VBZ
cord-302316-raf5rlkq	104	31	much	much	RB
cord-302316-raf5rlkq	104	32	less	less	JJR
cord-302316-raf5rlkq	104	33	diarrhoea	diarrhoea	NN
cord-302316-raf5rlkq	104	34	(	(	-LRB-
cord-302316-raf5rlkq	104	35	10	10	CD
cord-302316-raf5rlkq	104	36	%	%	NN
cord-302316-raf5rlkq	104	37	of	of	IN
cord-302316-raf5rlkq	104	38	patients	patient	NNS
cord-302316-raf5rlkq	104	39	)	)	-RRB-
cord-302316-raf5rlkq	104	40	than	than	IN
cord-302316-raf5rlkq	104	41	SARS	SARS	NNP
cord-302316-raf5rlkq	104	42	-	-	HYPH
cord-302316-raf5rlkq	104	43	CoV	CoV	NNP
cord-302316-raf5rlkq	104	44	,	,	,
cord-302316-raf5rlkq	104	45	but	but	CC
cord-302316-raf5rlkq	104	46	it	-PRON-	PRP
cord-302316-raf5rlkq	104	47	has	have	VBZ
cord-302316-raf5rlkq	104	48	more	more	RBR
cord-302316-raf5rlkq	104	49	neurological	neurological	JJ
cord-302316-raf5rlkq	104	50	manifestations	manifestation	NNS
cord-302316-raf5rlkq	104	51	(	(	-LRB-
cord-302316-raf5rlkq	104	52	confusion	confusion	NN
cord-302316-raf5rlkq	104	53	,	,	,
cord-302316-raf5rlkq	104	54	9	9	CD
cord-302316-raf5rlkq	104	55	%	%	NN
cord-302316-raf5rlkq	104	56	)	)	-RRB-
cord-302316-raf5rlkq	104	57	.	.	.
cord-302316-raf5rlkq	105	1	Such	such	JJ
cord-302316-raf5rlkq	105	2	distinct	distinct	JJ
cord-302316-raf5rlkq	105	3	dissimilarity	dissimilarity	NN
cord-302316-raf5rlkq	105	4	in	in	IN
cord-302316-raf5rlkq	105	5	organ	organ	NN
cord-302316-raf5rlkq	105	6	tropism	tropism	NN
cord-302316-raf5rlkq	105	7	was	be	VBD
cord-302316-raf5rlkq	105	8	also	also	RB
cord-302316-raf5rlkq	105	9	reflected	reflect	VBN
cord-302316-raf5rlkq	105	10	in	in	IN
cord-302316-raf5rlkq	105	11	the	the	DT
cord-302316-raf5rlkq	105	12	differences	difference	NNS
cord-302316-raf5rlkq	105	13	in	in	IN
cord-302316-raf5rlkq	105	14	their	-PRON-	PRP$
cord-302316-raf5rlkq	105	15	capacity	capacity	NN
cord-302316-raf5rlkq	105	16	to	to	TO
cord-302316-raf5rlkq	105	17	infect	infect	VB
cord-302316-raf5rlkq	105	18	pulmonary	pulmonary	JJ
cord-302316-raf5rlkq	105	19	,	,	,
cord-302316-raf5rlkq	105	20	intestinal	intestinal	JJ
cord-302316-raf5rlkq	105	21	and	and	CC
cord-302316-raf5rlkq	105	22	neurological	neurological	JJ
cord-302316-raf5rlkq	105	23	cell	cell	NN
cord-302316-raf5rlkq	105	24	lines	line	NNS
cord-302316-raf5rlkq	105	25	.	.	.
cord-302316-raf5rlkq	106	1	Ex	Ex	NNP
cord-302316-raf5rlkq	106	2	vivo	vivo	NN
cord-302316-raf5rlkq	106	3	studies	study	NNS
cord-302316-raf5rlkq	106	4	with	with	IN
cord-302316-raf5rlkq	106	5	human	human	JJ
cord-302316-raf5rlkq	106	6	tissues	tissue	NNS
cord-302316-raf5rlkq	106	7	obtained	obtain	VBN
cord-302316-raf5rlkq	106	8	during	during	IN
cord-302316-raf5rlkq	106	9	surgery	surgery	NN
cord-302316-raf5rlkq	106	10	demonstrated	demonstrate	VBD
cord-302316-raf5rlkq	106	11	that	that	IN
cord-302316-raf5rlkq	106	12	SARS	SARS	NNP
cord-302316-raf5rlkq	106	13	-	-	HYPH
cord-302316-raf5rlkq	106	14	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	106	15	infects	infect	VBZ
cord-302316-raf5rlkq	106	16	ciliated	ciliated	JJ
cord-302316-raf5rlkq	106	17	and	and	CC
cord-302316-raf5rlkq	106	18	mucus	mucus	NN
cord-302316-raf5rlkq	106	19	-	-	HYPH
cord-302316-raf5rlkq	106	20	producing	produce	VBG
cord-302316-raf5rlkq	106	21	goblet	goblet	NN
cord-302316-raf5rlkq	106	22	cells	cell	NNS
cord-302316-raf5rlkq	106	23	and	and	CC
cord-302316-raf5rlkq	106	24	club	club	NN
cord-302316-raf5rlkq	106	25	cells	cell	NNS
cord-302316-raf5rlkq	106	26	in	in	IN
cord-302316-raf5rlkq	106	27	the	the	DT
cord-302316-raf5rlkq	106	28	bronchi	bronchi	NN
cord-302316-raf5rlkq	106	29	,	,	,
cord-302316-raf5rlkq	106	30	pneumocytes	pneumocyte	NNS
cord-302316-raf5rlkq	106	31	in	in	IN
cord-302316-raf5rlkq	106	32	the	the	DT
cord-302316-raf5rlkq	106	33	lung	lung	NN
cord-302316-raf5rlkq	106	34	and	and	CC
cord-302316-raf5rlkq	106	35	the	the	DT
cord-302316-raf5rlkq	106	36	conjunctiva	conjunctiva	NN
cord-302316-raf5rlkq	106	37	of	of	IN
cord-302316-raf5rlkq	106	38	eyes	eye	NNS
cord-302316-raf5rlkq	107	1	(	(	-LRB-
cord-302316-raf5rlkq	107	2	Hui	Hui	NNP
cord-302316-raf5rlkq	107	3	et	et	NNP
cord-302316-raf5rlkq	107	4	al	al	NNP
cord-302316-raf5rlkq	107	5	.	.	NNP
cord-302316-raf5rlkq	107	6	,	,	,
cord-302316-raf5rlkq	107	7	2020	2020	CD
cord-302316-raf5rlkq	107	8	)	)	-RRB-
cord-302316-raf5rlkq	107	9	.	.	.
cord-302316-raf5rlkq	108	1	Organoids	Organoids	NNP
cord-302316-raf5rlkq	108	2	,	,	,
cord-302316-raf5rlkq	108	3	3-D	3-d	JJ
cord-302316-raf5rlkq	108	4	cell	cell	NN
cord-302316-raf5rlkq	108	5	structures	structure	NNS
cord-302316-raf5rlkq	108	6	grown	grow	VBN
cord-302316-raf5rlkq	108	7	from	from	IN
cord-302316-raf5rlkq	108	8	stem	stem	NN
cord-302316-raf5rlkq	108	9	cells	cell	NNS
cord-302316-raf5rlkq	108	10	that	that	WDT
cord-302316-raf5rlkq	108	11	recapitulate	recapitulate	VBP
cord-302316-raf5rlkq	108	12	key	key	JJ
cord-302316-raf5rlkq	108	13	aspects	aspect	NNS
cord-302316-raf5rlkq	108	14	of	of	IN
cord-302316-raf5rlkq	108	15	the	the	DT
cord-302316-raf5rlkq	108	16	organs	organ	NNS
cord-302316-raf5rlkq	108	17	,	,	,
cord-302316-raf5rlkq	108	18	were	be	VBD
cord-302316-raf5rlkq	108	19	obtained	obtain	VBN
cord-302316-raf5rlkq	108	20	from	from	IN
cord-302316-raf5rlkq	108	21	human	human	JJ
cord-302316-raf5rlkq	108	22	small	small	JJ
cord-302316-raf5rlkq	108	23	intestine	intestine	NN
cord-302316-raf5rlkq	108	24	and	and	CC
cord-302316-raf5rlkq	108	25	could	could	MD
cord-302316-raf5rlkq	108	26	also	also	RB
cord-302316-raf5rlkq	108	27	be	be	VB
cord-302316-raf5rlkq	108	28	successfully	successfully	RB
cord-302316-raf5rlkq	108	29	infected	infect	VBN
cord-302316-raf5rlkq	108	30	with	with	IN
cord-302316-raf5rlkq	108	31	SARS	SARS	NNP
cord-302316-raf5rlkq	108	32	-	-	HYPH
cord-302316-raf5rlkq	108	33	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	108	34	.	.	.
cord-302316-raf5rlkq	109	1	Enterocyte	Enterocyte	NNP
cord-302316-raf5rlkq	109	2	progenitors	progenitor	NNS
cord-302316-raf5rlkq	109	3	were	be	VBD
cord-302316-raf5rlkq	109	4	the	the	DT
cord-302316-raf5rlkq	109	5	primary	primary	JJ
cord-302316-raf5rlkq	109	6	viral	viral	JJ
cord-302316-raf5rlkq	109	7	target	target	NN
cord-302316-raf5rlkq	109	8	cells	cell	NNS
cord-302316-raf5rlkq	109	9	,	,	,
cord-302316-raf5rlkq	109	10	but	but	CC
cord-302316-raf5rlkq	109	11	also	also	RB
cord-302316-raf5rlkq	109	12	differentiated	differentiate	VBN
cord-302316-raf5rlkq	109	13	enterocytes	enterocyte	NNS
cord-302316-raf5rlkq	109	14	were	be	VBD
cord-302316-raf5rlkq	109	15	infected	infect	VBN
cord-302316-raf5rlkq	109	16	and	and	CC
cord-302316-raf5rlkq	109	17	no	no	DT
cord-302316-raf5rlkq	109	18	other	other	JJ
cord-302316-raf5rlkq	109	19	intestinal	intestinal	JJ
cord-302316-raf5rlkq	109	20	cell	cell	NN
cord-302316-raf5rlkq	109	21	types	type	NNS
cord-302316-raf5rlkq	109	22	.	.	.
cord-302316-raf5rlkq	110	1	The	the	DT
cord-302316-raf5rlkq	110	2	viral	viral	JJ
cord-302316-raf5rlkq	110	3	receptor	receptor	NN
cord-302316-raf5rlkq	110	4	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	110	5	was	be	VBD
cord-302316-raf5rlkq	110	6	abundantly	abundantly	RB
cord-302316-raf5rlkq	110	7	expressed	express	VBN
cord-302316-raf5rlkq	110	8	on	on	IN
cord-302316-raf5rlkq	110	9	the	the	DT
cord-302316-raf5rlkq	110	10	brush	brush	NN
cord-302316-raf5rlkq	110	11	border	border	NN
cord-302316-raf5rlkq	110	12	membranes	membrane	NNS
cord-302316-raf5rlkq	110	13	of	of	IN
cord-302316-raf5rlkq	110	14	enterocytes	enterocyte	NNS
cord-302316-raf5rlkq	110	15	.	.	.
cord-302316-raf5rlkq	111	1	Viral	viral	JJ
cord-302316-raf5rlkq	111	2	replication	replication	NN
cord-302316-raf5rlkq	111	3	occurred	occur	VBD
cord-302316-raf5rlkq	111	4	in	in	IN
cord-302316-raf5rlkq	111	5	intracellular	intracellular	JJ
cord-302316-raf5rlkq	111	6	'	'	``
cord-302316-raf5rlkq	111	7	viral	viral	JJ
cord-302316-raf5rlkq	111	8	factories	factory	NNS
cord-302316-raf5rlkq	111	9	'	'	POS
cord-302316-raf5rlkq	111	10	surrounded	surround	VBN
cord-302316-raf5rlkq	111	11	by	by	IN
cord-302316-raf5rlkq	111	12	a	a	DT
cord-302316-raf5rlkq	111	13	double	double	JJ
cord-302316-raf5rlkq	111	14	membrane	membrane	NN
cord-302316-raf5rlkq	111	15	.	.	.
cord-302316-raf5rlkq	112	1	Viruses	virus	NNS
cord-302316-raf5rlkq	112	2	were	be	VBD
cord-302316-raf5rlkq	112	3	mainly	mainly	RB
cord-302316-raf5rlkq	112	4	released	release	VBN
cord-302316-raf5rlkq	112	5	apically	apically	RB
cord-302316-raf5rlkq	112	6	from	from	IN
cord-302316-raf5rlkq	112	7	the	the	DT
cord-302316-raf5rlkq	112	8	enterocytes	enterocyte	NNS
cord-302316-raf5rlkq	112	9	.	.	.
cord-302316-raf5rlkq	113	1	SARS	SARS	NNP
cord-302316-raf5rlkq	113	2	-	-	HYPH
cord-302316-raf5rlkq	113	3	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	113	4	induced	induce	VBD
cord-302316-raf5rlkq	113	5	the	the	DT
cord-302316-raf5rlkq	113	6	transcription	transcription	NN
cord-302316-raf5rlkq	113	7	of	of	IN
cord-302316-raf5rlkq	113	8	cytokines	cytokine	NNS
cord-302316-raf5rlkq	113	9	and	and	CC
cord-302316-raf5rlkq	113	10	interferon	interferon	NN
cord-302316-raf5rlkq	113	11	-	-	HYPH
cord-302316-raf5rlkq	113	12	stimulated	stimulate	VBN
cord-302316-raf5rlkq	113	13	genes	gene	NNS
cord-302316-raf5rlkq	113	14	in	in	IN
cord-302316-raf5rlkq	113	15	gut	gut	NN
cord-302316-raf5rlkq	113	16	organoids	organoid	NNS
cord-302316-raf5rlkq	113	17	.	.	.
cord-302316-raf5rlkq	114	1	An	an	DT
cord-302316-raf5rlkq	114	2	impressive	impressive	JJ
cord-302316-raf5rlkq	114	3	approach	approach	NN
cord-302316-raf5rlkq	114	4	to	to	IN
cord-302316-raf5rlkq	114	5	tissue	tissue	NN
cord-302316-raf5rlkq	114	6	tropism	tropism	NN
cord-302316-raf5rlkq	114	7	was	be	VBD
cord-302316-raf5rlkq	114	8	published	publish	VBN
cord-302316-raf5rlkq	114	9	by	by	IN
cord-302316-raf5rlkq	114	10	the	the	DT
cord-302316-raf5rlkq	114	11	US	US	NNP
cord-302316-raf5rlkq	114	12	Lung	Lung	NNP
cord-302316-raf5rlkq	114	13	Biological	Biological	NNP
cord-302316-raf5rlkq	114	14	Network	Network	NNP
cord-302316-raf5rlkq	114	15	.	.	.
cord-302316-raf5rlkq	115	1	The	the	DT
cord-302316-raf5rlkq	115	2	consortium	consortium	NN
cord-302316-raf5rlkq	115	3	used	use	VBD
cord-302316-raf5rlkq	115	4	large	large	JJ
cord-302316-raf5rlkq	115	5	single	single	JJ
cord-302316-raf5rlkq	115	6	-	-	HYPH
cord-302316-raf5rlkq	115	7	cell	cell	NN
cord-302316-raf5rlkq	115	8	RNA	rna	NN
cord-302316-raf5rlkq	115	9	sequencing	sequencing	NN
cord-302316-raf5rlkq	115	10	(	(	-LRB-
cord-302316-raf5rlkq	115	11	scRNAseq	scRNAseq	NNP
cord-302316-raf5rlkq	115	12	)	)	-RRB-
cord-302316-raf5rlkq	115	13	data	datum	NNS
cord-302316-raf5rlkq	115	14	sets	set	NNS
cord-302316-raf5rlkq	115	15	from	from	IN
cord-302316-raf5rlkq	115	16	primates	primate	NNS
cord-302316-raf5rlkq	115	17	and	and	CC
cord-302316-raf5rlkq	115	18	humans	human	NNS
cord-302316-raf5rlkq	115	19	,	,	,
cord-302316-raf5rlkq	115	20	asking	ask	VBG
cord-302316-raf5rlkq	115	21	which	which	WDT
cord-302316-raf5rlkq	115	22	cellular	cellular	JJ
cord-302316-raf5rlkq	115	23	subsets	subset	NNS
cord-302316-raf5rlkq	115	24	coexpressed	coexpresse	VBD
cord-302316-raf5rlkq	115	25	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	115	26	and	and	CC
cord-302316-raf5rlkq	115	27	TMPRSS2	TMPRSS2	NNP
cord-302316-raf5rlkq	115	28	.	.	.
cord-302316-raf5rlkq	116	1	Doublepositive	Doublepositive	NNP
cord-302316-raf5rlkq	116	2	cells	cell	NNS
cord-302316-raf5rlkq	116	3	are	be	VBP
cord-302316-raf5rlkq	116	4	the	the	DT
cord-302316-raf5rlkq	116	5	likely	likely	JJ
cord-302316-raf5rlkq	116	6	support	support	NN
cord-302316-raf5rlkq	116	7	for	for	IN
cord-302316-raf5rlkq	116	8	in	in	IN
cord-302316-raf5rlkq	116	9	vivo	vivo	FW
cord-302316-raf5rlkq	116	10	viral	viral	JJ
cord-302316-raf5rlkq	116	11	replication	replication	NN
cord-302316-raf5rlkq	116	12	.	.	.
cord-302316-raf5rlkq	117	1	Seventeen	seventeen	CD
cord-302316-raf5rlkq	117	2	cell	cell	NN
cord-302316-raf5rlkq	117	3	types	type	NNS
cord-302316-raf5rlkq	117	4	were	be	VBD
cord-302316-raf5rlkq	117	5	distinguished	distinguish	VBN
cord-302316-raf5rlkq	117	6	in	in	IN
cord-302316-raf5rlkq	117	7	the	the	DT
cord-302316-raf5rlkq	117	8	lungs	lung	NNS
cord-302316-raf5rlkq	117	9	of	of	IN
cord-302316-raf5rlkq	117	10	rhesus	rhesu	NNS
cord-302316-raf5rlkq	117	11	monkeys	monkey	NNS
cord-302316-raf5rlkq	117	12	,	,	,
cord-302316-raf5rlkq	117	13	but	but	CC
cord-302316-raf5rlkq	117	14	only	only	JJ
cord-302316-raf5rlkq	117	15	type	type	NN
cord-302316-raf5rlkq	117	16	II	II	NNP
cord-302316-raf5rlkq	117	17	pneumocytes	pneumocyte	NNS
cord-302316-raf5rlkq	117	18	expressed	express	VBD
cord-302316-raf5rlkq	117	19	both	both	DT
cord-302316-raf5rlkq	117	20	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	117	21	and	and	CC
cord-302316-raf5rlkq	117	22	TMPRSS2	TMPRSS2	NNP
cord-302316-raf5rlkq	117	23	.	.	.
cord-302316-raf5rlkq	118	1	In	in	IN
cord-302316-raf5rlkq	118	2	lung	lung	NN
cord-302316-raf5rlkq	118	3	resection	resection	NN
cord-302316-raf5rlkq	118	4	material	material	NN
cord-302316-raf5rlkq	118	5	from	from	IN
cord-302316-raf5rlkq	118	6	humans	human	NNS
cord-302316-raf5rlkq	118	7	,	,	,
cord-302316-raf5rlkq	118	8	type	type	NN
cord-302316-raf5rlkq	118	9	II	II	NNP
cord-302316-raf5rlkq	118	10	pneumocytes	pneumocyte	NNS
cord-302316-raf5rlkq	118	11	and	and	CC
cord-302316-raf5rlkq	118	12	ciliated	ciliated	JJ
cord-302316-raf5rlkq	118	13	cells	cell	NNS
cord-302316-raf5rlkq	118	14	showed	show	VBD
cord-302316-raf5rlkq	118	15	this	this	DT
cord-302316-raf5rlkq	118	16	double	double	JJ
cord-302316-raf5rlkq	118	17	expression	expression	NN
cord-302316-raf5rlkq	118	18	.	.	.
cord-302316-raf5rlkq	119	1	A	a	DT
cord-302316-raf5rlkq	119	2	striking	striking	JJ
cord-302316-raf5rlkq	119	3	observation	observation	NN
cord-302316-raf5rlkq	119	4	both	both	CC
cord-302316-raf5rlkq	119	5	in	in	IN
cord-302316-raf5rlkq	119	6	rhesus	rhesus	NNP
cord-302316-raf5rlkq	119	7	monkey	monkey	NN
cord-302316-raf5rlkq	119	8	and	and	CC
cord-302316-raf5rlkq	119	9	in	in	IN
cord-302316-raf5rlkq	119	10	humans	human	NNS
cord-302316-raf5rlkq	119	11	was	be	VBD
cord-302316-raf5rlkq	119	12	that	that	IN
cord-302316-raf5rlkq	119	13	interferon	interferon	NN
cord-302316-raf5rlkq	119	14	-	-	HYPH
cord-302316-raf5rlkq	119	15	induced	induce	VBN
cord-302316-raf5rlkq	119	16	genes	gene	NNS
cord-302316-raf5rlkq	119	17	were	be	VBD
cord-302316-raf5rlkq	119	18	upregulated	upregulate	VBN
cord-302316-raf5rlkq	119	19	in	in	IN
cord-302316-raf5rlkq	119	20	these	these	DT
cord-302316-raf5rlkq	119	21	double	double	JJ
cord-302316-raf5rlkq	119	22	-	-	HYPH
cord-302316-raf5rlkq	119	23	positive	positive	JJ
cord-302316-raf5rlkq	119	24	cells	cell	NNS
cord-302316-raf5rlkq	119	25	.	.	.
cord-302316-raf5rlkq	120	1	Absorptive	absorptive	JJ
cord-302316-raf5rlkq	120	2	enterocytes	enterocyte	NNS
cord-302316-raf5rlkq	120	3	from	from	IN
cord-302316-raf5rlkq	120	4	the	the	DT
cord-302316-raf5rlkq	120	5	ileum	ileum	NN
cord-302316-raf5rlkq	120	6	and	and	CC
cord-302316-raf5rlkq	120	7	jejunumboth	jejunumboth	JJ
cord-302316-raf5rlkq	120	8	from	from	IN
cord-302316-raf5rlkq	120	9	monkeys	monkey	NNS
cord-302316-raf5rlkq	120	10	and	and	CC
cord-302316-raf5rlkq	120	11	from	from	IN
cord-302316-raf5rlkq	120	12	the	the	DT
cord-302316-raf5rlkq	120	13	biopsies	biopsy	NNS
cord-302316-raf5rlkq	120	14	of	of	IN
cord-302316-raf5rlkq	120	15	childrencoexpressed	childrencoexpresse	VBN
cord-302316-raf5rlkq	120	16	both	both	DT
cord-302316-raf5rlkq	120	17	genes	gene	NNS
cord-302316-raf5rlkq	120	18	,	,	,
cord-302316-raf5rlkq	120	19	explaining	explain	VBG
cord-302316-raf5rlkq	120	20	the	the	DT
cord-302316-raf5rlkq	120	21	viral	viral	JJ
cord-302316-raf5rlkq	120	22	tropism	tropism	NN
cord-302316-raf5rlkq	120	23	in	in	IN
cord-302316-raf5rlkq	120	24	the	the	DT
cord-302316-raf5rlkq	120	25	gut	gut	NN
cord-302316-raf5rlkq	120	26	.	.	.
cord-302316-raf5rlkq	121	1	In	in	IN
cord-302316-raf5rlkq	121	2	the	the	DT
cord-302316-raf5rlkq	121	3	upper	upper	JJ
cord-302316-raf5rlkq	121	4	respiratory	respiratory	JJ
cord-302316-raf5rlkq	121	5	tract	tract	NN
cord-302316-raf5rlkq	121	6	of	of	IN
cord-302316-raf5rlkq	121	7	humans	human	NNS
cord-302316-raf5rlkq	121	8	,	,	,
cord-302316-raf5rlkq	121	9	apical	apical	JJ
cord-302316-raf5rlkq	121	10	and	and	CC
cord-302316-raf5rlkq	121	11	ciliated	ciliated	JJ
cord-302316-raf5rlkq	121	12	cells	cell	NNS
cord-302316-raf5rlkq	121	13	of	of	IN
cord-302316-raf5rlkq	121	14	the	the	DT
cord-302316-raf5rlkq	121	15	ethmoid	ethmoid	NNP
cord-302316-raf5rlkq	121	16	sinus	sinus	NN
cord-302316-raf5rlkq	121	17	and	and	CC
cord-302316-raf5rlkq	121	18	secretory	secretory	JJ
cord-302316-raf5rlkq	121	19	goblet	goblet	NN
cord-302316-raf5rlkq	121	20	cells	cell	NNS
cord-302316-raf5rlkq	121	21	of	of	IN
cord-302316-raf5rlkq	121	22	the	the	DT
cord-302316-raf5rlkq	121	23	inferior	inferior	JJ
cord-302316-raf5rlkq	121	24	turbinate	turbinate	NN
cord-302316-raf5rlkq	121	25	of	of	IN
cord-302316-raf5rlkq	121	26	the	the	DT
cord-302316-raf5rlkq	121	27	nose	nose	NN
cord-302316-raf5rlkq	121	28	showed	show	VBD
cord-302316-raf5rlkq	121	29	this	this	DT
cord-302316-raf5rlkq	121	30	doubly	doubly	RB
cord-302316-raf5rlkq	121	31	positive	positive	JJ
cord-302316-raf5rlkq	121	32	expression	expression	NN
cord-302316-raf5rlkq	121	33	pattern	pattern	NN
cord-302316-raf5rlkq	121	34	,	,	,
cord-302316-raf5rlkq	121	35	and	and	CC
cord-302316-raf5rlkq	121	36	,	,	,
cord-302316-raf5rlkq	121	37	again	again	RB
cord-302316-raf5rlkq	121	38	,	,	,
cord-302316-raf5rlkq	121	39	showed	show	VBD
cord-302316-raf5rlkq	121	40	a	a	DT
cord-302316-raf5rlkq	121	41	concomitant	concomitant	JJ
cord-302316-raf5rlkq	121	42	upregulation	upregulation	NN
cord-302316-raf5rlkq	121	43	of	of	IN
cord-302316-raf5rlkq	121	44	an	an	DT
cord-302316-raf5rlkq	121	45	interferon	interferon	NN
cord-302316-raf5rlkq	121	46	alpha	alpha	NN
cord-302316-raf5rlkq	121	47	-	-	HYPH
cord-302316-raf5rlkq	121	48	stimulated	stimulate	VBN
cord-302316-raf5rlkq	121	49	gene	gene	NN
cord-302316-raf5rlkq	121	50	set	set	NN
cord-302316-raf5rlkq	121	51	.	.	.
cord-302316-raf5rlkq	122	1	In	in	IN
cord-302316-raf5rlkq	122	2	primary	primary	JJ
cord-302316-raf5rlkq	122	3	human	human	JJ
cord-302316-raf5rlkq	122	4	upper	upper	JJ
cord-302316-raf5rlkq	122	5	airway	airway	NN
cord-302316-raf5rlkq	122	6	epithelial	epithelial	JJ
cord-302316-raf5rlkq	122	7	cells	cell	NNS
cord-302316-raf5rlkq	122	8	,	,	,
cord-302316-raf5rlkq	122	9	the	the	DT
cord-302316-raf5rlkq	122	10	authors	author	NNS
cord-302316-raf5rlkq	122	11	tested	test	VBD
cord-302316-raf5rlkq	122	12	whether	whether	IN
cord-302316-raf5rlkq	122	13	interferon	interferon	NN
cord-302316-raf5rlkq	122	14	plays	play	VBZ
cord-302316-raf5rlkq	122	15	an	an	DT
cord-302316-raf5rlkq	122	16	active	active	JJ
cord-302316-raf5rlkq	122	17	role	role	NN
cord-302316-raf5rlkq	122	18	in	in	IN
cord-302316-raf5rlkq	122	19	upregulating	upregulate	VBG
cord-302316-raf5rlkq	122	20	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	122	21	expression	expression	NN
cord-302316-raf5rlkq	122	22	.	.	.
cord-302316-raf5rlkq	123	1	This	this	DT
cord-302316-raf5rlkq	123	2	was	be	VBD
cord-302316-raf5rlkq	123	3	indeed	indeed	RB
cord-302316-raf5rlkq	123	4	the	the	DT
cord-302316-raf5rlkq	123	5	case	case	NN
cord-302316-raf5rlkq	123	6	for	for	IN
cord-302316-raf5rlkq	123	7	interferon	interferon	NNP
cord-302316-raf5rlkq	123	8	alpha	alpha	NN
cord-302316-raf5rlkq	123	9	,	,	,
cord-302316-raf5rlkq	123	10	but	but	CC
cord-302316-raf5rlkq	123	11	not	not	RB
cord-302316-raf5rlkq	123	12	for	for	IN
cord-302316-raf5rlkq	123	13	interferon	interferon	NN
cord-302316-raf5rlkq	123	14	gamma	gamma	NN
cord-302316-raf5rlkq	123	15	.	.	.
cord-302316-raf5rlkq	124	1	When	when	WRB
cord-302316-raf5rlkq	124	2	screening	screen	VBG
cord-302316-raf5rlkq	124	3	the	the	DT
cord-302316-raf5rlkq	124	4	RNAseq	RNAseq	NNP
cord-302316-raf5rlkq	124	5	database	database	NN
cord-302316-raf5rlkq	124	6	,	,	,
cord-302316-raf5rlkq	124	7	the	the	DT
cord-302316-raf5rlkq	124	8	authors	author	NNS
cord-302316-raf5rlkq	124	9	found	find	VBD
cord-302316-raf5rlkq	124	10	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	124	11	upregulation	upregulation	NN
cord-302316-raf5rlkq	124	12	in	in	IN
cord-302316-raf5rlkq	124	13	human	human	JJ
cord-302316-raf5rlkq	124	14	lung	lung	NN
cord-302316-raf5rlkq	124	15	tissues	tissue	NNS
cord-302316-raf5rlkq	124	16	infected	infect	VBN
cord-302316-raf5rlkq	124	17	ex	ex	FW
cord-302316-raf5rlkq	124	18	vivo	vivo	NN
cord-302316-raf5rlkq	124	19	with	with	IN
cord-302316-raf5rlkq	124	20	influenza	influenza	NN
cord-302316-raf5rlkq	124	21	virus	virus	NN
cord-302316-raf5rlkq	124	22	.	.	.
cord-302316-raf5rlkq	125	1	These	these	DT
cord-302316-raf5rlkq	125	2	observations	observation	NNS
cord-302316-raf5rlkq	125	3	led	lead	VBD
cord-302316-raf5rlkq	125	4	to	to	IN
cord-302316-raf5rlkq	125	5	the	the	DT
cord-302316-raf5rlkq	125	6	hypothesis	hypothesis	NN
cord-302316-raf5rlkq	125	7	that	that	WDT
cord-302316-raf5rlkq	125	8	coronaviruses	coronaviruse	NNS
cord-302316-raf5rlkq	125	9	exploit	exploit	VBP
cord-302316-raf5rlkq	125	10	the	the	DT
cord-302316-raf5rlkq	125	11	antiviral	antiviral	JJ
cord-302316-raf5rlkq	125	12	interferon	interferon	NN
cord-302316-raf5rlkq	125	13	response	response	NN
cord-302316-raf5rlkq	125	14	to	to	IN
cord-302316-raf5rlkq	125	15	their	-PRON-	PRP$
cord-302316-raf5rlkq	125	16	advantage	advantage	NN
cord-302316-raf5rlkq	125	17	by	by	IN
cord-302316-raf5rlkq	125	18	increasing	increase	VBG
cord-302316-raf5rlkq	125	19	the	the	DT
cord-302316-raf5rlkq	125	20	expression	expression	NN
cord-302316-raf5rlkq	125	21	of	of	IN
cord-302316-raf5rlkq	125	22	their	-PRON-	PRP$
cord-302316-raf5rlkq	125	23	cell	cell	NN
cord-302316-raf5rlkq	125	24	receptor	receptor	NN
cord-302316-raf5rlkq	125	25	,	,	,
cord-302316-raf5rlkq	125	26	allowing	allow	VBG
cord-302316-raf5rlkq	125	27	a	a	DT
cord-302316-raf5rlkq	125	28	greater	great	JJR
cord-302316-raf5rlkq	125	29	number	number	NN
cord-302316-raf5rlkq	125	30	of	of	IN
cord-302316-raf5rlkq	125	31	cells	cell	NNS
cord-302316-raf5rlkq	125	32	to	to	TO
cord-302316-raf5rlkq	125	33	be	be	VB
cord-302316-raf5rlkq	125	34	infected	infect	VBN
cord-302316-raf5rlkq	125	35	.	.	.
cord-302316-raf5rlkq	126	1	The	the	DT
cord-302316-raf5rlkq	126	2	authors	author	NNS
cord-302316-raf5rlkq	126	3	caution	caution	VBP
cord-302316-raf5rlkq	126	4	against	against	IN
cord-302316-raf5rlkq	126	5	the	the	DT
cord-302316-raf5rlkq	126	6	use	use	NN
cord-302316-raf5rlkq	126	7	of	of	IN
cord-302316-raf5rlkq	126	8	interferon	interferon	NN
cord-302316-raf5rlkq	126	9	alpha	alpha	NN
cord-302316-raf5rlkq	126	10	in	in	IN
cord-302316-raf5rlkq	126	11	clinical	clinical	JJ
cord-302316-raf5rlkq	126	12	trials	trial	NNS
cord-302316-raf5rlkq	126	13	with	with	IN
cord-302316-raf5rlkq	126	14	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	126	15	patients	patient	NNS
cord-302316-raf5rlkq	126	16	(	(	-LRB-
cord-302316-raf5rlkq	126	17	Ziegler	Ziegler	NNP
cord-302316-raf5rlkq	126	18	et	et	NNP
cord-302316-raf5rlkq	126	19	al	al	NNP
cord-302316-raf5rlkq	126	20	.	.	NNP
cord-302316-raf5rlkq	126	21	,	,	,
cord-302316-raf5rlkq	126	22	2020	2020	CD
cord-302316-raf5rlkq	126	23	)	)	-RRB-
cord-302316-raf5rlkq	126	24	.	.	.
cord-302316-raf5rlkq	127	1	Testing	testing	NN
cord-302316-raf5rlkq	127	2	animals	animal	NNS
cord-302316-raf5rlkq	128	1	SARS	SARS	NNP
cord-302316-raf5rlkq	128	2	-	-	HYPH
cord-302316-raf5rlkq	128	3	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	128	4	is	be	VBZ
cord-302316-raf5rlkq	128	5	suspected	suspect	VBN
cord-302316-raf5rlkq	128	6	to	to	TO
cord-302316-raf5rlkq	128	7	have	have	VB
cord-302316-raf5rlkq	128	8	originated	originate	VBN
cord-302316-raf5rlkq	128	9	from	from	IN
cord-302316-raf5rlkq	128	10	bats	bat	NNS
cord-302316-raf5rlkq	128	11	,	,	,
cord-302316-raf5rlkq	128	12	but	but	CC
cord-302316-raf5rlkq	128	13	the	the	DT
cord-302316-raf5rlkq	128	14	intermediate	intermediate	JJ
cord-302316-raf5rlkq	128	15	host	host	NN
cord-302316-raf5rlkq	128	16	for	for	IN
cord-302316-raf5rlkq	128	17	the	the	DT
cord-302316-raf5rlkq	128	18	transfer	transfer	NN
cord-302316-raf5rlkq	128	19	to	to	IN
cord-302316-raf5rlkq	128	20	humans	human	NNS
cord-302316-raf5rlkq	128	21	is	be	VBZ
cord-302316-raf5rlkq	128	22	currently	currently	RB
cord-302316-raf5rlkq	128	23	unknown	unknown	JJ
cord-302316-raf5rlkq	128	24	.	.	.
cord-302316-raf5rlkq	129	1	Chinese	chinese	JJ
cord-302316-raf5rlkq	129	2	scientists	scientist	NNS
cord-302316-raf5rlkq	129	3	inoculated	inoculate	VBD
cord-302316-raf5rlkq	129	4	a	a	DT
cord-302316-raf5rlkq	129	5	number	number	NN
cord-302316-raf5rlkq	129	6	of	of	IN
cord-302316-raf5rlkq	129	7	animals	animal	NNS
cord-302316-raf5rlkq	129	8	with	with	IN
cord-302316-raf5rlkq	129	9	both	both	CC
cord-302316-raf5rlkq	129	10	an	an	DT
cord-302316-raf5rlkq	129	11	environmental	environmental	JJ
cord-302316-raf5rlkq	129	12	virus	virus	NN
cord-302316-raf5rlkq	129	13	isolate	isolate	VBP
cord-302316-raf5rlkq	129	14	from	from	IN
cord-302316-raf5rlkq	129	15	the	the	DT
cord-302316-raf5rlkq	129	16	wet	wet	JJ
cord-302316-raf5rlkq	129	17	food	food	NN
cord-302316-raf5rlkq	129	18	market	market	NN
cord-302316-raf5rlkq	129	19	in	in	IN
cord-302316-raf5rlkq	129	20	Wuhan	Wuhan	NNP
cord-302316-raf5rlkq	129	21	,	,	,
cord-302316-raf5rlkq	129	22	from	from	IN
cord-302316-raf5rlkq	129	23	where	where	WRB
cord-302316-raf5rlkq	129	24	the	the	DT
cord-302316-raf5rlkq	129	25	epidemic	epidemic	NN
cord-302316-raf5rlkq	129	26	started	start	VBD
cord-302316-raf5rlkq	129	27	,	,	,
cord-302316-raf5rlkq	129	28	and	and	CC
cord-302316-raf5rlkq	129	29	an	an	DT
cord-302316-raf5rlkq	129	30	isolate	isolate	NN
cord-302316-raf5rlkq	129	31	from	from	IN
cord-302316-raf5rlkq	129	32	a	a	DT
cord-302316-raf5rlkq	129	33	patient	patient	NN
cord-302316-raf5rlkq	129	34	from	from	IN
cord-302316-raf5rlkq	129	35	Wuhan	Wuhan	NNP
cord-302316-raf5rlkq	129	36	early	early	RB
cord-302316-raf5rlkq	129	37	in	in	IN
cord-302316-raf5rlkq	129	38	the	the	DT
cord-302316-raf5rlkq	129	39	epidemic	epidemic	NN
cord-302316-raf5rlkq	129	40	.	.	.
cord-302316-raf5rlkq	130	1	Ferrets	ferret	NNS
cord-302316-raf5rlkq	130	2	have	have	VBP
cord-302316-raf5rlkq	130	3	been	be	VBN
cord-302316-raf5rlkq	130	4	infected	infect	VBN
cord-302316-raf5rlkq	130	5	and	and	CC
cord-302316-raf5rlkq	130	6	developed	develop	VBN
cord-302316-raf5rlkq	130	7	an	an	DT
cord-302316-raf5rlkq	130	8	upper	upper	JJ
cord-302316-raf5rlkq	130	9	respiratory	respiratory	JJ
cord-302316-raf5rlkq	130	10	tract	tract	NN
cord-302316-raf5rlkq	130	11	infection	infection	NN
cord-302316-raf5rlkq	130	12	with	with	IN
cord-302316-raf5rlkq	130	13	fever	fever	NN
cord-302316-raf5rlkq	130	14	.	.	.
cord-302316-raf5rlkq	131	1	Outbred	outbreed	VBN
cord-302316-raf5rlkq	131	2	domestic	domestic	JJ
cord-302316-raf5rlkq	131	3	cats	cat	NNS
cord-302316-raf5rlkq	131	4	have	have	VBP
cord-302316-raf5rlkq	131	5	also	also	RB
cord-302316-raf5rlkq	131	6	been	be	VBN
cord-302316-raf5rlkq	131	7	infected	infect	VBN
cord-302316-raf5rlkq	131	8	and	and	CC
cord-302316-raf5rlkq	131	9	then	then	RB
cord-302316-raf5rlkq	131	10	have	have	VBP
cord-302316-raf5rlkq	131	11	developed	develop	VBN
cord-302316-raf5rlkq	131	12	respiratory	respiratory	JJ
cord-302316-raf5rlkq	131	13	tract	tract	NN
cord-302316-raf5rlkq	131	14	symptoms	symptom	NNS
cord-302316-raf5rlkq	131	15	and	and	CC
cord-302316-raf5rlkq	131	16	specific	specific	JJ
cord-302316-raf5rlkq	131	17	antibodies	antibody	NNS
cord-302316-raf5rlkq	131	18	.	.	.
cord-302316-raf5rlkq	132	1	Cats	cat	NNS
cord-302316-raf5rlkq	132	2	can	can	MD
cord-302316-raf5rlkq	132	3	transmit	transmit	VB
cord-302316-raf5rlkq	132	4	infection	infection	NN
cord-302316-raf5rlkq	132	5	via	via	IN
cord-302316-raf5rlkq	132	6	the	the	DT
cord-302316-raf5rlkq	132	7	airborne	airborne	JJ
cord-302316-raf5rlkq	132	8	route	route	NN
cord-302316-raf5rlkq	132	9	to	to	IN
cord-302316-raf5rlkq	132	10	other	other	JJ
cord-302316-raf5rlkq	132	11	cats	cat	NNS
cord-302316-raf5rlkq	132	12	.	.	.
cord-302316-raf5rlkq	133	1	Viral	Viral	NNP
cord-302316-raf5rlkq	133	2	RNA	RNA	NNP
cord-302316-raf5rlkq	133	3	,	,	,
cord-302316-raf5rlkq	133	4	but	but	CC
cord-302316-raf5rlkq	133	5	not	not	RB
cord-302316-raf5rlkq	133	6	infectious	infectious	JJ
cord-302316-raf5rlkq	133	7	virus	virus	NN
cord-302316-raf5rlkq	133	8	,	,	,
cord-302316-raf5rlkq	133	9	was	be	VBD
cord-302316-raf5rlkq	133	10	detected	detect	VBN
cord-302316-raf5rlkq	133	11	in	in	IN
cord-302316-raf5rlkq	133	12	the	the	DT
cord-302316-raf5rlkq	133	13	intestine	intestine	NN
cord-302316-raf5rlkq	133	14	of	of	IN
cord-302316-raf5rlkq	133	15	infected	infected	JJ
cord-302316-raf5rlkq	133	16	cats	cat	NNS
cord-302316-raf5rlkq	133	17	.	.	.
cord-302316-raf5rlkq	134	1	Young	young	JJ
cord-302316-raf5rlkq	134	2	cats	cat	NNS
cord-302316-raf5rlkq	134	3	were	be	VBD
cord-302316-raf5rlkq	134	4	found	find	VBN
cord-302316-raf5rlkq	134	5	to	to	TO
cord-302316-raf5rlkq	134	6	be	be	VB
cord-302316-raf5rlkq	134	7	more	more	RBR
cord-302316-raf5rlkq	134	8	susceptible	susceptible	JJ
cord-302316-raf5rlkq	134	9	to	to	IN
cord-302316-raf5rlkq	134	10	infection	infection	NN
cord-302316-raf5rlkq	134	11	than	than	IN
cord-302316-raf5rlkq	134	12	adult	adult	NN
cord-302316-raf5rlkq	134	13	cats	cat	NNS
cord-302316-raf5rlkq	134	14	.	.	.
cord-302316-raf5rlkq	135	1	Dogs	dog	NNS
cord-302316-raf5rlkq	135	2	that	that	WDT
cord-302316-raf5rlkq	135	3	have	have	VBP
cord-302316-raf5rlkq	135	4	been	be	VBN
cord-302316-raf5rlkq	135	5	infected	infect	VBN
cord-302316-raf5rlkq	135	6	showed	show	VBN
cord-302316-raf5rlkq	135	7	viral	viral	JJ
cord-302316-raf5rlkq	135	8	RNA	RNA	NNP
cord-302316-raf5rlkq	135	9	in	in	IN
cord-302316-raf5rlkq	135	10	the	the	DT
cord-302316-raf5rlkq	135	11	intestine	intestine	NN
cord-302316-raf5rlkq	135	12	,	,	,
cord-302316-raf5rlkq	135	13	but	but	CC
cord-302316-raf5rlkq	135	14	not	not	RB
cord-302316-raf5rlkq	135	15	in	in	IN
cord-302316-raf5rlkq	135	16	the	the	DT
cord-302316-raf5rlkq	135	17	lung	lung	NN
cord-302316-raf5rlkq	135	18	.	.	.
cord-302316-raf5rlkq	136	1	No	no	DT
cord-302316-raf5rlkq	136	2	infectious	infectious	JJ
cord-302316-raf5rlkq	136	3	virus	virus	NN
cord-302316-raf5rlkq	136	4	was	be	VBD
cord-302316-raf5rlkq	136	5	found	find	VBN
cord-302316-raf5rlkq	136	6	in	in	IN
cord-302316-raf5rlkq	136	7	the	the	DT
cord-302316-raf5rlkq	136	8	gut	gut	NN
cord-302316-raf5rlkq	136	9	of	of	IN
cord-302316-raf5rlkq	136	10	dogs	dog	NNS
cord-302316-raf5rlkq	136	11	,	,	,
cord-302316-raf5rlkq	136	12	indicating	indicate	VBG
cord-302316-raf5rlkq	136	13	low	low	JJ
cord-302316-raf5rlkq	136	14	susceptibility	susceptibility	NN
cord-302316-raf5rlkq	136	15	of	of	IN
cord-302316-raf5rlkq	136	16	dogs	dog	NNS
cord-302316-raf5rlkq	136	17	for	for	IN
cord-302316-raf5rlkq	136	18	this	this	DT
cord-302316-raf5rlkq	136	19	virus	virus	NN
cord-302316-raf5rlkq	136	20	.	.	.
cord-302316-raf5rlkq	137	1	Pigs	pig	NNS
cord-302316-raf5rlkq	137	2	,	,	,
cord-302316-raf5rlkq	137	3	chickens	chicken	NNS
cord-302316-raf5rlkq	137	4	and	and	CC
cord-302316-raf5rlkq	137	5	ducks	duck	NNS
cord-302316-raf5rlkq	137	6	could	could	MD
cord-302316-raf5rlkq	137	7	not	not	RB
cord-302316-raf5rlkq	137	8	be	be	VB
cord-302316-raf5rlkq	137	9	infected	infect	VBN
cord-302316-raf5rlkq	137	10	with	with	IN
cord-302316-raf5rlkq	137	11	SARS	SARS	NNP
cord-302316-raf5rlkq	137	12	-	-	HYPH
cord-302316-raf5rlkq	137	13	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	137	14	.	.	.
cord-302316-raf5rlkq	138	1	Animal	animal	NN
cord-302316-raf5rlkq	138	2	models	model	NNS
cord-302316-raf5rlkq	138	3	that	that	WDT
cord-302316-raf5rlkq	138	4	reproduce	reproduce	VBP
cord-302316-raf5rlkq	138	5	the	the	DT
cord-302316-raf5rlkq	138	6	human	human	JJ
cord-302316-raf5rlkq	138	7	infection	infection	NN
cord-302316-raf5rlkq	138	8	are	be	VBP
cord-302316-raf5rlkq	138	9	not	not	RB
cord-302316-raf5rlkq	138	10	only	only	RB
cord-302316-raf5rlkq	138	11	important	important	JJ
cord-302316-raf5rlkq	138	12	for	for	IN
cord-302316-raf5rlkq	138	13	the	the	DT
cord-302316-raf5rlkq	138	14	understanding	understanding	NN
cord-302316-raf5rlkq	138	15	of	of	IN
cord-302316-raf5rlkq	138	16	the	the	DT
cord-302316-raf5rlkq	138	17	pathology	pathology	NN
cord-302316-raf5rlkq	138	18	of	of	IN
cord-302316-raf5rlkq	138	19	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	138	20	infections	infection	NNS
cord-302316-raf5rlkq	138	21	but	but	CC
cord-302316-raf5rlkq	138	22	are	be	VBP
cord-302316-raf5rlkq	138	23	also	also	RB
cord-302316-raf5rlkq	138	24	crucial	crucial	JJ
cord-302316-raf5rlkq	138	25	for	for	IN
cord-302316-raf5rlkq	138	26	the	the	DT
cord-302316-raf5rlkq	138	27	preclinical	preclinical	JJ
cord-302316-raf5rlkq	138	28	testing	testing	NN
cord-302316-raf5rlkq	138	29	of	of	IN
cord-302316-raf5rlkq	138	30	antiviral	antiviral	JJ
cord-302316-raf5rlkq	138	31	drugs	drug	NNS
cord-302316-raf5rlkq	138	32	and	and	CC
cord-302316-raf5rlkq	138	33	vaccine	vaccine	NN
cord-302316-raf5rlkq	138	34	candidates	candidate	NNS
cord-302316-raf5rlkq	138	35	.	.	.
cord-302316-raf5rlkq	139	1	Ferrets	ferret	NNS
cord-302316-raf5rlkq	139	2	,	,	,
cord-302316-raf5rlkq	139	3	a	a	DT
cord-302316-raf5rlkq	139	4	popular	popular	JJ
cord-302316-raf5rlkq	139	5	model	model	NN
cord-302316-raf5rlkq	139	6	for	for	IN
cord-302316-raf5rlkq	139	7	respiratory	respiratory	JJ
cord-302316-raf5rlkq	139	8	viral	viral	JJ
cord-302316-raf5rlkq	139	9	infections	infection	NNS
cord-302316-raf5rlkq	139	10	,	,	,
cord-302316-raf5rlkq	139	11	developed	develop	VBN
cord-302316-raf5rlkq	139	12	fever	fever	NN
cord-302316-raf5rlkq	139	13	after	after	IN
cord-302316-raf5rlkq	139	14	intranasal	intranasal	NN
cord-302316-raf5rlkq	139	15	inoculation	inoculation	NN
cord-302316-raf5rlkq	139	16	with	with	IN
cord-302316-raf5rlkq	139	17	a	a	DT
cord-302316-raf5rlkq	139	18	virus	virus	NN
cord-302316-raf5rlkq	139	19	from	from	IN
cord-302316-raf5rlkq	139	20	a	a	DT
cord-302316-raf5rlkq	139	21	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	139	22	patient	patient	NN
cord-302316-raf5rlkq	139	23	.	.	.
cord-302316-raf5rlkq	140	1	Ferrets	ferret	NNS
cord-302316-raf5rlkq	140	2	showed	show	VBD
cord-302316-raf5rlkq	140	3	moderate	moderate	JJ
cord-302316-raf5rlkq	140	4	titres	titre	NNS
cord-302316-raf5rlkq	140	5	of	of	IN
cord-302316-raf5rlkq	140	6	virus	virus	NN
cord-302316-raf5rlkq	140	7	in	in	IN
cord-302316-raf5rlkq	140	8	the	the	DT
cord-302316-raf5rlkq	140	9	nose	nose	NN
cord-302316-raf5rlkq	140	10	and	and	CC
cord-302316-raf5rlkq	140	11	low	low	JJ
cord-302316-raf5rlkq	140	12	viral	viral	JJ
cord-302316-raf5rlkq	140	13	titres	titre	NNS
cord-302316-raf5rlkq	140	14	in	in	IN
cord-302316-raf5rlkq	140	15	the	the	DT
cord-302316-raf5rlkq	140	16	lung	lung	NN
cord-302316-raf5rlkq	140	17	and	and	CC
cord-302316-raf5rlkq	140	18	intestine	intestine	NN
cord-302316-raf5rlkq	140	19	and	and	CC
cord-302316-raf5rlkq	140	20	displayed	display	VBD
cord-302316-raf5rlkq	140	21	lung	lung	NN
cord-302316-raf5rlkq	140	22	tissue	tissue	NN
cord-302316-raf5rlkq	140	23	pathology	pathology	NN
cord-302316-raf5rlkq	140	24	.	.	.
cord-302316-raf5rlkq	141	1	Ferrets	ferret	NNS
cord-302316-raf5rlkq	141	2	recovered	recover	VBD
cord-302316-raf5rlkq	141	3	after	after	IN
cord-302316-raf5rlkq	141	4	2	2	CD
cord-302316-raf5rlkq	141	5	weeks	week	NNS
cord-302316-raf5rlkq	141	6	and	and	CC
cord-302316-raf5rlkq	141	7	seroconverted	seroconverte	VBD
cord-302316-raf5rlkq	141	8	with	with	IN
cord-302316-raf5rlkq	141	9	neutralizing	neutralize	VBG
cord-302316-raf5rlkq	141	10	antibodies	antibody	NNS
cord-302316-raf5rlkq	141	11	.	.	.
cord-302316-raf5rlkq	142	1	Infected	infected	JJ
cord-302316-raf5rlkq	142	2	ferrets	ferret	NNS
cord-302316-raf5rlkq	142	3	transmitted	transmit	VBD
cord-302316-raf5rlkq	142	4	the	the	DT
cord-302316-raf5rlkq	142	5	infection	infection	NN
cord-302316-raf5rlkq	142	6	efficiently	efficiently	RB
cord-302316-raf5rlkq	142	7	in	in	IN
cord-302316-raf5rlkq	142	8	the	the	DT
cord-302316-raf5rlkq	142	9	presymptomatic	presymptomatic	JJ
cord-302316-raf5rlkq	142	10	stage	stage	NN
cord-302316-raf5rlkq	142	11	to	to	IN
cord-302316-raf5rlkq	142	12	na€	na€	JJ
cord-302316-raf5rlkq	142	13	ıve	ıve	JJ
cord-302316-raf5rlkq	142	14	ferrets	ferret	NNS
cord-302316-raf5rlkq	142	15	not	not	RB
cord-302316-raf5rlkq	142	16	only	only	RB
cord-302316-raf5rlkq	142	17	via	via	IN
cord-302316-raf5rlkq	142	18	close	close	JJ
cord-302316-raf5rlkq	142	19	contact	contact	NN
cord-302316-raf5rlkq	142	20	,	,	,
cord-302316-raf5rlkq	142	21	but	but	CC
cord-302316-raf5rlkq	142	22	also	also	RB
cord-302316-raf5rlkq	142	23	,	,	,
cord-302316-raf5rlkq	142	24	albeit	albeit	IN
cord-302316-raf5rlkq	142	25	less	less	RBR
cord-302316-raf5rlkq	142	26	efficiently	efficiently	RB
cord-302316-raf5rlkq	142	27	,	,	,
cord-302316-raf5rlkq	142	28	to	to	IN
cord-302316-raf5rlkq	142	29	ferrets	ferret	NNS
cord-302316-raf5rlkq	142	30	in	in	IN
cord-302316-raf5rlkq	142	31	separate	separate	JJ
cord-302316-raf5rlkq	142	32	cages	cage	NNS
cord-302316-raf5rlkq	143	1	(	(	-LRB-
cord-302316-raf5rlkq	143	2	Kim	Kim	NNP
cord-302316-raf5rlkq	143	3	et	et	NNP
cord-302316-raf5rlkq	143	4	al	al	NNP
cord-302316-raf5rlkq	143	5	.	.	NNP
cord-302316-raf5rlkq	143	6	,	,	,
cord-302316-raf5rlkq	143	7	2020	2020	CD
cord-302316-raf5rlkq	143	8	)	)	-RRB-
cord-302316-raf5rlkq	143	9	.	.	.
cord-302316-raf5rlkq	144	1	Hamsters	hamster	NNS
cord-302316-raf5rlkq	144	2	,	,	,
cord-302316-raf5rlkq	144	3	infected	infect	VBN
cord-302316-raf5rlkq	144	4	with	with	IN
cord-302316-raf5rlkq	144	5	a	a	DT
cord-302316-raf5rlkq	144	6	virus	virus	NN
cord-302316-raf5rlkq	144	7	from	from	IN
cord-302316-raf5rlkq	144	8	a	a	DT
cord-302316-raf5rlkq	144	9	Hong	Hong	NNP
cord-302316-raf5rlkq	144	10	Kong	Kong	NNP
cord-302316-raf5rlkq	144	11	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	144	12	patient	patient	NN
cord-302316-raf5rlkq	144	13	,	,	,
cord-302316-raf5rlkq	144	14	showed	show	VBD
cord-302316-raf5rlkq	144	15	weight	weight	NN
cord-302316-raf5rlkq	144	16	loss	loss	NN
cord-302316-raf5rlkq	144	17	,	,	,
cord-302316-raf5rlkq	144	18	lethargy	lethargy	NN
cord-302316-raf5rlkq	144	19	and	and	CC
cord-302316-raf5rlkq	144	20	rapid	rapid	JJ
cord-302316-raf5rlkq	144	21	breathing	breathing	NN
cord-302316-raf5rlkq	144	22	.	.	.
cord-302316-raf5rlkq	145	1	High	high	JJ
cord-302316-raf5rlkq	145	2	virus	virus	NN
cord-302316-raf5rlkq	145	3	titres	titre	NNS
cord-302316-raf5rlkq	145	4	were	be	VBD
cord-302316-raf5rlkq	145	5	found	find	VBN
cord-302316-raf5rlkq	145	6	in	in	IN
cord-302316-raf5rlkq	145	7	the	the	DT
cord-302316-raf5rlkq	145	8	nose	nose	NN
cord-302316-raf5rlkq	145	9	,	,	,
cord-302316-raf5rlkq	145	10	the	the	DT
cord-302316-raf5rlkq	145	11	lung	lung	NN
cord-302316-raf5rlkq	145	12	and	and	CC
cord-302316-raf5rlkq	145	13	in	in	IN
cord-302316-raf5rlkq	145	14	the	the	DT
cord-302316-raf5rlkq	145	15	intestine	intestine	NN
cord-302316-raf5rlkq	145	16	.	.	.
cord-302316-raf5rlkq	146	1	Histopathological	Histopathological	NNP
cord-302316-raf5rlkq	146	2	changes	change	NNS
cord-302316-raf5rlkq	146	3	were	be	VBD
cord-302316-raf5rlkq	146	4	seen	see	VBN
cord-302316-raf5rlkq	146	5	in	in	IN
cord-302316-raf5rlkq	146	6	the	the	DT
cord-302316-raf5rlkq	146	7	nose	nose	NN
cord-302316-raf5rlkq	146	8	,	,	,
cord-302316-raf5rlkq	146	9	the	the	DT
cord-302316-raf5rlkq	146	10	trachea	trachea	NN
cord-302316-raf5rlkq	146	11	and	and	CC
cord-302316-raf5rlkq	146	12	the	the	DT
cord-302316-raf5rlkq	146	13	lung	lung	NN
cord-302316-raf5rlkq	146	14	displaying	display	VBG
cord-302316-raf5rlkq	146	15	alveolar	alveolar	JJ
cord-302316-raf5rlkq	146	16	destruction	destruction	NN
cord-302316-raf5rlkq	146	17	,	,	,
cord-302316-raf5rlkq	146	18	but	but	CC
cord-302316-raf5rlkq	146	19	also	also	RB
cord-302316-raf5rlkq	146	20	in	in	IN
cord-302316-raf5rlkq	146	21	the	the	DT
cord-302316-raf5rlkq	146	22	gut	gut	NN
cord-302316-raf5rlkq	146	23	demonstrating	demonstrate	VBG
cord-302316-raf5rlkq	146	24	epithelial	epithelial	JJ
cord-302316-raf5rlkq	146	25	necrosis	necrosis	NN
cord-302316-raf5rlkq	146	26	.	.	.
cord-302316-raf5rlkq	147	1	Interferon	interferon	NN
cord-302316-raf5rlkq	147	2	and	and	CC
cord-302316-raf5rlkq	147	3	pro	pro	JJ
cord-302316-raf5rlkq	147	4	-	-	JJ
cord-302316-raf5rlkq	147	5	inflammatory	inflammatory	JJ
cord-302316-raf5rlkq	147	6	cytokines	cytokine	NNS
cord-302316-raf5rlkq	147	7	were	be	VBD
cord-302316-raf5rlkq	147	8	rapidly	rapidly	RB
cord-302316-raf5rlkq	147	9	induced	induce	VBN
cord-302316-raf5rlkq	147	10	,	,	,
cord-302316-raf5rlkq	147	11	reached	reach	VBN
cord-302316-raf5rlkq	147	12	peak	peak	NN
cord-302316-raf5rlkq	147	13	titres	titre	NNS
cord-302316-raf5rlkq	147	14	and	and	CC
cord-302316-raf5rlkq	147	15	dropped	drop	VBD
cord-302316-raf5rlkq	147	16	after	after	IN
cord-302316-raf5rlkq	147	17	a	a	DT
cord-302316-raf5rlkq	147	18	week	week	NN
cord-302316-raf5rlkq	147	19	with	with	IN
cord-302316-raf5rlkq	147	20	the	the	DT
cord-302316-raf5rlkq	147	21	development	development	NN
cord-302316-raf5rlkq	147	22	of	of	IN
cord-302316-raf5rlkq	147	23	neutralizing	neutralize	VBG
cord-302316-raf5rlkq	147	24	antibodies	antibody	NNS
cord-302316-raf5rlkq	147	25	and	and	CC
cord-302316-raf5rlkq	147	26	recovery	recovery	NN
cord-302316-raf5rlkq	147	27	from	from	IN
cord-302316-raf5rlkq	147	28	disease	disease	NN
cord-302316-raf5rlkq	147	29	.	.	.
cord-302316-raf5rlkq	148	1	Na€	Na€	NNP
cord-302316-raf5rlkq	148	2	ıve	ıve	JJ
cord-302316-raf5rlkq	148	3	contact	contact	NN
cord-302316-raf5rlkq	148	4	hamster	hamster	NN
cord-302316-raf5rlkq	148	5	were	be	VBD
cord-302316-raf5rlkq	148	6	efficiently	efficiently	RB
cord-302316-raf5rlkq	148	7	infected	infect	VBN
cord-302316-raf5rlkq	148	8	,	,	,
cord-302316-raf5rlkq	148	9	but	but	CC
cord-302316-raf5rlkq	148	10	showed	show	VBD
cord-302316-raf5rlkq	148	11	less	less	JJR
cord-302316-raf5rlkq	148	12	weight	weight	NN
cord-302316-raf5rlkq	148	13	loss	loss	NN
cord-302316-raf5rlkq	148	14	.	.	.
cord-302316-raf5rlkq	149	1	Macaques	macaque	NNS
cord-302316-raf5rlkq	149	2	have	have	VBP
cord-302316-raf5rlkq	149	3	been	be	VBN
cord-302316-raf5rlkq	149	4	infected	infect	VBN
cord-302316-raf5rlkq	149	5	with	with	IN
cord-302316-raf5rlkq	149	6	SARS	SARS	NNP
cord-302316-raf5rlkq	149	7	-	-	HYPH
cord-302316-raf5rlkq	149	8	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	149	9	but	but	CC
cord-302316-raf5rlkq	149	10	showed	show	VBD
cord-302316-raf5rlkq	149	11	no	no	DT
cord-302316-raf5rlkq	149	12	clinical	clinical	JJ
cord-302316-raf5rlkq	149	13	symptoms	symptom	NNS
cord-302316-raf5rlkq	149	14	,	,	,
cord-302316-raf5rlkq	149	15	except	except	IN
cord-302316-raf5rlkq	149	16	for	for	IN
cord-302316-raf5rlkq	149	17	moderate	moderate	JJ
cord-302316-raf5rlkq	149	18	titres	titre	NNS
cord-302316-raf5rlkq	149	19	of	of	IN
cord-302316-raf5rlkq	149	20	virus	virus	NN
cord-302316-raf5rlkq	149	21	excreted	excrete	VBN
cord-302316-raf5rlkq	149	22	from	from	IN
cord-302316-raf5rlkq	149	23	the	the	DT
cord-302316-raf5rlkq	149	24	nose	nose	NN
cord-302316-raf5rlkq	149	25	and	and	CC
cord-302316-raf5rlkq	149	26	throat	throat	NN
cord-302316-raf5rlkq	149	27	.	.	.
cord-302316-raf5rlkq	150	1	Maximal	maximal	JJ
cord-302316-raf5rlkq	150	2	viral	viral	JJ
cord-302316-raf5rlkq	150	3	titres	titre	NNS
cord-302316-raf5rlkq	150	4	were	be	VBD
cord-302316-raf5rlkq	150	5	seen	see	VBN
cord-302316-raf5rlkq	150	6	early	early	RB
cord-302316-raf5rlkq	150	7	after	after	IN
cord-302316-raf5rlkq	150	8	infection	infection	NN
cord-302316-raf5rlkq	150	9	,	,	,
cord-302316-raf5rlkq	150	10	and	and	CC
cord-302316-raf5rlkq	150	11	titres	titre	NNS
cord-302316-raf5rlkq	150	12	were	be	VBD
cord-302316-raf5rlkq	150	13	higher	high	JJR
cord-302316-raf5rlkq	150	14	in	in	IN
cord-302316-raf5rlkq	150	15	older	old	JJR
cord-302316-raf5rlkq	150	16	animals	animal	NNS
cord-302316-raf5rlkq	150	17	.	.	.
cord-302316-raf5rlkq	151	1	Upon	upon	IN
cord-302316-raf5rlkq	151	2	autopsy	autopsy	JJ
cord-302316-raf5rlkq	151	3	,	,	,
cord-302316-raf5rlkq	151	4	pulmonary	pulmonary	JJ
cord-302316-raf5rlkq	151	5	damage	damage	NN
cord-302316-raf5rlkq	151	6	presented	present	VBN
cord-302316-raf5rlkq	151	7	as	as	IN
cord-302316-raf5rlkq	151	8	the	the	DT
cord-302316-raf5rlkq	151	9	diffuse	diffuse	JJ
cord-302316-raf5rlkq	151	10	alveolar	alveolar	NN
cord-302316-raf5rlkq	151	11	damage	damage	NN
cord-302316-raf5rlkq	151	12	that	that	WDT
cord-302316-raf5rlkq	151	13	is	be	VBZ
cord-302316-raf5rlkq	151	14	associated	associate	VBN
cord-302316-raf5rlkq	151	15	with	with	IN
cord-302316-raf5rlkq	151	16	replicating	replicate	VBG
cord-302316-raf5rlkq	151	17	virus	virus	NN
cord-302316-raf5rlkq	151	18	.	.	.
cord-302316-raf5rlkq	152	1	The	the	DT
cord-302316-raf5rlkq	152	2	animals	animal	NNS
cord-302316-raf5rlkq	152	3	seroconverted	seroconverte	VBD
cord-302316-raf5rlkq	152	4	(	(	-LRB-
cord-302316-raf5rlkq	152	5	Rockx	Rockx	NNP
cord-302316-raf5rlkq	152	6	et	et	NNP
cord-302316-raf5rlkq	152	7	al	al	NNP
cord-302316-raf5rlkq	152	8	.	.	NNP
cord-302316-raf5rlkq	152	9	,	,	,
cord-302316-raf5rlkq	152	10	2020	2020	CD
cord-302316-raf5rlkq	152	11	)	)	-RRB-
cord-302316-raf5rlkq	152	12	.	.	.
cord-302316-raf5rlkq	153	1	Also	also	RB
cord-302316-raf5rlkq	153	2	,	,	,
cord-302316-raf5rlkq	153	3	rhesus	rhesu	NNS
cord-302316-raf5rlkq	153	4	monkeys	monkey	NNS
cord-302316-raf5rlkq	153	5	showed	show	VBD
cord-302316-raf5rlkq	153	6	viral	viral	JJ
cord-302316-raf5rlkq	153	7	replication	replication	NN
cord-302316-raf5rlkq	153	8	in	in	IN
cord-302316-raf5rlkq	153	9	the	the	DT
cord-302316-raf5rlkq	153	10	pharynx	pharynx	NN
cord-302316-raf5rlkq	153	11	and	and	CC
cord-302316-raf5rlkq	153	12	severe	severe	JJ
cord-302316-raf5rlkq	153	13	interstitial	interstitial	JJ
cord-302316-raf5rlkq	153	14	pneumonia	pneumonia	NN
cord-302316-raf5rlkq	153	15	.	.	.
cord-302316-raf5rlkq	154	1	Lung	lung	NN
cord-302316-raf5rlkq	154	2	tissue	tissue	NN
cord-302316-raf5rlkq	154	3	from	from	IN
cord-302316-raf5rlkq	154	4	17	17	CD
cord-302316-raf5rlkq	154	5	of	of	IN
cord-302316-raf5rlkq	154	6	25	25	CD
cord-302316-raf5rlkq	154	7	Malayan	malayan	JJ
cord-302316-raf5rlkq	154	8	pangolins	pangolin	NNS
cord-302316-raf5rlkq	154	9	from	from	IN
cord-302316-raf5rlkq	154	10	a	a	DT
cord-302316-raf5rlkq	154	11	wildlife	wildlife	NN
cord-302316-raf5rlkq	154	12	rescue	rescue	NN
cord-302316-raf5rlkq	154	13	centre	centre	NN
cord-302316-raf5rlkq	154	14	in	in	IN
cord-302316-raf5rlkq	154	15	China	China	NNP
cord-302316-raf5rlkq	154	16	yielded	yield	VBD
cord-302316-raf5rlkq	154	17	a	a	DT
cord-302316-raf5rlkq	154	18	positive	positive	JJ
cord-302316-raf5rlkq	154	19	result	result	NN
cord-302316-raf5rlkq	154	20	for	for	IN
cord-302316-raf5rlkq	154	21	SARS	SARS	NNP
cord-302316-raf5rlkq	154	22	-	-	HYPH
cord-302316-raf5rlkq	154	23	CoV-2-related	cov-2-relate	VBN
cord-302316-raf5rlkq	154	24	sequences	sequence	NNS
cord-302316-raf5rlkq	154	25	.	.	.
cord-302316-raf5rlkq	155	1	Pangolins	pangolin	NNS
cord-302316-raf5rlkq	155	2	are	be	VBP
cord-302316-raf5rlkq	155	3	suspected	suspect	VBN
cord-302316-raf5rlkq	155	4	to	to	TO
cord-302316-raf5rlkq	155	5	have	have	VB
cord-302316-raf5rlkq	155	6	been	be	VBN
cord-302316-raf5rlkq	155	7	intermediate	intermediate	JJ
cord-302316-raf5rlkq	155	8	hosts	host	NNS
cord-302316-raf5rlkq	155	9	at	at	IN
cord-302316-raf5rlkq	155	10	the	the	DT
cord-302316-raf5rlkq	155	11	wet	wet	JJ
cord-302316-raf5rlkq	155	12	food	food	NN
cord-302316-raf5rlkq	155	13	market	market	NN
cord-302316-raf5rlkq	155	14	from	from	IN
cord-302316-raf5rlkq	155	15	Wuhan	Wuhan	NNP
cord-302316-raf5rlkq	155	16	,	,	,
cord-302316-raf5rlkq	155	17	where	where	WRB
cord-302316-raf5rlkq	155	18	the	the	DT
cord-302316-raf5rlkq	155	19	epidemic	epidemic	NN
cord-302316-raf5rlkq	155	20	started	start	VBD
cord-302316-raf5rlkq	155	21	.	.	.
cord-302316-raf5rlkq	156	1	Fourteen	fourteen	CD
cord-302316-raf5rlkq	156	2	of	of	IN
cord-302316-raf5rlkq	156	3	the	the	DT
cord-302316-raf5rlkq	156	4	pangolins	pangolin	NNS
cord-302316-raf5rlkq	156	5	died	die	VBD
cord-302316-raf5rlkq	156	6	,	,	,
cord-302316-raf5rlkq	156	7	showing	show	VBG
cord-302316-raf5rlkq	156	8	lung	lung	NN
cord-302316-raf5rlkq	156	9	consolidation	consolidation	NN
cord-302316-raf5rlkq	156	10	and	and	CC
cord-302316-raf5rlkq	156	11	diffuse	diffuse	VB
cord-302316-raf5rlkq	156	12	alveolar	alveolar	NN
cord-302316-raf5rlkq	156	13	damage	damage	NN
cord-302316-raf5rlkq	156	14	similar	similar	JJ
cord-302316-raf5rlkq	156	15	to	to	IN
cord-302316-raf5rlkq	156	16	human	human	JJ
cord-302316-raf5rlkq	156	17	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	156	18	victims	victim	NNS
cord-302316-raf5rlkq	156	19	.	.	.
cord-302316-raf5rlkq	157	1	A	a	DT
cord-302316-raf5rlkq	157	2	complete	complete	JJ
cord-302316-raf5rlkq	157	3	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	157	4	genome	genome	NN
cord-302316-raf5rlkq	157	5	has	have	VBZ
cord-302316-raf5rlkq	157	6	been	be	VBN
cord-302316-raf5rlkq	157	7	constructed	construct	VBN
cord-302316-raf5rlkq	157	8	from	from	IN
cord-302316-raf5rlkq	157	9	RNA	RNA	NNP
cord-302316-raf5rlkq	157	10	sequencing	sequencing	NN
cord-302316-raf5rlkq	157	11	of	of	IN
cord-302316-raf5rlkq	157	12	the	the	DT
cord-302316-raf5rlkq	157	13	lung	lung	NN
cord-302316-raf5rlkq	157	14	tissues	tissue	NNS
cord-302316-raf5rlkq	157	15	obtained	obtain	VBN
cord-302316-raf5rlkq	157	16	from	from	IN
cord-302316-raf5rlkq	157	17	trafficked	traffic	VBN
cord-302316-raf5rlkq	157	18	Malayan	Malayan	NNP
cord-302316-raf5rlkq	157	19	,	,	,
cord-302316-raf5rlkq	157	20	but	but	CC
cord-302316-raf5rlkq	157	21	not	not	RB
cord-302316-raf5rlkq	157	22	Chinese	chinese	JJ
cord-302316-raf5rlkq	157	23	,	,	,
cord-302316-raf5rlkq	157	24	pangolins	pangolin	NNS
cord-302316-raf5rlkq	157	25	which	which	WDT
cord-302316-raf5rlkq	157	26	represent	represent	VBP
cord-302316-raf5rlkq	157	27	two	two	CD
cord-302316-raf5rlkq	157	28	distinct	distinct	JJ
cord-302316-raf5rlkq	157	29	species	specie	NNS
cord-302316-raf5rlkq	157	30	.	.	.
cord-302316-raf5rlkq	158	1	The	the	DT
cord-302316-raf5rlkq	158	2	Malayan	malayan	JJ
cord-302316-raf5rlkq	158	3	pangolin	pangolin	NN
cord-302316-raf5rlkq	158	4	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	158	5	is	be	VBZ
cord-302316-raf5rlkq	158	6	not	not	RB
cord-302316-raf5rlkq	158	7	a	a	DT
cord-302316-raf5rlkq	158	8	direct	direct	JJ
cord-302316-raf5rlkq	158	9	precursor	precursor	NN
cord-302316-raf5rlkq	158	10	to	to	IN
cord-302316-raf5rlkq	158	11	SARS	SARS	NNP
cord-302316-raf5rlkq	158	12	-	-	HYPH
cord-302316-raf5rlkq	158	13	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	158	14	,	,	,
cord-302316-raf5rlkq	158	15	because	because	IN
cord-302316-raf5rlkq	158	16	its	-PRON-	PRP$
cord-302316-raf5rlkq	158	17	genome	genome	NN
cord-302316-raf5rlkq	158	18	differs	differ	VBZ
cord-302316-raf5rlkq	158	19	too	too	RB
cord-302316-raf5rlkq	158	20	much	much	RB
cord-302316-raf5rlkq	158	21	from	from	IN
cord-302316-raf5rlkq	158	22	the	the	DT
cord-302316-raf5rlkq	158	23	human	human	JJ
cord-302316-raf5rlkq	158	24	isolates	isolate	NNS
cord-302316-raf5rlkq	158	25	,	,	,
cord-302316-raf5rlkq	158	26	but	but	CC
cord-302316-raf5rlkq	158	27	may	may	MD
cord-302316-raf5rlkq	158	28	have	have	VB
cord-302316-raf5rlkq	158	29	contributed	contribute	VBN
cord-302316-raf5rlkq	158	30	the	the	DT
cord-302316-raf5rlkq	158	31	receptor	receptor	NN
cord-302316-raf5rlkq	158	32	binding	bind	VBG
cord-302316-raf5rlkq	158	33	domain	domain	NN
cord-302316-raf5rlkq	158	34	of	of	IN
cord-302316-raf5rlkq	158	35	the	the	DT
cord-302316-raf5rlkq	158	36	spike	spike	NN
cord-302316-raf5rlkq	158	37	protein	protein	NN
cord-302316-raf5rlkq	158	38	gene	gene	NN
cord-302316-raf5rlkq	158	39	by	by	IN
cord-302316-raf5rlkq	158	40	genetic	genetic	JJ
cord-302316-raf5rlkq	158	41	recombination	recombination	NN
cord-302316-raf5rlkq	158	42	with	with	IN
cord-302316-raf5rlkq	158	43	a	a	DT
cord-302316-raf5rlkq	158	44	bat	bat	NN
cord-302316-raf5rlkq	158	45	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	158	46	.	.	.
cord-302316-raf5rlkq	159	1	Pangolins	pangolin	NNS
cord-302316-raf5rlkq	159	2	and	and	CC
cord-302316-raf5rlkq	159	3	bats	bat	NNS
cord-302316-raf5rlkq	159	4	are	be	VBP
cord-302316-raf5rlkq	159	5	both	both	DT
cord-302316-raf5rlkq	159	6	nocturnal	nocturnal	JJ
cord-302316-raf5rlkq	159	7	animals	animal	NNS
cord-302316-raf5rlkq	159	8	that	that	WDT
cord-302316-raf5rlkq	159	9	both	both	DT
cord-302316-raf5rlkq	159	10	eat	eat	VBP
cord-302316-raf5rlkq	159	11	insects	insect	NNS
cord-302316-raf5rlkq	159	12	and	and	CC
cord-302316-raf5rlkq	159	13	share	share	VB
cord-302316-raf5rlkq	159	14	overlapping	overlap	VBG
cord-302316-raf5rlkq	159	15	ecological	ecological	JJ
cord-302316-raf5rlkq	159	16	niches	niche	NNS
cord-302316-raf5rlkq	159	17	,	,	,
cord-302316-raf5rlkq	159	18	rendering	render	VBG
cord-302316-raf5rlkq	159	19	contact	contact	NN
cord-302316-raf5rlkq	159	20	likely	likely	JJ
cord-302316-raf5rlkq	160	1	(	(	-LRB-
cord-302316-raf5rlkq	160	2	Xiao	Xiao	NNP
cord-302316-raf5rlkq	160	3	et	et	NNP
cord-302316-raf5rlkq	160	4	al	al	NNP
cord-302316-raf5rlkq	160	5	.	.	NNP
cord-302316-raf5rlkq	160	6	,	,	,
cord-302316-raf5rlkq	160	7	2020	2020	CD
cord-302316-raf5rlkq	160	8	)	)	-RRB-
cord-302316-raf5rlkq	160	9	.	.	.
cord-302316-raf5rlkq	161	1	To	to	TO
cord-302316-raf5rlkq	161	2	fulfil	fulfil	VB
cord-302316-raf5rlkq	161	3	Koch	Koch	NNP
cord-302316-raf5rlkq	161	4	's	's	POS
cord-302316-raf5rlkq	161	5	postulates	postulate	NNS
cord-302316-raf5rlkq	161	6	,	,	,
cord-302316-raf5rlkq	161	7	transgenic	transgenic	JJ
cord-302316-raf5rlkq	161	8	mice	mouse	NNS
cord-302316-raf5rlkq	161	9	expressing	express	VBG
cord-302316-raf5rlkq	161	10	the	the	DT
cord-302316-raf5rlkq	161	11	human	human	NN
cord-302316-raf5rlkq	161	12	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	161	13	were	be	VBD
cord-302316-raf5rlkq	161	14	infected	infect	VBN
cord-302316-raf5rlkq	161	15	with	with	IN
cord-302316-raf5rlkq	161	16	a	a	DT
cord-302316-raf5rlkq	161	17	SARS	SARS	NNP
cord-302316-raf5rlkq	161	18	-	-	HYPH
cord-302316-raf5rlkq	161	19	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	161	20	isolate	isolate	VBP
cord-302316-raf5rlkq	161	21	from	from	IN
cord-302316-raf5rlkq	161	22	a	a	DT
cord-302316-raf5rlkq	161	23	Chinese	chinese	JJ
cord-302316-raf5rlkq	161	24	patient	patient	NN
cord-302316-raf5rlkq	161	25	.	.	.
cord-302316-raf5rlkq	162	1	Transgenic	transgenic	JJ
cord-302316-raf5rlkq	162	2	mice	mouse	NNS
cord-302316-raf5rlkq	162	3	,	,	,
cord-302316-raf5rlkq	162	4	but	but	CC
cord-302316-raf5rlkq	162	5	not	not	RB
cord-302316-raf5rlkq	162	6	wild	wild	JJ
cord-302316-raf5rlkq	162	7	-	-	HYPH
cord-302316-raf5rlkq	162	8	type	type	NN
cord-302316-raf5rlkq	162	9	mice	mice	NN
cord-302316-raf5rlkq	162	10	(	(	-LRB-
cord-302316-raf5rlkq	162	11	which	which	WDT
cord-302316-raf5rlkq	162	12	lack	lack	VBP
cord-302316-raf5rlkq	162	13	the	the	DT
cord-302316-raf5rlkq	162	14	viral	viral	JJ
cord-302316-raf5rlkq	162	15	cell	cell	NN
cord-302316-raf5rlkq	162	16	receptor	receptor	NN
cord-302316-raf5rlkq	162	17	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	162	18	)	)	-RRB-
cord-302316-raf5rlkq	162	19	,	,	,
cord-302316-raf5rlkq	162	20	showed	show	VBD
cord-302316-raf5rlkq	162	21	symptoms	symptom	NNS
cord-302316-raf5rlkq	162	22	of	of	IN
cord-302316-raf5rlkq	162	23	disease	disease	NN
cord-302316-raf5rlkq	162	24	(	(	-LRB-
cord-302316-raf5rlkq	162	25	interstitial	interstitial	JJ
cord-302316-raf5rlkq	162	26	pneumonia	pneumonia	NN
cord-302316-raf5rlkq	162	27	)	)	-RRB-
cord-302316-raf5rlkq	162	28	thatpartiallyreproduced	thatpartiallyreproduce	VBD
cord-302316-raf5rlkq	162	29	the	the	DT
cord-302316-raf5rlkq	162	30	disease	disease	NN
cord-302316-raf5rlkq	162	31	in	in	IN
cord-302316-raf5rlkq	162	32	humans	human	NNS
cord-302316-raf5rlkq	162	33	.	.	.
cord-302316-raf5rlkq	163	1	The	the	DT
cord-302316-raf5rlkq	163	2	virus	virus	NN
cord-302316-raf5rlkq	163	3	replicated	replicate	VBD
cord-302316-raf5rlkq	163	4	in	in	IN
cord-302316-raf5rlkq	163	5	the	the	DT
cord-302316-raf5rlkq	163	6	organ	organ	NN
cord-302316-raf5rlkq	163	7	where	where	WRB
cord-302316-raf5rlkq	163	8	the	the	DT
cord-302316-raf5rlkq	163	9	pathology	pathology	NN
cord-302316-raf5rlkq	163	10	was	be	VBD
cord-302316-raf5rlkq	163	11	observed	observe	VBN
cord-302316-raf5rlkq	163	12	,	,	,
cord-302316-raf5rlkq	163	13	and	and	CC
cord-302316-raf5rlkq	163	14	-finally	-finally	RB
cord-302316-raf5rlkq	163	15	the	the	DT
cord-302316-raf5rlkq	163	16	virus	virus	NN
cord-302316-raf5rlkq	163	17	could	could	MD
cord-302316-raf5rlkq	163	18	be	be	VB
cord-302316-raf5rlkq	163	19	re	re	VBN
cord-302316-raf5rlkq	163	20	-	-	VBN
cord-302316-raf5rlkq	163	21	isolated	isolate	VBN
cord-302316-raf5rlkq	163	22	from	from	IN
cord-302316-raf5rlkq	163	23	this	this	DT
cord-302316-raf5rlkq	163	24	organ	organ	NN
cord-302316-raf5rlkq	163	25	.	.	.
cord-302316-raf5rlkq	164	1	One	one	CD
cord-302316-raf5rlkq	164	2	overt	overt	JJ
cord-302316-raf5rlkq	164	3	clinical	clinical	JJ
cord-302316-raf5rlkq	164	4	sign	sign	NN
cord-302316-raf5rlkq	164	5	was	be	VBD
cord-302316-raf5rlkq	164	6	weight	weight	NN
cord-302316-raf5rlkq	164	7	loss	loss	NN
cord-302316-raf5rlkq	164	8	in	in	IN
cord-302316-raf5rlkq	164	9	mice	mouse	NNS
cord-302316-raf5rlkq	164	10	.	.	.
cord-302316-raf5rlkq	165	1	Also	also	RB
cord-302316-raf5rlkq	165	2	,	,	,
cord-302316-raf5rlkq	165	3	viral	viral	JJ
cord-302316-raf5rlkq	165	4	replication	replication	NN
cord-302316-raf5rlkq	165	5	produced	produce	VBD
cord-302316-raf5rlkq	165	6	moderate	moderate	JJ
cord-302316-raf5rlkq	165	7	peak	peak	NN
cord-302316-raf5rlkq	165	8	titres	titre	NNS
cord-302316-raf5rlkq	165	9	and	and	CC
cord-302316-raf5rlkq	165	10	was	be	VBD
cord-302316-raf5rlkq	165	11	limited	limit	VBN
cord-302316-raf5rlkq	165	12	to	to	IN
cord-302316-raf5rlkq	165	13	the	the	DT
cord-302316-raf5rlkq	165	14	lung	lung	NN
cord-302316-raf5rlkq	165	15	and	and	CC
cord-302316-raf5rlkq	165	16	bronchi	bronchi	NN
cord-302316-raf5rlkq	165	17	.	.	.
cord-302316-raf5rlkq	166	1	After	after	IN
cord-302316-raf5rlkq	166	2	much	much	JJ
cord-302316-raf5rlkq	166	3	media	medium	NNS
cord-302316-raf5rlkq	166	4	hype	hype	NN
cord-302316-raf5rlkq	166	5	,	,	,
cord-302316-raf5rlkq	166	6	political	political	JJ
cord-302316-raf5rlkq	166	7	support	support	NN
cord-302316-raf5rlkq	166	8	and	and	CC
cord-302316-raf5rlkq	166	9	Emergency	Emergency	NNP
cord-302316-raf5rlkq	166	10	Use	Use	NNP
cord-302316-raf5rlkq	166	11	Authorization	Authorization	NNP
cord-302316-raf5rlkq	166	12	by	by	IN
cord-302316-raf5rlkq	166	13	the	the	DT
cord-302316-raf5rlkq	166	14	FDA	FDA	NNP
cord-302316-raf5rlkq	166	15	,	,	,
cord-302316-raf5rlkq	166	16	the	the	DT
cord-302316-raf5rlkq	166	17	initial	initial	JJ
cord-302316-raf5rlkq	166	18	high	high	JJ
cord-302316-raf5rlkq	166	19	hopes	hope	NNS
cord-302316-raf5rlkq	166	20	placed	place	VBN
cord-302316-raf5rlkq	166	21	in	in	IN
cord-302316-raf5rlkq	166	22	the	the	DT
cord-302316-raf5rlkq	166	23	repurposed	repurpose	VBN
cord-302316-raf5rlkq	166	24	malaria	malaria	NNP
cord-302316-raf5rlkq	166	25	drug	drug	NN
cord-302316-raf5rlkq	166	26	hydroxychloroquine	hydroxychloroquine	NNP
cord-302316-raf5rlkq	166	27	administered	administer	VBN
cord-302316-raf5rlkq	166	28	to	to	IN
cord-302316-raf5rlkq	166	29	hospitalized	hospitalize	VBN
cord-302316-raf5rlkq	166	30	COVID-19	COVID-19	,
cord-302316-raf5rlkq	166	31	patients	patient	NNS
cord-302316-raf5rlkq	166	32	were	be	VBD
cord-302316-raf5rlkq	166	33	not	not	RB
cord-302316-raf5rlkq	166	34	validated	validate	VBN
cord-302316-raf5rlkq	166	35	by	by	IN
cord-302316-raf5rlkq	166	36	clinical	clinical	JJ
cord-302316-raf5rlkq	166	37	data	datum	NNS
cord-302316-raf5rlkq	166	38	,	,	,
cord-302316-raf5rlkq	166	39	which	which	WDT
cord-302316-raf5rlkq	166	40	had	have	VBD
cord-302316-raf5rlkq	166	41	shown	show	VBN
cord-302316-raf5rlkq	166	42	only	only	RB
cord-302316-raf5rlkq	166	43	mixed	mixed	JJ
cord-302316-raf5rlkq	166	44	results	result	NNS
cord-302316-raf5rlkq	166	45	.	.	.
cord-302316-raf5rlkq	167	1	Chloroquine	chloroquine	NN
cord-302316-raf5rlkq	167	2	increases	increase	VBZ
cord-302316-raf5rlkq	167	3	endosomal	endosomal	NNP
cord-302316-raf5rlkq	167	4	and	and	CC
cord-302316-raf5rlkq	167	5	lysosomal	lysosomal	JJ
cord-302316-raf5rlkq	167	6	pH	ph	NN
cord-302316-raf5rlkq	167	7	and	and	CC
cord-302316-raf5rlkq	167	8	interferes	interfere	VBZ
cord-302316-raf5rlkq	167	9	with	with	IN
cord-302316-raf5rlkq	167	10	some	some	DT
cord-302316-raf5rlkq	167	11	viral	viral	JJ
cord-302316-raf5rlkq	167	12	infections	infection	NNS
cord-302316-raf5rlkq	167	13	in	in	IN
cord-302316-raf5rlkq	167	14	cell	cell	NN
cord-302316-raf5rlkq	167	15	culture	culture	NN
cord-302316-raf5rlkq	167	16	.	.	.
cord-302316-raf5rlkq	168	1	A	a	DT
cord-302316-raf5rlkq	168	2	small	small	JJ
cord-302316-raf5rlkq	168	3	Chinese	chinese	JJ
cord-302316-raf5rlkq	168	4	trial	trial	NN
cord-302316-raf5rlkq	168	5	enrolling	enrol	VBG
cord-302316-raf5rlkq	168	6	62	62	CD
cord-302316-raf5rlkq	168	7	COVID-19	covid-19	CD
cord-302316-raf5rlkq	168	8	patients	patient	NNS
cord-302316-raf5rlkq	168	9	on	on	IN
cord-302316-raf5rlkq	168	10	hydroxychloroquine	hydroxychloroquine	NN
cord-302316-raf5rlkq	168	11	,	,	,
cord-302316-raf5rlkq	168	12	or	or	CC
cord-302316-raf5rlkq	168	13	placebo	placebo	NN
cord-302316-raf5rlkq	168	14	,	,	,
cord-302316-raf5rlkq	168	15	showed	show	VBD
cord-302316-raf5rlkq	168	16	,	,	,
cord-302316-raf5rlkq	168	17	in	in	IN
cord-302316-raf5rlkq	168	18	fact	fact	NN
cord-302316-raf5rlkq	168	19	,	,	,
cord-302316-raf5rlkq	168	20	a	a	DT
cord-302316-raf5rlkq	168	21	shortened	shorten	VBN
cord-302316-raf5rlkq	168	22	period	period	NN
cord-302316-raf5rlkq	168	23	of	of	IN
cord-302316-raf5rlkq	168	24	recovery	recovery	NN
cord-302316-raf5rlkq	168	25	from	from	IN
cord-302316-raf5rlkq	168	26	fever	fever	NN
cord-302316-raf5rlkq	168	27	and	and	CC
cord-302316-raf5rlkq	168	28	cough	cough	NN
cord-302316-raf5rlkq	168	29	in	in	IN
cord-302316-raf5rlkq	168	30	the	the	DT
cord-302316-raf5rlkq	168	31	treatment	treatment	NN
cord-302316-raf5rlkq	168	32	group	group	NN
cord-302316-raf5rlkq	168	33	.	.	.
cord-302316-raf5rlkq	169	1	A	a	DT
cord-302316-raf5rlkq	169	2	French	french	JJ
cord-302316-raf5rlkq	169	3	study	study	NN
cord-302316-raf5rlkq	169	4	randomizing	randomize	VBG
cord-302316-raf5rlkq	169	5	181	181	CD
cord-302316-raf5rlkq	169	6	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	169	7	patients	patient	NNS
cord-302316-raf5rlkq	169	8	with	with	IN
cord-302316-raf5rlkq	169	9	pneumonia	pneumonia	NN
cord-302316-raf5rlkq	169	10	on	on	IN
cord-302316-raf5rlkq	169	11	hydroxychloroquine	hydroxychloroquine	NN
cord-302316-raf5rlkq	169	12	or	or	CC
cord-302316-raf5rlkq	169	13	placebo	placebo	NN
cord-302316-raf5rlkq	169	14	,	,	,
cord-302316-raf5rlkq	169	15	observed	observe	VBD
cord-302316-raf5rlkq	169	16	,	,	,
cord-302316-raf5rlkq	169	17	however	however	RB
cord-302316-raf5rlkq	169	18	,	,	,
cord-302316-raf5rlkq	169	19	no	no	DT
cord-302316-raf5rlkq	169	20	significant	significant	JJ
cord-302316-raf5rlkq	169	21	effect	effect	NN
cord-302316-raf5rlkq	169	22	of	of	IN
cord-302316-raf5rlkq	169	23	treatment	treatment	NN
cord-302316-raf5rlkq	169	24	on	on	IN
cord-302316-raf5rlkq	169	25	transfer	transfer	NN
cord-302316-raf5rlkq	169	26	to	to	IN
cord-302316-raf5rlkq	169	27	ICU	ICU	NNP
cord-302316-raf5rlkq	169	28	,	,	,
cord-302316-raf5rlkq	169	29	mortality	mortality	NN
cord-302316-raf5rlkq	169	30	,	,	,
cord-302316-raf5rlkq	169	31	or	or	CC
cord-302316-raf5rlkq	169	32	in	in	IN
cord-302316-raf5rlkq	169	33	the	the	DT
cord-302316-raf5rlkq	169	34	prevention	prevention	NN
cord-302316-raf5rlkq	169	35	of	of	IN
cord-302316-raf5rlkq	169	36	development	development	NN
cord-302316-raf5rlkq	169	37	of	of	IN
cord-302316-raf5rlkq	169	38	acute	acute	JJ
cord-302316-raf5rlkq	169	39	respiratory	respiratory	JJ
cord-302316-raf5rlkq	169	40	distress	distress	NN
cord-302316-raf5rlkq	169	41	syndrome	syndrome	NN
cord-302316-raf5rlkq	169	42	(	(	-LRB-
cord-302316-raf5rlkq	169	43	Mah	Mah	NNP
cord-302316-raf5rlkq	169	44	evas	evas	NNP
cord-302316-raf5rlkq	169	45	et	et	NNP
cord-302316-raf5rlkq	169	46	al	al	NNP
cord-302316-raf5rlkq	169	47	.	.	NNP
cord-302316-raf5rlkq	169	48	,	,	,
cord-302316-raf5rlkq	169	49	2020	2020	CD
cord-302316-raf5rlkq	169	50	)	)	-RRB-
cord-302316-raf5rlkq	169	51	.	.	.
cord-302316-raf5rlkq	170	1	Eighty	eighty	CD
cord-302316-raf5rlkq	170	2	-	-	HYPH
cord-302316-raf5rlkq	170	3	one	one	CD
cord-302316-raf5rlkq	170	4	adult	adult	NN
cord-302316-raf5rlkq	170	5	Brazilian	brazilian	JJ
cord-302316-raf5rlkq	170	6	patients	patient	NNS
cord-302316-raf5rlkq	170	7	with	with	IN
cord-302316-raf5rlkq	170	8	severe	severe	JJ
cord-302316-raf5rlkq	170	9	COVID-19	covid-19	NN
cord-302316-raf5rlkq	170	10	were	be	VBD
cord-302316-raf5rlkq	170	11	randomized	randomize	VBN
cord-302316-raf5rlkq	170	12	on	on	IN
cord-302316-raf5rlkq	170	13	a	a	DT
cord-302316-raf5rlkq	170	14	high	high	JJ
cord-302316-raf5rlkq	170	15	or	or	CC
cord-302316-raf5rlkq	170	16	a	a	DT
cord-302316-raf5rlkq	170	17	low	low	JJ
cord-302316-raf5rlkq	170	18	dose	dose	NN
cord-302316-raf5rlkq	170	19	of	of	IN
cord-302316-raf5rlkq	170	20	chloroquine	chloroquine	NN
cord-302316-raf5rlkq	170	21	plus	plus	CC
cord-302316-raf5rlkq	170	22	azithromycin	azithromycin	NNP
cord-302316-raf5rlkq	170	23	and	and	CC
cord-302316-raf5rlkq	170	24	oseltamivir	oseltamivir	NNP
cord-302316-raf5rlkq	170	25	.	.	.
cord-302316-raf5rlkq	171	1	A	a	DT
cord-302316-raf5rlkq	171	2	placebo	placebo	NN
cord-302316-raf5rlkq	171	3	group	group	NN
cord-302316-raf5rlkq	171	4	was	be	VBD
cord-302316-raf5rlkq	171	5	considered	consider	VBN
cord-302316-raf5rlkq	171	6	to	to	TO
cord-302316-raf5rlkq	171	7	have	have	VB
cord-302316-raf5rlkq	171	8	been	be	VBN
cord-302316-raf5rlkq	171	9	unethical	unethical	JJ
cord-302316-raf5rlkq	171	10	due	due	IN
cord-302316-raf5rlkq	171	11	to	to	IN
cord-302316-raf5rlkq	171	12	media	medium	NNS
cord-302316-raf5rlkq	171	13	support	support	NN
cord-302316-raf5rlkq	171	14	for	for	IN
cord-302316-raf5rlkq	171	15	chloroquine	chloroquine	NN
cord-302316-raf5rlkq	171	16	use	use	NN
cord-302316-raf5rlkq	171	17	.	.	.
cord-302316-raf5rlkq	172	1	Overall	overall	JJ
cord-302316-raf5rlkq	172	2	mortality	mortality	NN
cord-302316-raf5rlkq	172	3	was	be	VBD
cord-302316-raf5rlkq	172	4	27	27	CD
cord-302316-raf5rlkq	172	5	%	%	NN
cord-302316-raf5rlkq	172	6	,	,	,
cord-302316-raf5rlkq	172	7	which	which	WDT
cord-302316-raf5rlkq	172	8	was	be	VBD
cord-302316-raf5rlkq	172	9	not	not	RB
cord-302316-raf5rlkq	172	10	lower	low	JJR
cord-302316-raf5rlkq	172	11	than	than	IN
cord-302316-raf5rlkq	172	12	in	in	IN
cord-302316-raf5rlkq	172	13	historical	historical	JJ
cord-302316-raf5rlkq	172	14	controls	control	NNS
cord-302316-raf5rlkq	172	15	.	.	.
cord-302316-raf5rlkq	173	1	Mortality	mortality	NN
cord-302316-raf5rlkq	173	2	was	be	VBD
cord-302316-raf5rlkq	173	3	substantially	substantially	RB
cord-302316-raf5rlkq	173	4	higher	high	JJR
cord-302316-raf5rlkq	173	5	in	in	IN
cord-302316-raf5rlkq	173	6	the	the	DT
cord-302316-raf5rlkq	173	7	high	high	JJ
cord-302316-raf5rlkq	173	8	-	-	HYPH
cord-302316-raf5rlkq	173	9	dose	dose	NN
cord-302316-raf5rlkq	173	10	group	group	NN
cord-302316-raf5rlkq	173	11	compared	compare	VBN
cord-302316-raf5rlkq	173	12	with	with	IN
cord-302316-raf5rlkq	173	13	the	the	DT
cord-302316-raf5rlkq	173	14	lowdose	lowdose	NNP
cord-302316-raf5rlkq	173	15	chloroquine	chloroquine	NNP
cord-302316-raf5rlkq	173	16	group	group	NN
cord-302316-raf5rlkq	173	17	(	(	-LRB-
cord-302316-raf5rlkq	173	18	39	39	CD
cord-302316-raf5rlkq	173	19	vs.	vs.	CC
cord-302316-raf5rlkq	173	20	15	15	CD
cord-302316-raf5rlkq	173	21	%	%	NN
cord-302316-raf5rlkq	173	22	)	)	-RRB-
cord-302316-raf5rlkq	173	23	,	,	,
cord-302316-raf5rlkq	173	24	and	and	CC
cord-302316-raf5rlkq	173	25	the	the	DT
cord-302316-raf5rlkq	173	26	high	high	JJ
cord-302316-raf5rlkq	173	27	-	-	HYPH
cord-302316-raf5rlkq	173	28	dose	dose	NN
cord-302316-raf5rlkq	173	29	regime	regime	NN
cord-302316-raf5rlkq	173	30	was	be	VBD
cord-302316-raf5rlkq	173	31	stopped	stop	VBN
cord-302316-raf5rlkq	173	32	in	in	IN
cord-302316-raf5rlkq	173	33	this	this	DT
cord-302316-raf5rlkq	173	34	trial	trial	NN
cord-302316-raf5rlkq	173	35	by	by	IN
cord-302316-raf5rlkq	173	36	the	the	DT
cord-302316-raf5rlkq	173	37	data	data	NN
cord-302316-raf5rlkq	173	38	safety	safety	NNP
cord-302316-raf5rlkq	173	39	monitoring	monitoring	NNP
cord-302316-raf5rlkq	173	40	board	board	NN
cord-302316-raf5rlkq	173	41	.	.	.
cord-302316-raf5rlkq	174	1	On	on	IN
cord-302316-raf5rlkq	174	2	day	day	NN
cord-302316-raf5rlkq	174	3	4	4	CD
cord-302316-raf5rlkq	174	4	of	of	IN
cord-302316-raf5rlkq	174	5	hospitalization	hospitalization	NN
cord-302316-raf5rlkq	174	6	,	,	,
cord-302316-raf5rlkq	174	7	more	more	JJR
cord-302316-raf5rlkq	174	8	than	than	IN
cord-302316-raf5rlkq	174	9	80	80	CD
cord-302316-raf5rlkq	174	10	%	%	NN
cord-302316-raf5rlkq	174	11	of	of	IN
cord-302316-raf5rlkq	174	12	the	the	DT
cord-302316-raf5rlkq	174	13	patients	patient	NNS
cord-302316-raf5rlkq	174	14	in	in	IN
cord-302316-raf5rlkq	174	15	both	both	DT
cord-302316-raf5rlkq	174	16	groups	group	NNS
cord-302316-raf5rlkq	174	17	showed	show	VBD
cord-302316-raf5rlkq	174	18	viral	viral	JJ
cord-302316-raf5rlkq	174	19	RNA	RNA	NNP
cord-302316-raf5rlkq	174	20	in	in	IN
cord-302316-raf5rlkq	174	21	nasopharyngeal	nasopharyngeal	JJ
cord-302316-raf5rlkq	174	22	secretions	secretion	NNS
cord-302316-raf5rlkq	174	23	excluding	exclude	VBG
cord-302316-raf5rlkq	174	24	an	an	DT
cord-302316-raf5rlkq	174	25	antiviral	antiviral	JJ
cord-302316-raf5rlkq	174	26	effect	effect	NN
cord-302316-raf5rlkq	174	27	(	(	-LRB-
cord-302316-raf5rlkq	174	28	Borba	Borba	NNP
cord-302316-raf5rlkq	174	29	et	et	NNP
cord-302316-raf5rlkq	174	30	al	al	NNP
cord-302316-raf5rlkq	174	31	.	.	NNP
cord-302316-raf5rlkq	174	32	,	,	,
cord-302316-raf5rlkq	174	33	2020	2020	CD
cord-302316-raf5rlkq	174	34	)	)	-RRB-
cord-302316-raf5rlkq	174	35	.	.	.
cord-302316-raf5rlkq	175	1	One	one	CD
cord-302316-raf5rlkq	175	2	hundred	hundred	CD
cord-302316-raf5rlkq	175	3	and	and	CC
cord-302316-raf5rlkq	175	4	fifty	fifty	CD
cord-302316-raf5rlkq	175	5	COVID-19	covid-19	CD
cord-302316-raf5rlkq	175	6	patients	patient	NNS
cord-302316-raf5rlkq	175	7	from	from	IN
cord-302316-raf5rlkq	175	8	China	China	NNP
cord-302316-raf5rlkq	175	9	were	be	VBD
cord-302316-raf5rlkq	175	10	treated	treat	VBN
cord-302316-raf5rlkq	175	11	with	with	IN
cord-302316-raf5rlkq	175	12	oral	oral	JJ
cord-302316-raf5rlkq	175	13	hydroxychloroquine	hydroxychloroquine	NN
cord-302316-raf5rlkq	175	14	(	(	-LRB-
cord-302316-raf5rlkq	175	15	HCQ	HCQ	NNP
cord-302316-raf5rlkq	175	16	)	)	-RRB-
cord-302316-raf5rlkq	175	17	,	,	,
cord-302316-raf5rlkq	175	18	and	and	CC
cord-302316-raf5rlkq	175	19	this	this	DT
cord-302316-raf5rlkq	175	20	was	be	VBD
cord-302316-raf5rlkq	175	21	compared	compare	VBN
cord-302316-raf5rlkq	175	22	with	with	IN
cord-302316-raf5rlkq	175	23	standard	standard	JJ
cord-302316-raf5rlkq	175	24	treatment	treatment	NN
cord-302316-raf5rlkq	175	25	alone	alone	RB
cord-302316-raf5rlkq	175	26	in	in	IN
cord-302316-raf5rlkq	175	27	an	an	DT
cord-302316-raf5rlkq	175	28	open	open	JJ
cord-302316-raf5rlkq	175	29	clinical	clinical	JJ
cord-302316-raf5rlkq	175	30	trial	trial	NN
cord-302316-raf5rlkq	175	31	.	.	.
cord-302316-raf5rlkq	176	1	The	the	DT
cord-302316-raf5rlkq	176	2	treatment	treatment	NN
cord-302316-raf5rlkq	176	3	did	do	VBD
cord-302316-raf5rlkq	176	4	not	not	RB
cord-302316-raf5rlkq	176	5	result	result	VB
cord-302316-raf5rlkq	176	6	in	in	IN
cord-302316-raf5rlkq	176	7	an	an	DT
cord-302316-raf5rlkq	176	8	accelerated	accelerated	JJ
cord-302316-raf5rlkq	176	9	clearance	clearance	NN
cord-302316-raf5rlkq	176	10	of	of	IN
cord-302316-raf5rlkq	176	11	viral	viral	JJ
cord-302316-raf5rlkq	176	12	RNA	RNA	NNP
cord-302316-raf5rlkq	176	13	in	in	IN
cord-302316-raf5rlkq	176	14	upper	upper	JJ
cord-302316-raf5rlkq	176	15	and	and	CC
cord-302316-raf5rlkq	176	16	lower	low	JJR
cord-302316-raf5rlkq	176	17	respiratory	respiratory	JJ
cord-302316-raf5rlkq	176	18	tract	tract	NN
cord-302316-raf5rlkq	176	19	secretions	secretion	NNS
cord-302316-raf5rlkq	176	20	.	.	.
cord-302316-raf5rlkq	177	1	Clinical	clinical	JJ
cord-302316-raf5rlkq	177	2	symptom	symptom	NN
cord-302316-raf5rlkq	177	3	alleviation	alleviation	NN
cord-302316-raf5rlkq	177	4	within	within	IN
cord-302316-raf5rlkq	177	5	28	28	CD
cord-302316-raf5rlkq	177	6	days	day	NNS
cord-302316-raf5rlkq	177	7	was	be	VBD
cord-302316-raf5rlkq	177	8	not	not	RB
cord-302316-raf5rlkq	177	9	different	different	JJ
cord-302316-raf5rlkq	177	10	between	between	IN
cord-302316-raf5rlkq	177	11	the	the	DT
cord-302316-raf5rlkq	177	12	two	two	CD
cord-302316-raf5rlkq	177	13	groups	group	NNS
cord-302316-raf5rlkq	177	14	.	.	.
cord-302316-raf5rlkq	178	1	A	a	DT
cord-302316-raf5rlkq	178	2	more	more	RBR
cord-302316-raf5rlkq	178	3	rapid	rapid	JJ
cord-302316-raf5rlkq	178	4	symptom	symptom	NN
cord-302316-raf5rlkq	178	5	alleviation	alleviation	NN
cord-302316-raf5rlkq	178	6	was	be	VBD
cord-302316-raf5rlkq	178	7	seen	see	VBN
cord-302316-raf5rlkq	178	8	for	for	IN
cord-302316-raf5rlkq	178	9	HCQ	HCQ	NNP
cord-302316-raf5rlkq	178	10	,	,	,
cord-302316-raf5rlkq	178	11	over	over	IN
cord-302316-raf5rlkq	178	12	the	the	DT
cord-302316-raf5rlkq	178	13	control	control	NN
cord-302316-raf5rlkq	178	14	group	group	NN
cord-302316-raf5rlkq	178	15	during	during	IN
cord-302316-raf5rlkq	178	16	the	the	DT
cord-302316-raf5rlkq	178	17	second	second	JJ
cord-302316-raf5rlkq	178	18	week	week	NN
cord-302316-raf5rlkq	178	19	of	of	IN
cord-302316-raf5rlkq	178	20	treatment	treatment	NN
cord-302316-raf5rlkq	178	21	,	,	,
cord-302316-raf5rlkq	178	22	but	but	CC
cord-302316-raf5rlkq	178	23	it	-PRON-	PRP
cord-302316-raf5rlkq	178	24	was	be	VBD
cord-302316-raf5rlkq	178	25	not	not	RB
cord-302316-raf5rlkq	178	26	statistically	statistically	RB
cord-302316-raf5rlkq	178	27	significant	significant	JJ
cord-302316-raf5rlkq	178	28	.	.	.
cord-302316-raf5rlkq	179	1	This	this	DT
cord-302316-raf5rlkq	179	2	trend	trend	NN
cord-302316-raf5rlkq	179	3	became	become	VBD
cord-302316-raf5rlkq	179	4	even	even	RB
cord-302316-raf5rlkq	179	5	more	more	RBR
cord-302316-raf5rlkq	179	6	visible	visible	JJ
cord-302316-raf5rlkq	179	7	when	when	WRB
cord-302316-raf5rlkq	179	8	in	in	IN
cord-302316-raf5rlkq	179	9	a	a	DT
cord-302316-raf5rlkq	179	10	post	post	FW
cord-302316-raf5rlkq	179	11	hoc	hoc	FW
cord-302316-raf5rlkq	179	12	analysis	analysis	NN
cord-302316-raf5rlkq	179	13	only	only	RB
cord-302316-raf5rlkq	179	14	cases	case	NNS
cord-302316-raf5rlkq	179	15	of	of	IN
cord-302316-raf5rlkq	179	16	patients	patient	NNS
cord-302316-raf5rlkq	179	17	without	without	IN
cord-302316-raf5rlkq	179	18	other	other	JJ
cord-302316-raf5rlkq	179	19	antiviral	antiviral	JJ
cord-302316-raf5rlkq	179	20	agent	agent	NN
cord-302316-raf5rlkq	179	21	treatment	treatment	NN
cord-302316-raf5rlkq	179	22	were	be	VBD
cord-302316-raf5rlkq	179	23	investigated	investigate	VBN
cord-302316-raf5rlkq	179	24	.	.	.
cord-302316-raf5rlkq	180	1	HCQ	HCQ	NNP
cord-302316-raf5rlkq	180	2	led	lead	VBD
cord-302316-raf5rlkq	180	3	to	to	IN
cord-302316-raf5rlkq	180	4	a	a	DT
cord-302316-raf5rlkq	180	5	more	more	RBR
cord-302316-raf5rlkq	180	6	rapid	rapid	JJ
cord-302316-raf5rlkq	180	7	normalization	normalization	NN
cord-302316-raf5rlkq	180	8	of	of	IN
cord-302316-raf5rlkq	180	9	C	c	NN
cord-302316-raf5rlkq	180	10	-	-	HYPH
cord-302316-raf5rlkq	180	11	reactive	reactive	JJ
cord-302316-raf5rlkq	180	12	protein	protein	NN
cord-302316-raf5rlkq	180	13	levels	level	NNS
cord-302316-raf5rlkq	180	14	compared	compare	VBN
cord-302316-raf5rlkq	180	15	with	with	IN
cord-302316-raf5rlkq	180	16	those	those	DT
cord-302316-raf5rlkq	180	17	in	in	IN
cord-302316-raf5rlkq	180	18	the	the	DT
cord-302316-raf5rlkq	180	19	controls	control	NNS
cord-302316-raf5rlkq	180	20	.	.	.
cord-302316-raf5rlkq	181	1	HCQ	hcq	NN
cord-302316-raf5rlkq	181	2	addition	addition	NN
cord-302316-raf5rlkq	181	3	led	lead	VBD
cord-302316-raf5rlkq	181	4	to	to	IN
cord-302316-raf5rlkq	181	5	a	a	DT
cord-302316-raf5rlkq	181	6	higher	high	JJR
cord-302316-raf5rlkq	181	7	rate	rate	NN
cord-302316-raf5rlkq	181	8	of	of	IN
cord-302316-raf5rlkq	181	9	adverse	adverse	JJ
cord-302316-raf5rlkq	181	10	events	event	NNS
cord-302316-raf5rlkq	181	11	over	over	IN
cord-302316-raf5rlkq	181	12	the	the	DT
cord-302316-raf5rlkq	181	13	controls	control	NNS
cord-302316-raf5rlkq	181	14	(	(	-LRB-
cord-302316-raf5rlkq	181	15	30	30	CD
cord-302316-raf5rlkq	181	16	%	%	NN
cord-302316-raf5rlkq	181	17	vs	vs	IN
cord-302316-raf5rlkq	181	18	9	9	CD
cord-302316-raf5rlkq	181	19	%	%	NN
cord-302316-raf5rlkq	181	20	)	)	-RRB-
cord-302316-raf5rlkq	181	21	,	,	,
cord-302316-raf5rlkq	181	22	which	which	WDT
cord-302316-raf5rlkq	181	23	consisted	consist	VBD
cord-302316-raf5rlkq	181	24	mostly	mostly	RB
cord-302316-raf5rlkq	181	25	of	of	IN
cord-302316-raf5rlkq	181	26	diarrhoea	diarrhoea	NN
cord-302316-raf5rlkq	182	1	(	(	-LRB-
cord-302316-raf5rlkq	182	2	Tang	Tang	NNP
cord-302316-raf5rlkq	182	3	et	et	FW
cord-302316-raf5rlkq	182	4	al	al	NNP
cord-302316-raf5rlkq	182	5	.	.	NNP
cord-302316-raf5rlkq	182	6	,	,	,
cord-302316-raf5rlkq	182	7	2020b	2020b	CD
cord-302316-raf5rlkq	182	8	)	)	-RRB-
cord-302316-raf5rlkq	182	9	.	.	.
cord-302316-raf5rlkq	183	1	From	from	IN
cord-302316-raf5rlkq	183	2	1376	1376	CD
cord-302316-raf5rlkq	183	3	consecutive	consecutive	JJ
cord-302316-raf5rlkq	183	4	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	183	5	patients	patient	NNS
cord-302316-raf5rlkq	183	6	hospitalized	hospitalize	VBN
cord-302316-raf5rlkq	183	7	in	in	IN
cord-302316-raf5rlkq	183	8	New	New	NNP
cord-302316-raf5rlkq	183	9	York	York	NNP
cord-302316-raf5rlkq	183	10	City	City	NNP
cord-302316-raf5rlkq	183	11	,	,	,
cord-302316-raf5rlkq	183	12	811	811	CD
cord-302316-raf5rlkq	183	13	were	be	VBD
cord-302316-raf5rlkq	183	14	treated	treat	VBN
cord-302316-raf5rlkq	183	15	with	with	IN
cord-302316-raf5rlkq	183	16	a	a	DT
cord-302316-raf5rlkq	183	17	high	high	JJ
cord-302316-raf5rlkq	183	18	dose	dose	NN
cord-302316-raf5rlkq	183	19	of	of	IN
cord-302316-raf5rlkq	183	20	HCQ	HCQ	NNP
cord-302316-raf5rlkq	183	21	on	on	IN
cord-302316-raf5rlkq	183	22	day	day	NN
cord-302316-raf5rlkq	183	23	1	1	CD
cord-302316-raf5rlkq	183	24	,	,	,
cord-302316-raf5rlkq	183	25	and	and	CC
cord-302316-raf5rlkq	183	26	a	a	DT
cord-302316-raf5rlkq	183	27	low	low	JJ
cord-302316-raf5rlkq	183	28	dose	dose	NN
cord-302316-raf5rlkq	183	29	during	during	IN
cord-302316-raf5rlkq	183	30	the	the	DT
cord-302316-raf5rlkq	183	31	following	following	JJ
cord-302316-raf5rlkq	183	32	4	4	CD
cord-302316-raf5rlkq	183	33	days	day	NNS
cord-302316-raf5rlkq	183	34	.	.	.
cord-302316-raf5rlkq	184	1	Half	half	NN
cord-302316-raf5rlkq	184	2	of	of	IN
cord-302316-raf5rlkq	184	3	them	-PRON-	PRP
cord-302316-raf5rlkq	184	4	received	receive	VBD
cord-302316-raf5rlkq	184	5	the	the	DT
cord-302316-raf5rlkq	184	6	high	high	JJ
cord-302316-raf5rlkq	184	7	dose	dose	NN
cord-302316-raf5rlkq	184	8	within	within	IN
cord-302316-raf5rlkq	184	9	24	24	CD
cord-302316-raf5rlkq	184	10	h	h	NN
cord-302316-raf5rlkq	184	11	of	of	IN
cord-302316-raf5rlkq	184	12	hospitalization	hospitalization	NN
cord-302316-raf5rlkq	184	13	,	,	,
cord-302316-raf5rlkq	184	14	and	and	CC
cord-302316-raf5rlkq	184	15	the	the	DT
cord-302316-raf5rlkq	184	16	follow	follow	NN
cord-302316-raf5rlkq	184	17	-	-	HYPH
cord-302316-raf5rlkq	184	18	up	up	NN
cord-302316-raf5rlkq	184	19	course	course	NN
cord-302316-raf5rlkq	184	20	was	be	VBD
cord-302316-raf5rlkq	184	21	for	for	IN
cord-302316-raf5rlkq	184	22	three	three	CD
cord-302316-raf5rlkq	184	23	weeks	week	NNS
cord-302316-raf5rlkq	184	24	.	.	.
cord-302316-raf5rlkq	185	1	There	there	EX
cord-302316-raf5rlkq	185	2	were	be	VBD
cord-302316-raf5rlkq	185	3	565	565	CD
cord-302316-raf5rlkq	185	4	COVID-19	covid-19	CD
cord-302316-raf5rlkq	185	5	patients	patient	NNS
cord-302316-raf5rlkq	185	6	who	who	WP
cord-302316-raf5rlkq	185	7	did	do	VBD
cord-302316-raf5rlkq	185	8	not	not	RB
cord-302316-raf5rlkq	185	9	receive	receive	VB
cord-302316-raf5rlkq	185	10	HCQ	HCQ	NNP
cord-302316-raf5rlkq	185	11	.	.	.
cord-302316-raf5rlkq	186	1	The	the	DT
cord-302316-raf5rlkq	186	2	primary	primary	JJ
cord-302316-raf5rlkq	186	3	end	end	NN
cord-302316-raf5rlkq	186	4	-	-	HYPH
cord-302316-raf5rlkq	186	5	point	point	NN
cord-302316-raf5rlkq	186	6	was	be	VBD
cord-302316-raf5rlkq	186	7	intubation	intubation	NN
cord-302316-raf5rlkq	186	8	or	or	CC
cord-302316-raf5rlkq	186	9	death	death	NN
cord-302316-raf5rlkq	186	10	,	,	,
cord-302316-raf5rlkq	186	11	which	which	WDT
cord-302316-raf5rlkq	186	12	occurred	occur	VBD
cord-302316-raf5rlkq	186	13	in	in	IN
cord-302316-raf5rlkq	186	14	25	25	CD
cord-302316-raf5rlkq	186	15	%	%	NN
cord-302316-raf5rlkq	186	16	of	of	IN
cord-302316-raf5rlkq	186	17	the	the	DT
cord-302316-raf5rlkq	186	18	patients	patient	NNS
cord-302316-raf5rlkq	186	19	.	.	.
cord-302316-raf5rlkq	187	1	In	in	IN
cord-302316-raf5rlkq	187	2	crude	crude	JJ
cord-302316-raf5rlkq	187	3	,	,	,
cord-302316-raf5rlkq	187	4	unadjusted	unadjusted	JJ
cord-302316-raf5rlkq	187	5	analysis	analysis	NN
cord-302316-raf5rlkq	187	6	of	of	IN
cord-302316-raf5rlkq	187	7	this	this	DT
cord-302316-raf5rlkq	187	8	observational	observational	JJ
cord-302316-raf5rlkq	187	9	study	study	NN
cord-302316-raf5rlkq	187	10	,	,	,
cord-302316-raf5rlkq	187	11	HCQ	HCQ	NNP
cord-302316-raf5rlkq	187	12	-	-	HYPH
cord-302316-raf5rlkq	187	13	treated	treat	VBN
cord-302316-raf5rlkq	187	14	patients	patient	NNS
cord-302316-raf5rlkq	187	15	were	be	VBD
cord-302316-raf5rlkq	187	16	2.4	2.4	CD
cord-302316-raf5rlkq	187	17	times	time	NNS
cord-302316-raf5rlkq	187	18	more	more	RBR
cord-302316-raf5rlkq	187	19	likely	likely	JJ
cord-302316-raf5rlkq	187	20	to	to	TO
cord-302316-raf5rlkq	187	21	reach	reach	VB
cord-302316-raf5rlkq	187	22	the	the	DT
cord-302316-raf5rlkq	187	23	detrimental	detrimental	JJ
cord-302316-raf5rlkq	187	24	primary	primary	JJ
cord-302316-raf5rlkq	187	25	end	end	NN
cord-302316-raf5rlkq	187	26	-	-	HYPH
cord-302316-raf5rlkq	187	27	point	point	NN
cord-302316-raf5rlkq	187	28	than	than	IN
cord-302316-raf5rlkq	187	29	non	non	JJ
cord-302316-raf5rlkq	187	30	-	-	JJ
cord-302316-raf5rlkq	187	31	treated	treat	VBN
cord-302316-raf5rlkq	187	32	patients	patient	NNS
cord-302316-raf5rlkq	187	33	.	.	.
cord-302316-raf5rlkq	188	1	Since	since	IN
cord-302316-raf5rlkq	188	2	HCQ	HCQ	NNP
cord-302316-raf5rlkq	188	3	-	-	HYPH
cord-302316-raf5rlkq	188	4	treated	treat	VBN
cord-302316-raf5rlkq	188	5	patients	patient	NNS
cord-302316-raf5rlkq	188	6	were	be	VBD
cord-302316-raf5rlkq	188	7	,	,	,
cord-302316-raf5rlkq	188	8	at	at	IN
cord-302316-raf5rlkq	188	9	baseline	baseline	NN
cord-302316-raf5rlkq	188	10	,	,	,
cord-302316-raf5rlkq	188	11	more	more	RBR
cord-302316-raf5rlkq	188	12	severely	severely	RB
cord-302316-raf5rlkq	188	13	ill	ill	JJ
cord-302316-raf5rlkq	188	14	than	than	IN
cord-302316-raf5rlkq	188	15	non	non	JJ
cord-302316-raf5rlkq	188	16	-	-	JJ
cord-302316-raf5rlkq	188	17	treated	treat	VBN
cord-302316-raf5rlkq	188	18	patients	patient	NNS
cord-302316-raf5rlkq	188	19	(	(	-LRB-
cord-302316-raf5rlkq	188	20	by	by	IN
cord-302316-raf5rlkq	188	21	oxygenation	oxygenation	NN
cord-302316-raf5rlkq	188	22	index	index	NN
cord-302316-raf5rlkq	188	23	)	)	-RRB-
cord-302316-raf5rlkq	188	24	,	,	,
cord-302316-raf5rlkq	188	25	the	the	DT
cord-302316-raf5rlkq	188	26	811	811	CD
cord-302316-raf5rlkq	188	27	cases	case	NNS
cord-302316-raf5rlkq	188	28	of	of	IN
cord-302316-raf5rlkq	188	29	HCQ	HCQ	NNP
cord-302316-raf5rlkq	188	30	patients	patient	NNS
cord-302316-raf5rlkq	188	31	were	be	VBD
cord-302316-raf5rlkq	188	32	compared	compare	VBN
cord-302316-raf5rlkq	188	33	in	in	IN
cord-302316-raf5rlkq	188	34	a	a	DT
cord-302316-raf5rlkq	188	35	second	second	JJ
cord-302316-raf5rlkq	188	36	analysis	analysis	NN
cord-302316-raf5rlkq	188	37	to	to	IN
cord-302316-raf5rlkq	188	38	those	those	DT
cord-302316-raf5rlkq	188	39	of	of	IN
cord-302316-raf5rlkq	188	40	274	274	CD
cord-302316-raf5rlkq	188	41	better	well	RBR
cord-302316-raf5rlkq	188	42	matched	match	VBN
cord-302316-raf5rlkq	188	43	non	non	JJ
cord-302316-raf5rlkq	188	44	-	-	JJ
cord-302316-raf5rlkq	188	45	treated	treat	VBN
cord-302316-raf5rlkq	188	46	patients	patient	NNS
cord-302316-raf5rlkq	188	47	.	.	.
cord-302316-raf5rlkq	189	1	Neither	neither	DT
cord-302316-raf5rlkq	189	2	benefit	benefit	NN
cord-302316-raf5rlkq	189	3	nor	nor	CC
cord-302316-raf5rlkq	189	4	harm	harm	NN
cord-302316-raf5rlkq	189	5	has	have	VBZ
cord-302316-raf5rlkq	189	6	been	be	VBN
cord-302316-raf5rlkq	189	7	associated	associate	VBN
cord-302316-raf5rlkq	189	8	with	with	IN
cord-302316-raf5rlkq	189	9	HCQ	HCQ	NNP
cord-302316-raf5rlkq	189	10	use	use	NN
cord-302316-raf5rlkq	189	11	(	(	-LRB-
cord-302316-raf5rlkq	189	12	Geleris	Geleris	NNP
cord-302316-raf5rlkq	189	13	et	et	NNP
cord-302316-raf5rlkq	189	14	al	al	NNP
cord-302316-raf5rlkq	189	15	.	.	NNP
cord-302316-raf5rlkq	189	16	,	,	,
cord-302316-raf5rlkq	189	17	2020	2020	CD
cord-302316-raf5rlkq	189	18	)	)	-RRB-
cord-302316-raf5rlkq	189	19	.	.	.
cord-302316-raf5rlkq	190	1	In	in	IN
cord-302316-raf5rlkq	190	2	an	an	DT
cord-302316-raf5rlkq	190	3	open	open	JJ
cord-302316-raf5rlkq	190	4	-	-	HYPH
cord-302316-raf5rlkq	190	5	label	label	NN
cord-302316-raf5rlkq	190	6	and	and	CC
cord-302316-raf5rlkq	190	7	compassionate	compassionate	JJ
cord-302316-raf5rlkq	190	8	trial	trial	NN
cord-302316-raf5rlkq	190	9	,	,	,
cord-302316-raf5rlkq	190	10	53	53	CD
cord-302316-raf5rlkq	190	11	patients	patient	NNS
cord-302316-raf5rlkq	190	12	with	with	IN
cord-302316-raf5rlkq	190	13	severe	severe	JJ
cord-302316-raf5rlkq	190	14	COVID-19	covid-19	NN
cord-302316-raf5rlkq	190	15	,	,	,
cord-302316-raf5rlkq	190	16	in	in	IN
cord-302316-raf5rlkq	190	17	which	which	WDT
cord-302316-raf5rlkq	190	18	34	34	CD
cord-302316-raf5rlkq	190	19	of	of	IN
cord-302316-raf5rlkq	190	20	them	-PRON-	PRP
cord-302316-raf5rlkq	190	21	were	be	VBD
cord-302316-raf5rlkq	190	22	on	on	IN
cord-302316-raf5rlkq	190	23	invasive	invasive	JJ
cord-302316-raf5rlkq	190	24	ventilation	ventilation	NN
cord-302316-raf5rlkq	190	25	and	and	CC
cord-302316-raf5rlkq	190	26	received	receive	VBD
cord-302316-raf5rlkq	190	27	remdesivir	remdesivir	NNP
cord-302316-raf5rlkq	190	28	,	,	,
cord-302316-raf5rlkq	190	29	a	a	DT
cord-302316-raf5rlkq	190	30	nucleotide	nucleotide	JJ
cord-302316-raf5rlkq	190	31	analogue	analogue	NN
cord-302316-raf5rlkq	190	32	developed	develop	VBN
cord-302316-raf5rlkq	190	33	against	against	IN
cord-302316-raf5rlkq	190	34	Ebola	Ebola	NNP
cord-302316-raf5rlkq	190	35	virus	virus	NN
cord-302316-raf5rlkq	190	36	.	.	.
cord-302316-raf5rlkq	191	1	After	after	IN
cord-302316-raf5rlkq	191	2	3	3	CD
cord-302316-raf5rlkq	191	3	weeks	week	NNS
cord-302316-raf5rlkq	191	4	of	of	IN
cord-302316-raf5rlkq	191	5	follow	follow	NN
cord-302316-raf5rlkq	191	6	-	-	HYPH
cord-302316-raf5rlkq	191	7	up	up	NN
cord-302316-raf5rlkq	191	8	,	,	,
cord-302316-raf5rlkq	191	9	68	68	CD
cord-302316-raf5rlkq	191	10	%	%	NN
cord-302316-raf5rlkq	191	11	of	of	IN
cord-302316-raf5rlkq	191	12	them	-PRON-	PRP
cord-302316-raf5rlkq	191	13	showed	show	VBD
cord-302316-raf5rlkq	191	14	clinical	clinical	JJ
cord-302316-raf5rlkq	191	15	improvement	improvement	NN
cord-302316-raf5rlkq	191	16	;	;	:
cord-302316-raf5rlkq	191	17	57	57	CD
cord-302316-raf5rlkq	191	18	%	%	NN
cord-302316-raf5rlkq	191	19	of	of	IN
cord-302316-raf5rlkq	191	20	patients	patient	NNS
cord-302316-raf5rlkq	191	21	on	on	IN
cord-302316-raf5rlkq	191	22	mechanical	mechanical	JJ
cord-302316-raf5rlkq	191	23	ventilation	ventilation	NN
cord-302316-raf5rlkq	191	24	were	be	VBD
cord-302316-raf5rlkq	191	25	extubated	extubate	VBN
cord-302316-raf5rlkq	191	26	,	,	,
cord-302316-raf5rlkq	191	27	while	while	IN
cord-302316-raf5rlkq	191	28	13	13	CD
cord-302316-raf5rlkq	191	29	%	%	NN
cord-302316-raf5rlkq	191	30	died	die	VBD
cord-302316-raf5rlkq	191	31	.	.	.
cord-302316-raf5rlkq	192	1	This	this	DT
cord-302316-raf5rlkq	192	2	fatality	fatality	NN
cord-302316-raf5rlkq	192	3	rate	rate	NN
cord-302316-raf5rlkq	192	4	is	be	VBZ
cord-302316-raf5rlkq	192	5	a	a	DT
cord-302316-raf5rlkq	192	6	relatively	relatively	RB
cord-302316-raf5rlkq	192	7	better	well	JJR
cord-302316-raf5rlkq	192	8	result	result	NN
cord-302316-raf5rlkq	192	9	when	when	WRB
cord-302316-raf5rlkq	192	10	compared	compare	VBN
cord-302316-raf5rlkq	192	11	with	with	IN
cord-302316-raf5rlkq	192	12	a	a	DT
cord-302316-raf5rlkq	192	13	66	66	CD
cord-302316-raf5rlkq	192	14	%	%	NN
cord-302316-raf5rlkq	192	15	mortality	mortality	NN
cord-302316-raf5rlkq	192	16	rate	rate	NN
cord-302316-raf5rlkq	192	17	in	in	IN
cord-302316-raf5rlkq	192	18	Chinese	chinese	JJ
cord-302316-raf5rlkq	192	19	patients	patient	NNS
cord-302316-raf5rlkq	192	20	receiving	receive	VBG
cord-302316-raf5rlkq	192	21	invasive	invasive	JJ
cord-302316-raf5rlkq	192	22	ventilation	ventilation	NN
cord-302316-raf5rlkq	192	23	.	.	.
cord-302316-raf5rlkq	193	1	Due	due	IN
cord-302316-raf5rlkq	193	2	to	to	IN
cord-302316-raf5rlkq	193	3	a	a	DT
cord-302316-raf5rlkq	193	4	small	small	JJ
cord-302316-raf5rlkq	193	5	study	study	NN
cord-302316-raf5rlkq	193	6	size	size	NN
cord-302316-raf5rlkq	193	7	,	,	,
cord-302316-raf5rlkq	193	8	short	short	JJ
cord-302316-raf5rlkq	193	9	length	length	NN
cord-302316-raf5rlkq	193	10	of	of	IN
cord-302316-raf5rlkq	193	11	follow	follow	NN
cord-302316-raf5rlkq	193	12	-	-	HYPH
cord-302316-raf5rlkq	193	13	up	up	NN
cord-302316-raf5rlkq	193	14	and	and	CC
cord-302316-raf5rlkq	193	15	the	the	DT
cord-302316-raf5rlkq	193	16	lack	lack	NN
cord-302316-raf5rlkq	193	17	of	of	IN
cord-302316-raf5rlkq	193	18	a	a	DT
cord-302316-raf5rlkq	193	19	randomized	randomized	JJ
cord-302316-raf5rlkq	193	20	control	control	NN
cord-302316-raf5rlkq	193	21	group	group	NN
cord-302316-raf5rlkq	193	22	,	,	,
cord-302316-raf5rlkq	193	23	the	the	DT
cord-302316-raf5rlkq	193	24	outcome	outcome	NN
cord-302316-raf5rlkq	193	25	must	must	MD
cord-302316-raf5rlkq	193	26	be	be	VB
cord-302316-raf5rlkq	193	27	interpreted	interpret	VBN
cord-302316-raf5rlkq	193	28	with	with	IN
cord-302316-raf5rlkq	193	29	caution	caution	NN
cord-302316-raf5rlkq	193	30	(	(	-LRB-
cord-302316-raf5rlkq	193	31	Grein	Grein	NNP
cord-302316-raf5rlkq	193	32	et	et	NNP
cord-302316-raf5rlkq	193	33	al	al	NNP
cord-302316-raf5rlkq	193	34	.	.	NNP
cord-302316-raf5rlkq	193	35	,	,	,
cord-302316-raf5rlkq	193	36	2020	2020	CD
cord-302316-raf5rlkq	193	37	)	)	-RRB-
cord-302316-raf5rlkq	193	38	.	.	.
cord-302316-raf5rlkq	194	1	In	in	IN
cord-302316-raf5rlkq	194	2	Hubei	Hubei	NNP
cord-302316-raf5rlkq	194	3	,	,	,
cord-302316-raf5rlkq	194	4	there	there	EX
cord-302316-raf5rlkq	194	5	were	be	VBD
cord-302316-raf5rlkq	194	6	237	237	CD
cord-302316-raf5rlkq	194	7	Chinese	chinese	JJ
cord-302316-raf5rlkq	194	8	patients	patient	NNS
cord-302316-raf5rlkq	194	9	with	with	IN
cord-302316-raf5rlkq	194	10	severe	severe	JJ
cord-302316-raf5rlkq	194	11	COVID-19	covid-19	NN
cord-302316-raf5rlkq	194	12	who	who	WP
cord-302316-raf5rlkq	194	13	were	be	VBD
cord-302316-raf5rlkq	194	14	subsequently	subsequently	RB
cord-302316-raf5rlkq	194	15	randomized	randomize	VBN
cord-302316-raf5rlkq	194	16	on	on	IN
cord-302316-raf5rlkq	194	17	a	a	DT
cord-302316-raf5rlkq	194	18	2:1	2:1	CD
cord-302316-raf5rlkq	194	19	basis	basis	NN
cord-302316-raf5rlkq	194	20	for	for	IN
cord-302316-raf5rlkq	194	21	intravenous	intravenous	JJ
cord-302316-raf5rlkq	194	22	remdesivir	remdesivir	NNP
cord-302316-raf5rlkq	194	23	,	,	,
cord-302316-raf5rlkq	194	24	or	or	CC
cord-302316-raf5rlkq	194	25	placebo	placebo	NN
cord-302316-raf5rlkq	194	26	,	,	,
cord-302316-raf5rlkq	194	27	in	in	IN
cord-302316-raf5rlkq	194	28	a	a	DT
cord-302316-raf5rlkq	194	29	multicentre	multicentre	NNP
cord-302316-raf5rlkq	194	30	clinical	clinical	JJ
cord-302316-raf5rlkq	194	31	trial	trial	NN
cord-302316-raf5rlkq	194	32	.	.	.
cord-302316-raf5rlkq	195	1	The	the	DT
cord-302316-raf5rlkq	195	2	time	time	NN
cord-302316-raf5rlkq	195	3	it	-PRON-	PRP
cord-302316-raf5rlkq	195	4	took	take	VBD
cord-302316-raf5rlkq	195	5	to	to	TO
cord-302316-raf5rlkq	195	6	show	show	VB
cord-302316-raf5rlkq	195	7	clinical	clinical	JJ
cord-302316-raf5rlkq	195	8	improvement	improvement	NN
cord-302316-raf5rlkq	195	9	in	in	IN
cord-302316-raf5rlkq	195	10	the	the	DT
cord-302316-raf5rlkq	195	11	remdesivir	remdesivir	NNP
cord-302316-raf5rlkq	195	12	group	group	NN
cord-302316-raf5rlkq	195	13	was	be	VBD
cord-302316-raf5rlkq	195	14	statistically	statistically	RB
cord-302316-raf5rlkq	195	15	not	not	RB
cord-302316-raf5rlkq	195	16	significantly	significantly	RB
cord-302316-raf5rlkq	195	17	different	different	JJ
cord-302316-raf5rlkq	195	18	from	from	IN
cord-302316-raf5rlkq	195	19	that	that	DT
cord-302316-raf5rlkq	195	20	of	of	IN
cord-302316-raf5rlkq	195	21	the	the	DT
cord-302316-raf5rlkq	195	22	control	control	NN
cord-302316-raf5rlkq	195	23	group	group	NN
cord-302316-raf5rlkq	195	24	(	(	-LRB-
cord-302316-raf5rlkq	195	25	median	median	NN
cord-302316-raf5rlkq	195	26	21	21	CD
cord-302316-raf5rlkq	195	27	vs.	vs.	NN
cord-302316-raf5rlkq	195	28	23	23	CD
cord-302316-raf5rlkq	195	29	days	day	NNS
cord-302316-raf5rlkq	195	30	)	)	-RRB-
cord-302316-raf5rlkq	195	31	.	.	.
cord-302316-raf5rlkq	196	1	The	the	DT
cord-302316-raf5rlkq	196	2	time	time	NN
cord-302316-raf5rlkq	196	3	from	from	IN
cord-302316-raf5rlkq	196	4	onset	onset	NN
cord-302316-raf5rlkq	196	5	of	of	IN
cord-302316-raf5rlkq	196	6	symptoms	symptom	NNS
cord-302316-raf5rlkq	196	7	to	to	TO
cord-302316-raf5rlkq	196	8	start	start	VB
cord-302316-raf5rlkq	196	9	of	of	IN
cord-302316-raf5rlkq	196	10	treatment	treatment	NN
cord-302316-raf5rlkq	196	11	was	be	VBD
cord-302316-raf5rlkq	196	12	10	10	CD
cord-302316-raf5rlkq	196	13	days	day	NNS
cord-302316-raf5rlkq	196	14	.	.	.
cord-302316-raf5rlkq	197	1	Patients	patient	NNS
cord-302316-raf5rlkq	197	2	receiving	receive	VBG
cord-302316-raf5rlkq	197	3	the	the	DT
cord-302316-raf5rlkq	197	4	treatment	treatment	NN
cord-302316-raf5rlkq	197	5	during	during	IN
cord-302316-raf5rlkq	197	6	the	the	DT
cord-302316-raf5rlkq	197	7	first	first	JJ
cord-302316-raf5rlkq	197	8	9	9	CD
cord-302316-raf5rlkq	197	9	days	day	NNS
cord-302316-raf5rlkq	197	10	showed	show	VBD
cord-302316-raf5rlkq	197	11	a	a	DT
cord-302316-raf5rlkq	197	12	numerically	numerically	RB
cord-302316-raf5rlkq	197	13	greater	great	JJR
cord-302316-raf5rlkq	197	14	difference	difference	NN
cord-302316-raf5rlkq	197	15	for	for	IN
cord-302316-raf5rlkq	197	16	clinical	clinical	JJ
cord-302316-raf5rlkq	197	17	improvement	improvement	NN
cord-302316-raf5rlkq	197	18	(	(	-LRB-
cord-302316-raf5rlkq	197	19	18	18	CD
cord-302316-raf5rlkq	197	20	vs.	vs.	IN
cord-302316-raf5rlkq	197	21	Covid-19	covid-19	NN
cord-302316-raf5rlkq	197	22	:	:	:
cord-302316-raf5rlkq	197	23	Pathogenesis	pathogenesis	NN
cord-302316-raf5rlkq	197	24	and	and	CC
cord-302316-raf5rlkq	197	25	drugs	drug	NNS
cord-302316-raf5rlkq	197	26	5	5	CD
cord-302316-raf5rlkq	197	27	23	23	CD
cord-302316-raf5rlkq	197	28	days	day	NNS
cord-302316-raf5rlkq	197	29	)	)	-RRB-
cord-302316-raf5rlkq	197	30	,	,	,
cord-302316-raf5rlkq	197	31	but	but	CC
cord-302316-raf5rlkq	197	32	this	this	DT
cord-302316-raf5rlkq	197	33	difference	difference	NN
cord-302316-raf5rlkq	197	34	is	be	VBZ
cord-302316-raf5rlkq	197	35	not	not	RB
cord-302316-raf5rlkq	197	36	statistically	statistically	RB
cord-302316-raf5rlkq	197	37	significant	significant	JJ
cord-302316-raf5rlkq	197	38	.	.	.
cord-302316-raf5rlkq	198	1	The	the	DT
cord-302316-raf5rlkq	198	2	length	length	NN
cord-302316-raf5rlkq	198	3	of	of	IN
cord-302316-raf5rlkq	198	4	time	time	NN
cord-302316-raf5rlkq	198	5	of	of	IN
cord-302316-raf5rlkq	198	6	viral	viral	JJ
cord-302316-raf5rlkq	198	7	excretion	excretion	NN
cord-302316-raf5rlkq	198	8	in	in	IN
cord-302316-raf5rlkq	198	9	upper	upper	JJ
cord-302316-raf5rlkq	198	10	and	and	CC
cord-302316-raf5rlkq	198	11	lower	low	JJR
cord-302316-raf5rlkq	198	12	respiratory	respiratory	JJ
cord-302316-raf5rlkq	198	13	tract	tract	NN
cord-302316-raf5rlkq	198	14	samples	sample	NNS
cord-302316-raf5rlkq	198	15	did	do	VBD
cord-302316-raf5rlkq	198	16	not	not	RB
cord-302316-raf5rlkq	198	17	differ	differ	VB
cord-302316-raf5rlkq	198	18	between	between	IN
cord-302316-raf5rlkq	198	19	the	the	DT
cord-302316-raf5rlkq	198	20	two	two	CD
cord-302316-raf5rlkq	198	21	groups	group	NNS
cord-302316-raf5rlkq	198	22	,	,	,
cord-302316-raf5rlkq	198	23	demonstrating	demonstrate	VBG
cord-302316-raf5rlkq	198	24	a	a	DT
cord-302316-raf5rlkq	198	25	lack	lack	NN
cord-302316-raf5rlkq	198	26	of	of	IN
cord-302316-raf5rlkq	198	27	in	in	IN
cord-302316-raf5rlkq	198	28	vivo	vivo	NN
cord-302316-raf5rlkq	198	29	antiviral	antiviral	JJ
cord-302316-raf5rlkq	198	30	activity	activity	NN
cord-302316-raf5rlkq	198	31	of	of	IN
cord-302316-raf5rlkq	198	32	this	this	DT
cord-302316-raf5rlkq	198	33	nucleoside	nucleoside	NN
cord-302316-raf5rlkq	198	34	analog	analog	NN
cord-302316-raf5rlkq	198	35	.	.	.
cord-302316-raf5rlkq	199	1	The	the	DT
cord-302316-raf5rlkq	199	2	mortality	mortality	NN
cord-302316-raf5rlkq	199	3	rate	rate	NN
cord-302316-raf5rlkq	199	4	was	be	VBD
cord-302316-raf5rlkq	199	5	15	15	CD
cord-302316-raf5rlkq	199	6	%	%	NN
cord-302316-raf5rlkq	199	7	in	in	IN
cord-302316-raf5rlkq	199	8	the	the	DT
cord-302316-raf5rlkq	199	9	remdesivir	remdesivir	NNP
cord-302316-raf5rlkq	199	10	group	group	NN
cord-302316-raf5rlkq	199	11	,	,	,
cord-302316-raf5rlkq	199	12	and	and	CC
cord-302316-raf5rlkq	199	13	13	13	CD
cord-302316-raf5rlkq	199	14	%	%	NN
cord-302316-raf5rlkq	199	15	in	in	IN
cord-302316-raf5rlkq	199	16	the	the	DT
cord-302316-raf5rlkq	199	17	placebo	placebo	NN
cord-302316-raf5rlkq	199	18	group	group	NN
cord-302316-raf5rlkq	199	19	.	.	.
cord-302316-raf5rlkq	200	1	This	this	DT
cord-302316-raf5rlkq	200	2	otherwise	otherwise	RB
cord-302316-raf5rlkq	200	3	well	well	RB
cord-302316-raf5rlkq	200	4	-	-	HYPH
cord-302316-raf5rlkq	200	5	conducted	conduct	VBN
cord-302316-raf5rlkq	200	6	clinical	clinical	JJ
cord-302316-raf5rlkq	200	7	trial	trial	NN
cord-302316-raf5rlkq	200	8	was	be	VBD
cord-302316-raf5rlkq	200	9	underpowered	underpowere	VBN
cord-302316-raf5rlkq	200	10	because	because	IN
cord-302316-raf5rlkq	200	11	it	-PRON-	PRP
cord-302316-raf5rlkq	200	12	could	could	MD
cord-302316-raf5rlkq	200	13	not	not	RB
cord-302316-raf5rlkq	200	14	attain	attain	VB
cord-302316-raf5rlkq	200	15	the	the	DT
cord-302316-raf5rlkq	200	16	enrolment	enrolment	NN
cord-302316-raf5rlkq	200	17	of	of	IN
cord-302316-raf5rlkq	200	18	the	the	DT
cord-302316-raf5rlkq	200	19	planned	planned	JJ
cord-302316-raf5rlkq	200	20	453	453	CD
cord-302316-raf5rlkq	200	21	patients	patient	NNS
cord-302316-raf5rlkq	200	22	,	,	,
cord-302316-raf5rlkq	200	23	since	since	IN
cord-302316-raf5rlkq	200	24	the	the	DT
cord-302316-raf5rlkq	200	25	epidemic	epidemic	NN
cord-302316-raf5rlkq	200	26	stopped	stop	VBD
cord-302316-raf5rlkq	200	27	in	in	IN
cord-302316-raf5rlkq	200	28	Hubei	Hubei	NNP
cord-302316-raf5rlkq	200	29	as	as	IN
cord-302316-raf5rlkq	200	30	a	a	DT
cord-302316-raf5rlkq	200	31	consequence	consequence	NN
cord-302316-raf5rlkq	200	32	of	of	IN
cord-302316-raf5rlkq	200	33	containment	containment	NN
cord-302316-raf5rlkq	200	34	measures	measure	NNS
cord-302316-raf5rlkq	200	35	.	.	.
cord-302316-raf5rlkq	201	1	Both	both	DT
cord-302316-raf5rlkq	201	2	groups	group	NNS
cord-302316-raf5rlkq	201	3	did	do	VBD
cord-302316-raf5rlkq	201	4	not	not	RB
cord-302316-raf5rlkq	201	5	differ	differ	VB
cord-302316-raf5rlkq	201	6	in	in	IN
cord-302316-raf5rlkq	201	7	the	the	DT
cord-302316-raf5rlkq	201	8	types	type	NNS
cord-302316-raf5rlkq	201	9	of	of	IN
cord-302316-raf5rlkq	201	10	,	,	,
cord-302316-raf5rlkq	201	11	or	or	CC
cord-302316-raf5rlkq	201	12	number	number	NN
cord-302316-raf5rlkq	201	13	of	of	IN
cord-302316-raf5rlkq	201	14	adverse	adverse	JJ
cord-302316-raf5rlkq	201	15	events	event	NNS
cord-302316-raf5rlkq	201	16	,	,	,
cord-302316-raf5rlkq	201	17	demonstrating	demonstrate	VBG
cord-302316-raf5rlkq	201	18	the	the	DT
cord-302316-raf5rlkq	201	19	safety	safety	NN
cord-302316-raf5rlkq	201	20	of	of	IN
cord-302316-raf5rlkq	201	21	intravenous	intravenous	JJ
cord-302316-raf5rlkq	201	22	remdesivir	remdesivir	NNP
cord-302316-raf5rlkq	201	23	.	.	.
cord-302316-raf5rlkq	202	1	On	on	IN
cord-302316-raf5rlkq	202	2	1	1	CD
cord-302316-raf5rlkq	202	3	May	May	NNP
cord-302316-raf5rlkq	202	4	,	,	,
cord-302316-raf5rlkq	202	5	the	the	DT
cord-302316-raf5rlkq	202	6	FDA	FDA	NNP
cord-302316-raf5rlkq	202	7	granted	grant	VBD
cord-302316-raf5rlkq	202	8	an	an	DT
cord-302316-raf5rlkq	202	9	emergency	emergency	NN
cord-302316-raf5rlkq	202	10	use	use	NN
cord-302316-raf5rlkq	202	11	authorization	authorization	NN
cord-302316-raf5rlkq	202	12	for	for	IN
cord-302316-raf5rlkq	202	13	remdesivir	remdesivir	NNP
cord-302316-raf5rlkq	202	14	to	to	IN
cord-302316-raf5rlkq	202	15	physicians	physician	NNS
cord-302316-raf5rlkq	202	16	.	.	.
cord-302316-raf5rlkq	203	1	The	the	DT
cord-302316-raf5rlkq	203	2	decision	decision	NN
cord-302316-raf5rlkq	203	3	was	be	VBD
cord-302316-raf5rlkq	203	4	based	base	VBN
cord-302316-raf5rlkq	203	5	on	on	IN
cord-302316-raf5rlkq	203	6	the	the	DT
cord-302316-raf5rlkq	203	7	outcome	outcome	NN
cord-302316-raf5rlkq	203	8	of	of	IN
cord-302316-raf5rlkq	203	9	a	a	DT
cord-302316-raf5rlkq	203	10	clinical	clinical	JJ
cord-302316-raf5rlkq	203	11	trial	trial	NN
cord-302316-raf5rlkq	203	12	,	,	,
cord-302316-raf5rlkq	203	13	which	which	WDT
cord-302316-raf5rlkq	203	14	showed	show	VBD
cord-302316-raf5rlkq	203	15	an	an	DT
cord-302316-raf5rlkq	203	16	accelerated	accelerate	VBN
cord-302316-raf5rlkq	203	17	recovery	recovery	NN
cord-302316-raf5rlkq	203	18	in	in	IN
cord-302316-raf5rlkq	203	19	more	more	JJR
cord-302316-raf5rlkq	203	20	than	than	IN
cord-302316-raf5rlkq	203	21	1000	1000	CD
cord-302316-raf5rlkq	203	22	enrolled	enrol	VBN
cord-302316-raf5rlkq	203	23	patients	patient	NNS
cord-302316-raf5rlkq	203	24	treated	treat	VBN
cord-302316-raf5rlkq	203	25	with	with	IN
cord-302316-raf5rlkq	203	26	either	either	DT
cord-302316-raf5rlkq	203	27	remdesivir	remdesivir	NNS
cord-302316-raf5rlkq	203	28	or	or	CC
cord-302316-raf5rlkq	203	29	placebo	placebo	NN
cord-302316-raf5rlkq	203	30	(	(	-LRB-
cord-302316-raf5rlkq	203	31	11	11	CD
cord-302316-raf5rlkq	203	32	vs.	vs.	CC
cord-302316-raf5rlkq	203	33	15	15	CD
cord-302316-raf5rlkq	203	34	days	day	NNS
cord-302316-raf5rlkq	203	35	)	)	-RRB-
cord-302316-raf5rlkq	203	36	.	.	.
cord-302316-raf5rlkq	204	1	There	there	EX
cord-302316-raf5rlkq	204	2	were	be	VBD
cord-302316-raf5rlkq	204	3	fewer	few	JJR
cord-302316-raf5rlkq	204	4	deaths	death	NNS
cord-302316-raf5rlkq	204	5	in	in	IN
cord-302316-raf5rlkq	204	6	the	the	DT
cord-302316-raf5rlkq	204	7	group	group	NN
cord-302316-raf5rlkq	204	8	with	with	IN
cord-302316-raf5rlkq	204	9	treatment	treatment	NN
cord-302316-raf5rlkq	204	10	than	than	IN
cord-302316-raf5rlkq	204	11	in	in	IN
cord-302316-raf5rlkq	204	12	the	the	DT
cord-302316-raf5rlkq	204	13	placebo	placebo	NN
cord-302316-raf5rlkq	204	14	group	group	NN
cord-302316-raf5rlkq	204	15	,	,	,
cord-302316-raf5rlkq	204	16	but	but	CC
cord-302316-raf5rlkq	204	17	the	the	DT
cord-302316-raf5rlkq	204	18	difference	difference	NN
cord-302316-raf5rlkq	204	19	was	be	VBD
cord-302316-raf5rlkq	204	20	not	not	RB
cord-302316-raf5rlkq	204	21	statistically	statistically	RB
cord-302316-raf5rlkq	204	22	significant	significant	JJ
cord-302316-raf5rlkq	204	23	.	.	.
cord-302316-raf5rlkq	205	1	Details	detail	NNS
cord-302316-raf5rlkq	205	2	of	of	IN
cord-302316-raf5rlkq	205	3	the	the	DT
cord-302316-raf5rlkq	205	4	trial	trial	NN
cord-302316-raf5rlkq	205	5	have	have	VBP
cord-302316-raf5rlkq	205	6	not	not	RB
cord-302316-raf5rlkq	205	7	yet	yet	RB
cord-302316-raf5rlkq	205	8	been	be	VBN
cord-302316-raf5rlkq	205	9	published	publish	VBN
cord-302316-raf5rlkq	205	10	(	(	-LRB-
cord-302316-raf5rlkq	205	11	Ledford	Ledford	NNP
cord-302316-raf5rlkq	205	12	,	,	,
cord-302316-raf5rlkq	205	13	2020	2020	CD
cord-302316-raf5rlkq	205	14	)	)	-RRB-
cord-302316-raf5rlkq	205	15	.	.	.
cord-302316-raf5rlkq	206	1	A	a	DT
cord-302316-raf5rlkq	206	2	total	total	NN
cord-302316-raf5rlkq	206	3	of	of	IN
cord-302316-raf5rlkq	206	4	86	86	CD
cord-302316-raf5rlkq	206	5	COVID-19	covid-19	CD
cord-302316-raf5rlkq	206	6	cases	case	NNS
cord-302316-raf5rlkq	206	7	of	of	IN
cord-302316-raf5rlkq	206	8	patients	patient	NNS
cord-302316-raf5rlkq	206	9	from	from	IN
cord-302316-raf5rlkq	206	10	China	China	NNP
cord-302316-raf5rlkq	206	11	with	with	IN
cord-302316-raf5rlkq	206	12	mild	mild	JJ
cord-302316-raf5rlkq	206	13	/	/	SYM
cord-302316-raf5rlkq	206	14	moderate	moderate	JJ
cord-302316-raf5rlkq	206	15	disease	disease	NN
cord-302316-raf5rlkq	206	16	were	be	VBD
cord-302316-raf5rlkq	206	17	randomized	randomize	VBN
cord-302316-raf5rlkq	206	18	on	on	IN
cord-302316-raf5rlkq	206	19	the	the	DT
cord-302316-raf5rlkq	206	20	antiviral	antiviral	JJ
cord-302316-raf5rlkq	206	21	lopinavir	lopinavir	NNS
cord-302316-raf5rlkq	206	22	(	(	-LRB-
cord-302316-raf5rlkq	206	23	an	an	DT
cord-302316-raf5rlkq	206	24	inhibitor	inhibitor	NN
cord-302316-raf5rlkq	206	25	of	of	IN
cord-302316-raf5rlkq	206	26	HIV	HIV	NNP
cord-302316-raf5rlkq	206	27	protease	protease	NN
cord-302316-raf5rlkq	206	28	combined	combine	VBN
cord-302316-raf5rlkq	206	29	with	with	IN
cord-302316-raf5rlkq	206	30	ritonavir	ritonavir	NNS
cord-302316-raf5rlkq	206	31	,	,	,
cord-302316-raf5rlkq	206	32	which	which	WDT
cord-302316-raf5rlkq	206	33	prolongs	prolong	VBZ
cord-302316-raf5rlkq	206	34	the	the	DT
cord-302316-raf5rlkq	206	35	presence	presence	NN
cord-302316-raf5rlkq	206	36	of	of	IN
cord-302316-raf5rlkq	206	37	drugs	drug	NNS
cord-302316-raf5rlkq	206	38	in	in	IN
cord-302316-raf5rlkq	206	39	the	the	DT
cord-302316-raf5rlkq	206	40	body	body	NN
cord-302316-raf5rlkq	206	41	)	)	-RRB-
cord-302316-raf5rlkq	206	42	or	or	CC
cord-302316-raf5rlkq	206	43	the	the	DT
cord-302316-raf5rlkq	206	44	antiviral	antiviral	JJ
cord-302316-raf5rlkq	206	45	arbidol	arbidol	NN
cord-302316-raf5rlkq	206	46	(	(	-LRB-
cord-302316-raf5rlkq	206	47	an	an	DT
cord-302316-raf5rlkq	206	48	influenza	influenza	NN
cord-302316-raf5rlkq	206	49	virus	virus	NN
cord-302316-raf5rlkq	206	50	fusion	fusion	NN
cord-302316-raf5rlkq	206	51	inhibitor	inhibitor	NN
cord-302316-raf5rlkq	206	52	only	only	RB
cord-302316-raf5rlkq	206	53	registered	register	VBN
cord-302316-raf5rlkq	206	54	in	in	IN
cord-302316-raf5rlkq	206	55	Russia	Russia	NNP
cord-302316-raf5rlkq	206	56	)	)	-RRB-
cord-302316-raf5rlkq	206	57	or	or	CC
cord-302316-raf5rlkq	206	58	in	in	IN
cord-302316-raf5rlkq	206	59	a	a	DT
cord-302316-raf5rlkq	206	60	control	control	NN
cord-302316-raf5rlkq	206	61	group	group	NN
cord-302316-raf5rlkq	206	62	in	in	IN
cord-302316-raf5rlkq	206	63	a	a	DT
cord-302316-raf5rlkq	206	64	2:2:1	2:2:1	CD
cord-302316-raf5rlkq	206	65	ratio	ratio	NN
cord-302316-raf5rlkq	206	66	.	.	.
cord-302316-raf5rlkq	207	1	The	the	DT
cord-302316-raf5rlkq	207	2	primary	primary	JJ
cord-302316-raf5rlkq	207	3	end	end	NN
cord-302316-raf5rlkq	207	4	-	-	HYPH
cord-302316-raf5rlkq	207	5	point	point	NN
cord-302316-raf5rlkq	207	6	was	be	VBD
cord-302316-raf5rlkq	207	7	positive	positive	JJ
cord-302316-raf5rlkq	207	8	-	-	HYPH
cord-302316-raf5rlkq	207	9	to	to	IN
cord-302316-raf5rlkq	207	10	-	-	HYPH
cord-302316-raf5rlkq	207	11	negative	negative	JJ
cord-302316-raf5rlkq	207	12	conversion	conversion	NN
cord-302316-raf5rlkq	207	13	for	for	IN
cord-302316-raf5rlkq	207	14	viral	viral	JJ
cord-302316-raf5rlkq	207	15	RNA	RNA	NNP
cord-302316-raf5rlkq	207	16	in	in	IN
cord-302316-raf5rlkq	207	17	pharyngeal	pharyngeal	JJ
cord-302316-raf5rlkq	207	18	swabs	swab	NNS
cord-302316-raf5rlkq	207	19	.	.	.
cord-302316-raf5rlkq	208	1	No	no	DT
cord-302316-raf5rlkq	208	2	difference	difference	NN
cord-302316-raf5rlkq	208	3	was	be	VBD
cord-302316-raf5rlkq	208	4	seen	see	VBN
cord-302316-raf5rlkq	208	5	between	between	IN
cord-302316-raf5rlkq	208	6	the	the	DT
cord-302316-raf5rlkq	208	7	groups	group	NNS
cord-302316-raf5rlkq	208	8	.	.	.
cord-302316-raf5rlkq	209	1	Secondary	secondary	JJ
cord-302316-raf5rlkq	209	2	outcomes	outcome	NNS
cord-302316-raf5rlkq	209	3	were	be	VBD
cord-302316-raf5rlkq	209	4	represented	represent	VBN
cord-302316-raf5rlkq	209	5	by	by	IN
cord-302316-raf5rlkq	209	6	clinical	clinical	JJ
cord-302316-raf5rlkq	209	7	parameters	parameter	NNS
cord-302316-raf5rlkq	209	8	:	:	:
cord-302316-raf5rlkq	209	9	fever	fever	NN
cord-302316-raf5rlkq	209	10	,	,	,
cord-302316-raf5rlkq	209	11	cough	cough	NN
cord-302316-raf5rlkq	209	12	and	and	CC
cord-302316-raf5rlkq	209	13	lung	lung	NN
cord-302316-raf5rlkq	209	14	CT	CT	NNP
cord-302316-raf5rlkq	209	15	improvement	improvement	NN
cord-302316-raf5rlkq	209	16	.	.	.
cord-302316-raf5rlkq	210	1	Again	again	RB
cord-302316-raf5rlkq	210	2	,	,	,
cord-302316-raf5rlkq	210	3	no	no	DT
cord-302316-raf5rlkq	210	4	difference	difference	NN
cord-302316-raf5rlkq	210	5	was	be	VBD
cord-302316-raf5rlkq	210	6	seen	see	VBN
cord-302316-raf5rlkq	210	7	between	between	IN
cord-302316-raf5rlkq	210	8	the	the	DT
cord-302316-raf5rlkq	210	9	groups	group	NNS
cord-302316-raf5rlkq	210	10	.	.	.
cord-302316-raf5rlkq	211	1	Adverse	adverse	JJ
cord-302316-raf5rlkq	211	2	events	event	NNS
cord-302316-raf5rlkq	211	3	were	be	VBD
cord-302316-raf5rlkq	211	4	not	not	RB
cord-302316-raf5rlkq	211	5	observed	observe	VBN
cord-302316-raf5rlkq	211	6	in	in	IN
cord-302316-raf5rlkq	211	7	the	the	DT
cord-302316-raf5rlkq	211	8	controls	control	NNS
cord-302316-raf5rlkq	211	9	,	,	,
cord-302316-raf5rlkq	211	10	but	but	CC
cord-302316-raf5rlkq	211	11	in	in	IN
cord-302316-raf5rlkq	211	12	35	35	CD
cord-302316-raf5rlkq	211	13	%	%	NN
cord-302316-raf5rlkq	211	14	and	and	CC
cord-302316-raf5rlkq	211	15	14	14	CD
cord-302316-raf5rlkq	211	16	%	%	NN
cord-302316-raf5rlkq	211	17	of	of	IN
cord-302316-raf5rlkq	211	18	the	the	DT
cord-302316-raf5rlkq	211	19	lopinavir	lopinavir	NNS
cord-302316-raf5rlkq	211	20	and	and	CC
cord-302316-raf5rlkq	211	21	arbidol	arbidol	NNP
cord-302316-raf5rlkq	211	22	group	group	NN
cord-302316-raf5rlkq	211	23	,	,	,
cord-302316-raf5rlkq	211	24	respectively	respectively	RB
cord-302316-raf5rlkq	211	25	,	,	,
cord-302316-raf5rlkq	211	26	mainly	mainly	RB
cord-302316-raf5rlkq	211	27	manifested	manifest	VBN
cord-302316-raf5rlkq	211	28	as	as	IN
cord-302316-raf5rlkq	211	29	diarrhoea	diarrhoea	NN
cord-302316-raf5rlkq	211	30	.	.	.
cord-302316-raf5rlkq	212	1	Thirteen	thirteen	CD
cord-302316-raf5rlkq	212	2	patients	patient	NNS
cord-302316-raf5rlkq	212	3	progressed	progress	VBD
cord-302316-raf5rlkq	212	4	to	to	IN
cord-302316-raf5rlkq	212	5	severe	severe	JJ
cord-302316-raf5rlkq	212	6	disease	disease	NN
cord-302316-raf5rlkq	212	7	during	during	IN
cord-302316-raf5rlkq	212	8	hospitalization	hospitalization	NN
cord-302316-raf5rlkq	212	9	:	:	:
cord-302316-raf5rlkq	212	10	namely	namely	RB
cord-302316-raf5rlkq	212	11	8	8	CD
cord-302316-raf5rlkq	212	12	,	,	,
cord-302316-raf5rlkq	212	13	3	3	CD
cord-302316-raf5rlkq	212	14	and	and	CC
cord-302316-raf5rlkq	212	15	2	2	CD
cord-302316-raf5rlkq	212	16	in	in	IN
cord-302316-raf5rlkq	212	17	lopinavir	lopinavir	NNS
cord-302316-raf5rlkq	212	18	,	,	,
cord-302316-raf5rlkq	212	19	arbidol	arbidol	NN
cord-302316-raf5rlkq	212	20	and	and	CC
cord-302316-raf5rlkq	212	21	control	control	NN
cord-302316-raf5rlkq	212	22	group	group	NN
cord-302316-raf5rlkq	212	23	,	,	,
cord-302316-raf5rlkq	212	24	respectively	respectively	RB
cord-302316-raf5rlkq	212	25	.	.	.
cord-302316-raf5rlkq	213	1	The	the	DT
cord-302316-raf5rlkq	213	2	study	study	NN
cord-302316-raf5rlkq	213	3	is	be	VBZ
cord-302316-raf5rlkq	213	4	small	small	JJ
cord-302316-raf5rlkq	213	5	and	and	CC
cord-302316-raf5rlkq	213	6	was	be	VBD
cord-302316-raf5rlkq	213	7	only	only	RB
cord-302316-raf5rlkq	213	8	conducted	conduct	VBN
cord-302316-raf5rlkq	213	9	at	at	IN
cord-302316-raf5rlkq	213	10	a	a	DT
cord-302316-raf5rlkq	213	11	single	single	JJ
cord-302316-raf5rlkq	213	12	centre	centre	NN
cord-302316-raf5rlkq	213	13	,	,	,
cord-302316-raf5rlkq	213	14	but	but	CC
cord-302316-raf5rlkq	213	15	it	-PRON-	PRP
cord-302316-raf5rlkq	213	16	still	still	RB
cord-302316-raf5rlkq	213	17	confirms	confirm	VBZ
cord-302316-raf5rlkq	213	18	the	the	DT
cord-302316-raf5rlkq	213	19	lack	lack	NN
cord-302316-raf5rlkq	213	20	of	of	IN
cord-302316-raf5rlkq	213	21	efficacy	efficacy	NN
cord-302316-raf5rlkq	213	22	of	of	IN
cord-302316-raf5rlkq	213	23	lopinavir	lopinavir	NNP
cord-302316-raf5rlkq	213	24	/	/	SYM
cord-302316-raf5rlkq	213	25	ritonavir	ritonavir	NNP
cord-302316-raf5rlkq	213	26	treatment	treatment	NN
cord-302316-raf5rlkq	213	27	in	in	IN
cord-302316-raf5rlkq	213	28	severe	severe	JJ
cord-302316-raf5rlkq	213	29	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	213	30	cases	case	NNS
cord-302316-raf5rlkq	214	1	(	(	-LRB-
cord-302316-raf5rlkq	214	2	Li	Li	NNP
cord-302316-raf5rlkq	214	3	et	et	NNP
cord-302316-raf5rlkq	214	4	al	al	NNP
cord-302316-raf5rlkq	214	5	.	.	NNP
cord-302316-raf5rlkq	214	6	,	,	,
cord-302316-raf5rlkq	214	7	2020b	2020b	CD
cord-302316-raf5rlkq	214	8	)	)	-RRB-
cord-302316-raf5rlkq	214	9	.	.	.
cord-302316-raf5rlkq	215	1	In	in	IN
cord-302316-raf5rlkq	215	2	a	a	DT
cord-302316-raf5rlkq	215	3	retrospective	retrospective	JJ
cord-302316-raf5rlkq	215	4	cohort	cohort	NN
cord-302316-raf5rlkq	215	5	study	study	NN
cord-302316-raf5rlkq	215	6	with	with	IN
cord-302316-raf5rlkq	215	7	33	33	CD
cord-302316-raf5rlkq	215	8	Chinese	chinese	JJ
cord-302316-raf5rlkq	215	9	patients	patient	NNS
cord-302316-raf5rlkq	215	10	suffering	suffer	VBG
cord-302316-raf5rlkq	215	11	from	from	IN
cord-302316-raf5rlkq	215	12	moderate	moderate	JJ
cord-302316-raf5rlkq	215	13	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	215	14	showing	show	VBG
cord-302316-raf5rlkq	215	15	lung	lung	NN
cord-302316-raf5rlkq	215	16	CT	CT	NNP
cord-302316-raf5rlkq	215	17	abnormalities	abnormality	NNS
cord-302316-raf5rlkq	215	18	,	,	,
cord-302316-raf5rlkq	215	19	16	16	CD
cord-302316-raf5rlkq	215	20	patients	patient	NNS
cord-302316-raf5rlkq	215	21	were	be	VBD
cord-302316-raf5rlkq	215	22	treated	treat	VBN
cord-302316-raf5rlkq	215	23	with	with	IN
cord-302316-raf5rlkq	215	24	an	an	DT
cord-302316-raf5rlkq	215	25	arbidol	arbidol	NN
cord-302316-raf5rlkq	215	26	/	/	SYM
cord-302316-raf5rlkq	215	27	lopinavir	lopinavir	NNS
cord-302316-raf5rlkq	215	28	/	/	SYM
cord-302316-raf5rlkq	215	29	ritonavir	ritonavir	NNP
cord-302316-raf5rlkq	215	30	combination	combination	NN
cord-302316-raf5rlkq	215	31	while	while	IN
cord-302316-raf5rlkq	215	32	17	17	CD
cord-302316-raf5rlkq	215	33	patients	patient	NNS
cord-302316-raf5rlkq	215	34	received	receive	VBD
cord-302316-raf5rlkq	215	35	only	only	JJ
cord-302316-raf5rlkq	215	36	lopinavir	lopinavir	NNS
cord-302316-raf5rlkq	215	37	/	/	SYM
cord-302316-raf5rlkq	215	38	ritonavir	ritonavir	NNS
cord-302316-raf5rlkq	215	39	.	.	.
cord-302316-raf5rlkq	216	1	The	the	DT
cord-302316-raf5rlkq	216	2	group	group	NN
cord-302316-raf5rlkq	216	3	including	include	VBG
cord-302316-raf5rlkq	216	4	arbidol	arbidol	NN
cord-302316-raf5rlkq	216	5	in	in	IN
cord-302316-raf5rlkq	216	6	the	the	DT
cord-302316-raf5rlkq	216	7	combination	combination	NN
cord-302316-raf5rlkq	216	8	showed	show	VBD
cord-302316-raf5rlkq	216	9	a	a	DT
cord-302316-raf5rlkq	216	10	significantly	significantly	RB
cord-302316-raf5rlkq	216	11	shorter	short	JJR
cord-302316-raf5rlkq	216	12	nasopharyngeal	nasopharyngeal	JJ
cord-302316-raf5rlkq	216	13	and	and	CC
cord-302316-raf5rlkq	216	14	stool	stool	VB
cord-302316-raf5rlkq	216	15	excretion	excretion	NN
cord-302316-raf5rlkq	216	16	of	of	IN
cord-302316-raf5rlkq	216	17	SARS	SARS	NNP
cord-302316-raf5rlkq	216	18	-	-	HYPH
cord-302316-raf5rlkq	216	19	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	216	20	,	,	,
cord-302316-raf5rlkq	216	21	and	and	CC
cord-302316-raf5rlkq	216	22	an	an	DT
cord-302316-raf5rlkq	216	23	accelerated	accelerated	JJ
cord-302316-raf5rlkq	216	24	normalization	normalization	NN
cord-302316-raf5rlkq	216	25	of	of	IN
cord-302316-raf5rlkq	216	26	lung	lung	NN
cord-302316-raf5rlkq	216	27	CT	CT	NNP
cord-302316-raf5rlkq	216	28	,	,	,
cord-302316-raf5rlkq	216	29	compared	compare	VBN
cord-302316-raf5rlkq	216	30	with	with	IN
cord-302316-raf5rlkq	216	31	the	the	DT
cord-302316-raf5rlkq	216	32	control	control	NN
cord-302316-raf5rlkq	216	33	group	group	NN
cord-302316-raf5rlkq	216	34	.	.	.
cord-302316-raf5rlkq	217	1	The	the	DT
cord-302316-raf5rlkq	217	2	positive	positive	JJ
cord-302316-raf5rlkq	217	3	outcome	outcome	NN
cord-302316-raf5rlkq	217	4	must	must	MD
cord-302316-raf5rlkq	217	5	,	,	,
cord-302316-raf5rlkq	217	6	however	however	RB
cord-302316-raf5rlkq	217	7	,	,	,
cord-302316-raf5rlkq	217	8	be	be	VB
cord-302316-raf5rlkq	217	9	interpreted	interpret	VBN
cord-302316-raf5rlkq	217	10	with	with	IN
cord-302316-raf5rlkq	217	11	caution	caution	NN
cord-302316-raf5rlkq	217	12	since	since	IN
cord-302316-raf5rlkq	217	13	the	the	DT
cord-302316-raf5rlkq	217	14	two	two	CD
cord-302316-raf5rlkq	217	15	groups	group	NNS
cord-302316-raf5rlkq	217	16	differed	differ	VBD
cord-302316-raf5rlkq	217	17	significantly	significantly	RB
cord-302316-raf5rlkq	217	18	for	for	IN
cord-302316-raf5rlkq	217	19	glucocorticoid	glucocorticoid	NN
cord-302316-raf5rlkq	217	20	treatment	treatment	NN
cord-302316-raf5rlkq	217	21	(	(	-LRB-
cord-302316-raf5rlkq	217	22	6	6	CD
cord-302316-raf5rlkq	217	23	%	%	NN
cord-302316-raf5rlkq	217	24	vs.	vs.	NN
cord-302316-raf5rlkq	217	25	41	41	CD
cord-302316-raf5rlkq	217	26	%	%	NN
cord-302316-raf5rlkq	217	27	in	in	IN
cord-302316-raf5rlkq	217	28	control	control	NN
cord-302316-raf5rlkq	217	29	)	)	-RRB-
cord-302316-raf5rlkq	217	30	.	.	.
cord-302316-raf5rlkq	218	1	The	the	DT
cord-302316-raf5rlkq	218	2	better	well	JJR
cord-302316-raf5rlkq	218	3	outcome	outcome	NN
cord-302316-raf5rlkq	218	4	in	in	IN
cord-302316-raf5rlkq	218	5	the	the	DT
cord-302316-raf5rlkq	218	6	arbidol	arbidol	NN
cord-302316-raf5rlkq	218	7	arm	arm	NN
cord-302316-raf5rlkq	218	8	could	could	MD
cord-302316-raf5rlkq	218	9	therefore	therefore	RB
cord-302316-raf5rlkq	218	10	be	be	VB
cord-302316-raf5rlkq	218	11	due	due	JJ
cord-302316-raf5rlkq	218	12	to	to	IN
cord-302316-raf5rlkq	218	13	less	less	JJR
cord-302316-raf5rlkq	218	14	use	use	NN
cord-302316-raf5rlkq	218	15	of	of	IN
cord-302316-raf5rlkq	218	16	detrimental	detrimental	JJ
cord-302316-raf5rlkq	218	17	glucocorticoid	glucocorticoid	NN
cord-302316-raf5rlkq	218	18	.	.	.
cord-302316-raf5rlkq	219	1	Triple	triple	JJ
cord-302316-raf5rlkq	219	2	therapy	therapy	NN
cord-302316-raf5rlkq	219	3	:	:	:
cord-302316-raf5rlkq	219	4	lopinavir	lopinavir	NNP
cord-302316-raf5rlkq	219	5	,	,	.
cord-302316-raf5rlkq	220	1	ribavirin	ribavirin	RB
cord-302316-raf5rlkq	220	2	,	,	,
cord-302316-raf5rlkq	220	3	interferon	interferon	NN
cord-302316-raf5rlkq	221	1	beta-1b	beta-1b	NNS
cord-302316-raf5rlkq	222	1	In	in	IN
cord-302316-raf5rlkq	222	2	a	a	DT
cord-302316-raf5rlkq	222	3	multicentre	multicentre	NNP
cord-302316-raf5rlkq	222	4	trial	trial	NN
cord-302316-raf5rlkq	222	5	,	,	,
cord-302316-raf5rlkq	222	6	127	127	CD
cord-302316-raf5rlkq	222	7	COVID-19	covid-19	CD
cord-302316-raf5rlkq	222	8	patients	patient	NNS
cord-302316-raf5rlkq	222	9	from	from	IN
cord-302316-raf5rlkq	222	10	Hong	Hong	NNP
cord-302316-raf5rlkq	222	11	Kong	Kong	NNP
cord-302316-raf5rlkq	222	12	were	be	VBD
cord-302316-raf5rlkq	222	13	enrolled	enrol	VBN
cord-302316-raf5rlkq	222	14	into	into	IN
cord-302316-raf5rlkq	222	15	a	a	DT
cord-302316-raf5rlkq	222	16	prospective	prospective	NN
cord-302316-raf5rlkq	222	17	,	,	,
cord-302316-raf5rlkq	222	18	randomized	randomized	JJ
cord-302316-raf5rlkq	222	19	,	,	,
cord-302316-raf5rlkq	222	20	open	open	JJ
cord-302316-raf5rlkq	222	21	-	-	HYPH
cord-302316-raf5rlkq	222	22	label	label	NN
cord-302316-raf5rlkq	222	23	phase	phase	NN
cord-302316-raf5rlkq	222	24	2	2	CD
cord-302316-raf5rlkq	222	25	clinical	clinical	JJ
cord-302316-raf5rlkq	222	26	trial	trial	NN
cord-302316-raf5rlkq	222	27	.	.	.
cord-302316-raf5rlkq	223	1	Eighty	eighty	CD
cord-302316-raf5rlkq	223	2	-	-	HYPH
cord-302316-raf5rlkq	223	3	six	six	CD
cord-302316-raf5rlkq	223	4	patients	patient	NNS
cord-302316-raf5rlkq	223	5	received	receive	VBD
cord-302316-raf5rlkq	223	6	a	a	DT
cord-302316-raf5rlkq	223	7	combination	combination	NN
cord-302316-raf5rlkq	223	8	treatment	treatment	NN
cord-302316-raf5rlkq	223	9	of	of	IN
cord-302316-raf5rlkq	223	10	the	the	DT
cord-302316-raf5rlkq	223	11	lopinavir	lopinavir	NNS
cord-302316-raf5rlkq	223	12	(	(	-LRB-
cord-302316-raf5rlkq	223	13	plus	plus	CC
cord-302316-raf5rlkq	223	14	ritonavir	ritonavir	NNP
cord-302316-raf5rlkq	223	15	)	)	-RRB-
cord-302316-raf5rlkq	223	16	,	,	,
cord-302316-raf5rlkq	223	17	the	the	DT
cord-302316-raf5rlkq	223	18	nucleoside	nucleoside	NN
cord-302316-raf5rlkq	223	19	analog	analog	NN
cord-302316-raf5rlkq	223	20	ribavirin	ribavirin	NN
cord-302316-raf5rlkq	223	21	and	and	CC
cord-302316-raf5rlkq	223	22	interferon	interferon	NN
cord-302316-raf5rlkq	223	23	beta-1b	beta-1b	NNS
cord-302316-raf5rlkq	223	24	,	,	,
cord-302316-raf5rlkq	223	25	while	while	IN
cord-302316-raf5rlkq	223	26	the	the	DT
cord-302316-raf5rlkq	223	27	control	control	NN
cord-302316-raf5rlkq	223	28	group	group	NN
cord-302316-raf5rlkq	223	29	was	be	VBD
cord-302316-raf5rlkq	223	30	only	only	RB
cord-302316-raf5rlkq	223	31	treated	treat	VBN
cord-302316-raf5rlkq	223	32	with	with	IN
cord-302316-raf5rlkq	223	33	lopinavir	lopinavir	NNS
cord-302316-raf5rlkq	223	34	(	(	-LRB-
cord-302316-raf5rlkq	223	35	plus	plus	CC
cord-302316-raf5rlkq	223	36	ritonavir	ritonavir	NNP
cord-302316-raf5rlkq	223	37	)	)	-RRB-
cord-302316-raf5rlkq	223	38	.	.	.
cord-302316-raf5rlkq	224	1	At	at	IN
cord-302316-raf5rlkq	224	2	baseline	baseline	NN
cord-302316-raf5rlkq	224	3	,	,	,
cord-302316-raf5rlkq	224	4	both	both	DT
cord-302316-raf5rlkq	224	5	groups	group	NNS
cord-302316-raf5rlkq	224	6	were	be	VBD
cord-302316-raf5rlkq	224	7	well	well	RB
cord-302316-raf5rlkq	224	8	matched	match	VBN
cord-302316-raf5rlkq	224	9	and	and	CC
cord-302316-raf5rlkq	224	10	showed	show	VBD
cord-302316-raf5rlkq	224	11	mild	mild	JJ
cord-302316-raf5rlkq	224	12	-	-	HYPH
cord-302316-raf5rlkq	224	13	to	to	IN
cord-302316-raf5rlkq	224	14	-	-	HYPH
cord-302316-raf5rlkq	224	15	moderate	moderate	JJ
cord-302316-raf5rlkq	224	16	disease	disease	NN
cord-302316-raf5rlkq	224	17	.	.	.
cord-302316-raf5rlkq	225	1	The	the	DT
cord-302316-raf5rlkq	225	2	combination	combination	NN
cord-302316-raf5rlkq	225	3	group	group	NN
cord-302316-raf5rlkq	225	4	demonstrated	demonstrate	VBD
cord-302316-raf5rlkq	225	5	,	,	,
cord-302316-raf5rlkq	225	6	in	in	IN
cord-302316-raf5rlkq	225	7	comparison	comparison	NN
cord-302316-raf5rlkq	225	8	with	with	IN
cord-302316-raf5rlkq	225	9	the	the	DT
cord-302316-raf5rlkq	225	10	controls	control	NNS
cord-302316-raf5rlkq	225	11	,	,	,
cord-302316-raf5rlkq	225	12	a	a	DT
cord-302316-raf5rlkq	225	13	significantly	significantly	RB
cord-302316-raf5rlkq	225	14	reduced	reduce	VBN
cord-302316-raf5rlkq	225	15	time	time	NN
cord-302316-raf5rlkq	225	16	(	(	-LRB-
cord-302316-raf5rlkq	225	17	7	7	CD
cord-302316-raf5rlkq	225	18	vs.	vs.	NN
cord-302316-raf5rlkq	225	19	12	12	CD
cord-302316-raf5rlkq	225	20	days	day	NNS
cord-302316-raf5rlkq	225	21	)	)	-RRB-
cord-302316-raf5rlkq	225	22	to	to	IN
cord-302316-raf5rlkq	225	23	clearance	clearance	NN
cord-302316-raf5rlkq	225	24	of	of	IN
cord-302316-raf5rlkq	225	25	viral	viral	JJ
cord-302316-raf5rlkq	225	26	RNA	RNA	NNP
cord-302316-raf5rlkq	225	27	in	in	IN
cord-302316-raf5rlkq	225	28	the	the	DT
cord-302316-raf5rlkq	225	29	nasopharynx	nasopharynx	NN
cord-302316-raf5rlkq	225	30	(	(	-LRB-
cord-302316-raf5rlkq	225	31	the	the	DT
cord-302316-raf5rlkq	225	32	primary	primary	JJ
cord-302316-raf5rlkq	225	33	end	end	NN
cord-302316-raf5rlkq	225	34	-	-	HYPH
cord-302316-raf5rlkq	225	35	point	point	NN
cord-302316-raf5rlkq	225	36	)	)	-RRB-
cord-302316-raf5rlkq	225	37	,	,	,
cord-302316-raf5rlkq	225	38	as	as	RB
cord-302316-raf5rlkq	225	39	well	well	RB
cord-302316-raf5rlkq	225	40	as	as	IN
cord-302316-raf5rlkq	225	41	a	a	DT
cord-302316-raf5rlkq	225	42	shortening	shortening	NN
cord-302316-raf5rlkq	225	43	of	of	IN
cord-302316-raf5rlkq	225	44	oropharynx	oropharynx	NN
cord-302316-raf5rlkq	225	45	,	,	,
cord-302316-raf5rlkq	225	46	throat	throat	NN
cord-302316-raf5rlkq	225	47	and	and	CC
cord-302316-raf5rlkq	225	48	stool	stool	NN
cord-302316-raf5rlkq	225	49	virus	virus	NN
cord-302316-raf5rlkq	225	50	excretion	excretion	NN
cord-302316-raf5rlkq	225	51	.	.	.
cord-302316-raf5rlkq	226	1	The	the	DT
cord-302316-raf5rlkq	226	2	combination	combination	NN
cord-302316-raf5rlkq	226	3	therapy	therapy	NN
cord-302316-raf5rlkq	226	4	was	be	VBD
cord-302316-raf5rlkq	226	5	also	also	RB
cord-302316-raf5rlkq	226	6	associated	associate	VBN
cord-302316-raf5rlkq	226	7	with	with	IN
cord-302316-raf5rlkq	226	8	significant	significant	JJ
cord-302316-raf5rlkq	226	9	clinical	clinical	JJ
cord-302316-raf5rlkq	226	10	improvement	improvement	NN
cord-302316-raf5rlkq	226	11	compared	compare	VBN
cord-302316-raf5rlkq	226	12	with	with	IN
cord-302316-raf5rlkq	226	13	controls	control	NNS
cord-302316-raf5rlkq	226	14	,	,	,
cord-302316-raf5rlkq	226	15	and	and	CC
cord-302316-raf5rlkq	226	16	a	a	DT
cord-302316-raf5rlkq	226	17	shorter	short	JJR
cord-302316-raf5rlkq	226	18	hospitalization	hospitalization	NN
cord-302316-raf5rlkq	226	19	stay	stay	VB
cord-302316-raf5rlkq	226	20	.	.	.
cord-302316-raf5rlkq	227	1	There	there	EX
cord-302316-raf5rlkq	227	2	were	be	VBD
cord-302316-raf5rlkq	227	3	no	no	DT
cord-302316-raf5rlkq	227	4	fatalities	fatality	NNS
cord-302316-raf5rlkq	227	5	.	.	.
cord-302316-raf5rlkq	228	1	The	the	DT
cord-302316-raf5rlkq	228	2	treatment	treatment	NN
cord-302316-raf5rlkq	228	3	group	group	NN
cord-302316-raf5rlkq	228	4	also	also	RB
cord-302316-raf5rlkq	228	5	displayed	display	VBD
cord-302316-raf5rlkq	228	6	lower	low	JJR
cord-302316-raf5rlkq	228	7	IL-6	IL-6	NNP
cord-302316-raf5rlkq	228	8	values	value	NNS
cord-302316-raf5rlkq	228	9	than	than	IN
cord-302316-raf5rlkq	228	10	the	the	DT
cord-302316-raf5rlkq	228	11	controls	control	NNS
cord-302316-raf5rlkq	228	12	.	.	.
cord-302316-raf5rlkq	229	1	A	a	DT
cord-302316-raf5rlkq	229	2	post	post	FW
cord-302316-raf5rlkq	229	3	hoc	hoc	FW
cord-302316-raf5rlkq	229	4	subgroup	subgroup	NN
cord-302316-raf5rlkq	229	5	analysis	analysis	NN
cord-302316-raf5rlkq	229	6	comparing	compare	VBG
cord-302316-raf5rlkq	229	7	76	76	CD
cord-302316-raf5rlkq	229	8	patients	patient	NNS
cord-302316-raf5rlkq	229	9	(	(	-LRB-
cord-302316-raf5rlkq	229	10	52	52	CD
cord-302316-raf5rlkq	229	11	in	in	IN
cord-302316-raf5rlkq	229	12	combination	combination	NN
cord-302316-raf5rlkq	229	13	and	and	CC
cord-302316-raf5rlkq	229	14	24	24	CD
cord-302316-raf5rlkq	229	15	in	in	IN
cord-302316-raf5rlkq	229	16	control	control	NN
cord-302316-raf5rlkq	229	17	group	group	NN
cord-302316-raf5rlkq	229	18	)	)	-RRB-
cord-302316-raf5rlkq	229	19	,	,	,
cord-302316-raf5rlkq	229	20	who	who	WP
cord-302316-raf5rlkq	229	21	started	start	VBD
cord-302316-raf5rlkq	229	22	treatment	treatment	NN
cord-302316-raf5rlkq	229	23	less	less	JJR
cord-302316-raf5rlkq	229	24	than	than	IN
cord-302316-raf5rlkq	229	25	7	7	CD
cord-302316-raf5rlkq	229	26	days	day	NNS
cord-302316-raf5rlkq	229	27	after	after	IN
cord-302316-raf5rlkq	229	28	symptom	symptom	NN
cord-302316-raf5rlkq	229	29	onset	onset	NN
cord-302316-raf5rlkq	229	30	,	,	,
cord-302316-raf5rlkq	229	31	showed	show	VBD
cord-302316-raf5rlkq	229	32	again	again	RB
cord-302316-raf5rlkq	229	33	a	a	DT
cord-302316-raf5rlkq	229	34	significant	significant	JJ
cord-302316-raf5rlkq	229	35	difference	difference	NN
cord-302316-raf5rlkq	229	36	between	between	IN
cord-302316-raf5rlkq	229	37	the	the	DT
cord-302316-raf5rlkq	229	38	two	two	CD
cord-302316-raf5rlkq	229	39	groups	group	NNS
cord-302316-raf5rlkq	229	40	.	.	.
cord-302316-raf5rlkq	230	1	In	in	IN
cord-302316-raf5rlkq	230	2	contrast	contrast	NN
cord-302316-raf5rlkq	230	3	,	,	,
cord-302316-raf5rlkq	230	4	no	no	DT
cord-302316-raf5rlkq	230	5	difference	difference	NN
cord-302316-raf5rlkq	230	6	was	be	VBD
cord-302316-raf5rlkq	230	7	seen	see	VBN
cord-302316-raf5rlkq	230	8	between	between	IN
cord-302316-raf5rlkq	230	9	the	the	DT
cord-302316-raf5rlkq	230	10	two	two	CD
cord-302316-raf5rlkq	230	11	groups	group	NNS
cord-302316-raf5rlkq	230	12	when	when	WRB
cord-302316-raf5rlkq	230	13	the	the	DT
cord-302316-raf5rlkq	230	14	treatment	treatment	NN
cord-302316-raf5rlkq	230	15	was	be	VBD
cord-302316-raf5rlkq	230	16	initiated	initiate	VBN
cord-302316-raf5rlkq	230	17	after	after	IN
cord-302316-raf5rlkq	230	18	7	7	CD
cord-302316-raf5rlkq	230	19	days	day	NNS
cord-302316-raf5rlkq	230	20	.	.	.
cord-302316-raf5rlkq	231	1	Out	out	IN
cord-302316-raf5rlkq	231	2	of	of	IN
cord-302316-raf5rlkq	231	3	concern	concern	NN
cord-302316-raf5rlkq	231	4	for	for	IN
cord-302316-raf5rlkq	231	5	safety	safety	NN
cord-302316-raf5rlkq	231	6	,	,	,
cord-302316-raf5rlkq	231	7	patients	patient	NNS
cord-302316-raf5rlkq	231	8	in	in	IN
cord-302316-raf5rlkq	231	9	the	the	DT
cord-302316-raf5rlkq	231	10	combination	combination	NN
cord-302316-raf5rlkq	231	11	group	group	NN
cord-302316-raf5rlkq	231	12	did	do	VBD
cord-302316-raf5rlkq	231	13	not	not	RB
cord-302316-raf5rlkq	231	14	receive	receive	VB
cord-302316-raf5rlkq	231	15	interferon	interferon	NN
cord-302316-raf5rlkq	231	16	at	at	IN
cord-302316-raf5rlkq	231	17	later	later	JJ
cord-302316-raf5rlkq	231	18	stages	stage	NNS
cord-302316-raf5rlkq	231	19	of	of	IN
cord-302316-raf5rlkq	231	20	the	the	DT
cord-302316-raf5rlkq	231	21	infection	infection	NN
cord-302316-raf5rlkq	231	22	.	.	.
cord-302316-raf5rlkq	232	1	The	the	DT
cord-302316-raf5rlkq	232	2	therapeutic	therapeutic	JJ
cord-302316-raf5rlkq	232	3	effect	effect	NN
cord-302316-raf5rlkq	232	4	in	in	IN
cord-302316-raf5rlkq	232	5	the	the	DT
cord-302316-raf5rlkq	232	6	combination	combination	NN
cord-302316-raf5rlkq	232	7	group	group	NN
cord-302316-raf5rlkq	232	8	could	could	MD
cord-302316-raf5rlkq	232	9	be	be	VB
cord-302316-raf5rlkq	232	10	attributed	attribute	VBN
cord-302316-raf5rlkq	232	11	to	to	IN
cord-302316-raf5rlkq	232	12	either	either	CC
cord-302316-raf5rlkq	232	13	earlier	early	JJR
cord-302316-raf5rlkq	232	14	ribavirin	ribavirin	JJ
cord-302316-raf5rlkq	232	15	treatment	treatment	NN
cord-302316-raf5rlkq	232	16	or	or	CC
cord-302316-raf5rlkq	232	17	interferon	interferon	NN
cord-302316-raf5rlkq	232	18	inclusion	inclusion	NN
cord-302316-raf5rlkq	233	1	(	(	-LRB-
cord-302316-raf5rlkq	233	2	Hung	Hung	NNP
cord-302316-raf5rlkq	233	3	et	et	FW
cord-302316-raf5rlkq	233	4	al	al	NNP
cord-302316-raf5rlkq	233	5	.	.	NNP
cord-302316-raf5rlkq	233	6	,	,	,
cord-302316-raf5rlkq	233	7	2020	2020	CD
cord-302316-raf5rlkq	233	8	)	)	-RRB-
cord-302316-raf5rlkq	233	9	.	.	.
cord-302316-raf5rlkq	234	1	Anakinra	Anakinra	NNP
cord-302316-raf5rlkq	234	2	is	be	VBZ
cord-302316-raf5rlkq	234	3	a	a	DT
cord-302316-raf5rlkq	234	4	recombinant	recombinant	JJ
cord-302316-raf5rlkq	234	5	interleukin	interleukin	NN
cord-302316-raf5rlkq	234	6	IL-1	IL-1	NNP
cord-302316-raf5rlkq	234	7	receptor	receptor	NN
cord-302316-raf5rlkq	234	8	antagonist	antagonist	NN
cord-302316-raf5rlkq	234	9	.	.	.
cord-302316-raf5rlkq	235	1	High	high	JJ
cord-302316-raf5rlkq	235	2	-	-	HYPH
cord-302316-raf5rlkq	235	3	dose	dose	NN
cord-302316-raf5rlkq	235	4	intravenous	intravenous	JJ
cord-302316-raf5rlkq	235	5	anakinra	anakinra	NN
cord-302316-raf5rlkq	235	6	has	have	VBZ
cord-302316-raf5rlkq	235	7	FDA	FDA	NNP
cord-302316-raf5rlkq	235	8	and	and	CC
cord-302316-raf5rlkq	235	9	EMA	EMA	NNP
cord-302316-raf5rlkq	235	10	off	off	IN
cord-302316-raf5rlkq	235	11	-	-	HYPH
cord-302316-raf5rlkq	235	12	label	label	NN
cord-302316-raf5rlkq	235	13	approval	approval	NN
cord-302316-raf5rlkq	235	14	for	for	IN
cord-302316-raf5rlkq	235	15	the	the	DT
cord-302316-raf5rlkq	235	16	treatment	treatment	NN
cord-302316-raf5rlkq	235	17	of	of	IN
cord-302316-raf5rlkq	235	18	hyperinflammatory	hyperinflammatory	JJ
cord-302316-raf5rlkq	235	19	conditions	condition	NNS
cord-302316-raf5rlkq	235	20	such	such	JJ
cord-302316-raf5rlkq	235	21	as	as	IN
cord-302316-raf5rlkq	235	22	macrophage	macrophage	NN
cord-302316-raf5rlkq	235	23	activation	activation	NN
cord-302316-raf5rlkq	235	24	syndrome	syndrome	NN
cord-302316-raf5rlkq	235	25	(	(	-LRB-
cord-302316-raf5rlkq	235	26	see	see	VB
cord-302316-raf5rlkq	235	27	above	above	IN
cord-302316-raf5rlkq	235	28	coagulopathy	coagulopathy	NN
cord-302316-raf5rlkq	235	29	)	)	-RRB-
cord-302316-raf5rlkq	235	30	.	.	.
cord-302316-raf5rlkq	236	1	A	a	DT
cord-302316-raf5rlkq	236	2	Chinese	chinese	JJ
cord-302316-raf5rlkq	236	3	study	study	NN
cord-302316-raf5rlkq	236	4	used	use	VBD
cord-302316-raf5rlkq	236	5	anakinra	anakinra	NNP
cord-302316-raf5rlkq	236	6	in	in	IN
cord-302316-raf5rlkq	236	7	severe	severe	JJ
cord-302316-raf5rlkq	236	8	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	236	9	patients	patient	NNS
cord-302316-raf5rlkq	236	10	who	who	WP
cord-302316-raf5rlkq	236	11	could	could	MD
cord-302316-raf5rlkq	236	12	not	not	RB
cord-302316-raf5rlkq	236	13	receive	receive	VB
cord-302316-raf5rlkq	236	14	intensive	intensive	JJ
cord-302316-raf5rlkq	236	15	care	care	NN
cord-302316-raf5rlkq	236	16	due	due	IN
cord-302316-raf5rlkq	236	17	to	to	IN
cord-302316-raf5rlkq	236	18	overwhelming	overwhelming	JJ
cord-302316-raf5rlkq	236	19	patient	patient	JJ
cord-302316-raf5rlkq	236	20	numbers	number	NNS
cord-302316-raf5rlkq	236	21	.	.	.
cord-302316-raf5rlkq	237	1	Low	low	JJ
cord-302316-raf5rlkq	237	2	-	-	HYPH
cord-302316-raf5rlkq	237	3	dose	dose	NN
cord-302316-raf5rlkq	237	4	subcutaneous	subcutaneous	JJ
cord-302316-raf5rlkq	237	5	anakinra	anakinra	NN
cord-302316-raf5rlkq	237	6	(	(	-LRB-
cord-302316-raf5rlkq	237	7	the	the	DT
cord-302316-raf5rlkq	237	8	standard	standard	JJ
cord-302316-raf5rlkq	237	9	application	application	NN
cord-302316-raf5rlkq	237	10	)	)	-RRB-
cord-302316-raf5rlkq	237	11	had	have	VBD
cord-302316-raf5rlkq	237	12	no	no	DT
cord-302316-raf5rlkq	237	13	effect	effect	NN
cord-302316-raf5rlkq	237	14	on	on	IN
cord-302316-raf5rlkq	237	15	C	c	NN
cord-302316-raf5rlkq	237	16	-	-	HYPH
cord-302316-raf5rlkq	237	17	reactive	reactive	JJ
cord-302316-raf5rlkq	237	18	protein	protein	NN
cord-302316-raf5rlkq	237	19	levels	level	NNS
cord-302316-raf5rlkq	237	20	or	or	CC
cord-302316-raf5rlkq	237	21	clinical	clinical	JJ
cord-302316-raf5rlkq	237	22	parameters	parameter	NNS
cord-302316-raf5rlkq	237	23	,	,	,
cord-302316-raf5rlkq	237	24	compared	compare	VBN
cord-302316-raf5rlkq	237	25	with	with	IN
cord-302316-raf5rlkq	237	26	controls	control	NNS
cord-302316-raf5rlkq	237	27	.	.	.
cord-302316-raf5rlkq	238	1	High	high	JJ
cord-302316-raf5rlkq	238	2	-	-	HYPH
cord-302316-raf5rlkq	238	3	dose	dose	NN
cord-302316-raf5rlkq	238	4	intravenous	intravenous	JJ
cord-302316-raf5rlkq	238	5	anakinra	anakinra	NNP
cord-302316-raf5rlkq	238	6	application	application	NN
cord-302316-raf5rlkq	238	7	suppressed	suppress	VBD
cord-302316-raf5rlkq	238	8	hyperinflammation	hyperinflammation	NN
cord-302316-raf5rlkq	238	9	,	,	,
cord-302316-raf5rlkq	238	10	as	as	IN
cord-302316-raf5rlkq	238	11	documented	document	VBN
cord-302316-raf5rlkq	238	12	by	by	IN
cord-302316-raf5rlkq	238	13	a	a	DT
cord-302316-raf5rlkq	238	14	decrease	decrease	NN
cord-302316-raf5rlkq	238	15	in	in	IN
cord-302316-raf5rlkq	238	16	Creactive	Creactive	NNP
cord-302316-raf5rlkq	238	17	protein	protein	NN
cord-302316-raf5rlkq	238	18	,	,	,
cord-302316-raf5rlkq	238	19	and	and	CC
cord-302316-raf5rlkq	238	20	resulted	result	VBD
cord-302316-raf5rlkq	238	21	in	in	IN
cord-302316-raf5rlkq	238	22	a	a	DT
cord-302316-raf5rlkq	238	23	significantly	significantly	RB
cord-302316-raf5rlkq	238	24	higher	high	JJR
cord-302316-raf5rlkq	238	25	rate	rate	NN
cord-302316-raf5rlkq	238	26	of	of	IN
cord-302316-raf5rlkq	238	27	survival	survival	NN
cord-302316-raf5rlkq	238	28	at	at	IN
cord-302316-raf5rlkq	238	29	3	3	CD
cord-302316-raf5rlkq	238	30	weeks	week	NNS
cord-302316-raf5rlkq	238	31	compared	compare	VBN
cord-302316-raf5rlkq	238	32	with	with	IN
cord-302316-raf5rlkq	238	33	controls	control	NNS
cord-302316-raf5rlkq	238	34	(	(	-LRB-
cord-302316-raf5rlkq	238	35	90	90	CD
cord-302316-raf5rlkq	238	36	vs.	vs.	NN
cord-302316-raf5rlkq	238	37	56	56	CD
cord-302316-raf5rlkq	238	38	%	%	NN
cord-302316-raf5rlkq	238	39	)	)	-RRB-
cord-302316-raf5rlkq	238	40	.	.	.
cord-302316-raf5rlkq	239	1	The	the	DT
cord-302316-raf5rlkq	239	2	retrospective	retrospective	JJ
cord-302316-raf5rlkq	239	3	nature	nature	NN
cord-302316-raf5rlkq	239	4	and	and	CC
cord-302316-raf5rlkq	239	5	the	the	DT
cord-302316-raf5rlkq	239	6	small	small	JJ
cord-302316-raf5rlkq	239	7	number	number	NN
cord-302316-raf5rlkq	239	8	of	of	IN
cord-302316-raf5rlkq	239	9	patients	patient	NNS
cord-302316-raf5rlkq	239	10	treated	treat	VBN
cord-302316-raf5rlkq	239	11	limit	limit	VBP
cord-302316-raf5rlkq	239	12	positive	positive	JJ
cord-302316-raf5rlkq	239	13	conclusions	conclusion	NNS
cord-302316-raf5rlkq	239	14	(	(	-LRB-
cord-302316-raf5rlkq	239	15	Cavalli	Cavalli	NNP
cord-302316-raf5rlkq	239	16	et	et	FW
cord-302316-raf5rlkq	239	17	al	al	NNP
cord-302316-raf5rlkq	239	18	.	.	NNP
cord-302316-raf5rlkq	239	19	,	,	,
cord-302316-raf5rlkq	239	20	2020	2020	CD
cord-302316-raf5rlkq	239	21	)	)	-RRB-
cord-302316-raf5rlkq	239	22	.	.	.
cord-302316-raf5rlkq	240	1	According	accord	VBG
cord-302316-raf5rlkq	240	2	to	to	IN
cord-302316-raf5rlkq	240	3	a	a	DT
cord-302316-raf5rlkq	240	4	popular	popular	JJ
cord-302316-raf5rlkq	240	5	pathogenesis	pathogenesis	NN
cord-302316-raf5rlkq	240	6	model	model	NN
cord-302316-raf5rlkq	240	7	,	,	,
cord-302316-raf5rlkq	240	8	interleukin	interleukin	VBN
cord-302316-raf5rlkq	240	9	IL-6	IL-6	NNP
cord-302316-raf5rlkq	240	10	production	production	NN
cord-302316-raf5rlkq	240	11	induces	induce	VBZ
cord-302316-raf5rlkq	240	12	immunopathology	immunopathology	NN
cord-302316-raf5rlkq	240	13	in	in	IN
cord-302316-raf5rlkq	240	14	severe	severe	JJ
cord-302316-raf5rlkq	240	15	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	240	16	cases	case	NNS
cord-302316-raf5rlkq	240	17	.	.	.
cord-302316-raf5rlkq	241	1	Tocilizumab	Tocilizumab	NNP
cord-302316-raf5rlkq	241	2	,	,	,
cord-302316-raf5rlkq	241	3	a	a	DT
cord-302316-raf5rlkq	241	4	recombinant	recombinant	JJ
cord-302316-raf5rlkq	241	5	humanized	humanize	VBN
cord-302316-raf5rlkq	241	6	monoclonal	monoclonal	JJ
cord-302316-raf5rlkq	241	7	antibody	antibody	NN
cord-302316-raf5rlkq	241	8	,	,	,
cord-302316-raf5rlkq	241	9	which	which	WDT
cord-302316-raf5rlkq	241	10	binds	bind	VBZ
cord-302316-raf5rlkq	241	11	the	the	DT
cord-302316-raf5rlkq	241	12	IL-6	IL-6	NNP
cord-302316-raf5rlkq	241	13	receptor	receptor	NN
cord-302316-raf5rlkq	241	14	and	and	CC
cord-302316-raf5rlkq	241	15	inhibits	inhibit	VBZ
cord-302316-raf5rlkq	241	16	its	-PRON-	PRP$
cord-302316-raf5rlkq	241	17	signal	signal	NN
cord-302316-raf5rlkq	241	18	transduction	transduction	NN
cord-302316-raf5rlkq	241	19	,	,	,
cord-302316-raf5rlkq	241	20	has	have	VBZ
cord-302316-raf5rlkq	241	21	been	be	VBN
cord-302316-raf5rlkq	241	22	previously	previously	RB
cord-302316-raf5rlkq	241	23	used	use	VBN
cord-302316-raf5rlkq	241	24	in	in	IN
cord-302316-raf5rlkq	241	25	the	the	DT
cord-302316-raf5rlkq	241	26	treatment	treatment	NN
cord-302316-raf5rlkq	241	27	of	of	IN
cord-302316-raf5rlkq	241	28	a	a	DT
cord-302316-raf5rlkq	241	29	special	special	JJ
cord-302316-raf5rlkq	241	30	form	form	NN
cord-302316-raf5rlkq	241	31	of	of	IN
cord-302316-raf5rlkq	241	32	juvenile	juvenile	JJ
cord-302316-raf5rlkq	241	33	arthritis	arthritis	NN
cord-302316-raf5rlkq	241	34	associated	associate	VBN
cord-302316-raf5rlkq	241	35	with	with	IN
cord-302316-raf5rlkq	241	36	increased	increase	VBN
cord-302316-raf5rlkq	241	37	IL-6	IL-6	NNP
cord-302316-raf5rlkq	241	38	production	production	NN
cord-302316-raf5rlkq	241	39	.	.	.
cord-302316-raf5rlkq	242	1	This	this	DT
cord-302316-raf5rlkq	242	2	monoclonal	monoclonal	JJ
cord-302316-raf5rlkq	242	3	antibody	antibody	NN
cord-302316-raf5rlkq	242	4	led	lead	VBD
cord-302316-raf5rlkq	242	5	to	to	IN
cord-302316-raf5rlkq	242	6	a	a	DT
cord-302316-raf5rlkq	242	7	rapid	rapid	JJ
cord-302316-raf5rlkq	242	8	increase	increase	NN
cord-302316-raf5rlkq	242	9	in	in	IN
cord-302316-raf5rlkq	242	10	blood	blood	NN
cord-302316-raf5rlkq	242	11	lymphocytes	lymphocyte	NNS
cord-302316-raf5rlkq	242	12	in	in	IN
cord-302316-raf5rlkq	242	13	six	six	CD
cord-302316-raf5rlkq	242	14	COVID-19	covid-19	CD
cord-302316-raf5rlkq	242	15	patients	patient	NNS
cord-302316-raf5rlkq	242	16	(	(	-LRB-
cord-302316-raf5rlkq	242	17	Giamarellos	Giamarellos	NNP
cord-302316-raf5rlkq	242	18	-	-	HYPH
cord-302316-raf5rlkq	242	19	Bourboulis	Bourboulis	NNP
cord-302316-raf5rlkq	242	20	et	et	NNP
cord-302316-raf5rlkq	242	21	al	al	NNP
cord-302316-raf5rlkq	242	22	.	.	NNP
cord-302316-raf5rlkq	242	23	,	,	,
cord-302316-raf5rlkq	242	24	2020	2020	CD
cord-302316-raf5rlkq	242	25	)	)	-RRB-
cord-302316-raf5rlkq	242	26	.	.	.
cord-302316-raf5rlkq	243	1	Clinicians	clinician	NNS
cord-302316-raf5rlkq	243	2	from	from	IN
cord-302316-raf5rlkq	243	3	China	China	NNP
cord-302316-raf5rlkq	243	4	gave	give	VBD
cord-302316-raf5rlkq	243	5	tocilizumab	tocilizumab	NNS
cord-302316-raf5rlkq	243	6	to	to	IN
cord-302316-raf5rlkq	243	7	21	21	CD
cord-302316-raf5rlkq	243	8	patients	patient	NNS
cord-302316-raf5rlkq	243	9	with	with	IN
cord-302316-raf5rlkq	243	10	severe	severe	JJ
cord-302316-raf5rlkq	243	11	or	or	CC
cord-302316-raf5rlkq	243	12	critical	critical	JJ
cord-302316-raf5rlkq	243	13	COVID-19	covid-19	NN
cord-302316-raf5rlkq	243	14	who	who	WP
cord-302316-raf5rlkq	243	15	had	have	VBD
cord-302316-raf5rlkq	243	16	failed	fail	VBN
cord-302316-raf5rlkq	243	17	to	to	TO
cord-302316-raf5rlkq	243	18	respond	respond	VB
cord-302316-raf5rlkq	243	19	to	to	IN
cord-302316-raf5rlkq	243	20	standard	standard	JJ
cord-302316-raf5rlkq	243	21	therapy	therapy	NN
cord-302316-raf5rlkq	243	22	.	.	.
cord-302316-raf5rlkq	244	1	One	one	CD
cord-302316-raf5rlkq	244	2	day	day	NN
cord-302316-raf5rlkq	244	3	after	after	IN
cord-302316-raf5rlkq	244	4	the	the	DT
cord-302316-raf5rlkq	244	5	injection	injection	NN
cord-302316-raf5rlkq	244	6	of	of	IN
cord-302316-raf5rlkq	244	7	tocilizumab	tocilizumab	NNP
cord-302316-raf5rlkq	244	8	,	,	,
cord-302316-raf5rlkq	244	9	the	the	DT
cord-302316-raf5rlkq	244	10	fever	fever	NN
cord-302316-raf5rlkq	244	11	disappeared	disappear	VBD
cord-302316-raf5rlkq	244	12	in	in	IN
cord-302316-raf5rlkq	244	13	all	all	DT
cord-302316-raf5rlkq	244	14	patients	patient	NNS
cord-302316-raf5rlkq	244	15	,	,	,
cord-302316-raf5rlkq	244	16	C	c	NN
cord-302316-raf5rlkq	244	17	-	-	HYPH
cord-302316-raf5rlkq	244	18	reactive	reactive	JJ
cord-302316-raf5rlkq	244	19	protein	protein	NN
cord-302316-raf5rlkq	244	20	returned	return	VBD
cord-302316-raf5rlkq	244	21	to	to	IN
cord-302316-raf5rlkq	244	22	normal	normal	JJ
cord-302316-raf5rlkq	244	23	in	in	IN
cord-302316-raf5rlkq	244	24	most	most	JJS
cord-302316-raf5rlkq	244	25	of	of	IN
cord-302316-raf5rlkq	244	26	them	-PRON-	PRP
cord-302316-raf5rlkq	244	27	,	,	,
cord-302316-raf5rlkq	244	28	peripheral	peripheral	JJ
cord-302316-raf5rlkq	244	29	oxygen	oxygen	NN
cord-302316-raf5rlkq	244	30	saturation	saturation	NN
cord-302316-raf5rlkq	244	31	improved	improve	VBN
cord-302316-raf5rlkq	244	32	,	,	,
cord-302316-raf5rlkq	244	33	CT	CT	NNP
cord-302316-raf5rlkq	244	34	-	-	HYPH
cord-302316-raf5rlkq	244	35	documented	document	VBN
cord-302316-raf5rlkq	244	36	lung	lung	NN
cord-302316-raf5rlkq	244	37	damage	damage	NN
cord-302316-raf5rlkq	244	38	ameliorated	ameliorate	VBN
cord-302316-raf5rlkq	244	39	,	,	,
cord-302316-raf5rlkq	244	40	and	and	CC
cord-302316-raf5rlkq	244	41	the	the	DT
cord-302316-raf5rlkq	244	42	virus	virus	NN
cord-302316-raf5rlkq	244	43	was	be	VBD
cord-302316-raf5rlkq	244	44	cleared	clear	VBN
cord-302316-raf5rlkq	244	45	.	.	.
cord-302316-raf5rlkq	245	1	Adverse	adverse	JJ
cord-302316-raf5rlkq	245	2	effects	effect	NNS
cord-302316-raf5rlkq	245	3	were	be	VBD
cord-302316-raf5rlkq	245	4	not	not	RB
cord-302316-raf5rlkq	245	5	observed	observe	VBN
cord-302316-raf5rlkq	245	6	,	,	,
cord-302316-raf5rlkq	245	7	and	and	CC
cord-302316-raf5rlkq	245	8	all	all	DT
cord-302316-raf5rlkq	245	9	patients	patient	NNS
cord-302316-raf5rlkq	245	10	were	be	VBD
cord-302316-raf5rlkq	245	11	discharged	discharge	VBN
cord-302316-raf5rlkq	246	1	(	(	-LRB-
cord-302316-raf5rlkq	246	2	Xua	Xua	NNP
cord-302316-raf5rlkq	246	3	et	et	NNP
cord-302316-raf5rlkq	246	4	al	al	NNP
cord-302316-raf5rlkq	246	5	.	.	NNP
cord-302316-raf5rlkq	246	6	,	,	,
cord-302316-raf5rlkq	246	7	2020	2020	CD
cord-302316-raf5rlkq	246	8	)	)	-RRB-
cord-302316-raf5rlkq	246	9	.	.	.
cord-302316-raf5rlkq	247	1	Three	three	CD
cord-302316-raf5rlkq	247	2	weeks	week	NNS
cord-302316-raf5rlkq	247	3	after	after	IN
cord-302316-raf5rlkq	247	4	the	the	DT
cord-302316-raf5rlkq	247	5	onset	onset	NN
cord-302316-raf5rlkq	247	6	of	of	IN
cord-302316-raf5rlkq	247	7	disease	disease	NN
cord-302316-raf5rlkq	247	8	,	,	,
cord-302316-raf5rlkq	247	9	6	6	CD
cord-302316-raf5rlkq	247	10	severely	severely	RB
cord-302316-raf5rlkq	247	11	ill	ill	JJ
cord-302316-raf5rlkq	248	1	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	248	2	patients	patient	NNS
cord-302316-raf5rlkq	248	3	received	receive	VBD
cord-302316-raf5rlkq	248	4	plasma	plasma	NN
cord-302316-raf5rlkq	248	5	from	from	IN
cord-302316-raf5rlkq	248	6	convalescent	convalescent	JJ
cord-302316-raf5rlkq	248	7	COVID-19	covid-19	CD
cord-302316-raf5rlkq	248	8	patients	patient	NNS
cord-302316-raf5rlkq	248	9	,	,	,
cord-302316-raf5rlkq	248	10	while	while	IN
cord-302316-raf5rlkq	248	11	11	11	CD
cord-302316-raf5rlkq	248	12	COVID-19	covid-19	CD
cord-302316-raf5rlkq	248	13	patients	patient	NNS
cord-302316-raf5rlkq	248	14	received	receive	VBD
cord-302316-raf5rlkq	248	15	non	non	JJ
cord-302316-raf5rlkq	248	16	-	-	JJ
cord-302316-raf5rlkq	248	17	convalescent	convalescent	JJ
cord-302316-raf5rlkq	248	18	plasma	plasma	NN
cord-302316-raf5rlkq	248	19	as	as	IN
cord-302316-raf5rlkq	248	20	a	a	DT
cord-302316-raf5rlkq	248	21	control	control	NN
cord-302316-raf5rlkq	248	22	.	.	.
cord-302316-raf5rlkq	249	1	Convalescent	convalescent	JJ
cord-302316-raf5rlkq	249	2	plasma	plasma	NN
cord-302316-raf5rlkq	249	3	application	application	NN
cord-302316-raf5rlkq	249	4	was	be	VBD
cord-302316-raf5rlkq	249	5	linked	link	VBN
cord-302316-raf5rlkq	249	6	to	to	IN
cord-302316-raf5rlkq	249	7	a	a	DT
cord-302316-raf5rlkq	249	8	significantly	significantly	RB
cord-302316-raf5rlkq	249	9	higher	high	JJR
cord-302316-raf5rlkq	249	10	viral	viral	JJ
cord-302316-raf5rlkq	249	11	clearance	clearance	NN
cord-302316-raf5rlkq	249	12	over	over	IN
cord-302316-raf5rlkq	249	13	controls	control	NNS
cord-302316-raf5rlkq	249	14	(	(	-LRB-
cord-302316-raf5rlkq	249	15	100	100	CD
cord-302316-raf5rlkq	249	16	vs	vs	IN
cord-302316-raf5rlkq	249	17	21	21	CD
cord-302316-raf5rlkq	249	18	%	%	NN
cord-302316-raf5rlkq	249	19	)	)	-RRB-
cord-302316-raf5rlkq	249	20	but	but	CC
cord-302316-raf5rlkq	249	21	did	do	VBD
cord-302316-raf5rlkq	249	22	not	not	RB
cord-302316-raf5rlkq	249	23	affect	affect	VB
cord-302316-raf5rlkq	249	24	mortality	mortality	NN
cord-302316-raf5rlkq	249	25	which	which	WDT
cord-302316-raf5rlkq	249	26	was	be	VBD
cord-302316-raf5rlkq	249	27	high	high	JJ
cord-302316-raf5rlkq	249	28	in	in	IN
cord-302316-raf5rlkq	249	29	both	both	DT
cord-302316-raf5rlkq	249	30	groups	group	NNS
cord-302316-raf5rlkq	249	31	(	(	-LRB-
cord-302316-raf5rlkq	249	32	5/6	5/6	CD
cord-302316-raf5rlkq	249	33	and	and	CC
cord-302316-raf5rlkq	249	34	10/11	10/11	CD
cord-302316-raf5rlkq	249	35	died	die	VBD
cord-302316-raf5rlkq	249	36	)	)	-RRB-
cord-302316-raf5rlkq	249	37	.	.	.
cord-302316-raf5rlkq	250	1	In	in	IN
cord-302316-raf5rlkq	250	2	a	a	DT
cord-302316-raf5rlkq	250	3	retrospective	retrospective	JJ
cord-302316-raf5rlkq	250	4	study	study	NN
cord-302316-raf5rlkq	250	5	from	from	IN
cord-302316-raf5rlkq	250	6	China	China	NNP
cord-302316-raf5rlkq	250	7	,	,	,
cord-302316-raf5rlkq	250	8	20	20	CD
cord-302316-raf5rlkq	250	9	%	%	NN
cord-302316-raf5rlkq	250	10	of	of	IN
cord-302316-raf5rlkq	250	11	449	449	CD
cord-302316-raf5rlkq	250	12	severely	severely	RB
cord-302316-raf5rlkq	250	13	ill	ill	JJ
cord-302316-raf5rlkq	250	14	COVID-19	covid-19	CD
cord-302316-raf5rlkq	250	15	patients	patient	NNS
cord-302316-raf5rlkq	250	16	were	be	VBD
cord-302316-raf5rlkq	250	17	treated	treat	VBN
cord-302316-raf5rlkq	250	18	with	with	IN
cord-302316-raf5rlkq	250	19	the	the	DT
cord-302316-raf5rlkq	250	20	coagulation	coagulation	NN
cord-302316-raf5rlkq	250	21	inhibitor	inhibitor	NN
cord-302316-raf5rlkq	250	22	heparin	heparin	NN
cord-302316-raf5rlkq	250	23	.	.	.
cord-302316-raf5rlkq	251	1	Mortality	mortality	NN
cord-302316-raf5rlkq	251	2	was	be	VBD
cord-302316-raf5rlkq	251	3	30	30	CD
cord-302316-raf5rlkq	251	4	%	%	NN
cord-302316-raf5rlkq	251	5	,	,	,
cord-302316-raf5rlkq	251	6	irrespective	irrespective	RB
cord-302316-raf5rlkq	251	7	of	of	IN
cord-302316-raf5rlkq	251	8	whether	whether	IN
cord-302316-raf5rlkq	251	9	heparin	heparin	NN
cord-302316-raf5rlkq	251	10	was	be	VBD
cord-302316-raf5rlkq	251	11	given	give	VBN
cord-302316-raf5rlkq	251	12	or	or	CC
cord-302316-raf5rlkq	251	13	not	not	RB
cord-302316-raf5rlkq	251	14	.	.	.
cord-302316-raf5rlkq	252	1	However	however	RB
cord-302316-raf5rlkq	252	2	,	,	,
cord-302316-raf5rlkq	252	3	when	when	WRB
cord-302316-raf5rlkq	252	4	patients	patient	NNS
cord-302316-raf5rlkq	252	5	were	be	VBD
cord-302316-raf5rlkq	252	6	stratified	stratify	VBN
cord-302316-raf5rlkq	252	7	with	with	IN
cord-302316-raf5rlkq	252	8	respect	respect	NN
cord-302316-raf5rlkq	252	9	to	to	IN
cord-302316-raf5rlkq	252	10	coagulopathy	coagulopathy	NN
cord-302316-raf5rlkq	252	11	at	at	IN
cord-302316-raf5rlkq	252	12	baseline	baseline	NN
cord-302316-raf5rlkq	252	13	(	(	-LRB-
cord-302316-raf5rlkq	252	14	using	use	VBG
cord-302316-raf5rlkq	252	15	D	d	NN
cord-302316-raf5rlkq	252	16	-	-	HYPH
cord-302316-raf5rlkq	252	17	dimer	dimer	NN
cord-302316-raf5rlkq	252	18	concentration	concentration	NN
cord-302316-raf5rlkq	252	19	sixfold	sixfold	VBP
cord-302316-raf5rlkq	252	20	higher	higher	RBR
cord-302316-raf5rlkq	252	21	than	than	IN
cord-302316-raf5rlkq	252	22	normal	normal	JJ
cord-302316-raf5rlkq	252	23	as	as	IN
cord-302316-raf5rlkq	252	24	threshold	threshold	NN
cord-302316-raf5rlkq	252	25	)	)	-RRB-
cord-302316-raf5rlkq	252	26	,	,	,
cord-302316-raf5rlkq	252	27	a	a	DT
cord-302316-raf5rlkq	252	28	20	20	CD
cord-302316-raf5rlkq	252	29	%	%	NN
cord-302316-raf5rlkq	252	30	reduction	reduction	NN
cord-302316-raf5rlkq	252	31	in	in	IN
cord-302316-raf5rlkq	252	32	mortality	mortality	NN
cord-302316-raf5rlkq	252	33	was	be	VBD
cord-302316-raf5rlkq	252	34	associated	associate	VBN
cord-302316-raf5rlkq	252	35	with	with	IN
cord-302316-raf5rlkq	252	36	heparin	heparin	JJ
cord-302316-raf5rlkq	252	37	use	use	NN
cord-302316-raf5rlkq	252	38	.	.	.
cord-302316-raf5rlkq	253	1	The	the	DT
cord-302316-raf5rlkq	253	2	data	datum	NNS
cord-302316-raf5rlkq	253	3	need	need	VBP
cord-302316-raf5rlkq	253	4	to	to	TO
cord-302316-raf5rlkq	253	5	be	be	VB
cord-302316-raf5rlkq	253	6	interpreted	interpret	VBN
cord-302316-raf5rlkq	253	7	with	with	IN
cord-302316-raf5rlkq	253	8	caution	caution	NN
cord-302316-raf5rlkq	253	9	,	,	,
cord-302316-raf5rlkq	253	10	since	since	IN
cord-302316-raf5rlkq	253	11	they	-PRON-	PRP
cord-302316-raf5rlkq	253	12	come	come	VBP
cord-302316-raf5rlkq	253	13	from	from	IN
cord-302316-raf5rlkq	253	14	a	a	DT
cord-302316-raf5rlkq	253	15	retrospective	retrospective	JJ
cord-302316-raf5rlkq	253	16	subgroup	subgroup	NN
cord-302316-raf5rlkq	253	17	analysis	analysis	NN
cord-302316-raf5rlkq	253	18	.	.	.
cord-302316-raf5rlkq	254	1	Hydroxycytidine	Hydroxycytidine	NNP
cord-302316-raf5rlkq	254	2	A	a	DT
cord-302316-raf5rlkq	254	3	promising	promising	JJ
cord-302316-raf5rlkq	254	4	prodrug	prodrug	NN
cord-302316-raf5rlkq	254	5	is	be	VBZ
cord-302316-raf5rlkq	254	6	the	the	DT
cord-302316-raf5rlkq	254	7	nucleotide	nucleotide	JJ
cord-302316-raf5rlkq	254	8	analog	analog	NN
cord-302316-raf5rlkq	254	9	hydroxycytidine	hydroxycytidine	NNP
cord-302316-raf5rlkq	254	10	.	.	.
cord-302316-raf5rlkq	255	1	In	in	IN
cord-302316-raf5rlkq	255	2	cell	cell	NN
cord-302316-raf5rlkq	255	3	culture	culture	NN
cord-302316-raf5rlkq	255	4	infections	infection	NNS
cord-302316-raf5rlkq	255	5	,	,	,
cord-302316-raf5rlkq	255	6	this	this	DT
cord-302316-raf5rlkq	255	7	drug	drug	NN
cord-302316-raf5rlkq	255	8	is	be	VBZ
cord-302316-raf5rlkq	255	9	active	active	JJ
cord-302316-raf5rlkq	255	10	against	against	IN
cord-302316-raf5rlkq	255	11	a	a	DT
cord-302316-raf5rlkq	255	12	wide	wide	JJ
cord-302316-raf5rlkq	255	13	range	range	NN
cord-302316-raf5rlkq	255	14	of	of	IN
cord-302316-raf5rlkq	255	15	human	human	NN
cord-302316-raf5rlkq	255	16	and	and	CC
cord-302316-raf5rlkq	255	17	bat	bat	NN
cord-302316-raf5rlkq	255	18	coronaviruses	coronaviruse	NNS
cord-302316-raf5rlkq	255	19	thus	thus	RB
cord-302316-raf5rlkq	255	20	potentially	potentially	RB
cord-302316-raf5rlkq	255	21	offering	offer	VBG
cord-302316-raf5rlkq	255	22	inhibitory	inhibitory	JJ
cord-302316-raf5rlkq	255	23	activity	activity	NN
cord-302316-raf5rlkq	255	24	against	against	IN
cord-302316-raf5rlkq	255	25	future	future	JJ
cord-302316-raf5rlkq	255	26	spill	spill	NN
cord-302316-raf5rlkq	255	27	-	-	HYPH
cord-302316-raf5rlkq	255	28	over	over	RP
cord-302316-raf5rlkq	255	29	infections	infection	NNS
cord-302316-raf5rlkq	255	30	from	from	IN
cord-302316-raf5rlkq	255	31	animals	animal	NNS
cord-302316-raf5rlkq	255	32	(	(	-LRB-
cord-302316-raf5rlkq	255	33	zoonosis	zoonosis	NN
cord-302316-raf5rlkq	255	34	)	)	-RRB-
cord-302316-raf5rlkq	255	35	.	.	.
cord-302316-raf5rlkq	256	1	The	the	DT
cord-302316-raf5rlkq	256	2	drug	drug	NN
cord-302316-raf5rlkq	256	3	increases	increase	VBZ
cord-302316-raf5rlkq	256	4	the	the	DT
cord-302316-raf5rlkq	256	5	mutation	mutation	NN
cord-302316-raf5rlkq	256	6	rate	rate	NN
cord-302316-raf5rlkq	256	7	of	of	IN
cord-302316-raf5rlkq	256	8	the	the	DT
cord-302316-raf5rlkq	256	9	virus	virus	NN
cord-302316-raf5rlkq	256	10	during	during	IN
cord-302316-raf5rlkq	256	11	replication	replication	NN
cord-302316-raf5rlkq	256	12	resulting	result	VBG
cord-302316-raf5rlkq	256	13	in	in	IN
cord-302316-raf5rlkq	256	14	infectivity	infectivity	NN
cord-302316-raf5rlkq	256	15	losses	loss	NNS
cord-302316-raf5rlkq	256	16	.	.	.
cord-302316-raf5rlkq	257	1	In	in	IN
cord-302316-raf5rlkq	257	2	mouse	mouse	NN
cord-302316-raf5rlkq	257	3	infection	infection	NN
cord-302316-raf5rlkq	257	4	models	model	NNS
cord-302316-raf5rlkq	257	5	for	for	IN
cord-302316-raf5rlkq	257	6	SARS	SARS	NNP
cord-302316-raf5rlkq	257	7	-	-	HYPH
cord-302316-raf5rlkq	257	8	CoV	CoV	NNP
cord-302316-raf5rlkq	257	9	and	and	CC
cord-302316-raf5rlkq	257	10	MERS	MERS	NNP
cord-302316-raf5rlkq	257	11	virus	virus	NN
cord-302316-raf5rlkq	257	12	,	,	,
cord-302316-raf5rlkq	257	13	it	-PRON-	PRP
cord-302316-raf5rlkq	257	14	had	have	VBD
cord-302316-raf5rlkq	257	15	good	good	JJ
cord-302316-raf5rlkq	257	16	oral	oral	JJ
cord-302316-raf5rlkq	257	17	bioavailability	bioavailability	NN
cord-302316-raf5rlkq	257	18	,	,	,
cord-302316-raf5rlkq	257	19	ameliorated	ameliorated	JJ
cord-302316-raf5rlkq	257	20	lung	lung	NN
cord-302316-raf5rlkq	257	21	function	function	NN
cord-302316-raf5rlkq	257	22	,	,	,
cord-302316-raf5rlkq	257	23	reduced	reduce	VBN
cord-302316-raf5rlkq	257	24	virus	virus	NN
cord-302316-raf5rlkq	257	25	titre	titre	NN
cord-302316-raf5rlkq	257	26	and	and	CC
cord-302316-raf5rlkq	257	27	diminished	diminish	VBD
cord-302316-raf5rlkq	257	28	weight	weight	NN
cord-302316-raf5rlkq	257	29	loss	loss	NN
cord-302316-raf5rlkq	257	30	caused	cause	VBN
cord-302316-raf5rlkq	257	31	by	by	IN
cord-302316-raf5rlkq	257	32	the	the	DT
cord-302316-raf5rlkq	257	33	viral	viral	JJ
cord-302316-raf5rlkq	257	34	infection	infection	NN
cord-302316-raf5rlkq	257	35	.	.	.
cord-302316-raf5rlkq	258	1	The	the	DT
cord-302316-raf5rlkq	258	2	drug	drug	NN
cord-302316-raf5rlkq	258	3	demonstrated	demonstrate	VBD
cord-302316-raf5rlkq	258	4	therapeutic	therapeutic	JJ
cord-302316-raf5rlkq	258	5	effects	effect	NNS
cord-302316-raf5rlkq	258	6	up	up	IN
cord-302316-raf5rlkq	258	7	to	to	TO
cord-302316-raf5rlkq	258	8	24	24	CD
cord-302316-raf5rlkq	258	9	h	h	NN
cord-302316-raf5rlkq	258	10	after	after	IN
cord-302316-raf5rlkq	258	11	infection	infection	NN
cord-302316-raf5rlkq	258	12	,	,	,
cord-302316-raf5rlkq	258	13	which	which	WDT
cord-302316-raf5rlkq	258	14	is	be	VBZ
cord-302316-raf5rlkq	258	15	substantial	substantial	JJ
cord-302316-raf5rlkq	258	16	since	since	IN
cord-302316-raf5rlkq	258	17	mice	mouse	NNS
cord-302316-raf5rlkq	258	18	show	show	VBP
cord-302316-raf5rlkq	258	19	a	a	DT
cord-302316-raf5rlkq	258	20	compressed	compress	VBN
cord-302316-raf5rlkq	258	21	disease	disease	NN
cord-302316-raf5rlkq	258	22	course	course	NN
cord-302316-raf5rlkq	258	23	compared	compare	VBN
cord-302316-raf5rlkq	258	24	to	to	IN
cord-302316-raf5rlkq	258	25	that	that	DT
cord-302316-raf5rlkq	258	26	of	of	IN
cord-302316-raf5rlkq	258	27	humans	human	NNS
cord-302316-raf5rlkq	258	28	.	.	.
cord-302316-raf5rlkq	259	1	Coronaviruses	coronaviruse	NNS
cord-302316-raf5rlkq	259	2	that	that	WDT
cord-302316-raf5rlkq	259	3	had	have	VBD
cord-302316-raf5rlkq	259	4	become	become	VBN
cord-302316-raf5rlkq	259	5	resistant	resistant	JJ
cord-302316-raf5rlkq	259	6	to	to	IN
cord-302316-raf5rlkq	259	7	remdesivir	remdesivir	NNP
cord-302316-raf5rlkq	259	8	showed	show	VBD
cord-302316-raf5rlkq	259	9	enhanced	enhanced	JJ
cord-302316-raf5rlkq	259	10	susceptibility	susceptibility	NN
cord-302316-raf5rlkq	259	11	to	to	IN
cord-302316-raf5rlkq	259	12	inhibition	inhibition	NN
cord-302316-raf5rlkq	259	13	by	by	IN
cord-302316-raf5rlkq	259	14	hydroxycytidine	hydroxycytidine	NNP
cord-302316-raf5rlkq	259	15	(	(	-LRB-
cord-302316-raf5rlkq	259	16	Sheahan	Sheahan	NNP
cord-302316-raf5rlkq	259	17	et	et	NNP
cord-302316-raf5rlkq	259	18	al	al	NNP
cord-302316-raf5rlkq	259	19	.	.	NNP
cord-302316-raf5rlkq	259	20	,	,	,
cord-302316-raf5rlkq	259	21	2020	2020	CD
cord-302316-raf5rlkq	259	22	)	)	-RRB-
cord-302316-raf5rlkq	259	23	.	.	.
cord-302316-raf5rlkq	260	1	Hydroxycytidine	Hydroxycytidine	NNP
cord-302316-raf5rlkq	260	2	causes	cause	VBZ
cord-302316-raf5rlkq	260	3	mutagenesis	mutagenesis	NN
cord-302316-raf5rlkq	260	4	in	in	IN
cord-302316-raf5rlkq	260	5	the	the	DT
cord-302316-raf5rlkq	260	6	bacterium	bacterium	NN
cord-302316-raf5rlkq	260	7	Escherichia	Escherichia	NNP
cord-302316-raf5rlkq	260	8	coli	coli	NNS
cord-302316-raf5rlkq	260	9	and	and	CC
cord-302316-raf5rlkq	260	10	the	the	DT
cord-302316-raf5rlkq	260	11	fungus	fungus	NN
cord-302316-raf5rlkq	260	12	Neurospora	Neurospora	NNP
cord-302316-raf5rlkq	260	13	crassa	crassa	NN
cord-302316-raf5rlkq	260	14	.	.	.
cord-302316-raf5rlkq	261	1	Cell	cell	NN
cord-302316-raf5rlkq	261	2	protease	protease	NN
cord-302316-raf5rlkq	261	3	inhibitor	inhibitor	NN
cord-302316-raf5rlkq	261	4	SARS	SARS	NNP
cord-302316-raf5rlkq	261	5	-	-	HYPH
cord-302316-raf5rlkq	261	6	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	261	7	needs	need	VBZ
cord-302316-raf5rlkq	261	8	,	,	,
cord-302316-raf5rlkq	261	9	after	after	IN
cord-302316-raf5rlkq	261	10	the	the	DT
cord-302316-raf5rlkq	261	11	docking	docking	NN
cord-302316-raf5rlkq	261	12	of	of	IN
cord-302316-raf5rlkq	261	13	its	-PRON-	PRP$
cord-302316-raf5rlkq	261	14	spike	spike	NN
cord-302316-raf5rlkq	261	15	protein	protein	NN
cord-302316-raf5rlkq	261	16	to	to	IN
cord-302316-raf5rlkq	261	17	the	the	DT
cord-302316-raf5rlkq	261	18	cell	cell	NN
cord-302316-raf5rlkq	261	19	receptor	receptor	NN
cord-302316-raf5rlkq	261	20	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	261	21	,	,	,
cord-302316-raf5rlkq	261	22	a	a	DT
cord-302316-raf5rlkq	261	23	proteolytic	proteolytic	JJ
cord-302316-raf5rlkq	261	24	cleavage	cleavage	NN
cord-302316-raf5rlkq	261	25	of	of	IN
cord-302316-raf5rlkq	261	26	the	the	DT
cord-302316-raf5rlkq	261	27	spike	spike	NN
cord-302316-raf5rlkq	261	28	protein	protein	NN
cord-302316-raf5rlkq	261	29	at	at	IN
cord-302316-raf5rlkq	261	30	a	a	DT
cord-302316-raf5rlkq	261	31	polybasic	polybasic	JJ
cord-302316-raf5rlkq	261	32	site	site	NN
cord-302316-raf5rlkq	261	33	separating	separate	VBG
cord-302316-raf5rlkq	261	34	the	the	DT
cord-302316-raf5rlkq	261	35	S	S	NNP
cord-302316-raf5rlkq	261	36	protein	protein	NN
cord-302316-raf5rlkq	261	37	into	into	IN
cord-302316-raf5rlkq	261	38	two	two	CD
cord-302316-raf5rlkq	261	39	protein	protein	NN
cord-302316-raf5rlkq	261	40	fragments	fragment	NNS
cord-302316-raf5rlkq	261	41	S1	s1	NN
cord-302316-raf5rlkq	261	42	and	and	CC
cord-302316-raf5rlkq	261	43	S2	S2	NNP
cord-302316-raf5rlkq	261	44	,	,	,
cord-302316-raf5rlkq	261	45	where	where	WRB
cord-302316-raf5rlkq	261	46	S2	S2	NNP
cord-302316-raf5rlkq	261	47	mediates	mediate	VBZ
cord-302316-raf5rlkq	261	48	the	the	DT
cord-302316-raf5rlkq	261	49	fusion	fusion	NN
cord-302316-raf5rlkq	261	50	of	of	IN
cord-302316-raf5rlkq	261	51	the	the	DT
cord-302316-raf5rlkq	261	52	viral	viral	JJ
cord-302316-raf5rlkq	261	53	and	and	CC
cord-302316-raf5rlkq	261	54	cell	cell	NN
cord-302316-raf5rlkq	261	55	membranes	membrane	NNS
cord-302316-raf5rlkq	261	56	,	,	,
cord-302316-raf5rlkq	261	57	which	which	WDT
cord-302316-raf5rlkq	261	58	leads	lead	VBZ
cord-302316-raf5rlkq	261	59	to	to	IN
cord-302316-raf5rlkq	261	60	the	the	DT
cord-302316-raf5rlkq	261	61	entry	entry	NN
cord-302316-raf5rlkq	261	62	of	of	IN
cord-302316-raf5rlkq	261	63	the	the	DT
cord-302316-raf5rlkq	261	64	viral	viral	JJ
cord-302316-raf5rlkq	261	65	genome	genome	NN
cord-302316-raf5rlkq	261	66	into	into	IN
cord-302316-raf5rlkq	261	67	the	the	DT
cord-302316-raf5rlkq	261	68	infected	infected	JJ
cord-302316-raf5rlkq	261	69	cell	cell	NN
cord-302316-raf5rlkq	261	70	.	.	.
cord-302316-raf5rlkq	262	1	Cell	cell	NN
cord-302316-raf5rlkq	262	2	culture	culture	NN
cord-302316-raf5rlkq	262	3	infection	infection	NN
cord-302316-raf5rlkq	262	4	tests	test	NNS
cord-302316-raf5rlkq	262	5	demonstrated	demonstrate	VBD
cord-302316-raf5rlkq	262	6	that	that	IN
cord-302316-raf5rlkq	262	7	SARS	SARS	NNP
cord-302316-raf5rlkq	262	8	-	-	HYPH
cord-302316-raf5rlkq	262	9	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	262	10	uses	use	VBZ
cord-302316-raf5rlkq	262	11	two	two	CD
cord-302316-raf5rlkq	262	12	proteases	protease	NNS
cord-302316-raf5rlkq	262	13	for	for	IN
cord-302316-raf5rlkq	262	14	this	this	DT
cord-302316-raf5rlkq	262	15	proteolytic	proteolytic	JJ
cord-302316-raf5rlkq	262	16	processing	processing	NN
cord-302316-raf5rlkq	262	17	,	,	,
cord-302316-raf5rlkq	262	18	either	either	CC
cord-302316-raf5rlkq	262	19	the	the	DT
cord-302316-raf5rlkq	262	20	lysosomal	lysosomal	JJ
cord-302316-raf5rlkq	262	21	cathepsin	cathepsin	NN
cord-302316-raf5rlkq	262	22	CatB	CatB	NNP
cord-302316-raf5rlkq	262	23	/	/	SYM
cord-302316-raf5rlkq	262	24	L	L	NNP
cord-302316-raf5rlkq	262	25	or	or	CC
cord-302316-raf5rlkq	262	26	the	the	DT
cord-302316-raf5rlkq	262	27	transmembrane	transmembrane	NNP
cord-302316-raf5rlkq	262	28	protease	protease	NN
cord-302316-raf5rlkq	262	29	TMPRSS2	TMPRSS2	NNP
cord-302316-raf5rlkq	262	30	.	.	.
cord-302316-raf5rlkq	263	1	The	the	DT
cord-302316-raf5rlkq	263	2	serine	serine	JJ
cord-302316-raf5rlkq	263	3	protease	protease	NN
cord-302316-raf5rlkq	263	4	inhibitor	inhibitor	NN
cord-302316-raf5rlkq	263	5	camostat	camostat	NN
cord-302316-raf5rlkq	263	6	,	,	,
cord-302316-raf5rlkq	263	7	which	which	WDT
cord-302316-raf5rlkq	263	8	is	be	VBZ
cord-302316-raf5rlkq	263	9	a	a	DT
cord-302316-raf5rlkq	263	10	registered	registered	JJ
cord-302316-raf5rlkq	263	11	drug	drug	NN
cord-302316-raf5rlkq	263	12	in	in	IN
cord-302316-raf5rlkq	263	13	Japan	Japan	NNP
cord-302316-raf5rlkq	263	14	for	for	IN
cord-302316-raf5rlkq	263	15	gastroenterology	gastroenterology	NN
cord-302316-raf5rlkq	263	16	problems	problem	NNS
cord-302316-raf5rlkq	263	17	,	,	,
cord-302316-raf5rlkq	263	18	inhibits	inhibit	VBZ
cord-302316-raf5rlkq	263	19	TMPRSS2	TMPRSS2	NNP
cord-302316-raf5rlkq	263	20	and	and	CC
cord-302316-raf5rlkq	263	21	confers	confer	VBZ
cord-302316-raf5rlkq	263	22	partial	partial	JJ
cord-302316-raf5rlkq	263	23	resistance	resistance	NN
cord-302316-raf5rlkq	263	24	to	to	IN
cord-302316-raf5rlkq	263	25	infection	infection	NN
cord-302316-raf5rlkq	263	26	with	with	IN
cord-302316-raf5rlkq	263	27	SARS	SARS	NNP
cord-302316-raf5rlkq	263	28	-	-	HYPH
cord-302316-raf5rlkq	263	29	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	263	30	,	,	,
cord-302316-raf5rlkq	263	31	and	and	CC
cord-302316-raf5rlkq	263	32	total	total	JJ
cord-302316-raf5rlkq	263	33	protection	protection	NN
cord-302316-raf5rlkq	263	34	when	when	WRB
cord-302316-raf5rlkq	263	35	combined	combine	VBN
cord-302316-raf5rlkq	263	36	with	with	IN
cord-302316-raf5rlkq	263	37	E-64d	E-64d	NNP
cord-302316-raf5rlkq	263	38	,	,	,
cord-302316-raf5rlkq	263	39	an	an	DT
cord-302316-raf5rlkq	263	40	inhibitor	inhibitor	NN
cord-302316-raf5rlkq	263	41	of	of	IN
cord-302316-raf5rlkq	263	42	CatB	CatB	NNP
cord-302316-raf5rlkq	263	43	/	/	SYM
cord-302316-raf5rlkq	263	44	L	L	NNP
cord-302316-raf5rlkq	263	45	(	(	-LRB-
cord-302316-raf5rlkq	263	46	Hoffmann	Hoffmann	NNP
cord-302316-raf5rlkq	263	47	et	et	NNP
cord-302316-raf5rlkq	263	48	al	al	NNP
cord-302316-raf5rlkq	263	49	.	.	NNP
cord-302316-raf5rlkq	263	50	,	,	,
cord-302316-raf5rlkq	263	51	2020	2020	CD
cord-302316-raf5rlkq	263	52	)	)	-RRB-
cord-302316-raf5rlkq	263	53	.	.	.
cord-302316-raf5rlkq	264	1	Chinese	chinese	JJ
cord-302316-raf5rlkq	264	2	scientists	scientist	NNS
cord-302316-raf5rlkq	264	3	have	have	VBP
cord-302316-raf5rlkq	264	4	targeted	target	VBN
cord-302316-raf5rlkq	264	5	the	the	DT
cord-302316-raf5rlkq	264	6	SARS	SARS	NNP
cord-302316-raf5rlkq	264	7	-	-	HYPH
cord-302316-raf5rlkq	264	8	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	264	9	main	main	JJ
cord-302316-raf5rlkq	264	10	protease	protease	NN
cord-302316-raf5rlkq	264	11	for	for	IN
cord-302316-raf5rlkq	264	12	inhibition	inhibition	NN
cord-302316-raf5rlkq	264	13	.	.	.
cord-302316-raf5rlkq	265	1	After	after	IN
cord-302316-raf5rlkq	265	2	expressing	express	VBG
cord-302316-raf5rlkq	265	3	the	the	DT
cord-302316-raf5rlkq	265	4	protease	protease	NN
cord-302316-raf5rlkq	265	5	and	and	CC
cord-302316-raf5rlkq	265	6	designing	design	VBG
cord-302316-raf5rlkq	265	7	a	a	DT
cord-302316-raf5rlkq	265	8	fluorescence	fluorescence	NN
cord-302316-raf5rlkq	265	9	-	-	HYPH
cord-302316-raf5rlkq	265	10	labelled	label	VBN
cord-302316-raf5rlkq	265	11	substrate	substrate	NN
cord-302316-raf5rlkq	265	12	,	,	,
cord-302316-raf5rlkq	265	13	they	-PRON-	PRP
cord-302316-raf5rlkq	265	14	used	use	VBD
cord-302316-raf5rlkq	265	15	,	,	,
cord-302316-raf5rlkq	265	16	as	as	IN
cord-302316-raf5rlkq	265	17	an	an	DT
cord-302316-raf5rlkq	265	18	inhibitor	inhibitor	NN
cord-302316-raf5rlkq	265	19	,	,	,
cord-302316-raf5rlkq	265	20	compound	compound	NN
cord-302316-raf5rlkq	265	21	N3	n3	NN
cord-302316-raf5rlkq	265	22	which	which	WDT
cord-302316-raf5rlkq	265	23	was	be	VBD
cord-302316-raf5rlkq	265	24	active	active	JJ
cord-302316-raf5rlkq	265	25	against	against	IN
cord-302316-raf5rlkq	265	26	SARS	SARS	NNP
cord-302316-raf5rlkq	265	27	-	-	HYPH
cord-302316-raf5rlkq	265	28	CoV.	CoV.	NNP
cord-302316-raf5rlkq	266	1	In	in	IN
cord-302316-raf5rlkq	266	2	silico	silico	NN
cord-302316-raf5rlkq	266	3	docking	docking	NN
cord-302316-raf5rlkq	266	4	verified	verify	VBN
cord-302316-raf5rlkq	266	5	that	that	IN
cord-302316-raf5rlkq	266	6	it	-PRON-	PRP
cord-302316-raf5rlkq	266	7	could	could	MD
cord-302316-raf5rlkq	266	8	fit	fit	VB
cord-302316-raf5rlkq	266	9	into	into	IN
cord-302316-raf5rlkq	266	10	the	the	DT
cord-302316-raf5rlkq	266	11	predicted	predict	VBN
cord-302316-raf5rlkq	266	12	structure	structure	NN
cord-302316-raf5rlkq	266	13	of	of	IN
cord-302316-raf5rlkq	266	14	SARS	SARS	NNP
cord-302316-raf5rlkq	266	15	-	-	HYPH
cord-302316-raf5rlkq	266	16	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	266	17	main	main	JJ
cord-302316-raf5rlkq	266	18	protease	protease	NN
cord-302316-raf5rlkq	266	19	.	.	.
cord-302316-raf5rlkq	267	1	Kinetic	kinetic	JJ
cord-302316-raf5rlkq	267	2	analysis	analysis	NN
cord-302316-raf5rlkq	267	3	revealed	reveal	VBD
cord-302316-raf5rlkq	267	4	a	a	DT
cord-302316-raf5rlkq	267	5	two	two	CD
cord-302316-raf5rlkq	267	6	-	-	HYPH
cord-302316-raf5rlkq	267	7	step	step	NN
cord-302316-raf5rlkq	267	8	inactivation	inactivation	NN
cord-302316-raf5rlkq	267	9	process	process	NN
cord-302316-raf5rlkq	267	10	resulting	result	VBG
cord-302316-raf5rlkq	267	11	in	in	IN
cord-302316-raf5rlkq	267	12	N3	n3	NN
cord-302316-raf5rlkq	267	13	covalent	covalent	NN
cord-302316-raf5rlkq	267	14	binding	bind	VBG
cord-302316-raf5rlkq	267	15	to	to	IN
cord-302316-raf5rlkq	267	16	the	the	DT
cord-302316-raf5rlkq	267	17	catalytic	catalytic	JJ
cord-302316-raf5rlkq	267	18	site	site	NN
cord-302316-raf5rlkq	267	19	.	.	.
cord-302316-raf5rlkq	268	1	The	the	DT
cord-302316-raf5rlkq	268	2	crystal	crystal	NN
cord-302316-raf5rlkq	268	3	structure	structure	NN
cord-302316-raf5rlkq	268	4	for	for	IN
cord-302316-raf5rlkq	268	5	the	the	DT
cord-302316-raf5rlkq	268	6	protease	protease	NN
cord-302316-raf5rlkq	268	7	-	-	HYPH
cord-302316-raf5rlkq	268	8	bound	bind	VBN
cord-302316-raf5rlkq	268	9	N3	n3	NN
cord-302316-raf5rlkq	268	10	was	be	VBD
cord-302316-raf5rlkq	268	11	solved	solve	VBN
cord-302316-raf5rlkq	268	12	and	and	CC
cord-302316-raf5rlkq	268	13	was	be	VBD
cord-302316-raf5rlkq	268	14	followed	follow	VBN
cord-302316-raf5rlkq	268	15	by	by	IN
cord-302316-raf5rlkq	268	16	a	a	DT
cord-302316-raf5rlkq	268	17	virtual	virtual	JJ
cord-302316-raf5rlkq	268	18	screening	screening	NN
cord-302316-raf5rlkq	268	19	of	of	IN
cord-302316-raf5rlkq	268	20	a	a	DT
cord-302316-raf5rlkq	268	21	chemical	chemical	JJ
cord-302316-raf5rlkq	268	22	database	database	NN
cord-302316-raf5rlkq	268	23	for	for	IN
cord-302316-raf5rlkq	268	24	better	well	JJR
cord-302316-raf5rlkq	268	25	inhibitors	inhibitor	NNS
cord-302316-raf5rlkq	268	26	.	.	.
cord-302316-raf5rlkq	269	1	The	the	DT
cord-302316-raf5rlkq	269	2	next	next	JJ
cord-302316-raf5rlkq	269	3	step	step	NN
cord-302316-raf5rlkq	269	4	was	be	VBD
cord-302316-raf5rlkq	269	5	a	a	DT
cord-302316-raf5rlkq	269	6	highthroughput	highthroughput	NN
cord-302316-raf5rlkq	269	7	screening	screening	NN
cord-302316-raf5rlkq	269	8	of	of	IN
cord-302316-raf5rlkq	269	9	10'000	10'000	CD
cord-302316-raf5rlkq	269	10	compounds	compound	NNS
cord-302316-raf5rlkq	269	11	.	.	.
cord-302316-raf5rlkq	270	1	One	one	CD
cord-302316-raf5rlkq	270	2	of	of	IN
cord-302316-raf5rlkq	270	3	the	the	DT
cord-302316-raf5rlkq	270	4	best	good	JJS
cord-302316-raf5rlkq	270	5	inhibitors	inhibitor	NNS
cord-302316-raf5rlkq	270	6	was	be	VBD
cord-302316-raf5rlkq	270	7	an	an	DT
cord-302316-raf5rlkq	270	8	organo	organo	NN
cord-302316-raf5rlkq	270	9	-	-	HYPH
cord-302316-raf5rlkq	270	10	selenium	selenium	NN
cord-302316-raf5rlkq	270	11	compound	compound	NN
cord-302316-raf5rlkq	270	12	that	that	WDT
cord-302316-raf5rlkq	270	13	inhibited	inhibit	VBD
cord-302316-raf5rlkq	270	14	the	the	DT
cord-302316-raf5rlkq	270	15	infectivity	infectivity	NN
cord-302316-raf5rlkq	270	16	of	of	IN
cord-302316-raf5rlkq	270	17	SARS	SARS	NNP
cord-302316-raf5rlkq	270	18	-	-	HYPH
cord-302316-raf5rlkq	270	19	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	270	20	in	in	IN
cord-302316-raf5rlkq	270	21	a	a	DT
cord-302316-raf5rlkq	270	22	cell	cell	NN
cord-302316-raf5rlkq	270	23	culture	culture	NN
cord-302316-raf5rlkq	270	24	test	test	NN
cord-302316-raf5rlkq	270	25	.	.	.
cord-302316-raf5rlkq	271	1	Since	since	IN
cord-302316-raf5rlkq	271	2	this	this	DT
cord-302316-raf5rlkq	271	3	compound	compound	NN
cord-302316-raf5rlkq	271	4	has	have	VBZ
cord-302316-raf5rlkq	271	5	already	already	RB
cord-302316-raf5rlkq	271	6	been	be	VBN
cord-302316-raf5rlkq	271	7	investigated	investigate	VBN
cord-302316-raf5rlkq	271	8	for	for	IN
cord-302316-raf5rlkq	271	9	the	the	DT
cord-302316-raf5rlkq	271	10	treatment	treatment	NN
cord-302316-raf5rlkq	271	11	of	of	IN
cord-302316-raf5rlkq	271	12	several	several	JJ
cord-302316-raf5rlkq	271	13	diseases	disease	NNS
cord-302316-raf5rlkq	271	14	,	,	,
cord-302316-raf5rlkq	271	15	where	where	WRB
cord-302316-raf5rlkq	271	16	it	-PRON-	PRP
cord-302316-raf5rlkq	271	17	showed	show	VBD
cord-302316-raf5rlkq	271	18	a	a	DT
cord-302316-raf5rlkq	271	19	high	high	JJ
cord-302316-raf5rlkq	271	20	safety	safety	NN
cord-302316-raf5rlkq	271	21	profile	profile	NN
cord-302316-raf5rlkq	271	22	,	,	,
cord-302316-raf5rlkq	271	23	this	this	DT
cord-302316-raf5rlkq	271	24	repurposed	repurpose	VBN
cord-302316-raf5rlkq	271	25	drug	drug	NN
cord-302316-raf5rlkq	271	26	could	could	MD
cord-302316-raf5rlkq	271	27	be	be	VB
cord-302316-raf5rlkq	271	28	re	re	VBN
cord-302316-raf5rlkq	271	29	-	-	VBN
cord-302316-raf5rlkq	271	30	entered	enter	VBN
cord-302316-raf5rlkq	271	31	into	into	IN
cord-302316-raf5rlkq	271	32	clinical	clinical	JJ
cord-302316-raf5rlkq	271	33	trials	trial	NNS
cord-302316-raf5rlkq	271	34	relatively	relatively	RB
cord-302316-raf5rlkq	271	35	quickly	quickly	RB
cord-302316-raf5rlkq	271	36	.	.	.
cord-302316-raf5rlkq	272	1	US	US	NNP
cord-302316-raf5rlkq	272	2	researchers	researcher	NNS
cord-302316-raf5rlkq	272	3	have	have	VBP
cord-302316-raf5rlkq	272	4	expressed	express	VBN
cord-302316-raf5rlkq	272	5	in	in	IN
cord-302316-raf5rlkq	272	6	a	a	DT
cord-302316-raf5rlkq	272	7	cell	cell	NN
cord-302316-raf5rlkq	272	8	culture	culture	NN
cord-302316-raf5rlkq	272	9	system	system	NN
cord-302316-raf5rlkq	272	10	all	all	DT
cord-302316-raf5rlkq	272	11	of	of	IN
cord-302316-raf5rlkq	272	12	the	the	DT
cord-302316-raf5rlkq	272	13	SARS	SARS	NNP
cord-302316-raf5rlkq	272	14	-	-	HYPH
cord-302316-raf5rlkq	272	15	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	272	16	proteins	protein	NNS
cord-302316-raf5rlkq	272	17	that	that	WDT
cord-302316-raf5rlkq	272	18	were	be	VBD
cord-302316-raf5rlkq	272	19	tagged	tag	VBN
cord-302316-raf5rlkq	272	20	with	with	IN
cord-302316-raf5rlkq	272	21	a	a	DT
cord-302316-raf5rlkq	272	22	recognition	recognition	NN
cord-302316-raf5rlkq	272	23	peptide	peptide	NN
cord-302316-raf5rlkq	272	24	,	,	,
cord-302316-raf5rlkq	272	25	which	which	WDT
cord-302316-raf5rlkq	272	26	allowed	allow	VBD
cord-302316-raf5rlkq	272	27	the	the	DT
cord-302316-raf5rlkq	272	28	isolation	isolation	NN
cord-302316-raf5rlkq	272	29	of	of	IN
cord-302316-raf5rlkq	272	30	cellular	cellular	JJ
cord-302316-raf5rlkq	272	31	proteins	protein	NNS
cord-302316-raf5rlkq	272	32	interacting	interact	VBG
cord-302316-raf5rlkq	272	33	with	with	IN
cord-302316-raf5rlkq	272	34	the	the	DT
cord-302316-raf5rlkq	272	35	viral	viral	JJ
cord-302316-raf5rlkq	272	36	bait	bait	NN
cord-302316-raf5rlkq	272	37	protein	protein	NN
cord-302316-raf5rlkq	272	38	.	.	.
cord-302316-raf5rlkq	273	1	The	the	DT
cord-302316-raf5rlkq	273	2	protein	protein	NN
cord-302316-raf5rlkq	273	3	complexes	complex	NNS
cord-302316-raf5rlkq	273	4	were	be	VBD
cord-302316-raf5rlkq	273	5	collected	collect	VBN
cord-302316-raf5rlkq	273	6	by	by	IN
cord-302316-raf5rlkq	273	7	affinity	affinity	NN
cord-302316-raf5rlkq	273	8	chromatography	chromatography	NN
cord-302316-raf5rlkq	273	9	,	,	,
cord-302316-raf5rlkq	273	10	and	and	CC
cord-302316-raf5rlkq	273	11	the	the	DT
cord-302316-raf5rlkq	273	12	copurified	copurifie	VBN
cord-302316-raf5rlkq	273	13	cellular	cellular	JJ
cord-302316-raf5rlkq	273	14	proteins	protein	NNS
cord-302316-raf5rlkq	273	15	were	be	VBD
cord-302316-raf5rlkq	273	16	identified	identify	VBN
cord-302316-raf5rlkq	273	17	by	by	IN
cord-302316-raf5rlkq	273	18	mass	mass	NN
cord-302316-raf5rlkq	273	19	spectrometry	spectrometry	NN
cord-302316-raf5rlkq	273	20	.	.	.
cord-302316-raf5rlkq	274	1	This	this	DT
cord-302316-raf5rlkq	274	2	approach	approach	NN
cord-302316-raf5rlkq	274	3	yielded	yield	VBD
cord-302316-raf5rlkq	274	4	332	332	CD
cord-302316-raf5rlkq	274	5	highconfidence	highconfidence	NN
cord-302316-raf5rlkq	274	6	protein	protein	NN
cord-302316-raf5rlkq	274	7	-	-	HYPH
cord-302316-raf5rlkq	274	8	protein	protein	NN
cord-302316-raf5rlkq	274	9	interaction	interaction	NN
cord-302316-raf5rlkq	274	10	partners	partner	NNS
cord-302316-raf5rlkq	274	11	.	.	.
cord-302316-raf5rlkq	275	1	The	the	DT
cord-302316-raf5rlkq	275	2	captured	capture	VBN
cord-302316-raf5rlkq	275	3	proteins	protein	NNS
cord-302316-raf5rlkq	275	4	showed	show	VBD
cord-302316-raf5rlkq	275	5	high	high	JJ
cord-302316-raf5rlkq	275	6	expression	expression	NN
cord-302316-raf5rlkq	275	7	in	in	IN
cord-302316-raf5rlkq	275	8	lung	lung	NN
cord-302316-raf5rlkq	275	9	tissue	tissue	NN
cord-302316-raf5rlkq	275	10	,	,	,
cord-302316-raf5rlkq	275	11	and	and	CC
cord-302316-raf5rlkq	275	12	many	many	JJ
cord-302316-raf5rlkq	275	13	of	of	IN
cord-302316-raf5rlkq	275	14	them	-PRON-	PRP
cord-302316-raf5rlkq	275	15	also	also	RB
cord-302316-raf5rlkq	275	16	interacted	interact	VBD
cord-302316-raf5rlkq	275	17	with	with	IN
cord-302316-raf5rlkq	275	18	another	another	DT
cord-302316-raf5rlkq	275	19	lung	lung	NN
cord-302316-raf5rlkq	275	20	pathogen	pathogen	NN
cord-302316-raf5rlkq	275	21	,	,	,
cord-302316-raf5rlkq	275	22	Mycobacterium	Mycobacterium	NNP
cord-302316-raf5rlkq	275	23	tuberculosis	tuberculosis	NN
cord-302316-raf5rlkq	275	24	.	.	.
cord-302316-raf5rlkq	276	1	The	the	DT
cord-302316-raf5rlkq	276	2	viral	viral	JJ
cord-302316-raf5rlkq	276	3	proteins	protein	NNS
cord-302316-raf5rlkq	276	4	interacted	interact	VBN
cord-302316-raf5rlkq	276	5	with	with	IN
cord-302316-raf5rlkq	276	6	proteins	protein	NNS
cord-302316-raf5rlkq	276	7	from	from	IN
cord-302316-raf5rlkq	276	8	multiple	multiple	JJ
cord-302316-raf5rlkq	276	9	innate	innate	JJ
cord-302316-raf5rlkq	276	10	immune	immune	JJ
cord-302316-raf5rlkq	276	11	pathways	pathway	NNS
cord-302316-raf5rlkq	276	12	,	,	,
cord-302316-raf5rlkq	276	13	the	the	DT
cord-302316-raf5rlkq	276	14	host	host	NN
cord-302316-raf5rlkq	276	15	translation	translation	NN
cord-302316-raf5rlkq	276	16	machinery	machinery	NN
cord-302316-raf5rlkq	276	17	,	,	,
cord-302316-raf5rlkq	276	18	the	the	DT
cord-302316-raf5rlkq	276	19	ubiquitin	ubiquitin	NN
cord-302316-raf5rlkq	276	20	ligase	ligase	NN
cord-302316-raf5rlkq	276	21	complex	complex	NN
cord-302316-raf5rlkq	276	22	and	and	CC
cord-302316-raf5rlkq	276	23	proteins	protein	NNS
cord-302316-raf5rlkq	276	24	involved	involve	VBN
cord-302316-raf5rlkq	276	25	in	in	IN
cord-302316-raf5rlkq	276	26	transcriptional	transcriptional	JJ
cord-302316-raf5rlkq	276	27	regulation	regulation	NN
cord-302316-raf5rlkq	276	28	of	of	IN
cord-302316-raf5rlkq	276	29	antiviral	antiviral	JJ
cord-302316-raf5rlkq	276	30	responses	response	NNS
cord-302316-raf5rlkq	276	31	.	.	.
cord-302316-raf5rlkq	277	1	From	from	IN
cord-302316-raf5rlkq	277	2	a	a	DT
cord-302316-raf5rlkq	277	3	search	search	NN
cord-302316-raf5rlkq	277	4	of	of	IN
cord-302316-raf5rlkq	277	5	chemical	chemical	NN
cord-302316-raf5rlkq	277	6	databases	database	NNS
cord-302316-raf5rlkq	277	7	,	,	,
cord-302316-raf5rlkq	277	8	the	the	DT
cord-302316-raf5rlkq	277	9	scientists	scientist	NNS
cord-302316-raf5rlkq	277	10	identified	identify	VBD
cord-302316-raf5rlkq	277	11	69	69	CD
cord-302316-raf5rlkq	277	12	ligands	ligand	NNS
cord-302316-raf5rlkq	277	13	,	,	,
cord-302316-raf5rlkq	277	14	including	include	VBG
cord-302316-raf5rlkq	277	15	FDA	FDA	NNP
cord-302316-raf5rlkq	277	16	-	-	HYPH
cord-302316-raf5rlkq	277	17	approved	approve	VBN
cord-302316-raf5rlkq	277	18	drugs	drug	NNS
cord-302316-raf5rlkq	277	19	and	and	CC
cord-302316-raf5rlkq	277	20	compounds	compound	NNS
cord-302316-raf5rlkq	277	21	currently	currently	RB
cord-302316-raf5rlkq	277	22	used	use	VBN
cord-302316-raf5rlkq	277	23	in	in	IN
cord-302316-raf5rlkq	277	24	clinical	clinical	JJ
cord-302316-raf5rlkq	277	25	trials	trial	NNS
cord-302316-raf5rlkq	277	26	that	that	WDT
cord-302316-raf5rlkq	277	27	interacted	interact	VBD
cord-302316-raf5rlkq	277	28	with	with	IN
cord-302316-raf5rlkq	277	29	the	the	DT
cord-302316-raf5rlkq	277	30	identified	identify	VBN
cord-302316-raf5rlkq	277	31	proteins	protein	NNS
cord-302316-raf5rlkq	277	32	.	.	.
cord-302316-raf5rlkq	278	1	In	in	IN
cord-302316-raf5rlkq	278	2	cell	cell	NN
cord-302316-raf5rlkq	278	3	culture	culture	NN
cord-302316-raf5rlkq	278	4	,	,	,
cord-302316-raf5rlkq	278	5	several	several	JJ
cord-302316-raf5rlkq	278	6	compounds	compound	NNS
cord-302316-raf5rlkq	278	7	showed	show	VBD
cord-302316-raf5rlkq	278	8	inhibitory	inhibitory	JJ
cord-302316-raf5rlkq	278	9	activity	activity	NN
cord-302316-raf5rlkq	278	10	against	against	IN
cord-302316-raf5rlkq	278	11	SARS	SARS	NNP
cord-302316-raf5rlkq	278	12	-	-	HYPH
cord-302316-raf5rlkq	278	13	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	278	14	.	.	.
cord-302316-raf5rlkq	279	1	The	the	DT
cord-302316-raf5rlkq	279	2	candidate	candidate	NN
cord-302316-raf5rlkq	279	3	inhibitors	inhibitor	NNS
cord-302316-raf5rlkq	279	4	included	include	VBD
cord-302316-raf5rlkq	279	5	the	the	DT
cord-302316-raf5rlkq	279	6	following	follow	VBG
cord-302316-raf5rlkq	279	7	:	:	:
cord-302316-raf5rlkq	279	8	antihistamines	antihistamine	NNS
cord-302316-raf5rlkq	279	9	,	,	,
cord-302316-raf5rlkq	279	10	antitussives	antitussive	NNS
cord-302316-raf5rlkq	279	11	,	,	,
cord-302316-raf5rlkq	279	12	antipsychotics	antipsychotic	NNS
cord-302316-raf5rlkq	279	13	and	and	CC
cord-302316-raf5rlkq	279	14	interestingly	interestingly	RB
cord-302316-raf5rlkq	279	15	also	also	RB
cord-302316-raf5rlkq	279	16	hydroxychloroquine	hydroxychloroquine	VBP
cord-302316-raf5rlkq	279	17	(	(	-LRB-
cord-302316-raf5rlkq	279	18	Gordon	Gordon	NNP
cord-302316-raf5rlkq	279	19	et	et	NNP
cord-302316-raf5rlkq	279	20	al	al	NNP
cord-302316-raf5rlkq	279	21	.	.	NNP
cord-302316-raf5rlkq	279	22	,	,	,
cord-302316-raf5rlkq	279	23	2020	2020	CD
cord-302316-raf5rlkq	279	24	)	)	-RRB-
cord-302316-raf5rlkq	279	25	.	.	.
cord-302316-raf5rlkq	280	1	Parallel	parallel	JJ
cord-302316-raf5rlkq	280	2	to	to	IN
cord-302316-raf5rlkq	280	3	these	these	DT
cord-302316-raf5rlkq	280	4	state	state	NN
cord-302316-raf5rlkq	280	5	-	-	HYPH
cord-302316-raf5rlkq	280	6	of	of	IN
cord-302316-raf5rlkq	280	7	-	-	HYPH
cord-302316-raf5rlkq	280	8	the	the	DT
cord-302316-raf5rlkq	280	9	-	-	HYPH
cord-302316-raf5rlkq	280	10	art	art	NN
cord-302316-raf5rlkq	280	11	biochemical	biochemical	JJ
cord-302316-raf5rlkq	280	12	approaches	approach	NNS
cord-302316-raf5rlkq	280	13	,	,	,
cord-302316-raf5rlkq	280	14	one	one	PRP
cord-302316-raf5rlkq	280	15	must	must	MD
cord-302316-raf5rlkq	280	16	also	also	RB
cord-302316-raf5rlkq	280	17	mention	mention	VB
cord-302316-raf5rlkq	280	18	the	the	DT
cord-302316-raf5rlkq	280	19	traditional	traditional	JJ
cord-302316-raf5rlkq	280	20	approaches	approach	NNS
cord-302316-raf5rlkq	280	21	promoted	promote	VBN
cord-302316-raf5rlkq	280	22	in	in	IN
cord-302316-raf5rlkq	280	23	China	China	NNP
cord-302316-raf5rlkq	280	24	.	.	.
cord-302316-raf5rlkq	281	1	According	accord	VBG
cord-302316-raf5rlkq	281	2	to	to	IN
cord-302316-raf5rlkq	281	3	Chinese	chinese	JJ
cord-302316-raf5rlkq	281	4	state	state	NN
cord-302316-raf5rlkq	281	5	media	medium	NNS
cord-302316-raf5rlkq	281	6	,	,	,
cord-302316-raf5rlkq	281	7	Jinhua	Jinhua	NNP
cord-302316-raf5rlkq	281	8	Qinggan	Qinggan	NNP
cord-302316-raf5rlkq	281	9	herbal	herbal	JJ
cord-302316-raf5rlkq	281	10	granules	granule	NNS
cord-302316-raf5rlkq	281	11	accelerated	accelerate	VBN
cord-302316-raf5rlkq	281	12	,	,	,
cord-302316-raf5rlkq	281	13	in	in	IN
cord-302316-raf5rlkq	281	14	a	a	DT
cord-302316-raf5rlkq	281	15	clinical	clinical	JJ
cord-302316-raf5rlkq	281	16	trial	trial	NN
cord-302316-raf5rlkq	281	17	with	with	IN
cord-302316-raf5rlkq	281	18	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	281	19	patients	patient	NNS
cord-302316-raf5rlkq	281	20	,	,	,
cord-302316-raf5rlkq	281	21	conversion	conversion	NN
cord-302316-raf5rlkq	281	22	to	to	IN
cord-302316-raf5rlkq	281	23	a	a	DT
cord-302316-raf5rlkq	281	24	negative	negative	JJ
cord-302316-raf5rlkq	281	25	virus	virus	NN
cord-302316-raf5rlkq	281	26	test	test	NN
cord-302316-raf5rlkq	281	27	within	within	IN
cord-302316-raf5rlkq	281	28	2	2	CD
cord-302316-raf5rlkq	281	29	days	day	NNS
cord-302316-raf5rlkq	281	30	.	.	.
cord-302316-raf5rlkq	282	1	Xuebijing	Xuebijing	NNP
cord-302316-raf5rlkq	282	2	,	,	,
cord-302316-raf5rlkq	282	3	an	an	DT
cord-302316-raf5rlkq	282	4	extract	extract	NN
cord-302316-raf5rlkq	282	5	of	of	IN
cord-302316-raf5rlkq	282	6	five	five	CD
cord-302316-raf5rlkq	282	7	herbs	herb	NNS
cord-302316-raf5rlkq	282	8	,	,	,
cord-302316-raf5rlkq	282	9	reduced	reduce	VBN
cord-302316-raf5rlkq	282	10	mortality	mortality	NN
cord-302316-raf5rlkq	282	11	in	in	IN
cord-302316-raf5rlkq	282	12	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	282	13	by	by	IN
cord-302316-raf5rlkq	282	14	8.8	8.8	CD
cord-302316-raf5rlkq	282	15	%	%	NN
cord-302316-raf5rlkq	282	16	via	via	IN
cord-302316-raf5rlkq	282	17	removing	remove	VBG
cord-302316-raf5rlkq	282	18	blood	blood	NN
cord-302316-raf5rlkq	282	19	stasis	stasis	NN
cord-302316-raf5rlkq	282	20	.	.	.
cord-302316-raf5rlkq	283	1	Details	detail	NNS
cord-302316-raf5rlkq	283	2	of	of	IN
cord-302316-raf5rlkq	283	3	these	these	DT
cord-302316-raf5rlkq	283	4	trials	trial	NNS
cord-302316-raf5rlkq	283	5	are	be	VBP
cord-302316-raf5rlkq	283	6	not	not	RB
cord-302316-raf5rlkq	283	7	yet	yet	RB
cord-302316-raf5rlkq	283	8	available	available	JJ
cord-302316-raf5rlkq	284	1	(	(	-LRB-
cord-302316-raf5rlkq	284	2	Cyranosky	Cyranosky	NNP
cord-302316-raf5rlkq	284	3	,	,	,
cord-302316-raf5rlkq	284	4	2020	2020	CD
cord-302316-raf5rlkq	284	5	)	)	-RRB-
cord-302316-raf5rlkq	284	6	.	.	.
cord-302316-raf5rlkq	285	1	In	in	IN
cord-302316-raf5rlkq	285	2	the	the	DT
cord-302316-raf5rlkq	285	3	emergency	emergency	NN
cord-302316-raf5rlkq	285	4	situation	situation	NN
cord-302316-raf5rlkq	285	5	of	of	IN
cord-302316-raf5rlkq	285	6	the	the	DT
cord-302316-raf5rlkq	285	7	expanding	expand	VBG
cord-302316-raf5rlkq	285	8	pandemic	pandemic	NN
cord-302316-raf5rlkq	285	9	and	and	CC
cord-302316-raf5rlkq	285	10	in	in	IN
cord-302316-raf5rlkq	285	11	an	an	DT
cord-302316-raf5rlkq	285	12	effort	effort	NN
cord-302316-raf5rlkq	285	13	to	to	TO
cord-302316-raf5rlkq	285	14	save	save	VB
cord-302316-raf5rlkq	285	15	lives	life	NNS
cord-302316-raf5rlkq	285	16	,	,	,
cord-302316-raf5rlkq	285	17	severe	severe	JJ
cord-302316-raf5rlkq	285	18	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	285	19	cases	case	NNS
cord-302316-raf5rlkq	285	20	were	be	VBD
cord-302316-raf5rlkq	285	21	frequently	frequently	RB
cord-302316-raf5rlkq	285	22	treated	treat	VBN
cord-302316-raf5rlkq	285	23	with	with	IN
cord-302316-raf5rlkq	285	24	many	many	JJ
cord-302316-raf5rlkq	285	25	different	different	JJ
cord-302316-raf5rlkq	285	26	drugs	drug	NNS
cord-302316-raf5rlkq	285	27	.	.	.
cord-302316-raf5rlkq	286	1	This	this	DT
cord-302316-raf5rlkq	286	2	situation	situation	NN
cord-302316-raf5rlkq	286	3	leads	lead	VBZ
cord-302316-raf5rlkq	286	4	to	to	IN
cord-302316-raf5rlkq	286	5	complex	complex	JJ
cord-302316-raf5rlkq	286	6	drug	drug	NN
cord-302316-raf5rlkq	286	7	interaction	interaction	NN
cord-302316-raf5rlkq	286	8	,	,	,
cord-302316-raf5rlkq	286	9	potential	potential	JJ
cord-302316-raf5rlkq	286	10	detrimental	detrimental	JJ
cord-302316-raf5rlkq	286	11	side	side	NN
cord-302316-raf5rlkq	286	12	effects	effect	NNS
cord-302316-raf5rlkq	286	13	for	for	IN
cord-302316-raf5rlkq	286	14	the	the	DT
cord-302316-raf5rlkq	286	15	patients	patient	NNS
cord-302316-raf5rlkq	286	16	and	and	CC
cord-302316-raf5rlkq	286	17	difficulty	difficulty	NN
cord-302316-raf5rlkq	286	18	to	to	TO
cord-302316-raf5rlkq	286	19	disentangle	disentangle	VB
cord-302316-raf5rlkq	286	20	the	the	DT
cord-302316-raf5rlkq	286	21	effect	effect	NN
cord-302316-raf5rlkq	286	22	of	of	IN
cord-302316-raf5rlkq	286	23	tested	test	VBN
cord-302316-raf5rlkq	286	24	drugs	drug	NNS
cord-302316-raf5rlkq	286	25	in	in	IN
cord-302316-raf5rlkq	286	26	clinical	clinical	JJ
cord-302316-raf5rlkq	286	27	trials	trial	NNS
cord-302316-raf5rlkq	286	28	from	from	IN
cord-302316-raf5rlkq	286	29	concomitant	concomitant	JJ
cord-302316-raf5rlkq	286	30	treatment	treatment	NN
cord-302316-raf5rlkq	286	31	.	.	.
cord-302316-raf5rlkq	287	1	The	the	DT
cord-302316-raf5rlkq	287	2	extent	extent	NN
cord-302316-raf5rlkq	287	3	of	of	IN
cord-302316-raf5rlkq	287	4	the	the	DT
cord-302316-raf5rlkq	287	5	pandemic	pandemic	NN
cord-302316-raf5rlkq	287	6	also	also	RB
cord-302316-raf5rlkq	287	7	led	lead	VBD
cord-302316-raf5rlkq	287	8	to	to	IN
cord-302316-raf5rlkq	287	9	questions	question	NNS
cord-302316-raf5rlkq	287	10	about	about	IN
cord-302316-raf5rlkq	287	11	whether	whether	IN
cord-302316-raf5rlkq	287	12	the	the	DT
cord-302316-raf5rlkq	287	13	drug	drug	NN
cord-302316-raf5rlkq	287	14	treatment	treatment	NN
cord-302316-raf5rlkq	287	15	for	for	IN
cord-302316-raf5rlkq	287	16	existing	exist	VBG
cord-302316-raf5rlkq	287	17	morbidities	morbidity	NNS
cord-302316-raf5rlkq	287	18	of	of	IN
cord-302316-raf5rlkq	287	19	the	the	DT
cord-302316-raf5rlkq	287	20	patients	patient	NNS
cord-302316-raf5rlkq	287	21	increased	increase	VBD
cord-302316-raf5rlkq	287	22	the	the	DT
cord-302316-raf5rlkq	287	23	risk	risk	NN
cord-302316-raf5rlkq	287	24	for	for	IN
cord-302316-raf5rlkq	287	25	SARS	SARS	NNP
cord-302316-raf5rlkq	287	26	-	-	HYPH
cord-302316-raf5rlkq	287	27	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	287	28	infections	infection	NNS
cord-302316-raf5rlkq	287	29	,	,	,
cord-302316-raf5rlkq	287	30	or	or	CC
cord-302316-raf5rlkq	287	31	even	even	RB
cord-302316-raf5rlkq	287	32	led	lead	VBN
cord-302316-raf5rlkq	287	33	to	to	IN
cord-302316-raf5rlkq	287	34	a	a	DT
cord-302316-raf5rlkq	287	35	more	more	RBR
cord-302316-raf5rlkq	287	36	severe	severe	JJ
cord-302316-raf5rlkq	287	37	clinical	clinical	JJ
cord-302316-raf5rlkq	287	38	course	course	NN
cord-302316-raf5rlkq	287	39	.	.	.
cord-302316-raf5rlkq	288	1	From	from	IN
cord-302316-raf5rlkq	288	2	the	the	DT
cord-302316-raf5rlkq	288	3	large	large	JJ
cord-302316-raf5rlkq	288	4	selection	selection	NN
cord-302316-raf5rlkq	288	5	of	of	IN
cord-302316-raf5rlkq	288	6	literature	literature	NN
cord-302316-raf5rlkq	288	7	about	about	IN
cord-302316-raf5rlkq	288	8	treatment	treatment	NN
cord-302316-raf5rlkq	288	9	of	of	IN
cord-302316-raf5rlkq	288	10	other	other	JJ
cord-302316-raf5rlkq	288	11	diseases	disease	NNS
cord-302316-raf5rlkq	288	12	during	during	IN
cord-302316-raf5rlkq	288	13	the	the	DT
cord-302316-raf5rlkq	288	14	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	288	15	epidemic	epidemic	NN
cord-302316-raf5rlkq	288	16	,	,	,
cord-302316-raf5rlkq	288	17	I	-PRON-	PRP
cord-302316-raf5rlkq	288	18	have	have	VBP
cord-302316-raf5rlkq	288	19	selected	select	VBN
cord-302316-raf5rlkq	288	20	one	one	CD
cord-302316-raf5rlkq	288	21	which	which	WDT
cord-302316-raf5rlkq	288	22	was	be	VBD
cord-302316-raf5rlkq	288	23	cited	cite	VBN
cord-302316-raf5rlkq	288	24	as	as	IN
cord-302316-raf5rlkq	288	25	a	a	DT
cord-302316-raf5rlkq	288	26	major	major	JJ
cord-302316-raf5rlkq	288	27	risk	risk	NN
cord-302316-raf5rlkq	288	28	for	for	IN
cord-302316-raf5rlkq	288	29	developing	develop	VBG
cord-302316-raf5rlkq	288	30	severe	severe	JJ
cord-302316-raf5rlkq	288	31	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	288	32	,	,	,
cord-302316-raf5rlkq	288	33	namely	namely	RB
cord-302316-raf5rlkq	288	34	hypertension	hypertension	NN
cord-302316-raf5rlkq	288	35	.	.	.
cord-302316-raf5rlkq	289	1	ACE-2	ACE-2	NNP
cord-302316-raf5rlkq	289	2	is	be	VBZ
cord-302316-raf5rlkq	289	3	the	the	DT
cord-302316-raf5rlkq	289	4	cellular	cellular	JJ
cord-302316-raf5rlkq	289	5	receptor	receptor	NN
cord-302316-raf5rlkq	289	6	of	of	IN
cord-302316-raf5rlkq	289	7	SARS	SARS	NNP
cord-302316-raf5rlkq	289	8	-	-	HYPH
cord-302316-raf5rlkq	289	9	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	289	10	,	,	,
cord-302316-raf5rlkq	289	11	and	and	CC
cord-302316-raf5rlkq	289	12	it	-PRON-	PRP
cord-302316-raf5rlkq	289	13	is	be	VBZ
cord-302316-raf5rlkq	289	14	the	the	DT
cord-302316-raf5rlkq	289	15	target	target	NN
cord-302316-raf5rlkq	289	16	for	for	IN
cord-302316-raf5rlkq	289	17	a	a	DT
cord-302316-raf5rlkq	289	18	class	class	NN
cord-302316-raf5rlkq	289	19	of	of	IN
cord-302316-raf5rlkq	289	20	antihypertensive	antihypertensive	JJ
cord-302316-raf5rlkq	289	21	drugs	drug	NNS
cord-302316-raf5rlkq	289	22	that	that	WDT
cord-302316-raf5rlkq	289	23	block	block	VBP
cord-302316-raf5rlkq	289	24	this	this	DT
cord-302316-raf5rlkq	289	25	enzyme	enzyme	NN
cord-302316-raf5rlkq	289	26	,	,	,
cord-302316-raf5rlkq	289	27	which	which	WDT
cord-302316-raf5rlkq	289	28	leads	lead	VBZ
cord-302316-raf5rlkq	289	29	to	to	IN
cord-302316-raf5rlkq	289	30	its	-PRON-	PRP$
cord-302316-raf5rlkq	289	31	increased	increased	JJ
cord-302316-raf5rlkq	289	32	expression	expression	NN
cord-302316-raf5rlkq	289	33	.	.	.
cord-302316-raf5rlkq	290	1	Since	since	IN
cord-302316-raf5rlkq	290	2	hypertension	hypertension	NN
cord-302316-raf5rlkq	290	3	has	have	VBZ
cord-302316-raf5rlkq	290	4	been	be	VBN
cord-302316-raf5rlkq	290	5	frequently	frequently	RB
cord-302316-raf5rlkq	290	6	reported	report	VBN
cord-302316-raf5rlkq	290	7	as	as	IN
cord-302316-raf5rlkq	290	8	a	a	DT
cord-302316-raf5rlkq	290	9	risk	risk	NN
cord-302316-raf5rlkq	290	10	factor	factor	NN
cord-302316-raf5rlkq	290	11	in	in	IN
cord-302316-raf5rlkq	290	12	severe	severe	JJ
cord-302316-raf5rlkq	290	13	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	290	14	infections	infection	NNS
cord-302316-raf5rlkq	290	15	,	,	,
cord-302316-raf5rlkq	290	16	the	the	DT
cord-302316-raf5rlkq	290	17	safety	safety	NN
cord-302316-raf5rlkq	290	18	of	of	IN
cord-302316-raf5rlkq	290	19	antihypertensive	antihypertensive	JJ
cord-302316-raf5rlkq	290	20	drugs	drug	NNS
cord-302316-raf5rlkq	290	21	during	during	IN
cord-302316-raf5rlkq	290	22	the	the	DT
cord-302316-raf5rlkq	290	23	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	290	24	epidemic	epidemic	NN
cord-302316-raf5rlkq	290	25	has	have	VBZ
cord-302316-raf5rlkq	290	26	been	be	VBN
cord-302316-raf5rlkq	290	27	questioned	question	VBN
cord-302316-raf5rlkq	290	28	.	.	.
cord-302316-raf5rlkq	291	1	Cardiologists	cardiologist	NNS
cord-302316-raf5rlkq	291	2	studied	study	VBD
cord-302316-raf5rlkq	291	3	this	this	DT
cord-302316-raf5rlkq	291	4	question	question	NN
cord-302316-raf5rlkq	291	5	in	in	IN
cord-302316-raf5rlkq	291	6	New	New	NNP
cord-302316-raf5rlkq	291	7	York	York	NNP
cord-302316-raf5rlkq	291	8	City	City	NNP
cord-302316-raf5rlkq	291	9	,	,	,
cord-302316-raf5rlkq	291	10	an	an	DT
cord-302316-raf5rlkq	291	11	epicentre	epicentre	NN
cord-302316-raf5rlkq	291	12	of	of	IN
cord-302316-raf5rlkq	291	13	this	this	DT
cord-302316-raf5rlkq	291	14	pandemic	pandemic	NN
cord-302316-raf5rlkq	291	15	.	.	.
cord-302316-raf5rlkq	292	1	More	More	JJR
cord-302316-raf5rlkq	292	2	than	than	IN
cord-302316-raf5rlkq	292	3	12'000	12'000	CD
cord-302316-raf5rlkq	292	4	cases	case	NNS
cord-302316-raf5rlkq	292	5	were	be	VBD
cord-302316-raf5rlkq	292	6	investigated	investigate	VBN
cord-302316-raf5rlkq	292	7	,	,	,
cord-302316-raf5rlkq	292	8	nearly	nearly	RB
cord-302316-raf5rlkq	292	9	half	half	NN
cord-302316-raf5rlkq	292	10	of	of	IN
cord-302316-raf5rlkq	292	11	them	-PRON-	PRP
cord-302316-raf5rlkq	292	12	had	have	VBD
cord-302316-raf5rlkq	292	13	a	a	DT
cord-302316-raf5rlkq	292	14	positive	positive	JJ
cord-302316-raf5rlkq	292	15	viral	viral	JJ
cord-302316-raf5rlkq	292	16	test	test	NN
cord-302316-raf5rlkq	292	17	.	.	.
cord-302316-raf5rlkq	293	1	From	from	IN
cord-302316-raf5rlkq	293	2	these	these	DT
cord-302316-raf5rlkq	293	3	6'000	6'000	CD
cord-302316-raf5rlkq	293	4	cases	case	NNS
cord-302316-raf5rlkq	293	5	,	,	,
cord-302316-raf5rlkq	293	6	1'000	1'000	CD
cord-302316-raf5rlkq	293	7	had	have	VBD
cord-302316-raf5rlkq	293	8	severe	severe	JJ
cord-302316-raf5rlkq	293	9	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	293	10	,	,	,
cord-302316-raf5rlkq	293	11	726	726	CD
cord-302316-raf5rlkq	293	12	were	be	VBD
cord-302316-raf5rlkq	293	13	in	in	IN
cord-302316-raf5rlkq	293	14	intensive	intensive	JJ
cord-302316-raf5rlkq	293	15	care	care	NN
cord-302316-raf5rlkq	293	16	,	,	,
cord-302316-raf5rlkq	293	17	and	and	CC
cord-302316-raf5rlkq	293	18	447	447	CD
cord-302316-raf5rlkq	293	19	died	die	VBD
cord-302316-raf5rlkq	293	20	.	.	.
cord-302316-raf5rlkq	294	1	The	the	DT
cord-302316-raf5rlkq	294	2	researchers	researcher	NNS
cord-302316-raf5rlkq	294	3	ruled	rule	VBD
cord-302316-raf5rlkq	294	4	out	out	RP
cord-302316-raf5rlkq	294	5	a	a	DT
cord-302316-raf5rlkq	294	6	significant	significant	JJ
cord-302316-raf5rlkq	294	7	effect	effect	NN
cord-302316-raf5rlkq	294	8	from	from	IN
cord-302316-raf5rlkq	294	9	any	any	DT
cord-302316-raf5rlkq	294	10	of	of	IN
cord-302316-raf5rlkq	294	11	five	five	CD
cord-302316-raf5rlkq	294	12	common	common	JJ
cord-302316-raf5rlkq	294	13	antihypertensive	antihypertensive	JJ
cord-302316-raf5rlkq	294	14	drugs	drug	NNS
cord-302316-raf5rlkq	294	15	favouring	favour	VBG
cord-302316-raf5rlkq	294	16	infection	infection	NN
cord-302316-raf5rlkq	294	17	(	(	-LRB-
cord-302316-raf5rlkq	294	18	i.e.	i.e.	FW
cord-302316-raf5rlkq	294	19	from	from	IN
cord-302316-raf5rlkq	294	20	being	be	VBG
cord-302316-raf5rlkq	294	21	tested	test	VBN
cord-302316-raf5rlkq	294	22	positive	positive	JJ
cord-302316-raf5rlkq	294	23	for	for	IN
cord-302316-raf5rlkq	294	24	SARS	SARS	NNP
cord-302316-raf5rlkq	294	25	-	-	HYPH
cord-302316-raf5rlkq	294	26	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	294	27	)	)	-RRB-
cord-302316-raf5rlkq	294	28	or	or	CC
cord-302316-raf5rlkq	294	29	that	that	IN
cord-302316-raf5rlkq	294	30	they	-PRON-	PRP
cord-302316-raf5rlkq	294	31	increase	increase	VBP
cord-302316-raf5rlkq	294	32	the	the	DT
cord-302316-raf5rlkq	294	33	likelihood	likelihood	NN
cord-302316-raf5rlkq	294	34	of	of	IN
cord-302316-raf5rlkq	294	35	inducing	induce	VBG
cord-302316-raf5rlkq	294	36	severe	severe	JJ
cord-302316-raf5rlkq	294	37	COVID-19	covid-19	NN
cord-302316-raf5rlkq	294	38	.	.	.
cord-302316-raf5rlkq	295	1	Patients	patient	NNS
cord-302316-raf5rlkq	295	2	taking	take	VBG
cord-302316-raf5rlkq	295	3	beta	beta	NN
cord-302316-raf5rlkq	295	4	-	-	HYPH
cord-302316-raf5rlkq	295	5	blockers	blocker	NNS
cord-302316-raf5rlkq	295	6	even	even	RB
cord-302316-raf5rlkq	295	7	had	have	VBD
cord-302316-raf5rlkq	295	8	a	a	DT
cord-302316-raf5rlkq	295	9	significant	significant	JJ
cord-302316-raf5rlkq	295	10	,	,	,
cord-302316-raf5rlkq	295	11	although	although	IN
cord-302316-raf5rlkq	295	12	marginally	marginally	RB
cord-302316-raf5rlkq	295	13	lower	low	JJR
cord-302316-raf5rlkq	295	14	,	,	,
cord-302316-raf5rlkq	295	15	risk	risk	NN
cord-302316-raf5rlkq	295	16	of	of	IN
cord-302316-raf5rlkq	295	17	testing	test	VBG
cord-302316-raf5rlkq	295	18	positive	positive	JJ
cord-302316-raf5rlkq	295	19	for	for	IN
cord-302316-raf5rlkq	295	20	the	the	DT
cord-302316-raf5rlkq	295	21	virus	virus	NN
cord-302316-raf5rlkq	296	1	(	(	-LRB-
cord-302316-raf5rlkq	296	2	Reynolds	Reynolds	NNP
cord-302316-raf5rlkq	296	3	et	et	NNP
cord-302316-raf5rlkq	296	4	al	al	NNP
cord-302316-raf5rlkq	296	5	.	.	NNP
cord-302316-raf5rlkq	296	6	,	,	,
cord-302316-raf5rlkq	296	7	2020	2020	CD
cord-302316-raf5rlkq	296	8	)	)	-RRB-
cord-302316-raf5rlkq	296	9	.	.	.
cord-302316-raf5rlkq	297	1	The	the	DT
cord-302316-raf5rlkq	297	2	same	same	JJ
cord-302316-raf5rlkq	297	3	question	question	NN
cord-302316-raf5rlkq	297	4	was	be	VBD
cord-302316-raf5rlkq	297	5	addressed	address	VBN
cord-302316-raf5rlkq	297	6	in	in	IN
cord-302316-raf5rlkq	297	7	another	another	DT
cord-302316-raf5rlkq	297	8	epicentre	epicentre	NN
cord-302316-raf5rlkq	297	9	of	of	IN
cord-302316-raf5rlkq	297	10	the	the	DT
cord-302316-raf5rlkq	297	11	pandemic	pandemic	NN
cord-302316-raf5rlkq	297	12	,	,	,
cord-302316-raf5rlkq	297	13	in	in	IN
cord-302316-raf5rlkq	297	14	Lombardy	Lombardy	NNP
cord-302316-raf5rlkq	297	15	,	,	,
cord-302316-raf5rlkq	297	16	with	with	IN
cord-302316-raf5rlkq	297	17	a	a	DT
cord-302316-raf5rlkq	297	18	large	large	JJ
cord-302316-raf5rlkq	297	19	case	case	NN
cord-302316-raf5rlkq	297	20	-	-	HYPH
cord-302316-raf5rlkq	297	21	control	control	NN
cord-302316-raf5rlkq	297	22	study	study	NN
cord-302316-raf5rlkq	297	23	involving	involve	VBG
cord-302316-raf5rlkq	297	24	6'272	6'272	CD
cord-302316-raf5rlkq	297	25	COVID-19	covid-19	CD
cord-302316-raf5rlkq	297	26	patients	patient	NNS
cord-302316-raf5rlkq	297	27	and	and	CC
cord-302316-raf5rlkq	297	28	30'000	30'000	CD
cord-302316-raf5rlkq	297	29	controls	control	NNS
cord-302316-raf5rlkq	297	30	,	,	,
cord-302316-raf5rlkq	297	31	matched	match	VBN
cord-302316-raf5rlkq	297	32	for	for	IN
cord-302316-raf5rlkq	297	33	age	age	NN
cord-302316-raf5rlkq	297	34	,	,	,
cord-302316-raf5rlkq	297	35	sex	sex	NN
cord-302316-raf5rlkq	297	36	and	and	CC
cord-302316-raf5rlkq	297	37	municipality	municipality	NN
cord-302316-raf5rlkq	297	38	.	.	.
cord-302316-raf5rlkq	298	1	Angiotensin	angiotensin	NN
cord-302316-raf5rlkq	298	2	II	II	NNP
cord-302316-raf5rlkq	298	3	receptor	receptor	NN
cord-302316-raf5rlkq	298	4	blockers	blocker	NNS
cord-302316-raf5rlkq	298	5	(	(	-LRB-
cord-302316-raf5rlkq	298	6	ARB	ARB	NNP
cord-302316-raf5rlkq	298	7	)	)	-RRB-
cord-302316-raf5rlkq	298	8	and	and	CC
cord-302316-raf5rlkq	298	9	ACE	ACE	NNP
cord-302316-raf5rlkq	298	10	inhibitors	inhibitor	NNS
cord-302316-raf5rlkq	298	11	(	(	-LRB-
cord-302316-raf5rlkq	298	12	ACEI	ACEI	NNP
cord-302316-raf5rlkq	298	13	)	)	-RRB-
cord-302316-raf5rlkq	298	14	,	,	,
cord-302316-raf5rlkq	298	15	common	common	JJ
cord-302316-raf5rlkq	298	16	antihypertensive	antihypertensive	JJ
cord-302316-raf5rlkq	298	17	drugs	drug	NNS
cord-302316-raf5rlkq	298	18	,	,	,
cord-302316-raf5rlkq	298	19	were	be	VBD
cord-302316-raf5rlkq	298	20	more	more	RBR
cord-302316-raf5rlkq	298	21	frequently	frequently	RB
cord-302316-raf5rlkq	298	22	used	use	VBN
cord-302316-raf5rlkq	298	23	by	by	IN
cord-302316-raf5rlkq	298	24	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	298	25	patients	patient	NNS
cord-302316-raf5rlkq	298	26	than	than	IN
cord-302316-raf5rlkq	298	27	in	in	IN
cord-302316-raf5rlkq	298	28	the	the	DT
cord-302316-raf5rlkq	298	29	control	control	NN
cord-302316-raf5rlkq	298	30	group	group	NN
cord-302316-raf5rlkq	298	31	(	(	-LRB-
cord-302316-raf5rlkq	298	32	ARB	ARB	NNP
cord-302316-raf5rlkq	298	33	:	:	:
cord-302316-raf5rlkq	298	34	22	22	CD
cord-302316-raf5rlkq	298	35	vs	vs	IN
cord-302316-raf5rlkq	298	36	19	19	CD
cord-302316-raf5rlkq	298	37	%	%	NN
cord-302316-raf5rlkq	298	38	;	;	:
cord-302316-raf5rlkq	298	39	ACEI	ACEI	NNP
cord-302316-raf5rlkq	298	40	:	:	:
cord-302316-raf5rlkq	298	41	24	24	CD
cord-302316-raf5rlkq	298	42	vs.	vs.	CC
cord-302316-raf5rlkq	298	43	21	21	CD
cord-302316-raf5rlkq	298	44	%	%	NN
cord-302316-raf5rlkq	298	45	)	)	-RRB-
cord-302316-raf5rlkq	298	46	.	.	.
cord-302316-raf5rlkq	299	1	After	after	IN
cord-302316-raf5rlkq	299	2	multivariate	multivariate	JJ
cord-302316-raf5rlkq	299	3	analysis	analysis	NN
cord-302316-raf5rlkq	299	4	,	,	,
cord-302316-raf5rlkq	299	5	neither	neither	CC
cord-302316-raf5rlkq	299	6	ARB	ARB	NNP
cord-302316-raf5rlkq	299	7	,	,	,
cord-302316-raf5rlkq	299	8	ACEI	ACEI	NNP
cord-302316-raf5rlkq	299	9	nor	nor	CC
cord-302316-raf5rlkq	299	10	other	other	JJ
cord-302316-raf5rlkq	299	11	common	common	JJ
cord-302316-raf5rlkq	299	12	antihypertension	antihypertension	NN
cord-302316-raf5rlkq	299	13	drugs	drug	NNS
cord-302316-raf5rlkq	299	14	had	have	VBD
cord-302316-raf5rlkq	299	15	a	a	DT
cord-302316-raf5rlkq	299	16	significant	significant	JJ
cord-302316-raf5rlkq	299	17	association	association	NN
cord-302316-raf5rlkq	299	18	with	with	IN
cord-302316-raf5rlkq	299	19	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	299	20	.	.	.
cord-302316-raf5rlkq	300	1	The	the	DT
cord-302316-raf5rlkq	300	2	Italian	italian	JJ
cord-302316-raf5rlkq	300	3	study	study	NN
cord-302316-raf5rlkq	300	4	confirmed	confirm	VBD
cord-302316-raf5rlkq	300	5	the	the	DT
cord-302316-raf5rlkq	300	6	Chinese	chinese	JJ
cord-302316-raf5rlkq	300	7	observations	observation	NNS
cord-302316-raf5rlkq	300	8	that	that	IN
cord-302316-raf5rlkq	300	9	the	the	DT
cord-302316-raf5rlkq	300	10	COVID-19	covid-19	CD
cord-302316-raf5rlkq	300	11	patients	patient	NNS
cord-302316-raf5rlkq	300	12	were	be	VBD
cord-302316-raf5rlkq	300	13	in	in	IN
cord-302316-raf5rlkq	300	14	poorer	poor	JJR
cord-302316-raf5rlkq	300	15	health	health	NN
cord-302316-raf5rlkq	300	16	than	than	IN
cord-302316-raf5rlkq	300	17	the	the	DT
cord-302316-raf5rlkq	300	18	general	general	JJ
cord-302316-raf5rlkq	300	19	population	population	NN
cord-302316-raf5rlkq	300	20	matched	match	VBN
cord-302316-raf5rlkq	300	21	for	for	IN
cord-302316-raf5rlkq	300	22	age	age	NN
cord-302316-raf5rlkq	300	23	,	,	,
cord-302316-raf5rlkq	300	24	particularly	particularly	RB
cord-302316-raf5rlkq	300	25	with	with	IN
cord-302316-raf5rlkq	300	26	respect	respect	NN
cord-302316-raf5rlkq	300	27	to	to	IN
cord-302316-raf5rlkq	300	28	previous	previous	JJ
cord-302316-raf5rlkq	300	29	hospitalization	hospitalization	NN
cord-302316-raf5rlkq	300	30	for	for	IN
cord-302316-raf5rlkq	300	31	cardiovascular	cardiovascular	JJ
cord-302316-raf5rlkq	300	32	diseases	disease	NNS
cord-302316-raf5rlkq	300	33	(	(	-LRB-
cord-302316-raf5rlkq	300	34	Mancia	Mancia	NNP
cord-302316-raf5rlkq	300	35	et	et	NNP
cord-302316-raf5rlkq	300	36	al	al	NNP
cord-302316-raf5rlkq	300	37	.	.	NNP
cord-302316-raf5rlkq	300	38	,	,	,
cord-302316-raf5rlkq	300	39	2020	2020	CD
cord-302316-raf5rlkq	300	40	)	)	-RRB-
cord-302316-raf5rlkq	300	41	.	.	.
cord-302316-raf5rlkq	301	1	These	these	DT
cord-302316-raf5rlkq	301	2	conclusions	conclusion	NNS
cord-302316-raf5rlkq	301	3	were	be	VBD
cord-302316-raf5rlkq	301	4	corroborated	corroborate	VBN
cord-302316-raf5rlkq	301	5	in	in	IN
cord-302316-raf5rlkq	301	6	another	another	DT
cord-302316-raf5rlkq	301	7	study	study	NN
cord-302316-raf5rlkq	301	8	in	in	IN
cord-302316-raf5rlkq	301	9	which	which	WDT
cord-302316-raf5rlkq	301	10	8910	8910	CD
cord-302316-raf5rlkq	301	11	hospitalized	hospitalize	VBD
cord-302316-raf5rlkq	301	12	COVID-19	covid-19	CD
cord-302316-raf5rlkq	301	13	patients	patient	NNS
cord-302316-raf5rlkq	301	14	were	be	VBD
cord-302316-raf5rlkq	301	15	compared	compare	VBN
cord-302316-raf5rlkq	301	16	for	for	IN
cord-302316-raf5rlkq	301	17	outcome	outcome	NN
cord-302316-raf5rlkq	301	18	,	,	,
cord-302316-raf5rlkq	301	19	namely	namely	RB
cord-302316-raf5rlkq	301	20	death	death	NN
cord-302316-raf5rlkq	301	21	(	(	-LRB-
cord-302316-raf5rlkq	301	22	n	n	NN
cord-302316-raf5rlkq	301	23	=	=	SYM
cord-302316-raf5rlkq	301	24	515	515	CD
cord-302316-raf5rlkq	301	25	)	)	-RRB-
cord-302316-raf5rlkq	301	26	versus	versus	IN
cord-302316-raf5rlkq	301	27	survival	survival	NN
cord-302316-raf5rlkq	301	28	to	to	TO
cord-302316-raf5rlkq	301	29	discharge	discharge	NN
cord-302316-raf5rlkq	301	30	(	(	-LRB-
cord-302316-raf5rlkq	301	31	n	n	NN
cord-302316-raf5rlkq	301	32	=	=	SYM
cord-302316-raf5rlkq	301	33	8395	8395	CD
cord-302316-raf5rlkq	301	34	patients	patient	NNS
cord-302316-raf5rlkq	301	35	)	)	-RRB-
cord-302316-raf5rlkq	301	36	.	.	.
cord-302316-raf5rlkq	302	1	The	the	DT
cord-302316-raf5rlkq	302	2	cases	case	NNS
cord-302316-raf5rlkq	302	3	were	be	VBD
cord-302316-raf5rlkq	302	4	from	from	IN
cord-302316-raf5rlkq	302	5	hospitals	hospital	NNS
cord-302316-raf5rlkq	302	6	in	in	IN
cord-302316-raf5rlkq	302	7	North	North	NNP
cord-302316-raf5rlkq	302	8	America	America	NNP
cord-302316-raf5rlkq	302	9	,	,	,
cord-302316-raf5rlkq	302	10	Europe	Europe	NNP
cord-302316-raf5rlkq	302	11	and	and	CC
cord-302316-raf5rlkq	302	12	Asia	Asia	NNP
cord-302316-raf5rlkq	302	13	.	.	.
cord-302316-raf5rlkq	303	1	In	in	IN
cord-302316-raf5rlkq	303	2	multivariate	multivariate	JJ
cord-302316-raf5rlkq	303	3	analysis	analysis	NN
cord-302316-raf5rlkq	303	4	:	:	:
cord-302316-raf5rlkq	303	5	age	age	NN
cord-302316-raf5rlkq	303	6	greater	great	JJR
cord-302316-raf5rlkq	303	7	than	than	IN
cord-302316-raf5rlkq	303	8	65	65	CD
cord-302316-raf5rlkq	303	9	y	y	NN
cord-302316-raf5rlkq	303	10	,	,	,
cord-302316-raf5rlkq	303	11	coronary	coronary	JJ
cord-302316-raf5rlkq	303	12	artery	artery	NN
cord-302316-raf5rlkq	303	13	disease	disease	NN
cord-302316-raf5rlkq	303	14	,	,	,
cord-302316-raf5rlkq	303	15	congestive	congestive	JJ
cord-302316-raf5rlkq	303	16	heart	heart	NN
cord-302316-raf5rlkq	303	17	failure	failure	NN
cord-302316-raf5rlkq	303	18	,	,	,
cord-302316-raf5rlkq	303	19	cardiac	cardiac	JJ
cord-302316-raf5rlkq	303	20	arrhythmia	arrhythmia	NN
cord-302316-raf5rlkq	303	21	,	,	,
cord-302316-raf5rlkq	303	22	chronic	chronic	JJ
cord-302316-raf5rlkq	303	23	obstructive	obstructive	JJ
cord-302316-raf5rlkq	303	24	pulmonary	pulmonary	JJ
cord-302316-raf5rlkq	303	25	disease	disease	NN
cord-302316-raf5rlkq	303	26	and	and	CC
cord-302316-raf5rlkq	303	27	current	current	JJ
cord-302316-raf5rlkq	303	28	smoking	smoking	NN
cord-302316-raf5rlkq	303	29	were	be	VBD
cord-302316-raf5rlkq	303	30	all	all	DT
cord-302316-raf5rlkq	303	31	associated	associate	VBN
cord-302316-raf5rlkq	303	32	with	with	IN
cord-302316-raf5rlkq	303	33	a	a	DT
cord-302316-raf5rlkq	303	34	higher	high	JJR
cord-302316-raf5rlkq	303	35	risk	risk	NN
cord-302316-raf5rlkq	303	36	of	of	IN
cord-302316-raf5rlkq	303	37	in	in	IN
cord-302316-raf5rlkq	303	38	-	-	HYPH
cord-302316-raf5rlkq	303	39	hospital	hospital	NN
cord-302316-raf5rlkq	303	40	death	death	NN
cord-302316-raf5rlkq	303	41	.	.	.
cord-302316-raf5rlkq	304	1	ACE	ace	NN
cord-302316-raf5rlkq	304	2	inhibitor	inhibitor	NN
cord-302316-raf5rlkq	304	3	use	use	NN
cord-302316-raf5rlkq	304	4	was	be	VBD
cord-302316-raf5rlkq	304	5	associated	associate	VBN
cord-302316-raf5rlkq	304	6	with	with	IN
cord-302316-raf5rlkq	304	7	a	a	DT
cord-302316-raf5rlkq	304	8	significantly	significantly	RB
cord-302316-raf5rlkq	304	9	lower	low	JJR
cord-302316-raf5rlkq	304	10	risk	risk	NN
cord-302316-raf5rlkq	304	11	of	of	IN
cord-302316-raf5rlkq	304	12	death	death	NN
cord-302316-raf5rlkq	304	13	,	,	,
cord-302316-raf5rlkq	304	14	but	but	CC
cord-302316-raf5rlkq	304	15	might	may	MD
cord-302316-raf5rlkq	304	16	be	be	VB
cord-302316-raf5rlkq	304	17	a	a	DT
cord-302316-raf5rlkq	304	18	coincidental	coincidental	JJ
cord-302316-raf5rlkq	304	19	observation	observation	NN
cord-302316-raf5rlkq	304	20	for	for	IN
cord-302316-raf5rlkq	304	21	multiple	multiple	JJ
cord-302316-raf5rlkq	304	22	comparisons	comparison	NNS
cord-302316-raf5rlkq	304	23	.	.	.
cord-302316-raf5rlkq	305	1	However	however	RB
cord-302316-raf5rlkq	305	2	,	,	,
cord-302316-raf5rlkq	305	3	the	the	DT
cord-302316-raf5rlkq	305	4	data	datum	NNS
cord-302316-raf5rlkq	305	5	do	do	VBP
cord-302316-raf5rlkq	305	6	not	not	RB
cord-302316-raf5rlkq	305	7	provide	provide	VB
cord-302316-raf5rlkq	305	8	evidence	evidence	NN
cord-302316-raf5rlkq	305	9	for	for	IN
cord-302316-raf5rlkq	305	10	a	a	DT
cord-302316-raf5rlkq	305	11	detrimental	detrimental	JJ
cord-302316-raf5rlkq	305	12	effect	effect	NN
cord-302316-raf5rlkq	305	13	of	of	IN
cord-302316-raf5rlkq	305	14	antihypertensive	antihypertensive	JJ
cord-302316-raf5rlkq	305	15	drugs	drug	NNS
cord-302316-raf5rlkq	305	16	on	on	IN
cord-302316-raf5rlkq	305	17	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	305	18	mortality	mortality	NN
cord-302316-raf5rlkq	305	19	(	(	-LRB-
cord-302316-raf5rlkq	305	20	Mehra	Mehra	NNP
cord-302316-raf5rlkq	305	21	et	et	NNP
cord-302316-raf5rlkq	305	22	al	al	NNP
cord-302316-raf5rlkq	305	23	.	.	NNP
cord-302316-raf5rlkq	305	24	,	,	,
cord-302316-raf5rlkq	305	25	2020	2020	CD
cord-302316-raf5rlkq	305	26	)	)	-RRB-
cord-302316-raf5rlkq	305	27	.	.	.
cord-302316-raf5rlkq	305	28	 	 	_SP
cord-302316-raf5rlkq	306	1	Until	until	IN
cord-302316-raf5rlkq	306	2	now	now	RB
cord-302316-raf5rlkq	306	3	no	no	DT
cord-302316-raf5rlkq	306	4	prospective	prospective	NN
cord-302316-raf5rlkq	306	5	,	,	,
cord-302316-raf5rlkq	306	6	sufficiently	sufficiently	RB
cord-302316-raf5rlkq	306	7	powered	power	VBN
cord-302316-raf5rlkq	306	8	,	,	,
cord-302316-raf5rlkq	306	9	controlled	control	VBN
cord-302316-raf5rlkq	306	10	clinical	clinical	JJ
cord-302316-raf5rlkq	306	11	trial	trial	NN
cord-302316-raf5rlkq	306	12	that	that	WDT
cord-302316-raf5rlkq	306	13	has	have	VBZ
cord-302316-raf5rlkq	306	14	been	be	VBN
cord-302316-raf5rlkq	306	15	reported	report	VBN
cord-302316-raf5rlkq	306	16	in	in	IN
cord-302316-raf5rlkq	306	17	a	a	DT
cord-302316-raf5rlkq	306	18	peer	peer	NN
cord-302316-raf5rlkq	306	19	-	-	HYPH
cord-302316-raf5rlkq	306	20	reviewed	review	VBN
cord-302316-raf5rlkq	306	21	publication	publication	NN
cord-302316-raf5rlkq	306	22	has	have	VBZ
cord-302316-raf5rlkq	306	23	reported	report	VBN
cord-302316-raf5rlkq	306	24	an	an	DT
cord-302316-raf5rlkq	306	25	impact	impact	NN
cord-302316-raf5rlkq	306	26	of	of	IN
cord-302316-raf5rlkq	306	27	drug	drug	NN
cord-302316-raf5rlkq	306	28	interventions	intervention	NNS
cord-302316-raf5rlkq	306	29	on	on	IN
cord-302316-raf5rlkq	306	30	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	306	31	mortality	mortality	NN
cord-302316-raf5rlkq	306	32	,	,	,
cord-302316-raf5rlkq	306	33	despite	despite	IN
cord-302316-raf5rlkq	306	34	more	more	JJR
cord-302316-raf5rlkq	306	35	than	than	IN
cord-302316-raf5rlkq	306	36	1'000	1'000	CD
cord-302316-raf5rlkq	306	37	trials	trial	NNS
cord-302316-raf5rlkq	306	38	registered	register	VBN
cord-302316-raf5rlkq	306	39	on	on	IN
cord-302316-raf5rlkq	306	40	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-302316-raf5rlkq	306	41	,	,	,
cord-302316-raf5rlkq	306	42	including	include	VBG
cord-302316-raf5rlkq	306	43	600	600	CD
cord-302316-raf5rlkq	306	44	intervention	intervention	NN
cord-302316-raf5rlkq	306	45	studies	study	NNS
cord-302316-raf5rlkq	306	46	.	.	.
cord-302316-raf5rlkq	307	1	Technical	technical	JJ
cord-302316-raf5rlkq	307	2	problems	problem	NNS
cord-302316-raf5rlkq	307	3	,	,	,
cord-302316-raf5rlkq	307	4	such	such	JJ
cord-302316-raf5rlkq	307	5	as	as	IN
cord-302316-raf5rlkq	307	6	the	the	DT
cord-302316-raf5rlkq	307	7	lack	lack	NN
cord-302316-raf5rlkq	307	8	of	of	IN
cord-302316-raf5rlkq	307	9	true	true	JJ
cord-302316-raf5rlkq	307	10	control	control	NN
cord-302316-raf5rlkq	307	11	groups	group	NNS
cord-302316-raf5rlkq	307	12	,	,	,
cord-302316-raf5rlkq	307	13	concomitant	concomitant	JJ
cord-302316-raf5rlkq	307	14	other	other	JJ
cord-302316-raf5rlkq	307	15	treatments	treatment	NNS
cord-302316-raf5rlkq	307	16	,	,	,
cord-302316-raf5rlkq	307	17	make	make	VB
cord-302316-raf5rlkq	307	18	it	-PRON-	PRP
cord-302316-raf5rlkq	307	19	difficult	difficult	JJ
cord-302316-raf5rlkq	307	20	to	to	TO
cord-302316-raf5rlkq	307	21	disentangle	disentangle	VB
cord-302316-raf5rlkq	307	22	the	the	DT
cord-302316-raf5rlkq	307	23	effects	effect	NNS
cord-302316-raf5rlkq	307	24	.	.	.
cord-302316-raf5rlkq	308	1	Many	many	JJ
cord-302316-raf5rlkq	308	2	trials	trial	NNS
cord-302316-raf5rlkq	308	3	were	be	VBD
cord-302316-raf5rlkq	308	4	started	start	VBN
cord-302316-raf5rlkq	308	5	before	before	IN
cord-302316-raf5rlkq	308	6	the	the	DT
cord-302316-raf5rlkq	308	7	insight	insight	NN
cord-302316-raf5rlkq	308	8	into	into	IN
cord-302316-raf5rlkq	308	9	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	308	10	pathogenesis	pathogenesis	NN
cord-302316-raf5rlkq	308	11	,	,	,
cord-302316-raf5rlkq	308	12	which	which	WDT
cord-302316-raf5rlkq	308	13	are	be	VBP
cord-302316-raf5rlkq	308	14	now	now	RB
cord-302316-raf5rlkq	308	15	accumulating	accumulate	VBG
cord-302316-raf5rlkq	308	16	,	,	,
cord-302316-raf5rlkq	308	17	became	become	VBD
cord-302316-raf5rlkq	308	18	available	available	JJ
cord-302316-raf5rlkq	308	19	.	.	.
cord-302316-raf5rlkq	309	1	Probably	probably	RB
cord-302316-raf5rlkq	309	2	,	,	,
cord-302316-raf5rlkq	309	3	reliable	reliable	JJ
cord-302316-raf5rlkq	309	4	biomarkers	biomarker	NNS
cord-302316-raf5rlkq	309	5	for	for	IN
cord-302316-raf5rlkq	309	6	different	different	JJ
cord-302316-raf5rlkq	309	7	pathological	pathological	JJ
cord-302316-raf5rlkq	309	8	types	type	NNS
cord-302316-raf5rlkq	309	9	of	of	IN
cord-302316-raf5rlkq	309	10	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	309	11	forms	form	NNS
cord-302316-raf5rlkq	309	12	are	be	VBP
cord-302316-raf5rlkq	309	13	needed	need	VBN
cord-302316-raf5rlkq	309	14	in	in	IN
cord-302316-raf5rlkq	309	15	order	order	NN
cord-302316-raf5rlkq	309	16	to	to	TO
cord-302316-raf5rlkq	309	17	allow	allow	VB
cord-302316-raf5rlkq	309	18	more	more	RBR
cord-302316-raf5rlkq	309	19	precisely	precisely	RB
cord-302316-raf5rlkq	309	20	targeted	target	VBN
cord-302316-raf5rlkq	309	21	therapeutic	therapeutic	JJ
cord-302316-raf5rlkq	309	22	interventions	intervention	NNS
cord-302316-raf5rlkq	309	23	(	(	-LRB-
cord-302316-raf5rlkq	309	24	Bauchner	Bauchner	NNP
cord-302316-raf5rlkq	309	25	and	and	CC
cord-302316-raf5rlkq	309	26	Fontanarosa	Fontanarosa	NNP
cord-302316-raf5rlkq	309	27	,	,	,
cord-302316-raf5rlkq	309	28	2020	2020	CD
cord-302316-raf5rlkq	309	29	)	)	-RRB-
cord-302316-raf5rlkq	309	30	.	.	.
cord-302316-raf5rlkq	310	1	Many	many	JJ
cord-302316-raf5rlkq	310	2	approaches	approach	NNS
cord-302316-raf5rlkq	310	3	are	be	VBP
cord-302316-raf5rlkq	310	4	with	with	IN
cord-302316-raf5rlkq	310	5	repurposed	repurpose	VBN
cord-302316-raf5rlkq	310	6	drugs	drug	NNS
cord-302316-raf5rlkq	310	7	,	,	,
cord-302316-raf5rlkq	310	8	developed	develop	VBN
cord-302316-raf5rlkq	310	9	for	for	IN
cord-302316-raf5rlkq	310	10	other	other	JJ
cord-302316-raf5rlkq	310	11	infections	infection	NNS
cord-302316-raf5rlkq	310	12	,	,	,
cord-302316-raf5rlkq	310	13	in	in	IN
cord-302316-raf5rlkq	310	14	order	order	NN
cord-302316-raf5rlkq	310	15	to	to	TO
cord-302316-raf5rlkq	310	16	cut	cut	VB
cord-302316-raf5rlkq	310	17	down	down	RP
cord-302316-raf5rlkq	310	18	the	the	DT
cord-302316-raf5rlkq	310	19	time	time	NN
cord-302316-raf5rlkq	310	20	needed	need	VBN
cord-302316-raf5rlkq	310	21	for	for	IN
cord-302316-raf5rlkq	310	22	drugs	drug	NNS
cord-302316-raf5rlkq	310	23	to	to	TO
cord-302316-raf5rlkq	310	24	reach	reach	VB
cord-302316-raf5rlkq	310	25	patients	patient	NNS
cord-302316-raf5rlkq	310	26	in	in	IN
cord-302316-raf5rlkq	310	27	an	an	DT
cord-302316-raf5rlkq	310	28	emergency	emergency	NN
cord-302316-raf5rlkq	310	29	situation	situation	NN
cord-302316-raf5rlkq	310	30	.	.	.
cord-302316-raf5rlkq	311	1	These	these	DT
cord-302316-raf5rlkq	311	2	approaches	approach	NNS
cord-302316-raf5rlkq	311	3	need	need	VBP
cord-302316-raf5rlkq	311	4	to	to	TO
cord-302316-raf5rlkq	311	5	be	be	VB
cord-302316-raf5rlkq	311	6	complemented	complement	VBN
cord-302316-raf5rlkq	311	7	by	by	IN
cord-302316-raf5rlkq	311	8	trials	trial	NNS
cord-302316-raf5rlkq	311	9	specifically	specifically	RB
cord-302316-raf5rlkq	311	10	tailored	tailor	VBN
cord-302316-raf5rlkq	311	11	to	to	IN
cord-302316-raf5rlkq	311	12	the	the	DT
cord-302316-raf5rlkq	311	13	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	311	14	pathology	pathology	NN
cord-302316-raf5rlkq	311	15	.	.	.
cord-302316-raf5rlkq	312	1	A.	A.	NNP
cord-302316-raf5rlkq	312	2	Fauci	Fauci	NNP
cord-302316-raf5rlkq	312	3	reminded	remind	VBD
cord-302316-raf5rlkq	312	4	us	-PRON-	PRP
cord-302316-raf5rlkq	312	5	that	that	IN
cord-302316-raf5rlkq	312	6	drug	drug	NN
cord-302316-raf5rlkq	312	7	trials	trial	NNS
cord-302316-raf5rlkq	312	8	of	of	IN
cord-302316-raf5rlkq	312	9	HIV	HIV	NNP
cord-302316-raf5rlkq	312	10	infections	infection	NNS
cord-302316-raf5rlkq	312	11	progressed	progress	VBD
cord-302316-raf5rlkq	312	12	in	in	IN
cord-302316-raf5rlkq	312	13	small	small	JJ
cord-302316-raf5rlkq	312	14	steps	step	NNS
cord-302316-raf5rlkq	312	15	before	before	IN
cord-302316-raf5rlkq	312	16	effective	effective	JJ
cord-302316-raf5rlkq	312	17	drug	drug	NN
cord-302316-raf5rlkq	312	18	combinations	combination	NNS
cord-302316-raf5rlkq	312	19	could	could	MD
cord-302316-raf5rlkq	312	20	be	be	VB
cord-302316-raf5rlkq	312	21	developed	develop	VBN
cord-302316-raf5rlkq	312	22	.	.	.
cord-302316-raf5rlkq	313	1	The	the	DT
cord-302316-raf5rlkq	313	2	pathogenicity	pathogenicity	NN
cord-302316-raf5rlkq	313	3	of	of	IN
cord-302316-raf5rlkq	313	4	SARS	SARS	NNP
cord-302316-raf5rlkq	313	5	-	-	HYPH
cord-302316-raf5rlkq	313	6	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	313	7	in	in	IN
cord-302316-raf5rlkq	313	8	hACE2	hace2	NN
cord-302316-raf5rlkq	313	9	transgenic	transgenic	JJ
cord-302316-raf5rlkq	313	10	mice	mouse	NNS
cord-302316-raf5rlkq	314	1	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	314	2	Autopsies	Autopsies	NNPS
cord-302316-raf5rlkq	314	3	,	,	,
cord-302316-raf5rlkq	314	4	Oklahoma	Oklahoma	NNP
cord-302316-raf5rlkq	314	5	,	,	,
cord-302316-raf5rlkq	314	6	USA	USA	NNP
cord-302316-raf5rlkq	314	7	Randomized	Randomized	NNP
cord-302316-raf5rlkq	314	8	clinical	clinical	JJ
cord-302316-raf5rlkq	314	9	trials	trial	NNS
cord-302316-raf5rlkq	314	10	and	and	CC
cord-302316-raf5rlkq	314	11	COVID-19	covid-19	NN
cord-302316-raf5rlkq	314	12	:	:	:
cord-302316-raf5rlkq	314	13	managing	managing	NN
cord-302316-raf5rlkq	314	14	expectations	expectation	NNS
cord-302316-raf5rlkq	315	1	Imbalanced	imbalanced	JJ
cord-302316-raf5rlkq	315	2	host	host	NN
cord-302316-raf5rlkq	315	3	response	response	NN
cord-302316-raf5rlkq	315	4	to	to	IN
cord-302316-raf5rlkq	315	5	SARS	SARS	NNP
cord-302316-raf5rlkq	315	6	-	-	HYPH
cord-302316-raf5rlkq	315	7	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	315	8	drives	drive	VBZ
cord-302316-raf5rlkq	315	9	development	development	NN
cord-302316-raf5rlkq	315	10	of	of	IN
cord-302316-raf5rlkq	315	11	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	315	12	Effect	Effect	NNP
cord-302316-raf5rlkq	315	13	of	of	IN
cord-302316-raf5rlkq	315	14	high	high	JJ
cord-302316-raf5rlkq	315	15	vs	vs	IN
cord-302316-raf5rlkq	315	16	low	low	JJ
cord-302316-raf5rlkq	315	17	doses	dose	NNS
cord-302316-raf5rlkq	315	18	of	of	IN
cord-302316-raf5rlkq	315	19	chloroquine	chloroquine	NN
cord-302316-raf5rlkq	315	20	diphosphate	diphosphate	NN
cord-302316-raf5rlkq	315	21	as	as	IN
cord-302316-raf5rlkq	315	22	adjunctive	adjunctive	JJ
cord-302316-raf5rlkq	315	23	therapy	therapy	NN
cord-302316-raf5rlkq	315	24	for	for	IN
cord-302316-raf5rlkq	315	25	patients	patient	NNS
cord-302316-raf5rlkq	315	26	hospitalized	hospitalize	VBN
cord-302316-raf5rlkq	315	27	with	with	IN
cord-302316-raf5rlkq	315	28	severe	severe	JJ
cord-302316-raf5rlkq	315	29	acute	acute	JJ
cord-302316-raf5rlkq	315	30	respiratory	respiratory	JJ
cord-302316-raf5rlkq	315	31	syndrome	syndrome	NN
cord-302316-raf5rlkq	315	32	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	315	33	2	2	CD
cord-302316-raf5rlkq	316	1	(	(	-LRB-
cord-302316-raf5rlkq	316	2	SARS	SARS	NNP
cord-302316-raf5rlkq	316	3	-	-	HYPH
cord-302316-raf5rlkq	316	4	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	316	5	)	)	-RRB-
cord-302316-raf5rlkq	316	6	infection	infection	NN
cord-302316-raf5rlkq	316	7	:	:	:
cord-302316-raf5rlkq	316	8	a	a	DT
cord-302316-raf5rlkq	316	9	randomized	randomized	JJ
cord-302316-raf5rlkq	316	10	clinical	clinical	JJ
cord-302316-raf5rlkq	316	11	trial	trial	NN
cord-302316-raf5rlkq	316	12	Interleukin-1	Interleukin-1	NNP
cord-302316-raf5rlkq	316	13	blockade	blockade	NN
cord-302316-raf5rlkq	316	14	with	with	IN
cord-302316-raf5rlkq	316	15	high	high	JJ
cord-302316-raf5rlkq	316	16	-	-	HYPH
cord-302316-raf5rlkq	316	17	dose	dose	NN
cord-302316-raf5rlkq	316	18	anakinra	anakinra	NN
cord-302316-raf5rlkq	316	19	in	in	IN
cord-302316-raf5rlkq	316	20	patients	patient	NNS
cord-302316-raf5rlkq	316	21	with	with	IN
cord-302316-raf5rlkq	316	22	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	316	23	,	,	,
cord-302316-raf5rlkq	316	24	acute	acute	JJ
cord-302316-raf5rlkq	316	25	respiratory	respiratory	JJ
cord-302316-raf5rlkq	316	26	distress	distress	NN
cord-302316-raf5rlkq	316	27	syndrome	syndrome	NN
cord-302316-raf5rlkq	316	28	,	,	,
cord-302316-raf5rlkq	316	29	and	and	CC
cord-302316-raf5rlkq	316	30	hyperinflammation	hyperinflammation	NN
cord-302316-raf5rlkq	316	31	:	:	:
cord-302316-raf5rlkq	317	1	a	a	DT
cord-302316-raf5rlkq	317	2	retrospective	retrospective	JJ
cord-302316-raf5rlkq	317	3	cohort	cohort	NN
cord-302316-raf5rlkq	317	4	study	study	NN
cord-302316-raf5rlkq	317	5	Simulation	Simulation	NNP
cord-302316-raf5rlkq	317	6	of	of	IN
cord-302316-raf5rlkq	317	7	the	the	DT
cord-302316-raf5rlkq	317	8	clinical	clinical	JJ
cord-302316-raf5rlkq	317	9	and	and	CC
cord-302316-raf5rlkq	317	10	pathological	pathological	JJ
cord-302316-raf5rlkq	317	11	manifestations	manifestation	NNS
cord-302316-raf5rlkq	317	12	of	of	IN
cord-302316-raf5rlkq	317	13	Coronavirus	Coronavirus	NNP
cord-302316-raf5rlkq	317	14	Disease	Disease	NNP
cord-302316-raf5rlkq	317	15	2019	2019	CD
cord-302316-raf5rlkq	317	16	(	(	-LRB-
cord-302316-raf5rlkq	317	17	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	317	18	)	)	-RRB-
cord-302316-raf5rlkq	317	19	in	in	IN
cord-302316-raf5rlkq	317	20	golden	golden	JJ
cord-302316-raf5rlkq	317	21	Syrian	syrian	JJ
cord-302316-raf5rlkq	317	22	hamster	hamster	NN
cord-302316-raf5rlkq	317	23	model	model	NN
cord-302316-raf5rlkq	317	24	:	:	:
cord-302316-raf5rlkq	317	25	implications	implication	NNS
cord-302316-raf5rlkq	317	26	for	for	IN
cord-302316-raf5rlkq	317	27	disease	disease	NN
cord-302316-raf5rlkq	317	28	pathogenesis	pathogenesis	NN
cord-302316-raf5rlkq	317	29	and	and	CC
cord-302316-raf5rlkq	317	30	transmissibility	transmissibility	NN
cord-302316-raf5rlkq	317	31	Efficacy	Efficacy	NNP
cord-302316-raf5rlkq	317	32	of	of	IN
cord-302316-raf5rlkq	317	33	hydroxychloroquine	hydroxychloroquine	NN
cord-302316-raf5rlkq	317	34	in	in	IN
cord-302316-raf5rlkq	317	35	patients	patient	NNS
cord-302316-raf5rlkq	317	36	with	with	IN
cord-302316-raf5rlkq	317	37	COVID-19	covid-19	NN
cord-302316-raf5rlkq	317	38	:	:	:
cord-302316-raf5rlkq	317	39	results	result	NNS
cord-302316-raf5rlkq	317	40	of	of	IN
cord-302316-raf5rlkq	317	41	a	a	DT
cord-302316-raf5rlkq	317	42	randomized	randomized	JJ
cord-302316-raf5rlkq	317	43	clinical	clinical	JJ
cord-302316-raf5rlkq	317	44	trial	trial	NN
cord-302316-raf5rlkq	317	45	Detectable	detectable	JJ
cord-302316-raf5rlkq	317	46	serum	serum	NN
cord-302316-raf5rlkq	317	47	SARS	SARS	NNP
cord-302316-raf5rlkq	317	48	-	-	HYPH
cord-302316-raf5rlkq	317	49	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	317	50	viral	viral	JJ
cord-302316-raf5rlkq	317	51	load	load	NN
cord-302316-raf5rlkq	317	52	(	(	-LRB-
cord-302316-raf5rlkq	317	53	RNAaemia	RNAaemia	NNP
cord-302316-raf5rlkq	317	54	)	)	-RRB-
cord-302316-raf5rlkq	317	55	is	be	VBZ
cord-302316-raf5rlkq	317	56	closely	closely	RB
cord-302316-raf5rlkq	317	57	correlated	correlate	VBN
cord-302316-raf5rlkq	317	58	with	with	IN
cord-302316-raf5rlkq	317	59	drastically	drastically	RB
cord-302316-raf5rlkq	317	60	elevated	elevate	VBN
cord-302316-raf5rlkq	317	61	interleukin	interleukin	NN
cord-302316-raf5rlkq	317	62	6	6	CD
cord-302316-raf5rlkq	317	63	(	(	-LRB-
cord-302316-raf5rlkq	317	64	IL-6	IL-6	NNP
cord-302316-raf5rlkq	317	65	)	)	-RRB-
cord-302316-raf5rlkq	317	66	level	level	NN
cord-302316-raf5rlkq	317	67	in	in	IN
cord-302316-raf5rlkq	317	68	critically	critically	RB
cord-302316-raf5rlkq	317	69	ill	ill	JJ
cord-302316-raf5rlkq	317	70	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	317	71	patients	patient	NNS
cord-302316-raf5rlkq	317	72	Comparative	comparative	JJ
cord-302316-raf5rlkq	317	73	tropism	tropism	NN
cord-302316-raf5rlkq	317	74	,	,	,
cord-302316-raf5rlkq	317	75	replication	replication	NN
cord-302316-raf5rlkq	317	76	kinetics	kinetics	NN
cord-302316-raf5rlkq	317	77	,	,	,
cord-302316-raf5rlkq	317	78	and	and	CC
cord-302316-raf5rlkq	317	79	cell	cell	NN
cord-302316-raf5rlkq	317	80	damage	damage	NN
cord-302316-raf5rlkq	317	81	profiling	profiling	NN
cord-302316-raf5rlkq	317	82	of	of	IN
cord-302316-raf5rlkq	317	83	SARS	SARS	NNP
cord-302316-raf5rlkq	317	84	-	-	HYPH
cord-302316-raf5rlkq	317	85	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	317	86	and	and	CC
cord-302316-raf5rlkq	317	87	SARS	SARS	NNP
cord-302316-raf5rlkq	317	88	-	-	HYPH
cord-302316-raf5rlkq	317	89	CoV	CoV	NNP
cord-302316-raf5rlkq	317	90	with	with	IN
cord-302316-raf5rlkq	317	91	implications	implication	NNS
cord-302316-raf5rlkq	317	92	for	for	IN
cord-302316-raf5rlkq	317	93	clinical	clinical	JJ
cord-302316-raf5rlkq	317	94	manifestations	manifestation	NNS
cord-302316-raf5rlkq	317	95	,	,	,
cord-302316-raf5rlkq	317	96	transmissibility	transmissibility	NN
cord-302316-raf5rlkq	317	97	,	,	,
cord-302316-raf5rlkq	317	98	and	and	CC
cord-302316-raf5rlkq	317	99	laboratory	laboratory	NN
cord-302316-raf5rlkq	317	100	studies	study	NNS
cord-302316-raf5rlkq	317	101	of	of	IN
cord-302316-raf5rlkq	317	102	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	317	103	:	:	:
cord-302316-raf5rlkq	317	104	an	an	DT
cord-302316-raf5rlkq	317	105	observational	observational	JJ
cord-302316-raf5rlkq	317	106	study	study	NN
cord-302316-raf5rlkq	317	107	China	China	NNP
cord-302316-raf5rlkq	317	108	is	be	VBZ
cord-302316-raf5rlkq	317	109	promoting	promote	VBG
cord-302316-raf5rlkq	317	110	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	317	111	treatments	treatment	NNS
cord-302316-raf5rlkq	317	112	based	base	VBN
cord-302316-raf5rlkq	317	113	on	on	IN
cord-302316-raf5rlkq	317	114	unproven	unproven	JJ
cord-302316-raf5rlkq	317	115	traditional	traditional	JJ
cord-302316-raf5rlkq	317	116	medicines	medicine	NNS
cord-302316-raf5rlkq	317	117	Arbidol	Arbidol	NNP
cord-302316-raf5rlkq	317	118	combined	combine	VBN
cord-302316-raf5rlkq	317	119	with	with	IN
cord-302316-raf5rlkq	317	120	LPV	LPV	NNP
cord-302316-raf5rlkq	317	121	/	/	SYM
cord-302316-raf5rlkq	317	122	r	r	NN
cord-302316-raf5rlkq	317	123	versus	versus	IN
cord-302316-raf5rlkq	317	124	LPV	LPV	NNP
cord-302316-raf5rlkq	317	125	/	/	SYM
cord-302316-raf5rlkq	317	126	r	r	NN
cord-302316-raf5rlkq	317	127	alone	alone	RB
cord-302316-raf5rlkq	317	128	against	against	IN
cord-302316-raf5rlkq	317	129	corona	corona	NN
cord-302316-raf5rlkq	317	130	virus	virus	NN
cord-302316-raf5rlkq	317	131	disease	disease	NNP
cord-302316-raf5rlkq	317	132	2019	2019	CD
cord-302316-raf5rlkq	317	133	:	:	:
cord-302316-raf5rlkq	318	1	a	a	DT
cord-302316-raf5rlkq	318	2	retrospective	retrospective	JJ
cord-302316-raf5rlkq	318	3	cohort	cohort	NN
cord-302316-raf5rlkq	318	4	study	study	NN
cord-302316-raf5rlkq	318	5	Development	Development	NNP
cord-302316-raf5rlkq	318	6	of	of	IN
cord-302316-raf5rlkq	318	7	an	an	DT
cord-302316-raf5rlkq	318	8	inactivated	inactivated	JJ
cord-302316-raf5rlkq	318	9	vaccine	vaccine	NN
cord-302316-raf5rlkq	318	10	candidate	candidate	NN
cord-302316-raf5rlkq	318	11	for	for	IN
cord-302316-raf5rlkq	318	12	SARS	SARS	NNP
cord-302316-raf5rlkq	318	13	-	-	HYPH
cord-302316-raf5rlkq	318	14	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	318	15	Observational	observational	JJ
cord-302316-raf5rlkq	318	16	study	study	NN
cord-302316-raf5rlkq	318	17	of	of	IN
cord-302316-raf5rlkq	318	18	hydroxychloroquine	hydroxychloroquine	NNP
cord-302316-raf5rlkq	318	19	in	in	IN
cord-302316-raf5rlkq	318	20	hospitalized	hospitalize	VBN
cord-302316-raf5rlkq	318	21	patients	patient	NNS
cord-302316-raf5rlkq	318	22	with	with	IN
cord-302316-raf5rlkq	318	23	Covid-19	Covid-19	NNP
cord-302316-raf5rlkq	318	24	Complex	Complex	NNP
cord-302316-raf5rlkq	318	25	immune	immune	JJ
cord-302316-raf5rlkq	318	26	dysregulation	dysregulation	NN
cord-302316-raf5rlkq	318	27	in	in	IN
cord-302316-raf5rlkq	318	28	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	318	29	patients	patient	NNS
cord-302316-raf5rlkq	318	30	with	with	IN
cord-302316-raf5rlkq	318	31	severe	severe	JJ
cord-302316-raf5rlkq	318	32	respiratory	respiratory	JJ
cord-302316-raf5rlkq	318	33	failure	failure	NN
cord-302316-raf5rlkq	319	1	A	a	DT
cord-302316-raf5rlkq	319	2	SARS	SARS	NNP
cord-302316-raf5rlkq	319	3	-	-	HYPH
cord-302316-raf5rlkq	319	4	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	319	5	protein	protein	NN
cord-302316-raf5rlkq	319	6	interaction	interaction	NN
cord-302316-raf5rlkq	319	7	map	map	NN
cord-302316-raf5rlkq	319	8	reveals	reveal	VBZ
cord-302316-raf5rlkq	319	9	targets	target	NNS
cord-302316-raf5rlkq	319	10	for	for	IN
cord-302316-raf5rlkq	319	11	drug	drug	NN
cord-302316-raf5rlkq	319	12	repurposing	repurpose	VBG
cord-302316-raf5rlkq	319	13	Compassionate	compassionate	JJ
cord-302316-raf5rlkq	319	14	use	use	NN
cord-302316-raf5rlkq	319	15	of	of	IN
cord-302316-raf5rlkq	319	16	remdesivir	remdesivir	NNS
cord-302316-raf5rlkq	319	17	for	for	IN
cord-302316-raf5rlkq	319	18	patients	patient	NNS
cord-302316-raf5rlkq	319	19	with	with	IN
cord-302316-raf5rlkq	319	20	severe	severe	JJ
cord-302316-raf5rlkq	319	21	Covid-19	covid-19	NN
cord-302316-raf5rlkq	319	22	ª	ª	NN
cord-302316-raf5rlkq	319	23	2020	2020	CD
cord-302316-raf5rlkq	320	1	The	the	DT
cord-302316-raf5rlkq	320	2	Authors	author	NNS
cord-302316-raf5rlkq	320	3	.	.	.
cord-302316-raf5rlkq	321	1	Microbial	Microbial	NNP
cord-302316-raf5rlkq	321	2	Biotechnology	Biotechnology	NNP
cord-302316-raf5rlkq	321	3	published	publish	VBN
cord-302316-raf5rlkq	321	4	by	by	IN
cord-302316-raf5rlkq	321	5	John	John	NNP
cord-302316-raf5rlkq	321	6	Wiley	Wiley	NNP
cord-302316-raf5rlkq	321	7	&	&	CC
cord-302316-raf5rlkq	321	8	Sons	Sons	NNPS
cord-302316-raf5rlkq	321	9	Ltd	Ltd	NNP
cord-302316-raf5rlkq	321	10	and	and	CC
cord-302316-raf5rlkq	321	11	Society	Society	NNP
cord-302316-raf5rlkq	321	12	for	for	IN
cord-302316-raf5rlkq	321	13	Applied	Applied	NNP
cord-302316-raf5rlkq	321	14	Microbiology	Microbiology	NNP
cord-302316-raf5rlkq	321	15	.	.	.
cord-302316-raf5rlkq	322	1	Covid-19	Covid-19	NNP
cord-302316-raf5rlkq	322	2	:	:	:
cord-302316-raf5rlkq	322	3	Pathogenesis	pathogenesis	NN
cord-302316-raf5rlkq	322	4	and	and	CC
cord-302316-raf5rlkq	322	5	drugs	drug	NNS
cord-302316-raf5rlkq	322	6	9	9	CD
cord-302316-raf5rlkq	322	7	COVID-19	covid-19	VBP
cord-302316-raf5rlkq	322	8	:	:	:
cord-302316-raf5rlkq	322	9	A	a	DT
cord-302316-raf5rlkq	322	10	New	New	NNP
cord-302316-raf5rlkq	322	11	Virus	virus	NN
cord-302316-raf5rlkq	322	12	,	,	,
cord-302316-raf5rlkq	322	13	but	but	CC
cord-302316-raf5rlkq	322	14	a	a	DT
cord-302316-raf5rlkq	322	15	Familiar	familiar	JJ
cord-302316-raf5rlkq	322	16	Receptor	receptor	NN
cord-302316-raf5rlkq	322	17	and	and	CC
cord-302316-raf5rlkq	322	18	Cytokine	Cytokine	NNP
cord-302316-raf5rlkq	322	19	Release	Release	NNP
cord-302316-raf5rlkq	322	20	Syndrome	Syndrome	NNP
cord-302316-raf5rlkq	322	21	SARS	SARS	NNP
cord-302316-raf5rlkq	322	22	-	-	HYPH
cord-302316-raf5rlkq	322	23	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	322	24	cell	cell	NN
cord-302316-raf5rlkq	322	25	entry	entry	NN
cord-302316-raf5rlkq	322	26	depends	depend	VBZ
cord-302316-raf5rlkq	322	27	on	on	IN
cord-302316-raf5rlkq	322	28	ACE2	ACE2	NNP
cord-302316-raf5rlkq	322	29	and	and	CC
cord-302316-raf5rlkq	322	30	TMPRSS2	TMPRSS2	NNP
cord-302316-raf5rlkq	322	31	and	and	CC
cord-302316-raf5rlkq	322	32	is	be	VBZ
cord-302316-raf5rlkq	322	33	blocked	block	VBN
cord-302316-raf5rlkq	322	34	by	by	IN
cord-302316-raf5rlkq	322	35	a	a	DT
cord-302316-raf5rlkq	322	36	clinically	clinically	RB
cord-302316-raf5rlkq	322	37	proven	prove	VBN
cord-302316-raf5rlkq	322	38	protease	protease	NN
cord-302316-raf5rlkq	322	39	inhibitor	inhibitor	NN
cord-302316-raf5rlkq	322	40	Tropism	tropism	NN
cord-302316-raf5rlkq	322	41	,	,	,
cord-302316-raf5rlkq	322	42	replication	replication	NN
cord-302316-raf5rlkq	322	43	competence	competence	NN
cord-302316-raf5rlkq	322	44	,	,	,
cord-302316-raf5rlkq	322	45	and	and	CC
cord-302316-raf5rlkq	322	46	innate	innate	JJ
cord-302316-raf5rlkq	322	47	immune	immune	JJ
cord-302316-raf5rlkq	322	48	responses	response	NNS
cord-302316-raf5rlkq	322	49	of	of	IN
cord-302316-raf5rlkq	322	50	the	the	DT
cord-302316-raf5rlkq	322	51	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	322	52	SARS	SARS	NNP
cord-302316-raf5rlkq	322	53	-	-	HYPH
cord-302316-raf5rlkq	322	54	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	322	55	in	in	IN
cord-302316-raf5rlkq	322	56	human	human	JJ
cord-302316-raf5rlkq	322	57	respiratory	respiratory	JJ
cord-302316-raf5rlkq	322	58	tract	tract	NN
cord-302316-raf5rlkq	322	59	and	and	CC
cord-302316-raf5rlkq	322	60	conjunctiva	conjunctiva	NN
cord-302316-raf5rlkq	322	61	:	:	:
cord-302316-raf5rlkq	322	62	an	an	DT
cord-302316-raf5rlkq	322	63	analysis	analysis	NN
cord-302316-raf5rlkq	322	64	in	in	IN
cord-302316-raf5rlkq	322	65	ex	ex	JJ
cord-302316-raf5rlkq	322	66	-	-	NN
cord-302316-raf5rlkq	322	67	vivo	vivo	JJ
cord-302316-raf5rlkq	322	68	and	and	CC
cord-302316-raf5rlkq	322	69	in	in	IN
cord-302316-raf5rlkq	322	70	-	-	HYPH
cord-302316-raf5rlkq	322	71	vitro	vitro	FW
cord-302316-raf5rlkq	322	72	cultures	culture	NNS
cord-302316-raf5rlkq	322	73	Epub	epub	RB
cord-302316-raf5rlkq	322	74	ahead	ahead	RB
cord-302316-raf5rlkq	322	75	of	of	IN
cord-302316-raf5rlkq	322	76	print	print	NN
cord-302316-raf5rlkq	322	77	Triple	triple	JJ
cord-302316-raf5rlkq	322	78	combination	combination	NN
cord-302316-raf5rlkq	322	79	of	of	IN
cord-302316-raf5rlkq	322	80	interferon	interferon	NN
cord-302316-raf5rlkq	322	81	beta-1b	beta-1b	NNP
cord-302316-raf5rlkq	322	82	,	,	,
cord-302316-raf5rlkq	322	83	lopinavir	lopinavir	NNS
cord-302316-raf5rlkq	322	84	-	-	HYPH
cord-302316-raf5rlkq	322	85	ritonavir	ritonavir	NNS
cord-302316-raf5rlkq	322	86	,	,	,
cord-302316-raf5rlkq	322	87	and	and	CC
cord-302316-raf5rlkq	322	88	ribavirin	ribavirin	NN
cord-302316-raf5rlkq	322	89	in	in	IN
cord-302316-raf5rlkq	322	90	the	the	DT
cord-302316-raf5rlkq	322	91	treatment	treatment	NN
cord-302316-raf5rlkq	322	92	of	of	IN
cord-302316-raf5rlkq	322	93	patients	patient	NNS
cord-302316-raf5rlkq	322	94	admitted	admit	VBN
cord-302316-raf5rlkq	322	95	to	to	IN
cord-302316-raf5rlkq	322	96	hospital	hospital	NN
cord-302316-raf5rlkq	322	97	with	with	IN
cord-302316-raf5rlkq	322	98	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	322	99	:	:	:
cord-302316-raf5rlkq	322	100	an	an	DT
cord-302316-raf5rlkq	322	101	open	open	JJ
cord-302316-raf5rlkq	322	102	-	-	HYPH
cord-302316-raf5rlkq	322	103	label	label	NN
cord-302316-raf5rlkq	322	104	,	,	,
cord-302316-raf5rlkq	322	105	randomised	randomised	JJ
cord-302316-raf5rlkq	322	106	,	,	,
cord-302316-raf5rlkq	322	107	phase	phase	NN
cord-302316-raf5rlkq	322	108	2	2	CD
cord-302316-raf5rlkq	322	109	trial	trial	NN
cord-302316-raf5rlkq	322	110	Structure	Structure	NNP
cord-302316-raf5rlkq	322	111	of	of	IN
cord-302316-raf5rlkq	322	112	M(pro	M(pro	NNP
cord-302316-raf5rlkq	322	113	)	)	-RRB-
cord-302316-raf5rlkq	322	114	from	from	IN
cord-302316-raf5rlkq	322	115	SARS	SARS	NNP
cord-302316-raf5rlkq	322	116	-	-	HYPH
cord-302316-raf5rlkq	322	117	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	322	118	and	and	CC
cord-302316-raf5rlkq	322	119	discovery	discovery	NN
cord-302316-raf5rlkq	322	120	of	of	IN
cord-302316-raf5rlkq	322	121	its	-PRON-	PRP$
cord-302316-raf5rlkq	322	122	inhibitors	inhibitor	NNS
cord-302316-raf5rlkq	322	123	Infection	infection	NN
cord-302316-raf5rlkq	322	124	and	and	CC
cord-302316-raf5rlkq	322	125	rapid	rapid	JJ
cord-302316-raf5rlkq	322	126	transmission	transmission	NN
cord-302316-raf5rlkq	322	127	of	of	IN
cord-302316-raf5rlkq	322	128	SARS	SARS	NNP
cord-302316-raf5rlkq	322	129	-	-	HYPH
cord-302316-raf5rlkq	322	130	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	322	131	in	in	IN
cord-302316-raf5rlkq	322	132	ferrets	ferret	NNS
cord-302316-raf5rlkq	322	133	SARS	SARS	NNP
cord-302316-raf5rlkq	322	134	-	-	:
cord-302316-raf5rlkq	322	135	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	322	136	productively	productively	RB
cord-302316-raf5rlkq	322	137	infects	infect	VBZ
cord-302316-raf5rlkq	322	138	human	human	JJ
cord-302316-raf5rlkq	322	139	gut	gut	NN
cord-302316-raf5rlkq	322	140	enterocytes	enterocyte	NNS
cord-302316-raf5rlkq	323	1	Hopes	hope	NNS
cord-302316-raf5rlkq	323	2	rise	rise	VBP
cord-302316-raf5rlkq	323	3	for	for	IN
cord-302316-raf5rlkq	323	4	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	323	5	drug	drug	NN
cord-302316-raf5rlkq	323	6	remdesivir	remdesivir	NNP
cord-302316-raf5rlkq	323	7	Epub	Epub	NNP
cord-302316-raf5rlkq	323	8	ahead	ahead	RB
cord-302316-raf5rlkq	323	9	of	of	IN
cord-302316-raf5rlkq	323	10	print	print	NN
cord-302316-raf5rlkq	323	11	SARS	SARS	NNP
cord-302316-raf5rlkq	323	12	-	-	HYPH
cord-302316-raf5rlkq	323	13	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	323	14	and	and	CC
cord-302316-raf5rlkq	323	15	viral	viral	JJ
cord-302316-raf5rlkq	323	16	sepsis	sepsis	NN
cord-302316-raf5rlkq	323	17	:	:	:
cord-302316-raf5rlkq	324	1	observations	observation	NNS
cord-302316-raf5rlkq	324	2	and	and	CC
cord-302316-raf5rlkq	324	3	hypotheses	hypothesis	NNS
cord-302316-raf5rlkq	324	4	Efficacy	Efficacy	NNP
cord-302316-raf5rlkq	324	5	and	and	CC
cord-302316-raf5rlkq	324	6	safety	safety	NN
cord-302316-raf5rlkq	324	7	of	of	IN
cord-302316-raf5rlkq	324	8	lopinavir	lopinavir	NNP
cord-302316-raf5rlkq	324	9	/	/	SYM
cord-302316-raf5rlkq	324	10	ritonavir	ritonavir	NNP
cord-302316-raf5rlkq	324	11	or	or	CC
cord-302316-raf5rlkq	324	12	arbidol	arbidol	NN
cord-302316-raf5rlkq	324	13	in	in	IN
cord-302316-raf5rlkq	324	14	adult	adult	NN
cord-302316-raf5rlkq	324	15	patients	patient	NNS
cord-302316-raf5rlkq	324	16	with	with	IN
cord-302316-raf5rlkq	324	17	mild	mild	JJ
cord-302316-raf5rlkq	324	18	/	/	SYM
cord-302316-raf5rlkq	324	19	moderate	moderate	JJ
cord-302316-raf5rlkq	324	20	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	324	21	:	:	:
cord-302316-raf5rlkq	324	22	an	an	DT
cord-302316-raf5rlkq	324	23	exploratory	exploratory	NN
cord-302316-raf5rlkq	324	24	randomized	randomize	VBN
cord-302316-raf5rlkq	324	25	controlled	control	VBN
cord-302316-raf5rlkq	324	26	trial	trial	NN
cord-302316-raf5rlkq	324	27	No	no	DT
cord-302316-raf5rlkq	324	28	evidence	evidence	NN
cord-302316-raf5rlkq	324	29	of	of	IN
cord-302316-raf5rlkq	324	30	clinical	clinical	JJ
cord-302316-raf5rlkq	324	31	efficacy	efficacy	NN
cord-302316-raf5rlkq	324	32	of	of	IN
cord-302316-raf5rlkq	324	33	hydroxychloroquine	hydroxychloroquine	NN
cord-302316-raf5rlkq	324	34	in	in	IN
cord-302316-raf5rlkq	324	35	patients	patient	NNS
cord-302316-raf5rlkq	324	36	hospitalised	hospitalise	VBN
cord-302316-raf5rlkq	324	37	for	for	IN
cord-302316-raf5rlkq	324	38	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	324	39	infection	infection	NN
cord-302316-raf5rlkq	324	40	and	and	CC
cord-302316-raf5rlkq	324	41	requiring	require	VBG
cord-302316-raf5rlkq	324	42	oxygen	oxygen	NN
cord-302316-raf5rlkq	324	43	:	:	:
cord-302316-raf5rlkq	324	44	results	result	NNS
cord-302316-raf5rlkq	324	45	of	of	IN
cord-302316-raf5rlkq	324	46	a	a	DT
cord-302316-raf5rlkq	324	47	study	study	NN
cord-302316-raf5rlkq	324	48	using	use	VBG
cord-302316-raf5rlkq	324	49	routinely	routinely	RB
cord-302316-raf5rlkq	324	50	collected	collect	VBN
cord-302316-raf5rlkq	324	51	data	datum	NNS
cord-302316-raf5rlkq	324	52	to	to	TO
cord-302316-raf5rlkq	324	53	emulate	emulate	VB
cord-302316-raf5rlkq	324	54	a	a	DT
cord-302316-raf5rlkq	324	55	target	target	NN
cord-302316-raf5rlkq	324	56	trial	trial	NN
cord-302316-raf5rlkq	324	57	Renin	renin	NN
cord-302316-raf5rlkq	324	58	-	-	HYPH
cord-302316-raf5rlkq	324	59	angiotensin	angiotensin	NN
cord-302316-raf5rlkq	324	60	-	-	HYPH
cord-302316-raf5rlkq	324	61	aldosterone	aldosterone	NN
cord-302316-raf5rlkq	324	62	system	system	NN
cord-302316-raf5rlkq	324	63	blockers	blocker	NNS
cord-302316-raf5rlkq	324	64	and	and	CC
cord-302316-raf5rlkq	324	65	the	the	DT
cord-302316-raf5rlkq	324	66	risk	risk	NN
cord-302316-raf5rlkq	324	67	of	of	IN
cord-302316-raf5rlkq	324	68	Covid-19	Covid-19	NNP
cord-302316-raf5rlkq	324	69	Immune	Immune	NNP
cord-302316-raf5rlkq	324	70	mechanisms	mechanism	NNS
cord-302316-raf5rlkq	324	71	of	of	IN
cord-302316-raf5rlkq	324	72	pulmonary	pulmonary	JJ
cord-302316-raf5rlkq	324	73	intravascular	intravascular	JJ
cord-302316-raf5rlkq	324	74	coagulopathy	coagulopathy	NN
cord-302316-raf5rlkq	324	75	in	in	IN
cord-302316-raf5rlkq	324	76	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	324	77	pneumonia	pneumonia	NN
cord-302316-raf5rlkq	324	78	Cardiovascular	Cardiovascular	NNP
cord-302316-raf5rlkq	324	79	disease	disease	NN
cord-302316-raf5rlkq	324	80	,	,	,
cord-302316-raf5rlkq	324	81	drug	drug	NN
cord-302316-raf5rlkq	324	82	therapy	therapy	NN
cord-302316-raf5rlkq	324	83	,	,	,
cord-302316-raf5rlkq	324	84	and	and	CC
cord-302316-raf5rlkq	324	85	mortality	mortality	NN
cord-302316-raf5rlkq	324	86	in	in	IN
cord-302316-raf5rlkq	324	87	Covid-19	covid-19	NN
cord-302316-raf5rlkq	324	88	Silencing	silence	VBG
cord-302316-raf5rlkq	324	89	the	the	DT
cord-302316-raf5rlkq	324	90	cytokine	cytokine	NN
cord-302316-raf5rlkq	324	91	storm	storm	NN
cord-302316-raf5rlkq	324	92	:	:	:
cord-302316-raf5rlkq	324	93	the	the	DT
cord-302316-raf5rlkq	324	94	use	use	NN
cord-302316-raf5rlkq	324	95	of	of	IN
cord-302316-raf5rlkq	324	96	intravenous	intravenous	JJ
cord-302316-raf5rlkq	324	97	anakinra	anakinra	NN
cord-302316-raf5rlkq	324	98	in	in	IN
cord-302316-raf5rlkq	324	99	haemophagocytic	haemophagocytic	NNP
cord-302316-raf5rlkq	324	100	lymphohistiocytosis	lymphohistiocytosis	NNP
cord-302316-raf5rlkq	324	101	or	or	CC
cord-302316-raf5rlkq	324	102	macrophage	macrophage	NN
cord-302316-raf5rlkq	324	103	activation	activation	NN
cord-302316-raf5rlkq	324	104	syndrome	syndrome	NN
cord-302316-raf5rlkq	325	1	A	a	DT
cord-302316-raf5rlkq	325	2	dynamic	dynamic	JJ
cord-302316-raf5rlkq	325	3	immune	immune	JJ
cord-302316-raf5rlkq	325	4	response	response	NN
cord-302316-raf5rlkq	325	5	shapes	shape	NNS
cord-302316-raf5rlkq	326	1	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	326	2	progression	progression	NN
cord-302316-raf5rlkq	326	3	Renin	renin	NN
cord-302316-raf5rlkq	326	4	-	-	HYPH
cord-302316-raf5rlkq	326	5	angiotensin	angiotensin	NN
cord-302316-raf5rlkq	326	6	-	-	HYPH
cord-302316-raf5rlkq	326	7	aldosterone	aldosterone	NN
cord-302316-raf5rlkq	326	8	system	system	NN
cord-302316-raf5rlkq	326	9	inhibitors	inhibitor	NNS
cord-302316-raf5rlkq	326	10	and	and	CC
cord-302316-raf5rlkq	326	11	risk	risk	NN
cord-302316-raf5rlkq	326	12	of	of	IN
cord-302316-raf5rlkq	326	13	Covid-19	Covid-19	NNP
cord-302316-raf5rlkq	326	14	Comparative	Comparative	NNP
cord-302316-raf5rlkq	326	15	pathogenesis	pathogenesis	NN
cord-302316-raf5rlkq	326	16	of	of	IN
cord-302316-raf5rlkq	326	17	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	326	18	,	,	,
cord-302316-raf5rlkq	326	19	MERS	MERS	NNP
cord-302316-raf5rlkq	326	20	,	,	,
cord-302316-raf5rlkq	326	21	and	and	CC
cord-302316-raf5rlkq	326	22	SARS	SARS	NNP
cord-302316-raf5rlkq	326	23	in	in	IN
cord-302316-raf5rlkq	326	24	a	a	DT
cord-302316-raf5rlkq	326	25	nonhuman	nonhuman	NN
cord-302316-raf5rlkq	326	26	primate	primate	NN
cord-302316-raf5rlkq	326	27	model	model	NN
cord-302316-raf5rlkq	326	28	Type	type	NN
cord-302316-raf5rlkq	326	29	2	2	CD
cord-302316-raf5rlkq	326	30	and	and	CC
cord-302316-raf5rlkq	326	31	interferon	interferon	NN
cord-302316-raf5rlkq	326	32	inflammation	inflammation	NN
cord-302316-raf5rlkq	326	33	strongly	strongly	RB
cord-302316-raf5rlkq	326	34	regulate	regulate	VBP
cord-302316-raf5rlkq	326	35	SARS	SARS	NNP
cord-302316-raf5rlkq	326	36	-	-	HYPH
cord-302316-raf5rlkq	326	37	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	326	38	related	related	JJ
cord-302316-raf5rlkq	326	39	gene	gene	NN
cord-302316-raf5rlkq	326	40	expression	expression	NN
cord-302316-raf5rlkq	326	41	in	in	IN
cord-302316-raf5rlkq	326	42	the	the	DT
cord-302316-raf5rlkq	326	43	airway	airway	NN
cord-302316-raf5rlkq	326	44	epithelium	epithelium	NN
cord-302316-raf5rlkq	327	1	An	an	DT
cord-302316-raf5rlkq	327	2	orally	orally	RB
cord-302316-raf5rlkq	327	3	bioavailable	bioavailable	JJ
cord-302316-raf5rlkq	327	4	broad	broad	JJ
cord-302316-raf5rlkq	327	5	-	-	HYPH
cord-302316-raf5rlkq	327	6	spectrum	spectrum	NN
cord-302316-raf5rlkq	327	7	antiviral	antiviral	JJ
cord-302316-raf5rlkq	327	8	inhibits	inhibit	VBZ
cord-302316-raf5rlkq	327	9	SARS	SARS	NNP
cord-302316-raf5rlkq	327	10	-	-	HYPH
cord-302316-raf5rlkq	327	11	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	327	12	in	in	IN
cord-302316-raf5rlkq	327	13	human	human	JJ
cord-302316-raf5rlkq	327	14	airway	airway	NN
cord-302316-raf5rlkq	327	15	epithelial	epithelial	JJ
cord-302316-raf5rlkq	327	16	cell	cell	NN
cord-302316-raf5rlkq	327	17	cultures	culture	NNS
cord-302316-raf5rlkq	327	18	and	and	CC
cord-302316-raf5rlkq	327	19	multiple	multiple	JJ
cord-302316-raf5rlkq	327	20	coronaviruses	coronaviruse	NNS
cord-302316-raf5rlkq	327	21	in	in	IN
cord-302316-raf5rlkq	327	22	mice	mouse	NNS
cord-302316-raf5rlkq	327	23	Susceptibility	susceptibility	NN
cord-302316-raf5rlkq	327	24	of	of	IN
cord-302316-raf5rlkq	327	25	ferrets	ferret	NNS
cord-302316-raf5rlkq	327	26	,	,	,
cord-302316-raf5rlkq	327	27	cats	cat	NNS
cord-302316-raf5rlkq	327	28	,	,	,
cord-302316-raf5rlkq	327	29	dogs	dog	NNS
cord-302316-raf5rlkq	327	30	,	,	,
cord-302316-raf5rlkq	327	31	and	and	CC
cord-302316-raf5rlkq	327	32	other	other	JJ
cord-302316-raf5rlkq	327	33	domesticated	domesticated	JJ
cord-302316-raf5rlkq	327	34	animals	animal	NNS
cord-302316-raf5rlkq	327	35	to	to	IN
cord-302316-raf5rlkq	327	36	SARS	SARS	NNP
cord-302316-raf5rlkq	327	37	-	-	HYPH
cord-302316-raf5rlkq	327	38	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	327	39	2	2	CD
cord-302316-raf5rlkq	327	40	Anticoagulant	anticoagulant	JJ
cord-302316-raf5rlkq	327	41	treatment	treatment	NN
cord-302316-raf5rlkq	327	42	is	be	VBZ
cord-302316-raf5rlkq	327	43	associated	associate	VBN
cord-302316-raf5rlkq	327	44	with	with	IN
cord-302316-raf5rlkq	327	45	decreased	decrease	VBN
cord-302316-raf5rlkq	327	46	mortality	mortality	NN
cord-302316-raf5rlkq	327	47	in	in	IN
cord-302316-raf5rlkq	327	48	severe	severe	JJ
cord-302316-raf5rlkq	327	49	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	327	50	disease	disease	NN
cord-302316-raf5rlkq	327	51	2019	2019	CD
cord-302316-raf5rlkq	327	52	patients	patient	NNS
cord-302316-raf5rlkq	327	53	with	with	IN
cord-302316-raf5rlkq	327	54	coagulopathy	coagulopathy	NN
cord-302316-raf5rlkq	327	55	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-302316-raf5rlkq	327	56	in	in	IN
cord-302316-raf5rlkq	327	57	patients	patient	NNS
cord-302316-raf5rlkq	327	58	with	with	IN
cord-302316-raf5rlkq	327	59	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	327	60	:	:	:
cord-302316-raf5rlkq	327	61	an	an	DT
cord-302316-raf5rlkq	327	62	open	open	JJ
cord-302316-raf5rlkq	327	63	-	-	HYPH
cord-302316-raf5rlkq	327	64	label	label	NN
cord-302316-raf5rlkq	327	65	,	,	,
cord-302316-raf5rlkq	327	66	randomized	randomized	JJ
cord-302316-raf5rlkq	327	67	,	,	,
cord-302316-raf5rlkq	327	68	controlled	control	VBN
cord-302316-raf5rlkq	327	69	trial	trial	NN
cord-302316-raf5rlkq	327	70	Remdesivir	Remdesivir	NNP
cord-302316-raf5rlkq	327	71	in	in	IN
cord-302316-raf5rlkq	327	72	adults	adult	NNS
cord-302316-raf5rlkq	327	73	with	with	IN
cord-302316-raf5rlkq	327	74	severe	severe	JJ
cord-302316-raf5rlkq	327	75	COVID-19	covid-19	NN
cord-302316-raf5rlkq	327	76	:	:	:
cord-302316-raf5rlkq	327	77	a	a	DT
cord-302316-raf5rlkq	327	78	randomised	randomised	JJ
cord-302316-raf5rlkq	327	79	,	,	,
cord-302316-raf5rlkq	327	80	double	double	JJ
cord-302316-raf5rlkq	327	81	-	-	HYPH
cord-302316-raf5rlkq	327	82	blind	blind	JJ
cord-302316-raf5rlkq	327	83	,	,	,
cord-302316-raf5rlkq	327	84	placebo	placebo	NN
cord-302316-raf5rlkq	327	85	-	-	HYPH
cord-302316-raf5rlkq	327	86	controlled	control	VBN
cord-302316-raf5rlkq	327	87	,	,	,
cord-302316-raf5rlkq	327	88	multicentre	multicentre	NNP
cord-302316-raf5rlkq	327	89	trial	trial	NN
cord-302316-raf5rlkq	327	90	Autopsy	Autopsy	NNP
cord-302316-raf5rlkq	327	91	Findings	Findings	NNP
cord-302316-raf5rlkq	327	92	and	and	CC
cord-302316-raf5rlkq	327	93	Venous	Venous	NNP
cord-302316-raf5rlkq	327	94	Thromboembolism	Thromboembolism	NNP
cord-302316-raf5rlkq	327	95	in	in	IN
cord-302316-raf5rlkq	327	96	Patients	patient	NNS
cord-302316-raf5rlkq	327	97	With	with	IN
cord-302316-raf5rlkq	327	98	COVIDª	COVIDª	NNS
cord-302316-raf5rlkq	327	99	2020	2020	CD
cord-302316-raf5rlkq	328	1	The	the	DT
cord-302316-raf5rlkq	328	2	Authors	Authors	NNPS
cord-302316-raf5rlkq	328	3	Isolation	Isolation	NNP
cord-302316-raf5rlkq	328	4	of	of	IN
cord-302316-raf5rlkq	328	5	SARS	SARS	NNP
cord-302316-raf5rlkq	328	6	-	-	HYPH
cord-302316-raf5rlkq	328	7	CoV-2-related	cov-2-relate	VBN
cord-302316-raf5rlkq	328	8	coronavirus	coronavirus	NN
cord-302316-raf5rlkq	328	9	from	from	IN
cord-302316-raf5rlkq	328	10	malayan	malayan	JJ
cord-302316-raf5rlkq	328	11	pangolins	pangolin	NNS
cord-302316-raf5rlkq	329	1	Pathological	pathological	JJ
cord-302316-raf5rlkq	329	2	findings	finding	NNS
cord-302316-raf5rlkq	329	3	of	of	IN
cord-302316-raf5rlkq	329	4	COVID-19	COVID-19	NNP
cord-302316-raf5rlkq	329	5	associated	associate	VBN
cord-302316-raf5rlkq	329	6	with	with	IN
cord-302316-raf5rlkq	329	7	acute	acute	JJ
cord-302316-raf5rlkq	329	8	respiratory	respiratory	JJ
cord-302316-raf5rlkq	329	9	distress	distress	NN
cord-302316-raf5rlkq	329	10	syndrome	syndrome	NN
cord-302316-raf5rlkq	329	11	Effective	effective	JJ
cord-302316-raf5rlkq	329	12	treatment	treatment	NN
cord-302316-raf5rlkq	329	13	of	of	IN
cord-302316-raf5rlkq	329	14	severe	severe	JJ
cord-302316-raf5rlkq	329	15	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	329	16	patients	patient	NNS
cord-302316-raf5rlkq	329	17	with	with	IN
cord-302316-raf5rlkq	329	18	tocilizumab	tocilizumab	NNP
cord-302316-raf5rlkq	329	19	Effect	Effect	NNP
cord-302316-raf5rlkq	329	20	of	of	IN
cord-302316-raf5rlkq	329	21	convalescent	convalescent	JJ
cord-302316-raf5rlkq	329	22	plasma	plasma	NN
cord-302316-raf5rlkq	329	23	therapy	therapy	NN
cord-302316-raf5rlkq	329	24	on	on	IN
cord-302316-raf5rlkq	329	25	viral	viral	JJ
cord-302316-raf5rlkq	329	26	shedding	shedding	NN
cord-302316-raf5rlkq	329	27	and	and	CC
cord-302316-raf5rlkq	329	28	survival	survival	NN
cord-302316-raf5rlkq	329	29	in	in	IN
cord-302316-raf5rlkq	329	30	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	329	31	patients	patient	NNS
cord-302316-raf5rlkq	330	1	SARS	SARS	NNP
cord-302316-raf5rlkq	330	2	-	-	HYPH
cord-302316-raf5rlkq	330	3	CoV-2	CoV-2	NNP
cord-302316-raf5rlkq	330	4	receptor	receptor	NN
cord-302316-raf5rlkq	330	5	ACE2	ACE2	NNP
cord-302316-raf5rlkq	330	6	is	be	VBZ
cord-302316-raf5rlkq	330	7	an	an	DT
cord-302316-raf5rlkq	330	8	interferon	interferon	NN
cord-302316-raf5rlkq	330	9	-	-	HYPH
cord-302316-raf5rlkq	330	10	stimulated	stimulate	VBN
cord-302316-raf5rlkq	330	11	gene	gene	NN
cord-302316-raf5rlkq	330	12	in	in	IN
cord-302316-raf5rlkq	330	13	human	human	JJ
cord-302316-raf5rlkq	330	14	airway	airway	NN
cord-302316-raf5rlkq	330	15	epithelial	epithelial	JJ
cord-302316-raf5rlkq	330	16	cells	cell	NNS
cord-302316-raf5rlkq	330	17	and	and	CC
cord-302316-raf5rlkq	330	18	is	be	VBZ
cord-302316-raf5rlkq	330	19	detected	detect	VBN
cord-302316-raf5rlkq	330	20	in	in	IN
cord-302316-raf5rlkq	330	21	specific	specific	JJ
cord-302316-raf5rlkq	330	22	cell	cell	NN
cord-302316-raf5rlkq	330	23	subsets	subset	NNS
cord-302316-raf5rlkq	330	24	across	across	IN
cord-302316-raf5rlkq	330	25	tissues	tissue	NNS
cord-302316-raf5rlkq	331	1	I	-PRON-	PRP
cord-302316-raf5rlkq	331	2	thank	thank	VBP
cord-302316-raf5rlkq	331	3	Jacqueline	Jacqueline	NNP
cord-302316-raf5rlkq	331	4	Steinhauser	Steinhauser	NNP
cord-302316-raf5rlkq	331	5	,	,	,
cord-302316-raf5rlkq	331	6	and	and	CC
cord-302316-raf5rlkq	331	7	Kenneth	Kenneth	NNP
cord-302316-raf5rlkq	331	8	Timmis	Timmis	NNP
cord-302316-raf5rlkq	331	9	and	and	CC
cord-302316-raf5rlkq	331	10	Lutz	Lutz	NNP
cord-302316-raf5rlkq	331	11	Br€	Br€	NNP
cord-302316-raf5rlkq	331	12	ussow	ussow	NN
cord-302316-raf5rlkq	331	13	for	for	IN
cord-302316-raf5rlkq	331	14	critical	critical	JJ
cord-302316-raf5rlkq	331	15	reading	reading	NN
cord-302316-raf5rlkq	331	16	of	of	IN
cord-302316-raf5rlkq	331	17	the	the	DT
cord-302316-raf5rlkq	331	18	manuscript	manuscript	NN
cord-302316-raf5rlkq	331	19	.	.	.
cord-302316-raf5rlkq	332	1	The	the	DT
cord-302316-raf5rlkq	332	2	author	author	NN
cord-302316-raf5rlkq	332	3	consults	consult	VBZ
cord-302316-raf5rlkq	332	4	Nestl	Nestl	NNP
cord-302316-raf5rlkq	332	5	e	e	NNP
cord-302316-raf5rlkq	332	6	,	,	,
cord-302316-raf5rlkq	332	7	his	-PRON-	PRP$
cord-302316-raf5rlkq	332	8	former	former	JJ
cord-302316-raf5rlkq	332	9	employer	employer	NN
cord-302316-raf5rlkq	332	10	,	,	,
cord-302316-raf5rlkq	332	11	on	on	IN
cord-302316-raf5rlkq	332	12	the	the	DT
cord-302316-raf5rlkq	332	13	scientific	scientific	JJ
cord-302316-raf5rlkq	332	14	aspects	aspect	NNS
cord-302316-raf5rlkq	332	15	of	of	IN
cord-302316-raf5rlkq	332	16	the	the	DT
cord-302316-raf5rlkq	332	17	COVID-19	covid-19	JJ
cord-302316-raf5rlkq	332	18	epidemic	epidemic	NN
cord-302316-raf5rlkq	332	19	,	,	,
cord-302316-raf5rlkq	332	20	but	but	CC
cord-302316-raf5rlkq	332	21	he	-PRON-	PRP
cord-302316-raf5rlkq	332	22	does	do	VBZ
cord-302316-raf5rlkq	332	23	not	not	RB
cord-302316-raf5rlkq	332	24	consider	consider	VB
cord-302316-raf5rlkq	332	25	this	this	DT
cord-302316-raf5rlkq	332	26	as	as	IN
cord-302316-raf5rlkq	332	27	a	a	DT
cord-302316-raf5rlkq	332	28	conflict	conflict	NN
cord-302316-raf5rlkq	332	29	of	of	IN
cord-302316-raf5rlkq	332	30	interest	interest	NN
cord-302316-raf5rlkq	332	31	.	.	.